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Abstract 
Early Goal Directed Therapy for Adult Meningitis in Malawi 
Emma C Wall 
Introduction: Mortality from acute bacterial meningitis (ABM) in sub-Saharan African adults 
is 50-60%; twice that of more well-resourced settings. To date, interventions designed to 
impact on outcome have been ineffective in this setting.  This thesis addressed the 
hypothesis that high mortality is due in part to delayed or inappropriate acute care, and that 
this may be improved by goal directed resuscitation 
Methods: Clinical and laboratory surveillance data from a large central hospital in Malawi 
were analysed. Clinical predictors of poor outcome from ABM were synthesised into the 
Malawi Adult Meningitis Score (MAMS). To assess feasibility and outcome, patients with 
suspected ABM were recruited in the emergency department and  observed in year one 
under routine clinical care (Phase 1), and then managed with a meningitis-specific EGDT 
clinical care bundle in year two (Phase 2). Laboratory data were tested for outcome 
associations. 
 
Results: A significant decline in the total number of CSF isolates over 12 years was noted 
(incident rate ratio 0.93 [95% CI 0.92-0.94], p<0.001), entirely in children under 5 years (IRR 
=0.87, 95%CI 0.85-0.88, p<0.001) coinciding with Hib vaccination. Adult meningitis remained 
unchanged (IRR=0.99, 95%CI 0.97-1.0, p=0.135) despite extensive ART provision.   
Analysis of 715 historical episodes of adult ABM showed that the mortality was 54% at day 
40; HIV seroprevelence was 87%; and treatment delays were marked. Coma, seizures, 
tachycardia and anaemia but not HIV were significantly associated with mortality.    
The MAMS predicted outcome with good agreement, c statistic 0.74 (95% CI 0.65 : 0.82),  
estimated sensitivity  was 75%, specificity was 55%. 
24 
 
EGDT was found to be feasible, more clinical targets were met using EGDT, including 
reduced time to antibiotics (1hr 55 minutes in P1 v 1hr 13 minutes in P2 p<0.001), IV fluids 
and blood were more frequently given (median volume IV fluid P1 = 750mls, in P2 = 
1500mls p<0.001, blood transfusion 0/2 in P1, 2/3 in P2 p=0.4); airway placement was more 
likely (P1 0%, P2 77% p=0.04). There was no significant difference in outcome at 40 days; 
death or disability in 29/57 (51%) in P1 and 38/60 (63%) in P2 p=0.19.  
Neither high pneumococcal load, nor the presence of EBV co-infection in the CSF were 
associated with poor outcome. CSF white cell counts were lower in non-survivors, other 
markers of inflammation were not associated with outcome.  
Conclusion: The incidence of bacterial meningitis is not falling in adults in Malawi. Important 
clinical outcome predictors were identified and synthesised into a prediction tool. EGDT for 
ABM is feasible in adult patients in Malawi; a larger trial is required to test the impact on 
outcome. Further work to improve pre-hospital care and identify novel adjunctive treatments 
is necessary. 
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1. Introduction 
 
In this introduction, an overview of the diagnosis and treatment of acute bacterial meningitis 
(ABM) in adults will be given. The origins of the research questions addressed in this thesis, 
arising from previous work in ABM in Malawi and elsewhere will be discussed. A detailed 
examination of the literature associated with the two main research questions will be 
presented in Chapter Two.   
1.1 Background 
Acute bacterial meningitis 
Bacterial meningitis is defined as the presence of inflammation in the sub-arachnoid space 
and pia mata associated with invasion of bacteria into the sub-arachnoid space (Flexner, 
1907; Hoffman and Weber, 2009).  
 
Meningitis can be caused by bacteria, mycobacteria, fungi, viruses, malignancies and auto-
immune diseases (Jarvis et al., 2010; Dougherty and Jones, 1986). Bacterial meningitis is 
caused by pathogenic bacteria infecting the meninges lining the brain and the circulating 
cerebrospinal fluid (CSF) in the sub-arachnoid space. The most common aetiological 
bacteria are S.pneumoniae, N.meningitidis and Hib, however bacterial meningitis can be 
caused by gram negative pathogens including Escherichia coli, Salmonella Typhimurium, 
Salmonella typhi, Klebsiella pneumoniae, and by gram positive pathogens including Group B 
Streptococci, Group A Streptococci, Staphylococcus aureus, and Listeria monocytogenes 
(Brouwer et al., 2010b). 
Discrepancies exist in the worldwide epidemiology of bacterial meningitis, with the largest 
burden of both disease and mortality occurring in sub-Saharan Africa, with young children 
disproportionately at risk (Molyneux, 2005; Mueller et al., 2012; Pelkonen et al., 2009; 
Scarborough and Njalale, 2004).  
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Meningitis epidemiology varies between epidemic meningitis outbreaks of predominately 
meningococcal disease, and stable sporadic disease which is predominately pneumococcal, 
with the highest incidence of epidemic cases in the ‘meningitis belt’ region of West and 
Central Africa, and the highest incidence of sporadic cases found in sub-Saharan Africa 
(WHO, 2013b; Irving et al., 2012; Gessner et al., 2010; Molesworth et al., 2003). Malawi is 
far from the meningitis belt, but has seasonal pneumococcal disease and an estimated 
incidence of ABM in 2012 of 10/100000 population in adults and 20/100 000 population in 
children <14 years (Wall et al., 2014a). 
 
Community acquired acute bacterial meningitis (ABM) is one of the most rapidly fatal 
infectious diseases known, affecting humans of all ages. Untreated, bacterial meningitis 
caused by Streptococcus pneumoniae and Haemophilus influenzae type b (Hib) is 
universally fatal: untreated epidemic meningitis caused by Neisseria meningitidis had a 
mortality rate of 60-80% (Flexner, 1913; Swartz, 2004). In the antibiotic era, the case fatality 
rate (CFR) has declined substantially, but varies considerably with aetiology and 
geographical region. The overall CFR is 10-40% in children and 10-60% in adults (van de 
Beek et al., 2010). Pneumococcal meningitis is associated with the highest mortality rate in 
both children (20-30%) and adults (25-60%), meningococcal meningitis is associated with 
the lowest mortality rates (<10%) (Swartz, 2004) (Figure 1.1). In Malawi, the CFR in adults 
with predominately pneumococcal disease is 54%, in children with a mixture of 
pneumococcal, Hib and meningococcal meningitis the CFR is 30-40% (Scarborough et al., 
2007; Ajdukiewicz et al., 2011; McCormick et al., 2012; Carrol et al., 2007a).  
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Figure 1.1 Case fatality rates for bacterial meningitis 1900-2000 
Reproduced from Swartz 2004. Case Fatality Rates for different meningitis pathogens over 
time with the introduction of different therapies. 
 
The estimated death rate per 100 000 population world-wide caused by bacterial meningitis 
in all age groups declined from  8.1/100 000 in 1990  to 6.1/100 000 in 2010, falling from the 
21st most common cause of death world-wide to the 29th in 2010 (Lozano et al., 2012). This 
decline in meningitis mortality has been primarily driven by vaccination campaigns and 
improved neonatal and infant healthcare (Lozano et al., 2012). Survivors in all age groups 
have high rates of neurological morbidity including deafness and epilepsy (Ramakrishnan et 
al., 2009; Weisfelt et al., 2006c; de Louvois et al., 2007; Edmond et al., 2010).  
 
1.2 How is bacterial meningitis diagnosed? 
1.2.1 Clinical Diagnosis 
The intense inflammation in the sub-arachnoid space causes symptoms of severe 
headache, fever and may cause other signs of meningism such as neck stiffness, 
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photophobia, confusion or mental obtundation, seizures and coma (Nijman et al., 2013; 
Thompson et al., 2006; Durand et al., 1993). These classical signs may present late in the 
disease, and early symptoms are often similar to a non-specific influenza-like illness with 
fever, myalgia and mild headache. In the elderly, very young and immunocompromised, 
classical symptoms and signs may not develop, and a high index of clinical suspicion is 
required to detect meningitis in these patients (Brouwer et al., 2012; Thompson et al., 2006; 
Weisfelt et al., 2006f). 
However, The classical clinical triad of fever, neck stiffness and altered mental status are not 
commonly all present in cases of bacterial meningitis (van de Beek et al., 2004)(Attia et al., 
1999); the combined sensitivity of all three in European adults is only 44% (van de Beek et 
al., 2004). The diagnostic accuracy of clinical symptoms and signs to predict bacterial 
meningitis are low when applied individually to adults, however the lack of all three classical 
signs has a sensitivity of 99-100% in eliminating bacterial meningitis (Attia et al., 1999).  
A meta-analysis of three studies in adults with subsequently proven bacterial meningitis 
suggests Kernig’s sign (pain in the neck elicited when the hip is flexed and the knee 
extended) has a positive predictive value (PPV) for bacterial meningitis of 60% and a 
negative predictive value (NPV) of 60%. Neck stiffness alone has a PPV of 41% and a NPV 
61% (Thomas et al., 2002, Waghdhare et al., 2010, Brouwer et al., 2012).   
 
Therefore any patient presenting with a suggestive history or clinical feature of possible 
meningitis must undergo full clinical evaluation for bacterial meningitis, including lumbar 
puncture if indicated. A high index of suspicion is required to ensure bacterial meningitis is 
not missed, when this happens it is usually results in fatal consequences (Nigrovic et al., 
2012; Heyderman, 2005).   
 
A definitive diagnosis of ABM is dependent on analysis of the CSF using biochemistry, cell 
microscopy, microbiology and where available, pathogenic DNA detection using PCR. 
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Lumbar puncture is therefore essential to diagnose bacterial meningitis, as the identification 
of inflammation in the cerebrospinal fluid (CSF) can provide important data to discriminate 
between bacterial and other causes of meningitis; where bacteria are identified on culture or 
Gram stain the diagnosis is conclusive. Typical CSF findings in bacterial meningitis are a 
CSF pleocytosis with elevated protein and low paired CSF:blood glucose ratio of <0.6 
(Deisenhammer et al., 2006). Table 1.1details the typical CSF values for adults with viral and 
bacterial meningitis in resource rich settings where the prevalence of HIV co-infection in the 
population is <10%. 
Table 1.1 Summary of CSF values in meningitis 
Typical CSF values for different types of meningitis in adults, summary statistics 
from four different studies* 
CSF parameter Normal CSF Bacterial meningitis 
(range) 
Viral meningitis (range) 
Median CSF 
Protein (g/L) 
0.38  
(0.1 – 0.58) 
4.18  
(0.21 – 22.2) 
0.77 (0.11 – 4.0) 
CSF:Blood 
Glucose ratio 
0.6 <0.4 0.6 
Median White 
cell count 
(cells/mm3) 
0-5 1000-10000**  
(<100- >10000) 
<300  
(<100-<1000) 
*Data from: (Dougherty and Jones, 1986; Fitch and van de Beek, 2007; Seehusen et al., 2003; van de Beek et al., 2004) 
** wide discrepancy between median cell counts in the studies available, the data given are the range  of medians across the 
studies 
However these classical patterns may be substantially different in the presence of HIV 
infection. In African studies of adults with ABM who are HIV co-infected, the median CSF 
white cell count (WCC) in patients with culture proven ABM varies between 29 cells/mm3  to 
480 cells/mm3 compared to >1000 cells/mm3 in HIV antibody negative patients in Holland 
(Jarvis et al., 2010; van de Beek et al., 2004; Cohen et al., 2010c; Hakim et al., 2000; Wall et 
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al., 2013c). The data reporting CSF WCC in adults with proven meningitis from SSA are 
limited, Table 1.2 summarises the data from four different studies of adult meningitis in the 
region where CSF WCC were reported, from Zimbabwe, Malawi and South Africa. In each of 
these studies >90% of patients were HIV co-infected. The CSF WCC values are variable 
across the studies, but this likely to be due to substantial heterogeneity in recruitment and 
laboratory measurement. CSF biochemistry parameters where measured are similar to 
those from resource rich settings (Table 1.1), but the white cell response in all three studies 
appears to be substantially lower than that recorded in non-HIV studies. 
Table 1.2 CSF parameters in HIV co-infected African adults 
Bacterial meningitis in HIV co-infected adults in SSA* 
Study Median white 
cell count 
(cells/mm3, 
range) 
Percentage 
polymorphonuclear 
cells 
Median 
Protein (g/L) 
Median CSF 
glucose 
(mmol/L) 
Jarvis 2010 29 (5 – 420) Not reported 5.0 (2.7 - >5.0) 0.3 (<0.3 – 0.4) 
Cohen 2010* 260 (32 – 960) 90% NA NA 
Hakim 2000 100 (no range 
given)   
>50% neutrophils in 
87% 
> 0.45 in all 
patients 
<2.2 in 80% 
Wall 2013* 480  
(170 – 1680) 
Not reported Not reported Not reported 
Data from: (Jarvis et al., 2010; Cohen et al., 2010c; Hakim et al., 2000) 
*These studies had an entry criteria of cell count >100 cells/mm3 for entry to the study if CSF culture negative. 
 
The evidence from high HIV prevalence settings shows that the interpretation of CSF white 
cell count and chemistry data in HIV co-infected adults must take these data into account 
when diagnosing bacterial meningitis. CSF WCC responses to different pathogens and in 
different age groups will be explored in Chapter 4.3.4. 
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1.2.2 Laboratory diagnosis 
a) Culture methodology 
Traditional microscopy and culture-based microbiological laboratory techniques have 
been in use to diagnose ABM since the pneumococcus was first identified 
independently by Louis Pasteur and George Sternberg in 1881(Watson et al., 1993). 
The pneumococcus is a gram positive diplococcus, the meningococcus is a gram 
negative diplococcus (Figure 1.2).  
 
 
Figure 1.2 CSF gram stains in meningitis. 
Gram positive cocci in chains (panel 1) and intracellular gram negative diplococcic in 
pairs (panel 2).  
Optimal culture of the pneumococcus is on blood agar at 37 °C in 5% CO2, growth is 
observed as mucoid greyish colonies surrounded by a zone of alpha haemolysis, 
where the red blood cells have been haemolysed by pneumococcal toxins produced 
around the colonies (Figure 1.3).  
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Figure 1.3 Growth of Streptococcus pneumoniae on blood agar 
S.pneumoniae colonies on blood agar surrounded by a zone of alpha haemolysis. 
Image from www.bacteriainphotos.com 
Organism identification is done using optochin sensitivity (an antibiotic used only for 
pneumococcal identification, not clinical use) and where necessary bile sensitivity, 
where the bacterial colonies are lysed by the addition of bile salts (Werno and 
Murdoch, 2008).  In contrast the meningococcus may grow on blood agar, but is 
most commonly identified on chocolate agar (Figure 1.4). Colonies are grey and may 
merge together, they are catalase and oxidase positive and utilise maltose 
(Rouphael and Stephens, 2012).   
 
Figure 1.4 Growth of N.meningitidis on chocolate agar Figure from www.cdc.com 
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CSF culture is the most widely used methodology used to diagnose bacterial 
meningitis, however as it is a technique dependent on organism viability; the 
sensitivity and specificity are affected by the administration of antibiotics to the 
patient prior to lumbar puncture, and the sample transit time from the patient to the 
laboratory (when done out of hours).  The sensitivity and specificity of culture is 
estimated to be 81% and 97% respectively in optimal conditions (Wu et al., 2013);  
data from clinical trials suggest that the real life sensitivity of culture may be lower. 
Clinical trial data report CSF culture positivity data of between 50-70% for gram stain 
and 40- 70% for culture, when compared to patients recruited to clinical trials with 
ABM, with identical clinical and CSF parameters whose CSF is culture negative (de 
Gans and van de Beek, 2002; Scarborough et al., 2007).  
 
Blood culture, where positive for a pathogen known to cause meningitis, in the presence of 
evidence of CSF inflammation may be diagnostic for bacterial meningitis, blood culture 
positivity rates may be pathogen and location specific. Blood culture positivity rates for 
predominantly pneumococcal meningitis in adults are approximately 30% in Malawi and 60% 
in Europe (Scarborough et al., 2007; van de Beek et al., 2004).  
 
b) Molecular diagnostic methods 
Molecular diagnostics, using polymerase chain reaction (PCR) to amplify and then 
detect bacterial DNA is a highly sensitive diagnostic tool for pathogen-specific ABM 
(Corless et al., 2001; Wu et al., 2013; Carrol et al., 2000). PCR does not depend on 
organism viability, and is not limited by the administration of pre-hospital antibiotics. 
Very good multiplex PCR tests have been developed for ABM, which can be used on 
both blood and CSF and detect the presence of Hib, pneumococcus and the 
meningococcus simultaneously (Corless et al., 2001). The technique is discussed in 
more detail in Chapter 3.0.2, PCR is now used routinely in the CSF and blood of 
cases of suspected meningitis where available. 
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c) Bacterial antigen testing 
Urine testing for pneumococcal antigens is most commonly used in bacterial pneumonia, 
using latex antigen test kits, where the sensitivity approaches 77-88%(Gutierrez et al., 
2003). Sensitivity data in CSF are good, with well-resourced settings reporting sensitivities of 
95-100% compared to culture (Saha et al., 2005; Samra et al., 2003; Marcos et al., 2001). 
Sensitivities of the test have not been formally reported from SSA, estimates of sensitivity 
approach 95% (Moisi et al., 2009). A small additional yield in positive results over culture 
were reported in patients from Kenya, Nigeria and Burkina Faso (of cases of suspected ABM 
admitted to hospital,  culture identified 13% of pneumococci, with an additional 3% identified 
by antigen testing compared to Bangladesh and Pakistan (1.1% on culture, additional 5.3% 
on antigen testing (Moisi et al., 2009). 
Meningococcal antigen testing on the CSF is used predominately in the African meningitis 
belt to identify epidemic cases for diagnostics and surveillance. Kits designed to detect 
antigens for serogroups A and W135 have sensitivities approaching 87 and 85% 
respectively (Djibo et al., 2006; Borel et al., 2006). As the kits are serogroup dependent, the 
antigen test must be used appropriately for the local epidemiology (Sobanski et al., 2001). 
 
d) Cerebral imaging 
Brain imaging is commonly performed in suspected bacterial meningitis, to exclude causes 
of raised intracranial pressure that may preclude safety of lumbar puncture. Little data exist 
on the diagnostic potential of imaging scans, as a definitive diagnosis is easily made on CSF 
analysis (Michael et al., 2010). In adults with suspected ABM, a wide variety of pathologies 
were revealed on admission CT scans, including stroke, space occupying lesions and lepto-
meningeal enhancement, but reports of specific CT or MRI findings in adults with ABM that 
are diagnostic are lacking (Hasbun et al., 2001). The use of acute CT scans has been 
associated with delay to antibiotics, and possible harm (Michael et al., 2010). The majority of 
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acute cerebral imaging is done to reassure clinicians that a diagnostic lumbar puncture is 
safe (Joffe, 2007; Clark et al., 2006). However, CT findings are not necessarily accurate in 
determining LP safety, and delays to antibiotics for CT may be more harmful than the risk of 
cerebral coning with lumbar puncture (Brouwer et al., 2012; Joffe, 2007; Heldrich et al., 
1986). 
 
1.3 Treatment of bacterial meningitis 
All guidelines for the management of suspected bacterial meningitis stress urgency in 
making the diagnosis and starting parenteral antibiotics. Where evidence of systemic shock 
is present, the UK and U.S. guidelines also recommend resuscitation (Tunkel et al., 2004; 
Heyderman, 2005). Further discussion of the evidence base for resuscitation and adjunctive 
management of cases of suspected meningitis can be found in Chapter 2 Section 2.7.  
Adequate treatment of ABM initially requires a broad spectrum antimicrobial to be given at a 
dose that will penetrate the CSF, achieving above the minimum inhibitory concentration 
(MIC) of antibiotic required to kill the bacteria. Third generation cephalosporins are the 
treatment of choice, most guidelines recommend Ceftriaxone at a dose of 2 grams either 
once or twice per day (BD) (Heyderman, 2005; van de Beek et al., 2012; Tunkel et al., 2004) 
UK National Institute for Clinical Excellence (NICE) guidelines 
http://www.nice.org.uk/guidance/CG102/chapter/Key-priorities-for-implementation.  
Where cephalosporins are not available or un-affordable, high dose benzyl penicillin with 
chloramphenicol are given as alternatives (Sloan, 2012; WHO, 2010). Both antibiotics must 
be given concurrently to reduce the risk of poor responses due to  pathogen resistance to 
one of these antibiotics (Trachtenberg et al., 2007), in epidemic meningococcal disease a 
single dose of oily chloramphenicol monotherapy may be given (WHO, 2010). Outcomes 
with this approach are not inferior to those with cephalosporins, a systematic review 
including 19 trials concluded that the risk difference of death with using either antibiotic was 
0% (95% CI -3%-2%) (Prasad et al., 2007). In this systematic review, 
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ampicillin/chloramphenicol was also not associated with increased risk of deafness or 
treatment failure, but was associated with decreased risk of persistent CSF culture positivity 
at 48 hours with ceftriaxone (risk difference -6% (95% CI -11% - 0%) (Prasad et al., 2007).  
Penicillin resistant bacteria, particularly pneumococci, are an increasing problem world-wide 
(Klugman et al., 2008). Penicillin is now rarely used to first line to treat meningitis in 
developed settings, where it is used, either rifampicin or vancomycin are advised to be given 
concurrently to cover for penicillin resistant pneumococci (Rossoni et al., 2008; Tunkel et al., 
2004). Ceftriaxone resistant pneumococci are rarely reported, in one study from France, 4% 
of isolates had ceftriaxone resistance, but all with a minimum inhibitory concentration (MIC) 
of <2.0mg/l (Varon, 2009). 
Adjunctive treatments given with antibiotics, with the aim of reducing mortality from ABM will 
be discussed in detail in Chapter 2, Section 5.  
 
1.4 How does bacterial meningitis differ between well and low resourced settings? 
The focus of this thesis is on ABM in sub-Saharan Africa (SSA), particularly Malawi. This is 
because substantial differences in epidemiology and clinical outcome exist between ABM in 
SSA, compared to better-resourced settings such as Europe, Asia or the United States of 
America (USA). The estimated incidence of ABM in children in SSA is 70-100/100 000 
(Peltola, 2001), compared to 0.1-3/100 000 population in better resourced settings (Thigpen 
et al., 2011; Azevedo et al., 2013), there are few data from adults for  the region and this is  
addressed in Chapter 4 Section 4.3.1 and Section 4.3.2.  
 
In addition to a greatly increased burden of disease, the mortality rates from ABM in both 
adults and children are strikingly higher in SSA than anywhere else in the world (Table 1.3) 
(Scarborough and Njalale, 2004; van de Beek et al., 2004; McCormick et al., 2012; Edmond 
et al., 2010). Few studies have been done in adults with ABM in SSA, and limited data are 
available to determine why the mortality rates in this region are so dramatically different to all 
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other regions of the world. In this thesis the study was focussed on addressing ABM, which 
is a significant clinical problem, in the highest incidence region of the world with the highest 
rates of mortality and disabling sequelae. 
Table 1.3 Mortality from bacterial meningitis by region 
Regional Case Fatality rates (CFR) for bacterial meningitis in adults 
Study Region Number of 
cases 
CFR 
Ajdukiewicz 2011 
(Ajdukiewicz et al., 2011) 
Malawi 261 56% 
Thigpen 2011 (Thigpen et al., 2011) USA 3188 14.6% 
Georges 2009  
(Georges et al., 2009) 
France 82 20.7% 
Ishihara 2009 (Ishihara et al., 2009) Japan 71 23% 
Manga 2008  
(Manga et al., 2008) 
Senegal 73 70% 
Lazzarini 2008 (Lazzarini et al., 
2008) 
Italy 289 6.9% 
Scarborough 2007  
(Scarborough et al., 2007) 
Malawi 465 54% 
Nguyen 2007 (Nguyen et al., 2007) Vietnam 435 11% 
De Gans 2002  
(de Gans and van de Beek, 2002) 
Europe 301 11% 
Gordon 2000 
(Gordon et al., 2000) 
Malawi 64 65% 
Durand 1993  
(Durand et al., 1993) 
USA 296 25% 
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1.5 Project starting points 
1.5.1 Summary of available data from bacterial meningitis in African adults 
The highest burden of bacterial meningitis in adults is found in the meningitis belt region of 
Africa, stretching from West Africa across central Saharan Africa to Ethiopia (Figure 1.5), 
where large epidemics occur most years, caused primarily by N.meningitidis serogroups A, 
Y and X (Irving et al., 2012).  
 
Figure 1.5 Map of the meningitis belt region of Africa 
Figure reproduced from www.meningivax.org 
 
The study and control of meningitis in this region has been primarily related to epidemic 
management, including case identification and notification, mass vaccinations and 
surveillance. Treatment of epidemic meningitis in this region is commonly with oily 
chloramphenicol, given intramuscularly (Wali et al., 1979; WHO, 2013a). The adult case 
fatality rate in most meningococcal epidemics is 10% (Artenstein and LaForce, 2012). 
Epidemics of S.pneumoniae serotype one have also been described in the West African 
parts of the meningitis belt region, with a substantially higher mortality of 50-70% in adults 
(Traore et al., 2009; Gessner et al., 2010).  
The recent introduction of  a serogroup A vaccine in Chad was associated with  remarkable 
epidemic control, with a 94% reduction in case notifications of meningitis in regions receiving 
the vaccine from matched neighbouring regions where the vaccine was not given (Daugla et 
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al., 2014). Within this region, large collaborative research programmes exist studying 
epidemic disease, but no studies of clinical management, beyond the use of depot 
intramuscular antibiotics for outbreak control have been done. The effect of HIV co-infection 
in adults with meningitis in this region has also not been studied extensively, one study from 
central Africa showed 50-80% of cases of culture proven ABM over 5 years were co-infected 
with HIV, with an estimated population prevalence of 10-15% (Mbelesso et al., 2006), 
another study from the same centre demonstrated higher rates of ABM in HIV co-infected 
adults, 77% of a prospective cohort of adults with a meningitic illness were HIV co-infected,  
(Bekondi et al., 2006).  
 
Other centres in SSA beyond the meningitis belt have noted an increase in cases of 
bacterial meningitis since the start of the HIV epidemic, associated with high mortality 
(Walker et al., 2012; Williams et al., 1986; Wiersinga et al., 2004; Jarvis et al., 2010), but the 
data are primarily from community and laboratory surveillance. The only published data on 
clinical management, trials to test adjunctive therapies to reduce mortality, and laboratory 
work to investigate the causes of high mortality from ABM in adults have been done in 
Malawi.   
 
Queen Elizabeth Central Hospital (QECH) in Blantyre, Malawi, in collaboration with the 
Malawi Liverpool Wellcome Trust Clinical Research programme (MLW) has been the site for 
extensive research in both bacterial meningitis and invasive pneumococcal and salmonella 
infections in both adults and children for over 20 years. Two major clinical trials testing 
adjunctive therapies for ABM, and a pneumococcal vaccine trial were all undertaken in 
adults admitted to QECH between 2000-2010 (Scarborough et al., 2007; Ajdukiewicz et al., 
2011; French et al., 2010), further studies of the epidemiology and biomarkers of mortality 
from ABM were also undertaken (Gordon et al., 2000; Kelly et al., 2012; Goonetilleke et al., 
2010). Mortality in all studies was in excess of 50% and neither adjunctive therapy tested 
caused an improvement in mortality. The causes of such high mortality remained unclear, 
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although an association of mortality with anaemia and altered mental status was described 
(Scarborough et al., 2007).   
 
1.5.2 Origin of the research questions 
Two main questions arose from these previous studies.  Firstly, why is the mortality from 
ABM in adults in SSA so much higher than other settings, and secondly why did 
interventions with proven efficacy in other regions fail to impact on these poor mortality 
rates? The data presented in this thesis attempts to answer these questions by analysing 
data from surveillance of ABM in Malawi undertaken by MLW to determine the epidemiology 
of ABM in both adults and children, by analysing the data from the previous clinical trials, to 
determine the causes of poor outcome in adults, and by designing and implementing a 
clinical care bundle of resuscitation which was tested for feasibility in adults with ABM.  
 
1.6 Aims and Objectives 
1.6.1 Overall aim of the project 
The aims of the project were to determine the epidemiology and clinical predictors of ABM in 
Malawi, and to test if delivery of Early Goal Directed Therapy (EGDT) for acute bacterial 
meningitis in adults was feasible and safe in QECH.  
 
1.6.2 Specific study objectives 
a) To explore 12 years of surveillance data for ABM to examine trends in the causes and 
incidence rates of ABM over time in Blantyre 
b) Create a meningitis clinical database consisting of data from all appropriate studies of 
ABM in Malawi in the last 20 years and analyse the data for clinical predictors of poor 
outcome. 
c) Use the data from the previous objective to design a severity scoring tool to predict 
outcome from ABM in Malawian adults 
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d) Test the concept of Africa-appropriate EGDT for adults with ABM in a clinical feasibility 
trial in the emergency department of QECH. 
 
At the end of the work presented in this thesis, we hoped to achieve an impact on the 
unacceptably high rates of mortality and morbidity from ABM in Malawi, and a greater 
understanding of the causes of this high mortality. The project ended with the aim to go 
forward to design further intervention studies based on the data generated. 
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2. Review of the Literature 
 
2.1 Introduction  
This review will address two questions fundamental to this PhD thesis.  
1. What are the causes of mortality from bacterial meningitis, and why is mortality so 
high in sub-Saharan Africa? 
2. How can Early Goal Directed Therapy (EGDT) be used as an approach to bacterial 
meningitis in sub-Saharan Africa? 
 
2.1.1 Outline of the search strategies used 
The search strategies used were designed to be fully inclusive of all relevant literature to the 
field, and followed the search strategies developed by the Cochrane Collaboration (Higgins 
JPT, 2009). The National Library of Medicine (PubMed) and Medline databases were 
searched using the following search strategies: 
1. Meningitis, bacterial 
2. meningit*tw 
3. death 
4. mortal*tw 
5. outcome 
6. predictor 
7. therapy 
8. treatment 
Searches for question one were: (1 OR 2) AND (3 OR 4 OR 5 OR 6 OR 7 OR 8) 
The search strategy for question two was: 
1. Meningitis, bacterial 
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2. meningit*tw 
3. sepsis 
4. shock 
5. care bundle 
6. goal directed therapy 
7. outcome 
8. survival 
Searches for question two were: (1 OR 2 OR 3) AND (4 OR 5 OR 6 OR 7 OR 8). 
Search results were stratified according to human or animal work, human search results 
were further stratified into adults and children. Increased weight was applied to publications 
from prospectively collected human adult data and systematic reviews, data from paediatric 
studies and animal work was considered when adult human data were lacking. 
The first sections (2.2-3) of this review explores primarily human data available for 
pneumococcal meningitis, summarising work on pathogenesis with the focus on data that 
details mortality, with reference to animal work where relevant. Known predictors or 
associations with poor outcome will be discussed, followed by a summary of the evidence for 
tested and prospective adjunctive interventions. 
 
The rationale for the intervention tested in this thesis is discussed in the second section 
(2.6), with a review of the literature supporting early goal directed therapy in other conditions, 
and the reasons for testing it in bacterial meningitis. Finally, the evidence for each of the 
interventions comprising goal directed therapy in the Africa-appropriate care bundle tested 
will be summarised. 
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2.2 What are the causes of mortality from bacterial meningitis? 
2.2.1 Pathogenesis of ABM 
S. pneumoniae is a human commensal. In well-resourced settings, it is found in the 
nasopharynx in of up to 50% of healthy children under age 5 years, and up to 10% of adults 
(Huang et al., 2004; Bogaert et al., 2004). In SSA, rates of colonisation are much higher in 
both adults and children, with up to 90% of children under age 5 years having demonstrable 
pneumococcal carriage (Huang et al., 2004; Egere et al., 2012; Anthony et al., 2012). In 
adults, carriage is higher in HIV-infected adults (38%) compared to HIV uninfected adults 
(13%) (Glennie et al., 2013).  
 
Bacterial carriage in the nasopharynx is a dynamic state, triggering immunological 
responses in the host, which are impaired in HIV-infected adults (Ferreira et al., 2013; 
Glennie et al., 2011). The host responses are mediated by humoral CD4 cells and mucosal 
T-regulatory cells, which maintain carriage but prevent invasive disease (Pido-Lopez et al., 
2011; Zhang et al., 2011).  HIV co-infection causes substantial alterations to the normal 
dynamic carriage state in adults (Glennie et al., 2013). The switch from carriage to invasive 
phenotype that occurs in the bacteria is not fully described, but may be due to alterations in 
the biome in the nasopharynx, caused by factors including viral infections which up-regulate 
receptors used by the pneumococci to bind to the epithelial membrane, and factors that 
cause decreased muco-cilliary clearance (McCullers, 2006; Wolter et al., 2014b; Trivedi et 
al., 2011). It is also possible that a temperature change, caused by either environmental 
factors or viral infection may alter expression of virulence markers and immune evasion in 
the pneumococcus, as seen in the meningococcus (Loh et al., 2013), or alterations in the 
mucosal biome may lead to emergence of a pathogenic phenotype (Hajishengallis et al., 
2012). Environmental factors which have been shown to influence carriage include humidity, 
high winds and ambient temperature (Mueller et al., 2008; Kinlin et al., 2009). 
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Once the pneumococcus has bound to the epithelial cells lining the nasopharynx, the 
bacteria transmigrates the epithelial layers to the basement membrane through many 
mechanisms, including cell transport via down-regulation of several receptors to permit 
bacterial entry and squeezing through tight junctions to enter the bloodstream (Mook-
Kanamori et al., 2011). Once in the circulation, the pneumococcus must evade the host 
responses to enter the CNS either through the cribriform plate, or through the systemic 
circulation.  
An estimated two thirds of patients with ABM have concurrent proven bacteraemia in Europe 
(van de Beek et al., 2004) only 30% have proven bacteraemia in Malawi (Scarborough et al., 
2007). 
Mucosal carriage leads to immunological tolerance through low level production of serum 
IgG to pneumococcal proteins, so it is possible that this tolerance permits very low levels of 
bacteraemia to avoid host killing after transmigration into the blood (Ferreira et al., 2013; 
Mook-Kanamori et al., 2011). Further host evasion in the blood occurs through 
encapsulation, to evade complement mediated killing (Mook-Kanamori et al., 2011).  
Once bacteria reach the CNS, they must cross the blood brain barrier (BBB) either through 
very tight junctions between brain endothelial cells and capillary blood vessels and 
astrocytes in the case of pneumococci (Abbott, 2002), or through binding to host endothelial 
cells and entering through arachnoid granulations using type four pili in the case of 
meningococci (Miller et al., 2014; Brissac et al., 2012). Once within the CSF space, the 
bacteria can multiply rapidly, and are circulated throughout the CSF triggering an intense 
host inflammatory response (Mook-Kanamori et al., 2011). Bacterial cell wall proteins and 
toxins bind to pathogen recognition receptors in the walls of brain endothelial cells lining the 
blood brain barrier (BBB), triggering both innate CNS inflammatory responses, and 
neutrophil recruitment through the BBB endothelial cells from the cerebral venous plexus, 
leading to breakdown of the BBB and further inflammation (Mook-Kanamori et al., 2011). 
Neutrophils that phagocytose pneumococci then undergo autolysis, releasing further 
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inflammatory products into the CSF, leading to degradation of cellular integrity of cells in the 
surface layers of the brain (Neal and Gasque, 2013). Pneumococcal toxins, the most studied 
of which is pneumolysin (PLY), then penetrate the CNS tissues through all six cortical layers, 
causing synaptic disruption and resulting brain dysfunction (Wippel et al., 2013). Activated 
pro-coagulant factors in the blood cause microhaemorrhage and thrombi within the CNS, 
further disrupting brain cell function (Pryde et al., 2013). 
 
The net physical result of this intense inflammation within the CNS is clinical presentation 
with severe headache, altered consciousness, neck stiffness, seizures and in some patients, 
evidence of a systemic inflammatory response to sepsis (SIRS), (Weisfelt et al., 2007b). 
Studies in both animals and humans demonstrate that intracranial pressure rises in 
response to the inflammation (Choi et al., 2005; Goh and Minns, 1993; Lindvall et al., 2004; 
Lorenzl et al., 1996; Minns and Engleman, 1988; Park and Chang, 2000), which if it is not 
controlled, will eventually lead to brain cell death, (Glimaker et al., 2014; Tunkel, 2004). 
 
Why some patients who experience this process survive and others die is not clear. The 
level of consciousness on admission clearly influences outcome: the Glasgow Coma Score 
(GCS) at presentation has the strongest association with outcome of all the clinical variables 
that have been studied. (Dzupova et al., 2009; Roine et al., 2008; van de Beek et al., 2004; 
Wall et al., 2013c; Durand et al., 1993). Seizures, a marker of severe CNS dysfunction, are 
also a strong predictor of poor outcome (Wall et al., 2013c; Aronin et al., 1998; Durand et al., 
1993; Zoons et al., 2008). Despite having good data about the clinical predictors of outcome 
in meningitis, their relationship to CSF inflammation and biomarkers of poor outcome is very 
limited.   Such data as are available into the individual underlying causes for non-survival are 
discussed in the following section. 
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2.3 Pathological features of ABM and relationship to outcome 
2.3.1 CSF WCC and outcome 
White cells, predominately neutrophils, are found in the CSF during ABM in response to the 
presence of the pathogen. The host response is predominantly dependent on adequate 
numbers of neutrophils present to phagocytose and remove bacteria from the CSF (Neal 
and Gasque, 2013). 
HIV uninfected adults with pneumococcal meningitis in Europe and Vietnam have a 
substantially higher CSF WCC than the Malawian patients. The mean cell count in Europe in 
data from the dexamethasone trial was 7753 cells/mm3 (SD 14736), and 2970 cells/mm3 
(IQR 1-64000) in adults in Vietnam where 10% were HIV co-infected, compared to a median 
cell count of 480 cells/mm3 (IQR 170 – 1680) in adults in Malawi, where 90% were HIV co-
infected  (van de Beek et al., 2004; Wall et al., 2013c; Nguyen et al., 2007). 
 
Studies from several settings show that a low CSF WCC count is associated with poor 
outcome from ABM (Weisfelt et al., 2006d; Bruyn et al., 1988; Roine et al., 2014b; Wall et 
al., 2014b) 
In the trials of dexamethasone done in Europe and Vietnam, a small proportion of patients 
presented with ABM had a low CSF WCC with a corresponding increase in mortality in these 
patients. In Vietnam, the overall trial CFR was 11.2%, but the mortality rate was 28% in 
patients with CSF WCC <100 cells/mm3 (personal communication Dr Mai, OUCRU Vietnam, 
(Nguyen et al., 2007). In the Dutch data, where a CSF WCC of <1000 cells/mm3 was shown 
to be significantly associated with mortality (van de Beek et al., 2004), the Odd’s Ratio of 
mortality with a CSF cell count of <100 cells/mm3 was 3.4, p<0.001 (personal 
communication Dr Brouwer).  
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In Malawian data from the SAM and GLAM trials, the median CSF WCC was substantially 
below the 1000 cells/mm3 threshold, and low CSF WCC were also associated with poor 
outcome (Wall et al., 2014b; Scarborough et al., 2007; Ajdukiewicz et al., 2011).  
Why are low CSF WCC associated with poor outcome? While the inflammatory products 
released during neutrophil apoptosis in the CSF trigger further CNS inflammation, the lack 
of, or severe reduction in the neutrophil response appears to have more adverse effects in 
allowing further replication of pneumococci and release of toxins through autolysis (Mook-
Kanamori et al., 2011). No data exist examining the functional ability of CSF macrophages in 
response to infection with ABM in HIV infection. Laboratory data exploring the effects of HIV 
on macrophage function demonstrate that the presence of HIV related proteins may alter the 
functional ability of macrophages (Olivetta et al., 2014; Chihara et al., 2012; Cobos-Jimenez 
et al., 2011).  
 
HIV infection of the CNS is well recognised, and is associated with specific neuro-cognitive 
decline(Garvey et al., 2014; Ances and Ellis, 2007). HIV affects the functioning of microglial 
cells, and may alter the intrinsic reaction of the CNS to pathogen, and cause increasing 
neuronal cell apoptosis (Geffin and McCarthy, 2013; Li et al., 2013).  
All CSF WCC have transmigrated from the blood, and were produced in the bone marrow, 
and as such are affected by systematic conditions that may cause bone marrow suppression 
such as HIV infection. Conditions that are associated with invasive pneumococcal disease, 
including ABM, are associated with weakened immunity and bone marrow suppression 
including HIV-1 infection, diabetes, alcoholism and malignancy (van de Beek et al., 2004; 
Harboe et al., 2009; Domingo et al., 2009; Wall et al., 2013c; Muhammad et al., 2013).  
Ethnic neutropaenia is commonly observed in adults and children from SSA, and does not 
appear to alter neutrophil function (Haddy et al., 1999). However it is possibly associated 
53 
 
with increased HIV transmission (Ramsuran et al., 2011). The effect of ethnic neutropaenia 
on the inflammatory response in the CSF to ABM is not clear, further data are required. 
 
2.3.2 Cytokines, chemokines and outcome 
Cytokines, and a subset of cytokines called chemokines are molecules with a wide variety of 
functions in inter-cellular and intracellular signalling in the immune system (Borish and 
Steinke, 2003). Chemokines specifically cause neutrophil migration towards sites of infection 
and inflammation, and have been associated with increased blood-brain-barrier permeability 
(Commins et al., 2010; Stamatovic et al., 2005). In the presence of infection, cytokines and 
chemokines are produced by inflammatory cells in response to inflammation, co-ordinating 
the response by both stimulating further inflammatory activity, and by limiting the extent of 
that activity. In systemic sepsis, poor outcome has been linked to inadequate pro-
inflammatory cytokine activity, without appropriate counter-balancing anti-inflammatory 
activity (Emonts et al., 2007; Chung et al., 2009; Angus and van der Poll, 2013) (Figure 2.1). 
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Figure 2.1 Host pathogen interactions in sepsis 
Abbreviations: TLR, toll-like receptors; CLRs, C-type lectin receptors; RLRs, retinoic acid inducible 
gene 1–like receptors; NLRs, nucleotide-binding oligomerization domain–like receptors. 
Figure reproduced from: (Angus and van der Poll, 2013) 
In sepsis, two host parallel responses, one pro-inflammatory and one anti-inflammatory, are 
activated, and the balance between the two responses determines outcome (2.1) (Kasten et 
al., 2010; van der Poll and Opal, 2008; Angus and van der Poll, 2013). Excessive 
inflammation causes collateral tissue damage, such as acute kidney injury, and excessive 
anti-inflammation causes weak responses to the primary infection and increases 
susceptibility to secondary infections (Angus and van der Poll, 2013). Conditions such as 
HIV, diabetes, alcoholism and advanced age all may lead to a weakened pro-inflammatory 
response. 
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Similar responses are activated in the CSF compartment in bacterial meningitis as in the 
peripheral blood to sepsis; both failure of, and over-activity of the cytokine response to ABM 
within the CNS are implicated in excessive inflammation and neurological damage seen in 
patients with poor outcome (Nau and Eiffert, 2005). 
The presence of bacteria in the CSF triggers a wide range of innate and adaptive immune 
responses. Cytokines and chemokines have been measured in the CSF of animal models of 
meningitis and humans with ABM (Coutinho et al., 2013; Geldhoff et al., 2013; Grandgirard 
et al., 2013). Pro-inflammatory cytokines are produced by perivascular endothelial cells in 
the BBB, meningeal macrophages and astrocytes, and play a significant role recruiting cells 
from the peripheral circulation into the CSF and therefore intensifying the inflammatory 
process (Szelenyi, 2001; Gerber and Nau, 2010). These recruited cells then produce further 
cytokines, determining if the cytokine originated from the CNS or the peripheral cells is 
therefore difficult.  
 
Cytokine responses are markedly raised in the CSF of patients with pneumococcal 
meningitis, and levels of response relate to outcome, with increased pro-inflammatory 
cytokines seen in poor outcome groups. In children in Malawi, high levels of TNFα, IL1β,IL6, 
and IL10 were associated with a poor outcome in HIV co-infected children with 
pneumococcal meningitis, but  were not significant for HIV uninfected children (Carrol et al., 
2007a). In the same children, chemokine responses were again more enhanced in children 
with pneumococcal meningitis and HIV co-infection compared to HIV un-infected children 
(Carrol et al., 2007b), the only chemokine associated with outcome in that study after 
correction for multiple variables was CCL2 (Carrol et al., 2007b). This chemokine specifically 
recruits monocytes and memory T cells to sites of inflammation, and has been shown to with 
correlate with the degree of brain injury in HIV infection (Ragin et al., 2006). Although HIV 
infection alone can induce a measurable cytokine response in the CSF, patients with ABM 
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had substantially higher chemokine levels than in HIV infected control patients (Carrol et al., 
2007b). 
In children with Hib meningitis, CSF high levels of activity of TNFα and IL-1β have been 
associated with seizures and neurological damage: the effect of the cytokine activity 
appeared to be attenuated by adjunctive dexamethasone (Mustafa et al., 1989c; Mustafa et 
al., 1989d; Arditi et al., 1990; Mertsola et al., 1991; Ichiyama et al., 1997). One study in 
children with predominantly Hib meningitis showed that TNFα was elevated in the CSF, high 
levels were associated again with poor outcome (Leppert et al., 2000). However these 
studies were done in the pre-Hib vaccine era, the results are important, but less relevant to 
adult pneumococcal and meningococcal meningitis. 
Few studies have examined host CSF response and outcome from ABM in adults. The 
inflammasome is a multi-molecular structure built in inflammatory cells, triggered by 
activation of toll-like receptors by inflammatory particles (Lamkanfi and Dixit, 2014). The 
inflammasome then activates caspases, leading to cytokine production and the innate 
immune response (Martinon et al., 2002).  A study from Holland showed high levels of 
inflammasome associated cytokines IL1β and IL18 to be associated with a poor outcome 
phenotype, but no other cytokines were measured in that study, and cytokine response was 
not correlated with either immune status or CSF WCC (Geldhoff et al., 2013). 
 
Interestingly, CSF cytokine responses only varied minimally in follow up CSF samples taken 
at 48 hours in patients randomised to either dexamethasone or placebo in Vietnam, 
dexamethasone was shown to have a mild immunosuppressive effect only. (Mai et al., 
2009). The relationship of cytokine levels to outcome was not examined. In a small number 
of adults and children in West Africa, higher levels of pro-inflammatory cytokines were 
observed in patients with a poor outcome, including TNFα, IL-1β and IL-6 (Grandgirard et al., 
2013). The majority of patients in that study had meningococcal (n=22), or pneumococcal 
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meningitis (n=14). However these data are difficult to interpret fully as there are significant 
differences in cytokine response between pathogen, and these two pathogens have 
substantially different mortality rates, although there is a probable association between 
pneumococcal meningitis, high CSF cytokine levels and poor outcome. HIV data were not 
included in the analysis. 
In Malawian adults recruited to the SAM trial, cytokines TNF α, IL1β, IFN γ, IL6, IL8, IL10 
and IL12 were also present at very high levels, but no clinically relevant differences in CSF 
cytokine level by outcome were seen after correcting for HIV status (Wall et al., 2014b).  In 
the same study, low CSF WCC was associated with poor outcome, but CSF WCC did not 
correlate with any of the CSF cytokine results. 
Dexamethasone therapy, given with the first dose of antibiotic, has been shown in animal 
models to attenuate the pro-inflammatory cytokine response, particularly TNFα and IL-1β 
(Mertsola et al., 1989; Mustafa et al., 1989a; Paris et al., 1997). This mechanism was 
postulated as the explanation for the beneficial effect of dexamethasone treatment in several 
clinical trials (de Gans and van de Beek, 2002; Lebel et al., 1988; van de Beek et al., 2010). 
The lack of relationship between cytokine levels and outcome in the SAM trial may partly 
explain why dexamethasone had no impact on outcome in that trial. 
 
2.3.3 Bacterial load and outcome 
The CSF compartment is a sterile site with limited acute immunological responses (Geffin 
and McCarthy, 2013). Therefore bacterial multiplication can occur rapidly, with a doubling 
rate of approximately 20 minutes, and immunological responses may take time to achieve 
control of the infection (Ernst et al., 1983). Bacterial products, particularly cell wall 
lipopolysaccharides (LPS) and toxins such as pneumolysin, have been shown to be potently 
immunogenic in the CSF of animals with experimental meningitis (Leib et al., 2000; Mustafa 
et al., 1989b; Mustafa et al., 1989e; Wippel et al., 2013). Therefore, if bacterial loads are 
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high, the quantity of bacterial product is likely also to be high, and require an increased 
immunological pro-inflammatory response to obtain control. The increased levels of 
inflammation are hypothesised to be associated with increasing neurological damage and 
poor outcome (Nau and Eiffert, 2005). 
Bacterial load, measured in DNA copy number/ml of CSF using Real-Time PCR (RT-PCR) 
has been examined in both adults and children with pneumococcal meningitis in Malawi, and 
in the UK with meningococcal meningitis, and children in Finland with pneumococcal 
meningitis (Carrol et al., 2007a; Roine et al., 2009; Darton et al., 2009; Hackett et al., 2002; 
Wall et al., 2014b). The three paediatric studies demonstrated a relationship between higher 
bacterial loads and poor outcome (Carrol et al., 2007a; Roine et al., 2009; Hackett et al., 
2002), as did the adult UK study of meningococcal meningitis, although in that study the 
differences in bacterial load by outcome were more marked in the blood than in the CSF 
(Darton et al., 2009; Darton et al., 2011). The only study of bacterial load in adults with 
pneumococcal meningitis was done in Malawi and showed no difference between the 
bacterial load and outcome (Wall et al., 2014b).  Why there are differences in the 
relationship between bacterial load and outcome between adult and paediatric patients in 
the same setting is intriguing. CSF WCCs were low in the adult study (median 760 
cells/mm3, IQR 181-2600), and the rate of HIV co-infection was very high (82%). In the 
Malawian paediatric study, the HIV co-infection rate was 62%, neither the median CSF WCC 
nor the relationship between CSF WCC and bacterial load was reported. The relationship 
between bacterial loads, CSF WCC and outcome will be further explored in Chapter 7 
Section 7.3.1 and 7.3.3. 
 
2.4.4 Bacterial toxins and proteins and outcome 
Bacterial toxins are produced by the pathogen to facilitate bacterial growth and to inhibit the 
immunological response to infection (Friedland et al., 1993; Lacroix et al., 1998). Different 
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toxins have different mechanisms of action, but toxins may also damage host cells including 
neurones as well as immune cells through indiscriminate action, and therefore may be 
associated with poor outcome. Pneumolysin (PLY) is the best characterised of 
pneumococcal toxins; one of the roles of PLY is to create pores in cell membranes of cells of 
the host, and disrupt immunological killing (Hirst et al., 2004).  
Animal models of meningitis using both wild type and PLY deficient strains of pneumococci 
show a mild disease only in those infected with the non-PLY producing strains, and markedly 
more severe disease in the wild type infections  (Wippel et al., 2013). In humans, failure to 
clear PLY from the CSF at 48 hours, despite reductions in the bacterial load is associated 
with poor outcome in a small number of adults with pneumococcal meningitis in Malawi (Wall 
et al., 2012). High levels of PLY in the CNS are highly neuro-toxic, and cause considerable 
synaptic damage and dysfunction at all layers of the cerebral cortex (Wippel et al., 2013). 
Definitive studies of the role of pneumolysin and outcome in humans with pneumococcal 
meningitis are lacking, but it is likely that PLY production and clearance plays a significant 
role in outcome, removal of toxin from the CSF is likely to limit toxin-mediated damage 
(Gerber and Nau, 2010; Marriott et al., 2008). Further work on both meningococcal and 
pneumococcal toxins in humans is required to understand their roles in pathogenesis further.  
 
2.3.5 Viral co-infection 
i) Influenza and bacterial meningitis 
Viral co-infections may increase the risk of meningitis by causing bacteria carried in the 
nasopharynx to become invasive (Section 2.2.1). Viral infection, particularly influenza is well-
recognised to lead to pneumococcal pneumonia, through inhibiting the host response to the 
invasive infection, allowing increasing bacterial loads in the nasopharynx which are then 
aspirated, and pre-disposing the lung to pneumococcal adherence and invasion (Wolter et 
al., 2014a; McCullers, 2006). Epidemiological studies have shown that the seasonality of 
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influenza is temporally associated with peaks of invasive pneumococcal disease in South 
Africa, The Netherlands and the USA (Dangor et al., 2014; Jansen et al., 2008; Kim et al., 
1996).  No clinical data currently exist to show if influenza infection is directly associated with 
pneumococcal meningitis, mathematical models from France suggest that pneumococcal 
meningitis seasonality may be temporarily associated with peak influenza transmission 
(Opatowski et al., 2013). A study in mice showed that inflammation from influenza A virus in 
the middle ear, pre-disposed animals to pneumococcal otitis media (Short et al., 2013). Otitis 
media was the source of ABM in 34% of adults with ABM, (Almirante et al., 1995). Children 
in the USA, in the pre-Hib vaccine era, had a history of upper respiratory symptoms 
preceding the onset of ABM in 60% of cases, active viral infection was found in 40% of 
children with proven ABM (Krasinski et al., 1987). 
A direct causal association between influenza infection and pneumococcal meningitis 
remains to be proven, but given the epidemiological relationship, causation is possible. 
 
ii) Herpes viruses and bacterial meningitis and CSF viral co-infection 
EBV is thought to infect up to 90% of the world’s population and is found widely in the serum 
of children and adults in SSA (Schaftenaar et al., 2014; Vetsika and Callan, 2004). Primary 
infection in children is often asymptomatic, but leads to lifelong latency in B memory cells 
(Vetsika and Callan, 2004). 
Active infection commonly found in HIV co-infected individuals in SSA (Petrara et al., 2013), 
and it is associated with HIV associated opportunistic infections  as well as a rare cause of 
viral encephalitis in children (Hung et al., 2000; Siddiqi et al., 2014). Several common 
malignancies including Burkitt’s lymphoma and non-Hodgkin’s lymphoma are caused by 
chronic EBV infection (Kabyemera et al., 2013; Petrara et al., 2013; Mutalima et al., 2008; 
Molyneux et al., 2012).  
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In HIV co-infected patients with meningitis in Malawi recruited to the GLAM trial, high levels 
of EBV infection in the CSF were found, and these were associated with mortality in HIV co-
infected patients (Kelly et al., 2012). A small number of patients had dual EBV and CMV 
infection, all of these died (Kelly et al., 2012; Ajdukiewicz et al., 2011). However when the 
CSF of patients with ABM in Europe (none with HIV co-infection) were tested for the same 
viruses, no DNA from either EBV or CMV was found (Brouwer et al., 2013).  
EBV and CMV were both isolated from the Malawian meningitis patients, however other 
herpes viruses including HSV-1 and Varicella Zoster virus were not isolated (Kelly et al., 
2012), but were found in patients with aseptic meningitis (Benjamin et al., 2013). Children in 
Angola with bacterial meningitis had several herpes viruses including HSV and EBV were 
found in the CSF, no formal association between viral co-infection outcome from ABM was 
shown, but the numbers were small (Pelkonen et al., 2013).  
While a relationship exists between EBV and viral illnesses and malignancies, it is not clear 
from the Malawian study if the EBV found in the CSF was involved in active meningitis 
pathogenesis, or was a marker of advanced immunosuppression (Kelly et al., 2012), no data 
are currently available from other studies to explore this further. The relationship between 
EBV and CMV and outcome will be explored further in Chapter 7 Section 7.3.2. 
 
2.4 Clinical studies and determined predictors of mortality 
Many studies have been done in well-resourced settings exploring clinical parameters and 
prediction of poor outcome at the bedside of adults with bacterial meningitis (Dzupova et al., 
2009; Durand et al., 1993; van de Beek et al., 2004; Aronin et al., 1998; Chang et al., 2008; 
Georges et al., 2009; Ishihara et al., 2009; Lu et al., 2001b; Merkelbach et al., 1999; Zoons 
et al., 2008). One severity score has been derived from these data to predict outcome in 
Europe (Weisfelt et al., 2008). These studies all show that presentation with altered mental 
status, seizures, older age, presence of co-morbidities such as diabetes or alcoholism, 
62 
 
pneumococcal disease and low CSF WCC are associated with poor outcome (van de Beek 
et al., 2004; Dzupova et al., 2009; Weisfelt et al., 2006b; Lepur and Barsic, 2007; Nguyen et 
al., 2007). However the mortality in these studies ranges between 10-30% and does not 
approach the high mortality rates in adults in SSA with ABM, where case fatality rates (CFR) 
of >50% are commonly recorded (Gessner et al., 2010; Scarborough et al., 2007). A study, 
which is the focus of Chapter 4 Section 4.5 details the clinical predictors of poor outcome 
from ABM in Malawian adults, show that these differ from the European data and include 
presentation with coma and altered mental status, anaemia, seizures, tachycardia and low 
CSF WCC (Wall et al., 2013a). In addition, hypoxaemia was associated with poor outcome 
in a small number of patients on univariate analysis, data were too few to include in the 
multivariate analysis and the causes of hypoxaemia were unclear (Wall et al., 2013a). 
Hypoxia and outcome will be examined in Chapter 6 Section 6.3.8. 
In summary, pathogenesis of bacterial meningitis is a complex interaction between host and 
pathogen, with the fatal outcome due to synaptic and cellular dysfunction, microvascular and 
microcellular thrombi and breakdown of the blood brain barrier, leading to rising intracranial 
pressure and brain death (Section 2.2.1). These processes are summarised in Figure 2.3. 
 
Figure 2.1 Meningitis pathogenesis in African adults 
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2.4.1 Previously tested interventions in bacterial meningitis  
Despite the overall declining mortality rates from ABM over the last 100 years (Swartz, 
2004), many interventions have been developed as adjuncts to antibiotics in attempts to 
reduce or eliminate mortality. The next section details different treatments that have been 
tested to impact on mortality from ABM, with a discussion of the different responses seen in 
different settings. The focus will be on meningitis in adults. 
a) Dexamethasone 
The most widely tested adjunctive intervention to antibiotics in acute bacterial meningitis 
(ABM) has been dexamethasone. The rationale for testing dexamethasone was the 
hypothesis that neurological damage in ABM is mediated by excesses of the host 
inflammatory response, and that by reducing inflammation within the CSF compartment, 
intracranial pressure would be reduced and host-mediated inflammatory damage would be 
attenuated (Martos et al., 1995; Pecco et al., 1991; Townsend and Scheld, 1996; Tunkel and 
Scheld, 1989).  Animal models of ABM using dexamethasone showed mixed results, with 
some studies showing benefit (Tauber et al., 1985; Scheld et al., 1980; Mustafa et al., 
1989d; Kadurugamuwa et al., 1989; Nolan et al., 1978), and others showing problems, 
including delayed antibiotic penetration to the CSF with dexamethasone (Paris et al., 1994), 
increased cerebral oxidative stress (Barichello et al., 2011) or failure to prevent deafness 
(Coimbra et al., 2007). 
Large, well conducted studies in well-resourced settings demonstrated significant mortality 
benefit from adjunctive dexamethasone in both adults and children (de Gans and van de 
Beek, 2002; Lebel et al., 1988; van de Beek et al., 2007; Nguyen et al., 2007). These studies 
were done predominantly in the pre-Hib and pre-pneumococcal vaccines era with the 
majority of disease being caused by Hib in children, and by the pneumococcus in adults. 
As a result of these studies, many national guidelines for the treatment of ABM were 
changed to include dexamethasone, given at high dose with the first dose of antibiotics 
(Brouwer et al., 2010a; Weisfelt et al., 2007a; Heyderman, 2005). 
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The beneficial effect of dexamethasone in adults appeared to be greatest in adults with 
pneumococcal meningitis (de Gans and van de Beek, 2002) and in Streptococcus suis 
meningitis in Vietnam (Nguyen et al., 2007). Children with both pneumococcal and Hib 
meningitis appeared to benefit in terms of mortality reduction and lower rates of deafness in 
survivors (Lebel et al., 1988; Kilpi et al., 1995; Peltola and Roine, 2009). 
However, when dexamethasone was tested in Malawi in both adults and children, no 
reduction in either endpoint of mortality or deafness was observed (Scarborough et al., 2007; 
Molyneux et al., 2002). A large subsequent meta-analysis of individual patient data shows 
that the effect of dexamethasone is confined to patients with ABM in well-resourced settings 
and  that it is not an effective intervention in less well-resourced countries (van de Beek et 
al., 2010). Why, when the causative pathogens are the same, an adjunctive intervention has 
been found to have varying effects by geographical location is intriguing and will be 
discussed further in section 2.5. 
 
b) Glycerol 
Glycerol is a hyper-osmolar agent that is taken orally, and enters the bloodstream, exerting 
an osmotic effect on surrounding tissues when concentrated in capillary beds. Within the 
CNS, this effect is thought to draw excessive water from the CNS following an acute 
inflammatory insult, and reduce intracranial pressure (Frank et al., 1981). Glycerol has an 
excellent safety profile, low cost and easy administration (Righetti et al., 2004) and as such 
has been tested for efficacy in ABM, first in children and subsequently in adults. The overall 
quality of the evidence, (tested using the GRADE criteria (Guyatt et al., 2011) 
http://www.gradeworkinggroup.org/intro.htm) examining the effects of Glycerol in ABM is 
weak (Wall et al., 2013b). Paediatric studies of glycerol have shown marginal efficacy in 
reducing deafness in survivors of childhood meningitis in Finland and South America, with 
even more limited effects noted in small, less well conducted studies in India (Kilpi et al., 
1995; Peltola et al., 2007; Singhi et al., 2008), no effect was noted in a trial in Malawi 
(Molyneux et al., 2014).   
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An adult trial in Malawi was stopped by the data monitoring committee when excessive 
deaths were noted in the group randomised to receive glycerol, adjusted OR for poor 
outcome with glycerol was 2.4 (95% CI 1.3-4.2) p=0.003 (Ajdukiewicz et al., 2011). A meta-
analysis of all trials testing glycerol for ABM noted overall no effect from glycerol in children, 
and harm in adults (Wall et al., 2013b). Concerns were raised over the adult trial in the use 
of 50% dextrose as the agent in the placebo arm of the trial, due to possible osmotic effects 
of dextrose, however the baseline mortality in the placebo group was the same as observed 
in the dexamethasone trial, and harmful effect of glycerol appeared to be independent of this 
(Brouwer and van de Beek, 2011).  Glycerol is therefore not advocated for adult meningitis. 
Other osmotic therapies in clinical use, such as mannitol and hypertonic saline have been 
used on an ad-hoc basis but  have not been formally tested for bacterial meningitis, and 
have mixed effects in other conditions associated with raised intracranial pressure 
(Foundation, 2000; Ichai et al., 2009; Okoromah and Afolabi, 2004). 
 
c) Hypothermia 
In animal models of experimental meningitis, brain cooling through hypothermia was shown 
to attenuate markers of inflammation in the brains of animals with E. coli meningitis (Park et 
al., 2001; Rowin et al., 2001) and is used in intensive care for adults surviving cardiac arrest, 
undergoing aneurysm clipping and for children with head injury and other neurosurgical 
conditions, although evidence to support its use is limited (Milani et al., 2011; Sydenham et 
al., 2009; Corry, 2012). Preliminary observational evidence suggested that hypothermia may 
be a useful adjunct to adults admitted to intensive care with ABM (Lepur et al., 2011), 
however a large European randomised controlled trial revealed harm in the group 
randomised to brain cooling and the trial was stopped early (Mourvillier et al., 2013).  
 
d) Intracranial Pressure Management 
A major result of the acute inflammation associated with ABM is raised intracranial pressure 
(ICP) (Haarman et al., 2008; Goh and Minns, 1993; Moller et al., 2000). No randomised 
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controlled trials of management of raised ICP in meningitis currently exist, but observational 
data suggest that in patients on intensive care with meningitis and documented raised ICP, 
aggressive management strategies including lumbar and ventricular drains may be helpful in 
reducing ICP and possibly improving outcome (Abulhasan et al., 2013; Glimaker et al., 2014; 
Lindvall et al., 2004).  However given the inherent biases of observational data, and the 
failure of glycerol to improve outcome when reducing ICP in adults with ABM, this 
management approach must be used with caution until data from randomised trials are 
available. None of the strategies described so far would be feasible in resource-limited 
settings without access to neurosurgical support and intensive care. 
 
e) Antibiotic strategies 
Antibiotic strategies that have been tested in animal models include bacteriostatic antibiotics 
compared to bactericidal antibiotics, intra-ventricular antibiotics and combination antibiotic 
therapy.  Animal models of experimental bacterial meningitis have shown improved 
outcomes in animals treated with bacteriostatic as opposed to bactericidal antibiotics 
(Bottcher et al., 2004; Egermann et al., 2009; Mook-Kanamori et al., 2009). This observation 
has been explained by preservation of the bacterial cell wall by the bacteriostatic antibiotics, 
with limited release of highly inflammatory cell wall compartments and intracellular bacterial 
products into the CSF, therefore leading to a less aggressive host response and hence less 
serious neurological damage (Pankey and Sabath, 2004). In these models, antibiotics were 
given via the intra-ventricular route as well as the parenteral route. However, when CSF 
penetration of these antibiotics was examined following  intramuscular administration of 
antibiotics, only antimicrobial therapy that achieved a bactericidal effect in the CSF was 
associated with clearance of bacteria from the CSF; animals treated at bacteriostatic doses 
failed to clear infection from the CSF at 5 days (Scheld and Sande, 1983). Children with 
penicillin resistant, chloramphenicol sensitive pneumococcal meningitis were more likely to 
fail treatment and have a poor outcome when treated with chloramphenicol compared to 
cephalosporin treatment (Friedland and Klugman, 1992). 
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Clinical trials of bacteriostatic versus bactericidal antibiotics have not been undertaken in 
humans to date. Effective antibiotic therapy is considered to be high dose beta-lactam 
antibiotics, which when given at the correct dose and early in the disease course are 
effective in killing all the common meningitis pathogens in the CSF (Scarborough et al., 
2007; Girgis et al., 1988). Most bacteriostatic antibiotics have not been tested clinically in 
ABM, and may not penetrate the CSF adequately (Scheld and Sande, 1983). Bacteriostatic 
antibiotics are effective in treating either gram positive or gram negative localised or 
systemic infections, but rarely both (Pankey and Sabath, 2004). As ABM may be caused by 
one of several pathogens from across the gram stain spectrum, bacteriostatic agents alone 
are never going to be appropriate first line therapy for ABM (Finberg et al., 2004). Further 
concerns about the use of bacteriostatic antibiotics to treat ABM in humans include negative 
interactions with bactericidal antibiotics in-vivo (Ostergaard et al., 2003; Scheld et al., 1980), 
and the potential slow rate of in-vivo clearance of pathogen from the CSF when such 
antibiotics are used, which may be harmful (Ribes et al., 2005; Scheld and Sande, 1983; 
Lepper and Dowling, 1951; Chowdhury and Tunkel, 2000; Finberg et al., 2004).  
 
In summary, third generation cephalosporins as the first line antibiotic treatment of choice for 
ABM have good evidence of efficacy, resistance rates are currently low, and their use is 
supported by published guidelines (WHO, 2010; Tunkel et al., 2004; Heyderman, 2005; Fitch 
and van de Beek, 2007). Bacteriocidal antibiotics remain useful treatments as adjunctive 
therapies in the treatment of penicillin-resistant pneumococcal meningitis, but are not used 
as primary treatment (Tunkel et al., 2004; Rossoni et al., 2008). 
  
f) Conventional drugs as adjuncts  
Statins 
Statin therapy has been proposed as an adjunct to several infectious diseases including 
sepsis and dengue fever, as a powerful anti-inflammatory effect from the use of statins has 
been observed in animal models, and in patients taking statins for other reasons (Quist-
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Paulsen, 2010; Rosch et al., 2010). Despite significant heterogeneity, a systematic review 
shows that patients who are taking statins incidentally as outpatients may have better 
outcomes from infectious diseases than those not taking statins (Ma et al., 2012). One 
animal model has shown that statin therapy in adjunct to antibiotics for experimental 
meningitis effectively reduces the CSF WCC compared to animals treated with antibiotics 
alone (Winkler et al., 2009). Given that  a low CSF WCC has been shown to be a marker of 
poor outcome, it is unlikely that human trials of statin therapy for ABM will be granted ethical 
approval in the near future without substantial further data .  
 
Anti-pyretics 
Anti-pyretic therapies have been tested twice in children in sub-Saharan Africa, and neither 
trial showed any difference in mortality from receipt of high dose paracetamol with antibiotics 
on admission with ABM (Molyneux et al., 2014; Pelkonen et al., 2011). No studies have 
tested this approach in adults. 
 
g) Future directions  
P4 is a peptide derived from a pneumococcal surface protein (PsaA) that has been 
developed by the Centres for Disease Control (CDC) and shown to enhance opsonisation of 
pneumococci and hence enhance macrophage phagocytosis. P4 has been tested in 
macrophage cell lines and in animal models of pneumonia and sepsis in combination with 
intravenous immunoglobulin (IVIG) as an adjunct to antibiotics. In these models, animal 
mortality from pneumococcal sepsis was substantially lower than with antibiotics alone, and 
P4 was shown to independently improve mortality when given without antibiotic treatment 
(Bangert et al., 2012; Rajam et al., 2010; Bangert et al., 2013). CSF penetration of P4 is not 
known, and its adjunctive effect on pneumococcal meningitis is unclear. When tested in 
macrophages from healthy HIV un-infected Malawians, a much less substantial effect on 
macrophage killing was noted compared to macrophages from healthy Europeans (Bangert 
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et al., 2013). P4 is now in development for phase one clinical trials, and represents a 
promising adjunct for pneumococcal sepsis and meningitis in the future. 
 
As discussed in a previous section, intense cytokine responses in the CSF of patients with 
meningitis may be associated with worse neurological damage and higher rates of non-
survival. However no drugs blocking particular cytokines have been tested in humans with 
ABM to date. In animal models, IFNγ knockout mice had better outcomes from experimental 
pneumococcal meningitis than wild type (Too et al., 2014), IFNγ given as an adjunct to 
amphotericin for cryptococcal meningitis improved  clearance of fungus from the CSF, but no 
effect on outcome was seen (Jarvis et al., 2012). There are no clinical data to help determine 
whether augmenting or blocking the action of IFNγ would be a useful therapeutic approach 
in pneumococcal meningitis 
 
Another compound inflammatory molecule associated with poor outcome in pneumococcal 
meningitis is matrix metalloproteinase nine (MMP9) (Roine et al., 2014a). MMPs are 
caspases produced as part of the innate immune response and are involved in apoptosis, 
MMP9 is involved in the degradation of protein from the extracellular cell matrix, and high 
levels  are associated with poor outcome (Leib et al., 2000; Roine et al., 2014a; Tsai et al., 
2008). Mice who received a compound blocking MMP9 had better outcomes from 
experimental pneumococcal meningitis compared to controls (Liechti et al., 2014), however 
no clinical trials of MMP9 blocking treatment have been undertaken in ABM. 
Dexamethasone blocks MMP9 production in TBM, and therefore may partially contribute to 
the beneficial effect of dexamethasone in some studies ABM (Green et al., 2009). 
Citicoline is an essential component in the synthesis of phospholipids in cell membranes 
(Morton et al., 2013). Bacterial inhibition of this compound has been shown to increase 
neuronal apoptosis in an animal model of pneumococcal meningitis (Zweigner et al., 2004). 
Citicoline has been shown to reduce the size of the area of ischaemia in stroke (Bustamante 
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et al., 2012), and it is hypothesised that it may be an effective adjunct in bacterial meningitis. 
However only one animal study has been performed to date, Citicoline prevented cell death 
and attenuated hippocampal apoptosis in animals with pneumococcal meningitis (Zweigner 
et al., 2004). Clinical human data are lacking. 
 
Further future directions for the treatment of ABM beyond these topics discussed include the 
use of newer anti-seizure agents for patients at risk of seizures, other mechanisms for 
reduction of intracranial pressure, newer adjuncts and newer antibiotics. However as 
vaccination reduces the burden of ABM worldwide, particularly in resource rich settings, it is 
a significant concern that less attention will be given to the development of further therapies 
to improve outcome from adults and children with ABM. 
 
h) Prevention of bacterial meningitis 
Where introduced to the paediatric population, vaccination against the most common 
pathogens causing paediatric meningitis has resulted in substantial decreases in the burden 
of disease, irrespective of the development status of that country (McIntyre et al., 2012).  
Currently available vaccines for ABM include the following (Table 2.1). 
Hib meningitis is rare in adults, but was the most common cause of ABM in children 
(Chandran et al., 2005). the highly effective vaccine has resulted in substantial decreases in 
disease burden in children, with possible herd effects reducing sporadic diseases in adults 
(Adam et al., 2010; Ulanova et al., 2011; Adegbola et al., 2005; Cohen et al., 2010d; Cisse 
et al., 2010; Daza et al., 2006; Giufre et al., 2011).  
The pneumococcus is the commonest contemporary cause of bacterial meningitis in both 
adults and children (Brouwer et al., 2010b; van de Beek, 2012). 
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Table 2.1 Available vaccines for bacterial meningitis 
Vaccines for bacterial meningitis 
Pathogen Serogroup/serotypes covered 
H.influenzae Type b    
N.meningitidis C ACWY A B (newly licensed) 
S.pneumoniae 23-valent 
polysaccharide 
PCV-7 
(4,6B,9V,14,18C,19F, 
and 23F) 
PCV-10 (1, 4, 5, 6B, 7F, 9V, 14, 
18C) 
 
   PCV-13 (1, 3, 4, 5, 6A, 6B, 7F, 
9V, 14, 18C, 19A, 19F, 23F) 
 
The first widely used vaccine developed to prevent IPD and pneumococcal pneumonia was 
the 23 valent polysaccharide vaccine. Efficacy of this vaccine was limited in 
immunocompromised individuals, particularly HIV co-infected adults, and its use has now 
been replaced with the newer, serotype specific conjugate vaccines that are more effective 
in IPD prevention (Nielsen et al., 1998; Opravil et al., 1991; van Hoek et al., 2012; French et 
al., 2000; French et al., 2010). 
The overall incidence of pneumococcal meningitis has decreased following the use of PCV 7 
in children, although increases in disease caused by non-vaccine serotypes has been 
observed (Hsu et al., 2009b). Invasive adult pneumococcal disease has declined in several 
centres after childhood vaccination has been introduced, through herd immunity and 
reduction in transmission through lower carriage rates in children (Muhammad et al., 2013; 
Griffin et al., 2013). Data show that this effect of herd immunity from PCV-7 has reached 
adults in the USA with HIV co-infection, where the burden of IPD in this community has 
decreased from 7.81 cases/1000 person-years to 3.69 cases/1000 person-years (-53%; 95% 
confidence interval: -65% to -36%, p< 0.001) (Burgos et al., 2012b). Another study noted the 
same phenomenon in the USA (Flannery et al., 2006; Cohen et al., 2010a), although also 
noted serotype replacement occurring. No data on IPD in HIV positive adults in SSA 
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following the introduction of PCV-7 or PCV-13 are yet available, but IPD in all age groups 
has decreased over the last 10 years in Malawi prior to the introduction of PCV-13 into the 
paediatric schedule in 2012 (Everett et al., 2011), but the incidence of adult pneumococcal 
meningitis has not changed (Wall et al., 2014a). Data on the indirect effects of the 
pneumococcal vaccine on HIV co-infected adults in SSA are awaited. A trial testing the 
effect of PCV-7 on the recurrent IPD in HIV co-infected adults in Malawi showed that the 
vaccine significantly reduced the risk of recurrent IPD, but meningitis cases were few and no 
effect on reduction of pneumococcal ABM can be extrapolated (French et al., 2010). No data 
currently are published to show if vaccination in African adults can prevent primary IPD. 
 
In SSA, IPD is commonly caused by serotypes one and five, which are not included in PCV-
7. Introduction of PCV-13 into the paediatric vaccination schedule in SSA has started, 
supported by the Global Alliance for Vaccines and Immunisation (GAVI), 
(http://www.gavialliance.org/about/ghd/ ), surveillance data on the effects of this vaccine on 
IPD from the continent are awaited.  
 
However despite dramatic reductions in disease in both children and adults following 
introduction of PCV-7, overall incidence of IPD over time are starting to increase, caused by 
non-vaccine serotype disease, ‘serotype replacement’ (Byington et al., 2010; Elston et al., 
2012; Flannery et al., 2006). It is not clear yet if this phenomenon will extend to PCV-13, but 
given that only 13 serotypes are covered of a possible 90-100, it may be problematic in the 
future (Feldman and Anderson, 2014). This subject is beyond the scope of this review, but is 
an important reason for continuous surveillance of IPD and ongoing development of 
vaccines that are protective against all serotypes.  
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With regards to meningococcal prevention through vaccination, fewer data exist for adults 
compared to children. Meningococcal meningitis in the UK has substantially decreased in 
children, adults and adolescents following vaccination for N. meningitidis serogroup c (Martin 
et al., 2014; Okike et al., 2014). Meningococcal meningitis incidence has been substantially 
reduced in the meningitis belt region of Africa where meningococcal serogroup A vaccination 
has been introduced (Daugla et al., 2014) and roll out of this vaccine for epidemic control is 
now supported by GAVI. Meningococcal meningitis beyond the meningitis belt is a sporadic 
and relatively rare disease in SSA, meningococcal vaccines are not currently a priority for 
expansion in the region ( http://www.gavialliance.org/search/?SearchText=meningitis ). The 
newly licensed serogroup B meningococcal vaccination is likely to be effective in preventing 
serogroup B disease (Elena Santolaya et al., 2013; Gossger et al., 2012), however as this 
serogroup is rare in Africa it is unlikely to be relevant on the continent. 
The incidence of IPD and pneumococcal ABM may be substantially reduced in African adults 
from herd immunity from paediatric vaccination campaigns, but with the limitations of the 
current vaccines and the serotype replacement phenomenon, it is unlikely that this strategy 
will result in eradication of this disease, and on-going research into improvement in detection 
and treatment remains a priority.  
 
2.5 Why have adjunctive interventions failed in African Adults? 
It is notable that two major interventions, dexamethasone and glycerol, failed to reduce the 
CFR from ABM in SSA compared to potential beneficial effects in other countries. It is 
unclear in particular why glycerol was found to be harmful when it had benign effects 
elsewhere. The substantial differences exist between the populations in SSA and Europe 
might contribute to differential effects of these interventions.  
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2.5.1 Delay 
Adults with pneumococcal meningitis in Malawi have different demographics compared to 
those studied in other settings outside SSA; they are younger (median age 33 years 
compared to 50 years in Europe), are commonly HIV co-infected, present late to hospital 
and they experience in-hospital delays to lumbar puncture and antibiotic treatment 
(Desmond et al., 2013; Wall et al., 2013a). Time from symptom onset to lumbar puncture in 
the two main trials in Malawi was 3-5 days, compared to <48-72 hours for most European 
studies (Scarborough et al., 2007; Ajdukiewicz et al., 2011; Lepur and Barsic, 2007; 
Thompson et al., 2006; de Gans and van de Beek, 2002).  
Prompt recognition of ABM and rapid access to specialised treatment was instrumental in 
reducing mortality in paediatric ABM in the UK from 30-40% to <10% (Nadel et al., 1998; 
Harnden et al., 2006). Part of this strategy was rapid in-hospital antibiotics, which have been 
associated with decreasing mortality in both adults and children (Lepur and Barsic, 2007; 
Hsu et al., 2009a). In Malawi the median wait in hospital for parenteral antibiotics was 3-5 
hours (Wall et al., 2013c). 
 
2.5.2 Disease severity 
An alternative cause for higher mortality rates in SSA is the possibility that disease severity 
was higher in patients in this region. A severity score designed by the Dutch group to predict 
outcome from ABM, derived from the data from the dexamethasone trial was of low 
predictive quality when applied to Malawian data, underlying the differences between these 
two populations (Weisfelt et al., 2008; Schut et al., 2012). An objective, direct comparison of 
disease severity on admission between the two populations is not possible as the inefficacy 
of the score reveals, a comparison will require more sensitive tools than those currently 
reported. 
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2.5.3 Disease severity: role of the pathogen 
In SSA, pneumococcal disease is caused disproportionately by serotype 1, compared to 
other settings where serotype 1 disease is rare (Martin et al., 2014; Mueller et al., 2012; 
Everett et al., 2012; van Hoek et al., 2012). In Europe, IPD caused by serotype one has 
been shown to be associated with lower disease severity and mortality than other serotypes 
(Burgos et al., 2012a). In contrast, in Malawi, pneumococcal meningitis caused by serotype 
one may be associated with marginally higher mortality than other serotypes (CFR serotype 
one was 59%, all other serotypes CRF was 50.1%) (Wall et al., 2013c). Mortality from 
epidemic pneumococcal meningitis in West Africa caused by serotype one reaches 40-60% 
(Gessner et al., 2010; Leimkugel et al., 2005). The differences in serotype causing disease 
in different settings may be due to either additional virulence potential or increased 
transmissibility potential within populations in Africa (Ritchie et al., 2012). Data from the 
PAGE project investigating the genetics of African serotype one disease will reveal more 
http://www.pagegenomes.org/.  
Data from studies of pneumococcal meningitis in either the meningitis belt or in SSA may 
therefore not be directly comparable to data from other regions. 
 
2.5.4 Disease severity: host 
African adults are at higher risk of IPD than adults in other settings, with increased risk in 
those who are HIV co-infected (Walker et al., 2012; Scott et al., 2000; Nunes et al., 2011; 
French et al., 2010; Gilks et al., 1996).  
Eighty seven percent of the patients in the Malawian meningitis data were HIV-antibody 
positive compared to 0% from the European series (Wall et al., 2013c; van de Beek et al., 
2004). Median GCS on presentation in Malawi was 12/15, compared to 11/15 in Europe, the 
seizure frequency was 44.9% compared to 15% in Europe and the rates of tachycardia >120 
beats per minute were similar (Wall et al., 2013c; van de Beek et al., 2004). 
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The presence of low CSF WCC responses in African adults to meningitis pathogens (Wall et 
al., 2014b), combined with high rates of HIV co-infection, severe anaemia (Wall et al., 
2013c), poverty (Desmond et al., 2013) malnutrition (Zachariah et al., 2009) and high levels 
of carriage (Glennie et al., 2013) may all be important in determining disease severity in the 
host. HIV co-infection alters serological responses to pneumococci (Glennie et al., 2011; 
Glennie et al., 2013), macrophages in healthy Malawian adults may be less able to handle 
infection with pneumococci compared to healthy European adults, a factor that may be 
compounded by HIV infection and exposure to biofuels (Bangert et al., 2013; Fullerton et al., 
2009).  
High rates of HIV co-infection and particularly aggressive pathogens may mean that the 
effect of adjunctive treatments designed to reduce intracranial inflammation were insufficient 
to overcome disease severity in the absence of high quality resuscitation and medical care.  
 
2.5.5 Disease severity: Poor clinical care 
The admission units (Room 6 and ward 4B) at QECH (described in Chapter 3 Section 3.3.5) 
possibly provided inadequate basic medical care for the patients with ABM studied in 
Malawi. Severe anaemia is common in adult and paediatric Malawian inpatients, and is 
associated with high mortality from a number of conditions, access to blood transfusion is 
limited, particularly in adults (Lewis et al., 2005).  Seizures can be controlled in resource-rich 
settings with effective drugs, in Malawi access to these drugs is profoundly limited, and the 
options for seizure treatment are few (Ogutu et al., 2002).  
In addition, patients admitted with severe ABM into clinical trials in other settings had the 
option for admission to intensive care, and support for failing organ systems was provided. 
These facilities are lacking for the majority of patients in Malawi and without access to this 
supportive care this may have further impacted on mortality. 
A summary of the factors influencing outcome for patients with ABM in Malawi is shown in 
Figure 2.4. It is possible that patients in Malawi presented too late to hospital, compounded 
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by delays in hospital for the effects of either glycerol or dexamethasone to be effective, as 
opposed to intrinsic inefficacy in this population compared to other centre.  
 
 
Figure 2.2 Factors influencing outcome from meningitis in Malawi 
 
In summary, adults in presenting with suspected ABM in Malawi are different to those 
presenting in more well-resource settings. Access to resuscitation on admission and 
intensive care support are lacking. From the factors shown in Figure 2.4 that are susceptible 
to intervention, improving delays in access and optimising in-hospital recognition and 
treatment of ABM is a clear priority towards improving treatment and possibly outcome from 
ABM. The next section outlines the rationale for the intervention tested in this PhD thesis, 
Early Goal Directed Therapy for adult meningitis in Malawi. 
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2.6 How can Early Goal Directed Therapy (EGDT) be used as an approach to 
bacterial meningitis in sub-Saharan Africa? 
2.6.1 What is EGDT? 
Early Goal Directed Therapy is a term for protocolised resuscitation care, delivered to set 
clinical targets within an acute time period, first defined by in the study by Emanuel Rivers of 
goal directed therapy for septic shock in 2001 (Rivers et al., 2001) . EGDT was originally 
developed for sepsis, but has been used for several other clinical conditions such as post-
operative care, ventilator associated pneumonia, central venous catheter line management 
and post cardiac arrest protocols amongst others (Wip and Napolitano, 2009; Cecconi et al., 
2013; Marwick and Davey, 2009; Gaieski et al., 2009). The concept of EGDT has led to 
development of clinical care, protocolised into a package called a ‘care bundle’. Clinical care 
bundles can be applied, as developed for acute resuscitation, but are also now used for 
many interventions in critical care. This review will primarily cover the rationale for EGDT for 
acute resuscitation in adult medicine.  
 
Valid care bundles require clinically effective components, each with individual evidence of 
benefit (Barochia et al., 2010). One meta-analysis of ten care bundles for sepsis found that 
the overall benefit of the care bundle is greater than that would be expected by the evidence 
supporting the individual components (Barochia et al., 2010).  
 
2.6.2 Testing EGDT in clinical trials; the evaluation of complex interventions  
The evaluation of complex interventions is difficult (Campbell et al., 2007; Council, 2008). 
When one single intervention is tested against a control, well established methodologies 
exist to calculate the appropriate sample size and the size of the effect of the intervention 
compared to control on the study endpoints; in a well-designed study with adequate 
numbers, the effect of the intervention is clear (Oakley et al., 2006). When designing a 
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complex intervention incorporating several individual elements such as EGDT, both design 
and methodological difficulties must be met in parallel with the analysis plan of the data 
(Campbell et al., 2000). 
 
The Medical Research Council published guidelines for evaluating complex interventions, 
including but not limited to EGDT in 2000, updated in 2008 (Campbell et al., 2000; Campbell 
et al., 2007). These guidelines defines a complex intervention as having any one of the 
following (Council, 2008): 
i. Number of interacting components within the experimental and control interventions 
ii. Number and difficulty of behaviours required by those delivering or receiving the 
intervention 
iii. Number of groups or organisational levels targeted by the intervention 
iv. Number and variability of outcomes 
v. Degree of flexibility or tailoring of the intervention permitted 
EGDT encompasses all of these complexities, particularly with the number of interacting 
components within the care bundle and controls, and the flexibility and tailoring of the care 
bundle to the clinical needs of each participant. 
.  
Figure 2.3 Developing and evaluating complex interventions 
Figure  adapted from MRC 2008 guidelines (Council, 2008). 
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In the analysis of EGDT, given the complex nature of the care bundle and the degree of 
flexibility involved on an individual patient level, it is not possible to determine if one 
individual element of the care bundle was the cause of a good or negative outcomeInstead, 
the entire care bundle must be treated statistically as one intervention and the evaluation 
designed as such. Larger sample sizes are often required to ensure that all variability within 
the care bundle can be taken into consideration (Council, 2008; Campbell et al., 2000). 
Given the complexity in study design and analysis, pilot studies are recommended by the 
MRC guidelines, to ensure that issues of intervention delivery and acceptability are tested 
before larger studies planned (Figure 2.5) (Power et al., 2004; Eldridge et al., 2005). 
 
Randomised controlled trials provide the best methodology for evaluating EGDT, as parallel 
recruitment and delivery of the EGDT or the control hospital based care minimise allocation 
and observer biases (Oakley et al., 2006). The Consolidated Standard of Reporting of Trials 
(CONSORT) statement has been updated to account for complex interventions beyond 
pharmacological interventions (Boutron et al., 2008). In RCTs testing EGDT,  blinding is 
usually not possible due to the complex nature of the intervention, and neither the treating 
investigator nor the patient can be blinded (Oakley et al., 2006). Single site RCTs that recruit 
in parallel are therefore subject to the potential for cross-contamination between study 
teams;  delivery of EGDT to one patient and routine care to another by members of the 
same team means that it is difficult to determine if the ‘routine care’ was not influenced by 
the presence of the study team and surrounding education and resources (Eldridge et al., 
2005; Campbell et al., 2007). Cluster randomised trials are the ideal design for testing 
EGDT, as randomisation by centre rather than  patient ensures that all patients recruited to 
one centre can be managed in the same way and a true comparison between routine care 
and EGDT can be made, providing that the centres are equally matched for resources and 
patient attendance (Campbell et al., 2007). 
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Due to the cost and complexity of using RCTs to test EGDT, most studies of EGDT have 
been observational in nature, commonly in a before/after study design. This design enables 
the team to monitor routine care in the first defined time period, and then deliver the EGDT in 
the second time period, and  then make comparisons between the two groups. However this 
design is subject to many biases, including observer bias, allocation bias and confounding of 
the results over time by external changes within the study environment not controlled by the 
study team. The MRC does not recommend observational studies for evaluating complex 
interventions unless randomisation in a parallel design is not practical or feasible for local 
reasons (Council, 2008). However observational data to provide feasibility and pilot 
information before embarking on a RCT are recommended by the guidelines (Figure 2.5) 
(Council, 2008). The quality of evidence provided from observational studies of EGDT is 
weaker than those from RCTs, with the strongest evidence provided by cluster randomised 
RCTs (Campbell et al., 2007). 
 
2.6.3 Is EGDT effective? 
2.6.3.1 Sepsis 
EGDT has been most extensively tested in severe sepsis with shock (Rivers et al., 2001; El 
Solh et al., 2008; Levy et al., 2012; Nguyen et al., 2011; Wang et al., 2013; Yan, 2010; Yealy 
et al., 2014). A landmark trial published in 2001 described a significant reduction in mortality 
from sepsis with the use of EGDT compared to routine care. This study was performed in 
one large hospital over three years (Rivers et al., 2001), patients were randomised to receive 
either EGDT or routine care on admission to the emergency department. Mortality from 
severe sepsis was reported as 30.5% in the EGDT group, compared to 46.5% in the 
standard care group, a relative risk reduction in all patients of 0.58 (95% CI 0.39 – 0.87) 
(Rivers et al., 2001). The key protocol components in this study were early appropriate 
antibiotics and an aggressive fluid resuscitation strategy that included central venous 
pressure and venous blood lactate monitoring, with specific targets set for both CVP and 
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venous lactate measurements. In addition blood was given to target a haematocrit of >30% 
(Hb >10g/dL).  
 
The success of the study led, with the support of the Institute for Healthcare Improvement, a 
US based non-government organisation (www. http://www.ihi.org/Pages/default.aspx), to 
development of surviving sepsis guidelines, which were widely published and implemented 
in order to attempt to improve the management of sepsis world-wide (Dellinger et al., 2004). 
Given the success of the study, other centres attempted to replicate the results of the six 
hour resuscitation protocol with varying effect, most of these studies were observational 
before/after studies compared to randomised controlled trials (Barochia et al., 2010). A 
meta-analysis of data from these studies showed that early antibiotics and the overall use of 
a care bundle were associated with substantial mortality reduction; other care bundle 
elements were not individually assessed due to heterogeneity between the studies (Barochia 
et al., 2010) (Figure 2.6).  
 
Figure 2.4 Effect size of Early Goal Directed Therapy for sepsis 
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Forest plot of eight studies testing EGDT for sepsis. Rivers et al was a randomised controlled 
clinical trial, the others all before/after observational studies. Figure reproduced from Barochia 
2010. 
 
A separate review of bundled care for sepsis included 21 studies, and found again that six 
hour resuscitation bundles were effective in reducing mortality, and that 24 hour bundles 
were less effective than six hour bundles, but still resulted in mortality reduction over routine 
care (OR 1.646, 95% CI 1.036 - 2.614, p < 0.035)  (Chamberlain et al., 2011). This larger but 
statistically weaker meta-analysis included only results from observational studies and did 
not include data from the Rivers trial. Data from the other studies included in Barochia 2010, 
and additional smaller studies were included. As the data included are purely observational, 
the quality of the review and the conclusions drawn are limited (Chamberlain et al., 2011).  
Data for both meta-analyses were predominately from open label before/after studies, 
although Barochia and colleagues did include the Rivers 2001 trial data, and therefore 
definitive conclusions from these reviews are limited. Future meta-analyses that include data 
from newer EGDT parallel randomised controlled trials, of which there have been three 
published to date (Rivers et al., 2001; Yealy et al., 2014; Yan, 2010) are awaited.  
 
A RCT in China tested EGDT as a sepsis bundle in a parallel design against routine hospital 
care across eight hospitals. 303 patients with severe sepsis were included, the 28 day 
mortality rate was 24.8% in the EGDT group compared to 43.5% in the routine care group 
p=0.01 (Yan, 2010). This study is published in Chinese language only, no translation is 
available currently, so the quality of randomisation and detail of any biases cannot be fully 
assessed (Yan, 2010). 
In 2014, a large multicentre randomised trial throughout 30 hospitals in the USA was 
published that compared the Rivers protocol against either a less intensive EGDT protocol or 
standard hospital care (PROCESS trial)(Yealy et al., 2014). Overall case fatality rates were 
18-21% and did not differ between the three arms of the study, despite increased CVP 
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monitoring, fluid resuscitation and vaso-active agents and blood being given in the goal 
directed protocol arms. The Rivers protocol arm of the PROCESS trial had set targets based 
on central venous monitoring of lactate and venous oxygen saturation, the hospital sepsis 
protocol arm had more simplified targets based on monitoring of blood pressure response to 
intravenous fluids and inotropes delivered through a peripheral catheter, and routine care in 
the third arm was dictated by the treating physician. (Yealy et al., 2014). All hospitals 
enrolled in the study had to have used surviving sepsis guidelines in the past, but did not 
have hospital-specific protocols in place at the start of the study.  
When the Yealy and Rivers studies were compared, patients in the Rivers study were 
slightly older with more comorbidity, had lower central venous saturation measurements on 
admission, and may have had more persistent shock (Yealy et al., 2014; Rivers et al., 2001), 
but otherwise patients between the two studies were equally matched.  The authors 
speculate that the significantly reduced mortality across 13 years between the two studies 
may be due to overall improvements in recognition and management of patients with sepsis, 
particularly early recognition in the community and improvements made in intensive care 
with regards to critical organ support (Yealy et al., 2014). Results from two further 
randomised controlled trials of EGDT in sepsis are awaited ARISE NCT00975793, and 
ProMISE ISRCTN36307479.  
 
In summary, EGDT when tested in hospitals where it had not been previously used, appears 
to be highly effective in reducing mortality from sepsis, with the potential of national 
campaigns to improve clinical management resulting in influences on routine care and 
overall reduced mortality from sepsis since the original Rivers trial (Huang et al., 2013). The 
PROCESS study shows that in the USA, mortality from sepsis has reduced substantially 
over 10 years since the surviving sepsis campaign was introduced (Yealy et al., 2014). Data 
from further RCTs are awaited to see if these successes have been replicated in other 
settings, or if the impact of the SSG has led to overall improvements in sepsis management, 
without the need for further EGDT testing (Yealy et al., 2014). The success of EGDT for 
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sepsis has led to goal directed therapy strategy being used for other areas of medicine, 
including intensive care medicine and post-operative survival patients (see following 
section).  
 
2.6.3.2 Post-operative care 
The majority of patients undergoing surgery experience only minor complications (Cecconi et 
al., 2013). However for high risk patients, the post-operative period is associated with 
increased risk of complications including sepsis, shock and organ failure. The principles of 
EGDT, when applied to the fluid and oxygen management of these patients have been 
shown to improve outcome (Futier et al., 2010; Nisanevich et al., 2005). Subsequent 
systematic reviews have shown these benefits to be mainly limited to the very high risk 
patients, care bundles reducing both complications (OR 0.45, [95% CI 0.34 to 0.60]; 
p<0.00001) and death in high risk patients (OR 0.20, [95% CI 0.09 to 0.41]; p<0.0001) 
(Arulkumaran et al., 2014; Cecconi et al., 2013). 
 
2.6.3.3 Bundles used in Intensive Care Units (ICU) 
Clinical care bundles tested in intensive care unit include reduction of ventilator associated 
pneumonia (VAP) and catheter associated blood stream infections and tight glycaemic 
control, with an overall relative risk reduction of harm by 25% (Marwick and Davey, 2009). 
One interesting facet of these bundles, is that, in contrast to sepsis, where one protocol was 
has been used in different studies, several studies in VAP have tested different elements 
over time, and a consensus has been reached to include the most efficacious elements of 
the VAP bundles only (Wip and Napolitano, 2009).  Overall ICU bundles have met with 
considerable success in reducing complications in patients associated with prolonged ICU 
stay, with a number needed to treat between 3-11 for different ICU bundles (Marwick and 
Davey, 2009). From these studies a considerable literature has been generated on 
optimising compliance and sustainability of a care bundle once in use (Lipshutz et al., 2008; 
Levy et al., 2004; Noritomi et al., 2014; Rangachari et al., 2014).  
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2.6.3.4 Care bundles in other conditions 
The care bundle approach has been tested in a small number of studies in sub-arachnoid 
haemorrhage (Molyneux, 2006; Mutoh et al., 2007; Mutoh et al., 2009; Mutoh et al., 2014; 
Wartenberg and Mayer, 2006), in one study the proportion of patients with a mRS of zero at 
3 months was 52% in those who received the bundle versus 36% who received routine care; 
p=0.026 (Mutoh et al., 2014). Care bundles for kidney injury prevention are being trialled, no 
detailed data are available  (Ronco, 2004). A full discussion of the benefits and risks of these 
bundles is beyond the scope of this chapter, but given the expanding literature on the 
subject of goal directed therapy, particularly when improved outcomes and cost-efficacy are 
demonstrated, more bundles designed to improve clinical care are likely to be developed 
(Ebm et al., 2014). 
 
2.6.3.5 Quality improvement initiatives to ensure care bundle success and 
sustainability 
Care bundles now form part of quality improvement (QI) initiatives that have been taken on 
in many countries after the success of care bundles in improving outcomes. The success of 
a care bundle is dependent on the QI processes, and sustainability of care bundles amongst 
medical, nursing and ancillary staff within a hospital is required to ensure the high standards 
of care delivered by the bundle are maintained (Rangachari et al., 2014; Robb et al., 2010; 
Chamberlain et al., 2011). The body of evidence exploring reasons behind care bundle 
failures has grown to inform bundle implementation and success. QI initiatives revolve 
around the loop of PDSA, ‘Plan, Do, Study, Act’ (Lipshutz et al., 2008), where each stage is 
important to ensure that problems are identified early, and effective changes are made to 
sustain the initiative.  
 
One study examined issues around the implementation and sustainability of three different 
care bundles within one hospital, and found that nurse-led care bundles in critical care were 
sustained by both regular audit of and publicity about check list use for the four components 
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of the care bundle, and dissemination of data showing improving outcomes from the use of 
the bundle (Lipshutz et al., 2008). However the implementation in the same hospital of 
EGDT for sepsis was much more problematic with issues arising in both the nursing and 
medical teams relating to clinician autonomy and additional nursing burdens involved in the 
care bundle (Lipshutz et al., 2008).  
 
In a hospital in Brazil, QI initiatives and improved communication within the emergency 
department led to a substantial increase in adults with sepsis receiving bundled care, from 
13% to 62%, associated with decreased all cause hospital mortality and substantial cost 
savings (Noritomi et al., 2014). Care bundles to reduce central line infections have been 
shown to be effective, but problems have also been encountered in bundle implementation, 
particularly over agreement within a multidisciplinary team to adhere to a care bundle, and 
sustainability of adherence over time (Rangachari et al., 2014; Levy et al., 2004). Improved 
communication between the teams in ICU and PICU in one hospital led to increasing 
compliance with the bundle, a decrease in line infections and considerable estimated cost 
savings (Rangachari et al., 2014). 
 
Concerns have been raised about the feasibility of all the elements in the Rivers protocol 
(Levy et al., 2012), and full compliance with the bundle was found to be difficult in some 
studies (Levy et al., 2004; Otero et al., 2006). The surviving sepsis guidelines were revised 
to reflect this in 2013, with a divide in the timeframe for the goals, with antibiotic and fluid 
resuscitation to be completed within three hours, and targeted vasopressor treatment and 
oxygenation within six hours (Barochia et al., 2013; Dellinger et al., 2013).  
 
To implement and sustain a care bundle, several factors have been shown to be important: 
high quality planning involving all the entire multidisciplinary team, regular feedback and 
support, involving the whole team in discussions, celebrating successes and pilot testing 
with step-wise implementation (Lipshutz et al., 2008) (Levy et al., 2004; Noritomi et al., 2014; 
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Rangachari et al., 2014). The principles of QI for care bundles were taken forward and used 
to set up and sustain the care bundle tested in this study. 
 
2.6.3.6 Cost efficacy of care bundles 
Clinical care bundles have been primarily tested to examine efficacy in reducing serious 
outcomes such as death and disability. However, given the overall evidence of the benefit of 
this approach, data are now required to test if this approach is cost-effective. One study from 
Brazil, not only showed that a sepsis bundle reduced mortality from sepsis, but was 
associated with an estimated decreased cost of $11800 per patient treated with the bundle 
compared to routine care (mean difference -11,815; 95% CI -18,604 to -5,338) (Noritomi et 
al., 2014). Further data on cost-efficacy of care bundles are required. 
 
2.6.3.7 Care bundles in resource-limited settings 
Clinical care bundles have been well described and tested in resource rich hospitals in 
developed and emerging economies. However goal directed therapy has not been formally 
tested for sepsis in sub-Saharan Africa in either adults or children.  
A large, well conducted paediatric study of fluid resuscitation for unwell African children 
showed that fluid boluses compared to maintenance fluid therapy were associated with 
higher risk of death (Maitland et al., 2011a). This study did not formally test the clinical care 
bundle concept, but the mortality observed was lower than expected when the sample size 
calculation was done. Prior to randomisation, the study team introduced significant QI to the 
hospitals involved in the trial, including early antibiotics, prompt recognition of critical illness 
and triage of children according to degree of illness severity. An extrapolation of the lower 
mortality rates observed during the trial due to introduction of elements of sepsis care 
bundles is possible (Myburgh, 2011). It is therefore possible that the introduction of these QI 
processes into African hospitals may have an effect on mortality, formal testing is required.  
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EGDT for sepsis has been tested successfully in Asia and South America, in relatively well-
resourced hospitals (Kuan et al., 2013; Nguyen et al., 2011; Noritomi et al., 2014; Na et al., 
2012; Yan, 2010; Wang et al., 2013; Chen et al., 2008) (Table 2.2).  
Table 2.2 Early Goal Directed Therapy studies in emerging countries 
Studies of EGDT in emerging settings 
Study Location Trial 
design 
Intervention Outcome Statistically 
significant?  
p value 
Kuan 
2013 
Singapore Before/after Sepsis bundle 
compared to 
routine care 
2/18 deaths in the 
bundle group, 29/99 
deaths in the 
observational group 
0.15 
Nguyen 
2011 
8 centres in 
Asia 
(ATLAS) 
Before/after SSG bundle 
compared to 
modified SSG 
bundle with 
lactate clearance 
The ratio of the 
relative risk reduction 
in mortality with 
bundle = 1.94 (95% CI 
1.45 to 39.1) 
No p value 
given 
Na 2012 8 centres in 
Asia 
(ATLAS) 
Before/after Sepsis bundle 
compared to 
modified sepsis 
bundle 
27/193 (24.5%) 
deaths in ‘bundle 
completed’, 119/364 
(37.2%) deaths in 
bundle not completed 
group 
0.04 
Noritomi 
2014 
10 
hospitals in 
Brazil 
Before/after Sepsis bundle 
compared to 
routine care 
112/203 (55%) before 
group, 41/161 (26%) 
in full bundle 
compliance group 
<0.001 
2010 8 hospitals 
in China 
Multicentre 
RCT  
Sepsis bundle 
compared to 
routine care 
Routine hospital care 
mortality rate 42.5%, 
sepsis bundle 
mortality rate 24.8% 
<0.01 
Wang 
2013 
China Before/after 
single site, 
ICU care 
Sepsis bundle 
compared to 
routine care 
Before group mortality 
44.8%, after group 
mortality 31.6% 
P<0.05 
Chen 
2008 
China Before/after 
single site, 
ICU care 
Sepsis bundle 
compared to 
routine care 
Before group mortality 
72.5%, after group 
55.1% 
P=0.01 
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However there is substantial heterogeneity between these studies and the quality of the data 
is variable. Using EGDT to improve survival is highly applicable to resource limited hospitals. 
In 2001, the Department of Paediatrics in Queen Elizabeth Central Hospital (QECH) 
developed Emergency Triage and Treatment (ETAT) in their clinic to prioritise the care of 
sick children, and have shown an overall reduction in mortality amongst emergency 
admissions from 18% to 9% (Molyneux et al., 2006). Rapid recognition and management of 
acute illness in adults is part of the 2004 WHO guidelines on the management of unwell 
adults in resource limited settings ‘Integrated management of adolescent and adult illnesses’ 
(WHO, 2004). Although neither EGDT nor ETAT are specifically mentioned in this 
publication, the principles that underline both of these methodologies are recommended in 
the guidelines. 
No formal trials of any element of goal directed therapy for sepsis in adults have been done 
to date in sub-Saharan Africa. A team in Uganda compared two cohorts of patients, three 
years apart, who had different volumes of fluid given, and extrapolated that mortality 
differences between the two cohorts were due in part to the increased volumes of fluids 
given to the later cohort (Jacob et al., 2012). However this observational study was subject 
to several biases in data capture, particularly due to the time differences between the two 
cohorts, and as such the conclusion that increased fluid administration for sepsis improves 
mortality cannot be supported by the data presented.  
 
This group are now planning a clinical trial testing a fluid resuscitation strategy with or 
without dopamine for sepsis within the context of a randomised controlled trial, although they 
are not formally testing EGDT within that trial entitled ‘Adaptive Randomization Trial of Early 
Management Interventions for Sepsis in Uganda (ARTEMIS-Uganda)’. This trial is not 
cluster randomised, but randomised on an individual level across four centres, which leaves 
the study team again open to allocation bias and potential contamination between the two 
groups by members of the study team. Another trial is planned in Zambia and Zimbabwe, 
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also testing fluid resuscitation strategies with the addition of vasopressor support, this trial 
has also yet to start recruitment, and the group’s early data have yet to be published. These 
trials have yet to be registered on the clinical trial registries. 
 
2.7 What evidence is there to use EGDT for bacterial meningitis?  
As discussed in Section 2.2.4, several interventions have been tested for bacterial meningitis 
in adults and children. However the clinical care bundle concept has not been tested formally 
for meningitis in either group. As an acute, severe infection, with critical time pressure, 
bacterial meningitis is potentially an ideal disease to utilise the delivery of optimised clinical 
care in the form of goal directed therapy. The sepsis bundle approach has been used for 
children with meningococcal septicaemia (Kjaergaard et al., 2006), and a care bundle has 
been developed by neurosurgeons to reduce the incidence of meningitis in patients with 
ventricular drains in-situ (Leverstein-van Hall et al., 2010), but has not been tested 
prospectively to determine if this approach is safe or feasible for bacterial meningitis in 
adults.  
 
Applying EGDT to bacterial meningitis in Africa 
Given the success with which EGDT has reduced mortality and improved clinical care for 
sepsis in resource-rich settings, applying this approach to a critical illness in a profoundly 
resource limited environment should be appropriate.  EGDT is associated with cost savings 
and is dependent upon nurse-led care (Lipshutz et al., 2008; Barochia et al., 2010; Tromp et 
al., 2010), two factors which support testing feasibility and efficacy of EGDT in a profoundly 
resource-limited hospital environment in Africa. 
 
Acute bacterial meningitis is a condition where early recognition and treatment is deemed 
essential to optimise outcome (Heyderman, 2005; Prasad et al., 2004; Harnden et al., 2006; 
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Auburtin et al., 2006; Fitch and van de Beek, 2007; Gjini et al., 2006a), and therefore 
potentially an ideal condition to test EGDT. 
The evidence behind each intervention chosen for inclusion in the care bundle is discussed 
in the following section. 
 
2.8 What evidence exists to support the individual elements of the care bundle 
in BAM? 
All elements of the bundle have strong evidence to support their use in ABM, and are based 
on the surviving sepsis guidelines (Dellinger et al., 2008b; Dellinger et al., 2013). All have 
been adapted to be feasible in a low income setting. The surviving sepsis guidelines were 
used as a backbone to design the care bundle, as they are the most well evidence-based 
guidelines for care bundles in critical illness available. The UK meningitis treatment 
guidelines were also used (Heyderman et al., 2003). The care bundle elements were based 
around the ABCDE approach to resuscitation, advocated by the UK and US resuscitation 
council guidelines (Council, 2010). 
 
2.8.1 Airway and Oxygenation 
Airway management has been shown to reduce the risk of airway obstruction in coma 
(Foundation, 2000; Roberts et al., 2005; Stocker and Biro, 2005), and is essential for a 
patient with seizures who is at risk of airway obstruction (Roberts et al., 2005). However 
endotracheal-tubes and formal airway protection require the patient to be sedated and 
ventilated, such facilities are essentially unavailable in Malawi where access to intensive 
care is severely limited (Branson et al., 2014; Stocker and Biro, 2005). Naso-pharyngeal 
airways are the safest option where invasive ventilation is not available, as this allows 
supports the airway to allow  oxygen can pass, although no protection against aspiration is 
offered (Roberts et al., 2005).  
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Cerebral oxygenation and perfusion are essential in ABM (Moller et al., 2002). Oxygen 
saturations of less than 93% on univariate analysis were shown to be associated with an 
increased risk of death in an analysis of mortality from meningitis in Malawi (Wall et al., 
2013c). Patients with ABM may have lower cerebral oxygen metabolism compared to 
controls (Moller et al., 2002), and adequate oxygen delivery to the brain is critical if 
intracranial pressure is increased (Glimaker et al., 2014). Oxygen delivery to tissues in 
critically ill patients has been shown to decrease significantly when the haemoglobin is 
<7g/dL, and transfusion to a haematocrit of >30% forms a component of the surviving sepsis 
guidelines (Shander, 2004; Dellinger et al., 2008a). Oxygen was only available in QECH via 
concentrators that take ambient air and concentrate the oxygen to a maximum 28%. All 
patients who had hypoxaemia were given oxygen via a concentrator and nasal prongs rather 
than facemask oxygen, due to resource limitations. Where a nasopharyngeal airway was 
required, the nasal prongs were inserted into the airway to deliver oxygen. 
 
The WHO guidelines on blood transfusion state that a transfusion should be given when 
tissue hypoxia is compromised by anaemia (WHO, 2009). Blood was not independently 
provided for the study, and the team were dependent on hospital supplies, which were often 
critically low. Therefore we could only justify the use of blood acutely in this study when the 
patients met the in-hospital criteria for adult transfusion (<5-6g/dL). 
 
2.8.2 Intracranial pressure management 
Extensive studies have attempted to manage the raised intracranial pressure associated 
with bacterial meningitis using either lumbar drains or intra-ventricular drains (Murad et al., 
2008; Glimaker et al., 2014; Abulhasan et al., 2013). Repeat lumbar punctures have been 
used successfully in cryptococcal meningitis where a clear relationship between raised CSF 
pressure and outcome have been documented, with improvements in pressure and possibly 
outcome by serial LP (Wijewardana et al., 2011; Bicanic et al., 2009). However this 
approach has not been tested in bacterial meningitis and other approaches to the 
94 
 
management of raised intracranial pressure are not suitable for resource limited hospitals 
without access to both critical care and an experienced neurosurgeon (Murad et al., 2008; 
Abulhasan et al., 2013). In addition, serial lumbar punctures would require ongoing clinical 
ward management and as such would not be suitable for inclusion in an acute clinical care 
bundle.  
In the literature from sub-arachnoid haemorrhages (SAH) and brain trauma, a 30°C head tilt 
has been shown to optimise perfusion and minimise oedema in brain injury (Molyneux, 
2006). As SAH is also a condition with acute inflammation with the sub-arachnoid space, 
parallels between the effects of SAH and ABM on raised intracranial pressure can be drawn. 
This simple intervention of a head tilt was adapted and applied to all patients in BAM with a 
GCS <11. Intracranial pressure monitoring to test the efficacy of the head tilt was not 
available. 
 
2.8.3 Tissue perfusion 
Fluid resuscitation in ABM is more controversial, as no RCTs have been performed to test 
different resuscitation strategies. Fluid restriction in children was originally thought to be a 
useful treatment in paediatric meningitis, as the syndrome of inappropriate anti-diuretic 
hormone (SIADH) was a recognised consequence of ABM, and associated with poor 
outcome (Mendoza, 1976). Studies testing fluid restriction in ABM showed this strategy is 
associated with harm in meningitis (Duke et al., 2002), and for children, parenteral fluids 
treatment to maintain euvolaemia are currently advocated (Maconochie et al., 2008; Oates-
Whitehead et al., 2005). Extensive data shows that initial aggressive resuscitation in adult 
sepsis is associated with survival (Dellinger et al., 2008a). However, bolus resuscitation was 
harmful for children with shock in East Africa compared to maintenance fluid treatment 
(Maitland et al., 2011a). This study included children with both malaria and sepsis, very few 
children with meningitis were included, and no sub-analysis of fluid treatment and meningitis 
was done. Policies on fluid resuscitation for shocked children have been extensively re-
considered following this trial. 
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No consensus exists regarding fluid resuscitation in adults with meningitis. UK guidelines 
state that resuscitation should be given if the patient is shocked, but this statement is backed 
with little data (Heyderman et al., 2003). Therefore if adults met the surviving sepsis 
guidelines criteria for clinical shock, they were resuscitated with fluid as per the surviving 
sepsis guidelines, but if no clinical evidence of shock was seen, the patient received 
maintenance IV fluids at 125ml/hour for the duration of the intervention 
 
2.8.4 Early Antibiotics 
Early antibiotics in meningitis have been shown to have a significant association with 
survival in several studies, when given by community practitioners pre-hospital, or rapidly in-
hospital (Harnden et al., 2006; Auburtin et al., 2006; Durand et al., 1993; Koster-Rasmussen 
et al., 2008). However, no randomised clinical trials of delayed versus rapid treatment have 
been done as this has been considered unethical; all data are observational and hence 
subject to bias (Radetsky, 1992). . A delay of >3 hours from hospital admission to parenteral 
antibiotics was detrimental in pneumococcal meningitis (Auburtin et al., 2006). In another 
study in Denmark, delay to in-hospital antibiotics and poor outcome were even more closely 
linked, with time to antibiotics of > two hours independently associated with poor outcome 
(Koster-Rasmussen et al., 2008). The evidenced based recommendation from the surviving 
sepsis guidelines, and included in the majority of trial protocols included within those 
guidelines, is for parenteral antibiotics to be delivered within one hour from admission to the 
emergency department (Dellinger et al., 2008b; Dellinger et al., 2013). From these data a 
target of one hour from admission to parenteral antibiotics was set in the Adult Emergency 
and Trauma Centre at Queen Elizabeth Central Hospital in Blantyre, with the expectation 
that in attempting to meet this target, all patients would receive antibiotics within two hours.  
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2.8.5 Summary 
Adult patients with bacterial meningitis in Malawi have important differences to patients 
presenting with ABM elsewhere, and predictors of mortality in this setting are different. 
Interventions designed in resource- rich countries have been ineffective in reducing mortality 
from ABM in Malawi. Improvement in in-hospital care, particularly access to early disease 
recognition and parenteral antibiotic therapy has impacted on mortality from ABM elsewhere.  
Early Goal Directed Therapy offers a well validated methodology to introduce rapid disease 
recognition and targeted treatment protocols to the treatment of ABM in Malawi. The 
methodology for the trial testing this approach in Queen Elizabeth Central Hospital are found 
in Chapter 3 Section 3.4, and the results in Chapter 6 Section 6.3.4. 
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3 Patients, Materials and Methods 
 
3.0  General methodology 
3.0.1 Introduction 
The clinical burden and mortality rates from bacterial meningitis are substantially higher in 
sub-Saharan Africa compared to Europe. In the last 10 years, numerous public health 
interventions such as the roll out of ART and co-trimoxazole prophylaxis, intensification of 
malaria control, improvements in child nutrition have been introduced into Malawi that have 
been associated with considerable improvements in under-5 childhood mortality and 
substantial decreases in the mortality rate of HIV-infected adults. However, it is less certain 
how these interventions have impacted on the burden and mortality rates of ABM in adults. 
In addition, two adjunctive interventions (dexamethasone and glycerol) that have 
demonstrated efficacy in reducing mortality and morbidity from acute bacterial meningitis 
(ABM) in other settings have been ineffective in Malawian adults with ABM, the Steroids for 
Adult Meningitis (SAM) and Glycerol for Adult Meningitis (GLAM) trials (Scarborough et al., 
2007; Ajdukiewicz et al., 2011).  It is unclear why these trials failed to show benefit. A better 
understanding the of the disease burden and causes of high mortality was required before 
embarking on the design of any further clinical interventions to reduce mortality, including the 
intervention tested in this thesis.  
 
Firstly, two analyses of historical meningitis surveillance and clinical data from MLW were 
undertaken, to understand better the disease epidemiology and clinical phenotype ABM in 
adults in Malawi. The first analysis was designed to examine epidemiological trends in 
bacterial meningitis in adults and children using laboratory surveillance data, and the second 
to identify clinical markers of poor prognosis in adults using data from all clinical trials where 
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adults with bacterial meningitis had been recruited. Details for the specific statistical methods 
and research questions can be found in Chapter 4 Section 4.4.2. 
Secondly, these data were then taken forward to synthesise a clinical scoring system to 
attempt to predict outcome from ABM in adults in Malawi, the detailed methodology for this 
can be found in Chapter 5 Section 5.2.  
Data generated from these analyses were used to inform the design and analysis of the 
clinical trial of early goal directed therapy for adult meningitis that is the focus of this PhD 
thesis, of which the detailed methods can be found in this Chapter, Section 3.4.  
The results from the data generated by the clinical trial were used to examine for predictors 
of poor survival versus healthy survival in the BAM cohort patients and compared to the 
mortality predictors in the historical cohort. In addition real-time PCR was used to detect 
causes of culture negative meningitis and bacterial and viral co-infection loads were 
estimated using this technology. The specific methods for this are in this chapter, Section 
3.1. 
 
Methods used across these different chapters including definitions of bacterial meningitis 
cases, database creation, laboratory and statistical methods are discussed in Section 3,0.2 
and 3.1-2. Specific methods for the early goal directed therapy trial are discussed in in 
Section 3.4. 
 
3.0.2  Cross-chapter Bacterial meningitis methodology 
3.0.2.1 Definitions of bacterial meningitis and generic inclusion and exclusion criteria 
Bacterial meningitis is defined as either the presence of a bacteria known to cause 
meningitis in the CSF on stain, bacterial culture or DNA detected by PCR, or evidence of 
severe inflammation in the CSF including an elevated WCC of over 100 cells/mm3 with a 
marked neutrophilia (>50%) in the presence of a presenting clinical phenotype (Brouwer et 
al., 2012). HIV infection may substantially alter the CSF WCC response in bacterial 
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meningitis, and classical cut off of >100cells/mm3 may not be accurate for HIV infected 
adults (Jarvis et al., 2010). Where CSF chemistry is available, in the presence of an elevated 
CSF WCC and presenting clinical phenotype, a CSF protein of >0.5 g/L and a CSF:Blood 
glucose ratio of <0.4 are considered to be indicative of bacterial meningitis (van de Beek et 
al., 2004; Tamune et al., 2013; White et al., 2012). In this thesis, cases of bacterial 
meningitis where an organism was found to be present on Gram’s stain, culture or PCR 
were defined as ‘proven’ cases, and cases where bacterial meningitis was highly likely with a 
clinical presentation and typical CSF findings in the absence of a proven bacterial pathogen 
were defined as ‘probable’ cases. The CSF WCC is critical in determining the probability of 
bacterial meningitis in probable cases, where the WCC is not sufficiently elevated or is 
represented by predominately lymphocytes and no prior antibiotics have been given, the 
chances of the meningitis being caused by another pathogen are significant (White et al., 
2012). The CSF WCC cut off to determine probable cases for the historical clinical cases 
and the BAM study differed slightly. The specific case definitions and reasons for choosing 
that definition for each study are therefore included in the methods section for that chapter.  
 
3.0.2.2 Patients and hospital setting 
Queen Elizabeth Central Hospital is a tertiary referral hospital for Southern Malawi, and the 
District General Hospital for Blantyre city. The hospital serves a population of approximately 
1 million people, and an estimated 10-12 000 adults are admitted to medicine each year 
(Sanjoaquin et al., 2013). Patients over the age of 14 years are admitted to the adult wards, 
and therefore considered as adolescent adults for the purposes of this thesis. Prior to 2011, 
all admissions to adult medicine were screened and triaged in an area of the outpatient 
department of the hospital called Room 6, where they were given an initial diagnosis. 
Patients to be admitted were then transferred to a medical admissions ward called 4B where 
they were seen by a nurse and clinician and treatment was initiated (Figure 3.1). All patients 
with bacterial meningitis included in the historical data 2000-2011 were admitted to QECH 
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through this system. Patients admitted after November 2011 were assessed in the Adult 
Emergency and Trauma Centre (AETC) where they were reviewed by emergency-trained 
clinicians and nurses and given treatment prior to transfer to the medical wards. Further 
methodological explanation of this system is given in Section 2. 
3a      3b 
 
Figure 3.1 Comparison of old and new QECH admission areas 
3a: Waiting area and Room 6 clinic rooms. 3b: Entrance to AETC 
Once admitted to an adult medical ward, all patients were assigned a bed space, which may 
have been either an actual bed or mattress on the floor in the ward or corridor, depending on 
the number of admitted patients. Two to three nurses were commonly available on shift to 
nurse up to 100 patients at any one time, and therefore all patients required an attending 
guardian to assist with their needs. Guardians were commonly close family members and 
provide services not performed by the nurses including giving food and water, changing 
dressings, toileting, cleaning and other care needs (Hoffman et al., 2012). Guardians were 
also commonly asked if they felt able to provide informed consent for entry into clinical 
studies where the patient was not able to give consent for medical reasons such as altered 
Glasgow coma score (Section 3.3.10). Therapeutic drug supplies were often erratic on the 
medical wards and the medical and nurses work in a profoundly resource constrained 
environment with limited access to basic necessities such as clean running water, hand 
soap, intravenous fluids amongst others. Conditions on the medical wards did not change 
substantially during the period studied (2000-2013). 
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3.1 General Sampling & Laboratory methods 
 
3.1.1 Sample collection and storage 
Since 2000, all adults (14-years or older) and children presenting to QECH with a clinical 
suspicion of meningitis have routinely undergone lumbar puncture (LP) (Everett et al., 2011). 
Diagnostic CSF was obtained by LP, a procedure where a needle is passed through the skin 
and subcutaneous tissues into the CSF space between the vertebral bodies, usually at the 
L4 space (Kneen et al., 2002). The CSF was drained into a sterile container and where 
possible transported immediately to the laboratory. Where CSF was taken at night, the 
sample was stored at room temperature until analysis the following morning. 
 
Clinical indications for LP did not change in the hospital between 2000 to the present time. 
Clinical studies at QECH recruited patients who had undergone a clinically required LP, and 
whose CSF WCC met specific inclusion criteria.  
 
3.1.2 Microbiology 
All diagnostic testing at the MLW Clinical Research Programme laboratory was quality 
controlled as part of internationally recognised quality control programmes. A Gram’s stain 
was performed if CSF white cell count (WCC) was >10/mm3; India ink stain was performed 
on all adult CSF samples. Samples were cultured on sheep blood and chocolate agar for 48 
hours under aerobic and microaerophilic conditions. Bacteria and fungi were identified using 
standard methods (Barrow and Feltham, 1993). Antibiotic susceptibilities of all bacterial 
isolates were determined by the disc diffusion method (Oxoid, UK) using standard guidelines 
(2001). CSF biochemistry was determined using a Beckman Coulter CX5 Synchron Pro 
analyser (Beckman Dickinson USA) from 2009 onwards. 
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3.1.3 Molecular diagnostics 
Molecular diagnostic methods including PCR, pneumococcal antigen screening and CSF 
lactate were not available routinely for the diagnosis of ABM. These methods were used 
during the BAM trial in a sub-set of included patients, results are found in Chapters 6 Section 
6.3.2 and 7 Section 7.3.1-2 
Routine CSF Cryptococcal Antigen (CrAg) testing using latex agglutination strips (IMMY, 
USA) became available during 2013, funded by a cryptococcal meningitis clinical trial, ACTA 
ISRCTN45035509 http://www.sgul.ac.uk/research/centres/ii/projects/cryptococcal-
meningitis-group/clinical-trials-in-progress.  
 
3.1.3.1 DNA extraction for PCR 
To extract bacterial DNA and viral DNA and RNA, the following protocol was followed using 
standard pneumococcal extraction methodology (Corless et al., 2001; Greiner et al., 2001). 
CSF stored at -80°C was thawed (no additional preservatives were used). 100-200μl of CSF 
was removed from each sample depending on the volume of CSF available, and subjected 
to a lysozyme-buffer digestion protocol to break down the thick encapsulated pneumococcal 
wall. 180ul of digestion buffer was used per sample. The buffer consisted of 20mM Tris.HCl 
pH 8.0, 2mM EDTA, 1.2% Triton-X-100, 100ul of 10x lysozyme and 10ul of 10x lysostaphin 
(obtained from Sigma Aldrich USA) (Greiner et al., 2001; Rello et al., 2009). The sample was 
incubated for 30 minutes at 37°C, and then 40ul of Proteinase K and 200ul of 100% ethanol 
were added. The sample was then incubated for 1 hour at 56°C. DNA was extracted 
manually using Qiagen mini-blood and tissue kits (Qiagen, Germany) following the 
manufacturer’s protocol as follows: 
1) Add 200μl ethanol to each sample and mix 
2) Pipet the mixture including any precipitate into the DNeasy Mini spin column, placed 
in a 2ml collection tube. 
3) Centrifuge at 6000g/8000 RPM for 1 minute. Discard flow through and collection tube 
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4) Place the DNeasy mini spin column in a new 2ml collection tube. 
5) Add 500μl of buffer AW2 
6) Centrifuge for 3 minutes at 20000g or 14000 RPM. Discard flow through and 
collection tube 
7) Place DNeasy mini spin colum in a clean 1.5ml or 2ml microcentrifuge tube 
8) Pipet 200 μl buffer AE directly onto the DNeasy membrane 
9) Incubate at room temperature for 1 min and then centrifuge at >6000g (8000RPM) 
for 1 minute to elute. 
10) Repeat elution step 6-8 to maximise DNA yield. 
 
 Extracts for bacterial PCR were stored at -80°C until PCR could be performed. 
 
3.1.3.2 Methods for Real-Time PCR 
Real-Time PCR (RT-PCR) was performed on all samples and controls using the Viaa7 Real-
Time PCR system (Applied Biosystems, USA). Primers and probes for RT-PCR were 
supplied in diagnostic kits from Fast Track Diagnostics (FTD) for bacterial and viral 
meningitis (Table 3.1). Samples were thawed and the PCR plate set up. The reaction 
mixture consisted of primer/probe mix for the pathogens tested per kit (either SpN, NM and 
Hib or CMV and EBV), buffer (Life Technologies) and AgPath-ID enzyme (Life technologies) 
and was set up as follows. The complete protocol can be downloaded from FTD at 
http://www.fast-trackdiagnostics.com/ 
 
1. Take a 96 well plate which is compatible with the Viaa7. 
2. Pipette 15 μl of the BacMeng PP with the “2xRT PCR buffer” and the “25x 
RT-PCR enzyme mix” in the wells.  
3. Add 10 μl of the extracted samples, the extracted negative control and the 
positive control (which is not extracted). 
4. Each run must include a negative and a positive control 
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5. Mix briefly by pipetting up and down. 
6. Close the plate with the ABI optical adhesive film.  
7. Centrifuge briefly at 4000 RPM for 1 minute. 
8. Put the plate in the Viaa7 with the correct wells identified on the Viaa7 
software for each sample. 
9. Set up the PCR programme for the following:  
50°C for 15 minutes hold 
95°C for 10 minutes hold 
40 cycles of: 95°C for 8 sec alternating with 60°C for 34 sec. 
 
The number of wells used was calculated for each sample to be run in duplicate for each 
multiplex kit tested. Therefore four wells per sample were used, two for the bacterial 
meningitis kit and two for the EBV/CMV kit. All samples were duplicated so that the mean of 
Ct values and copy numbers could be used. 
 
The multiplex PCR kits tested for the following pathogens in individual kits: Bacterial 
meningitis (Hib, N. meningitidis, S. pneumoniae), viral meningitis (EBV, CMV). Cycle 
threshold (Ct) values were determined from the PCR reaction for each sample. Ct values of 
>38 were discarded and deemed non-significant. Only results where a true exponential 
curve with a Ct value of <38 were included as true results ( 
Figure 3.2). This was because a Ct value above this threshold indicates the copy number is 
<10 copies/ml of CSF, at which point the sensitivity of the assay is significantly reduced and 
the result is not reliable (Greiner et al., 2001). 
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Figure 3.2 Example of exponential curves for Real-Time PCR 
Cycle Threshold line shown as the horizontal green line. Exponential lines represent individual 
samples. 
 
Positive and negative controls supplied in the kits by FTD were run with each plate. Positive 
internal controls consisted of Streptococcus suis DNA, to a predetermined Ct value of 33, 
the material in the negative controls was not released by FTD. Negative controls were 
extracted with the samples to test the integrity of the extraction procedure; positive controls 
to test the integrity of each reaction were added to the lysis buffer for each sample. Where 
doubt existed over the validity of the results, the sample was re-extracted with a new 
negative control. The estimated bacterial loads, expressed in copies/ml, were extrapolated 
from the Ct values denoted by the positive control following pathogen specific calculations 
provided by FTD (Table 3.1). Viral quantification was done by estimations based on the 
Cycle threshold (Ct) value compared against a standard curve of known quantification 
standards provided by FTD in each kit (Kelly et al., 2012). 
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Table 3.1 Targets for multiplex Real-Time PCR 
Gene targets and quantification methods provided by FTD.  
X denotes the final copy number, y denotes the Ct value measured in the sample. 
Pathogen Gene target Quantification formula 
N. meningitidis ctrA X=e ((y-43.424)/-1.433) 
S. pneumoniae LytA X=e ((y-44.054)/-1.429) 
H. influenza oompP2 X=e ((y-45.995)/1.491) 
Epstein Barr Virus Proprietary information from 
FTD not supplied 
Via standard curves 
Cytomegalovirus Proprietary information from 
FTD not supplied 
Via standard curves 
 
 
3.1.4 Sample storage  
a) Patient samples 
All diagnostic CSF taken for historical patients enrolled in clinical research was rapidly 
centrifuged, a CSF WCC was done on the pellet, and biochemistry testing performed on the 
supernatant. Remaining CSF supernatant from samples that met the initial CSF WCC 
inclusion criteria for the diagnosis of bacterial meningitis, taken in working hours for  
research studies was immediately frozen at -80°C (Scarborough et al., 2007; Ajdukiewicz et 
al., 2011). BAM CSF samples for research were taken by the research team in a separate 
container and frozen whole at -80°C immediately, irrespective of CSF WCC. When full CSF 
results were available and an inclusion/exclusion decision had been made, samples from 
patients who were excluded were discarded. 
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b) Microbiological isolates 
All culture positive CSF isolates of bacteria of interest to ongoing surveillance work were 
beaded on glycerol [REF] and stored at -80°C as part of the MLW microbiology surveillance 
programme from 2001.  
  
3.2 General Data Management and Statistical methods  
3.2.1 Data Management Methods  
3.2.1.1 Laboratory database 
All culture positive isolates were logged by date, isolate and patient sex and age. These data 
were logged in laboratory books, and entered manually into a computer spreadsheet for 
analysis between 2000-2010. In 2010, the Laboratory Information Management System 
(LIMS) was introduced to the MLW laboratory, replacing the paper system with an electronic 
sample management system. These electronic data were imported directly from the 
laboratory system to the MLW data department in an Excel spreadsheet (Microsoft Office 
2007). The data from the manual and electronic databases were merged prior to analysis. 
Details of the data cleaning process can be found in Chapter 4, Section 4.4.2. 
 
3.2.1.2 Clinical database 
All clinical trials and observational studies (published and unpublished) undertaken at the 
Department of Medicine, College of Medicine, QECH between 1990-to the current time, 
where adults with ABM were recruited prospectively and data were freely available were 
identified. Published studies were found using an online literature search of the medical 
literature database PubMed from the National Institute of Health in the United States. Un-
published studies were identified by consultation with the previous and current MLW 
directors, Professors Malcolm Molyneux and Rob Heyderman, and with consultation of the 
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heads of the Department of Medicine, Professors Ed Zijlstra and Theresa Allain. Free 
access for each study database was obtained from the principal investigator of the individual 
study included. Selected variables were standardised with matching names, and re-coded 
for unification. Data from these variables were then merged from each individual database 
into a single database with the help of Philip Gichiru, statistician at LSTM using IBM SPSS 
version 17 for Windows. The clinical database was cleaned, removing cases where no 
mortality data at day 10 or day 40 were available. Further cases that did not meet the criteria 
for the diagnosis of bacterial meningitis (CSF WCC >100 cells/mm3 in HIV negative, or >5 
cells/mm3 in HIV positive, or proven evidence of ABM). Details of the full inclusion criteria for 
this database can be found in Chapter 4, Section 4.4.2. The database was cross-checked for 
coding errors using basic frequency analysis, and missing data identified. Where possible, 
the contributing clinician was contacted for details on coding and missing data.  
   
3.2.2 Epidemiology of bacterial meningitis 
The laboratory database was cleaned, removing duplicate cases and all cases whose isolate 
was not consistent with bacterial meningitis. A separate database was kept of all culture 
negative samples. The database was first interrogated for pathogen seasonality, incidence. 
All isolates were then divided into age groups, the incidence, trends and frequency of each 
pathogen over time per age group were calculated. Detailed methods including data 
cleaning can be found in Chapter 4, Section 4.2.2. All analysis was undertaken using Stata 
version 10 (Statcorp USA), tables and charts were generated using Microsoft Excel.  
3.2.3 Predictors of poor outcome using logistic regression 
The clinical database was interrogated using univariate and multivariate logistic regression 
to test for variables that independently predicted poor outcome at 10 days and 40 days post 
admission with bacterial meningitis. Data were analysed using IBM SPSS/PASW version 17-
20. For continuous variables, parametric (Student t) and non-parametric (Mann-Whitney U) 
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tests were used to compare survivors and non-survivors; Fisher exact / chi-square tests 
were used to compare categorical variables. Backwards stepwise logistic regression 
methods were used to estimate the influence of different variables on clinical outcome; each 
model was compared at each step with the previous model and only variables that remained 
significant at the 90% level were retained in the analysis for the next step. The first analysis 
plan denoted that only variables reaching statistical significance at or greater than the 95% 
level univariately were to be included in multivariate analyses. However variables that were 
predicted to be significant from previously published data that were found to be non-
significant on univariate analysis were subsequently included in the multivariate analysis to 
test the strength of the negative association. The strength of relationships was expressed 
using odds ratios with 95% confidence intervals. All statistical tests were two-tailed, and a p 
value of <0.05 was used to denote statistical significance. 
This approach was used to analyse the data from the historical clinical database (Chapter 4), 
to synthesise the predictive outcome score (Chapter 5), to compare data in Phase 1 and 
Phase 2 of BAM (Chapter 6) and to identify predictors or poor survival outcomes from BAM 
(Chapter 7). Selection methods for the variables used in the multivariate models for each 
chapter can be found in the relevant methods sections of those chapters. 
 
3.2.4 Statistical methods for specific chapters 
a) Derivation and validation of a score to predict poor outcome from bacterial 
meningitis 
The clinical database was divided randomly into separate derivation and validation cohorts. 
The BAM Phase 1 data was added to the validation cohort to obtain a case ratio of 2:1 
between the two cohorts. The severity score was derived first by using methods detailed in 
section 1.4.3 to determine predictors of poor outcome using logistic regression. Variables 
were then put forward into a nomogram to calculate a total score with a predictive index. The 
Nomogram was then applied to the validation cohort and sensitivity and specificity, plus 
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predictive index of the nomogram was calculated. Detailed methods are available in Chapter 
5, Section 5.2. 
   
b) Methods to analyse the BAM study before/after design 
Standard approaches to clinical trial analysis were applied to the BAM data to compare 
Phase 1 and Phase 2 data for each endpoint. These include Kaplan-Meier curves, Fisher’s 
exact and Chi square tests, logistic regression and composite analysis of individual elements 
of the clinical care bundle to test for the proportion of targets achieved. Full statistical 
methods are detailed in this Chapter, Section 3.3.12.  
 
3.3 Ethical approvals for studies on human subjects 
3.3.1 Ethical approval for historical data analysis 
Data collection for surveillance at QECH by MLW was approved by the College of Medicine, 
University of Malawi, Research and Ethics committee (COMREC) in 2000. All constituent 
studies for the mortality analysis had been approved by COMREC and by the Liverpool 
School of Tropical Medicine (LSTM) Research Ethics committee and conformed to 
institutional guidelines. All participants in the included clinical trials and studies gave written 
informed consent, or this was given by a named guardian if the participant was under 18 
years of age. No additional ethical approval was required for all historical analyses including 
the synthesis of the meningitis severity score. 
 
3.3.2 Ethical approval for the BAM study 
Ethical approval for the main clinical study (BAM) and the sub-studies tested in this PhD 
thesis was granted by LSTM Research Ethics committee (approval number 10.70), and 
COMREC approval number P.09/10/980. The laboratory analyses of the BAM data were 
approved under the umbrella approval of the BAM trial.  
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3.4 Methods for the prospective non-randomised clinical trial testing a clinical 
care bundle for adult meningitis in Malawi (BAM study). 
3.3.2 Introduction 
Goal directed therapy combines a set of clinical interventions, each with a clinical evidence 
base, and delivered as a protocolised package of care (Rivers et al., 2001; Dellinger et al., 
2013). The evidence behind goal directed therapy for sepsis demonstrates that the effect 
size of the care bundle is greater than predicted from the evidence behind the individual 
interventions (Barochia et al., 2010). In this section the methodology for this study testing a 
clinical care bundle for meningitis will be outlined. In addition the study design and ethical 
considerations related to study design and informed consent in emergency evidence based 
clinical intervention studies will be discussed. 
 
3.3.3 Objectives and research question 
Research questions 
1. Is the delivery of a clinical care bundle of resuscitation over a 6 hour time period for adults 
with suspected bacterial meningitis feasible and safe in a central teaching hospital in 
Malawi?  
2. Can early goal directed therapy impact on mortality and neurological morbidity from adult 
bacterial meningitis in Malawi? 
 
2.1.2 Broad main objective 
Assessment of the efficacy of early goal directed therapy to deliver target directed 
resuscitation in a resource limited setting for adults with suspected bacterial meningitis using 
a clinical care bundle. 
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Specific objectives 
1. To assess the feasibility of achieving each clinical target by using the clinical bundle, 
and perform a composite assessment of all targets achieved by the care bundle. 
2. To assess the relative change in mortality due to ABM in adults receiving the bundle 
compared to standard hospital care 
3. To estimate if the bundle has an impact on the incidence of acute seizures and 
neurological disability in survivors of ABM 
 
3.3.4 Study participants, inclusion and exclusion criteria  
This study recruited adults (defined in Malawi as aged 14 or over, the age at which 
admission to adult medicine is permitted) presenting to the AETC with clinically suspected 
bacterial meningitis. All adults presenting to the AETC were screened by a study nurse and 
patients meeting the screening inclusion criteria for initial entry into the study were enrolled, 
subject to verbal assent. These screening inclusion criteria were as follows: 
 
Inclusion criteria at screening 
• Adults ≥14 years age 
AND 
• Fever/history of fever plus at least one or more of the following presenting features: 
1. Coma/altered mental status 
2. Severe Headache 
3. Nuchal rigidity 
4. Seizures 
5. Confusion  
 
These screening inclusion criteria were chosen based on clinical inclusion criteria for 
previous meningitis trials at QECH, and on the high sensitivity of these clinical presenting 
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features for the diagnosis of ABM (Brouwer et al., 2012; Thomas et al., 2002). The diagnosis 
of suspected ABM from these screening inclusion criteria led the study team to perform a 
lumbar puncture and obtain CSF samples for a definitive diagnosis. 
A formal inclusion or exclusion decision was made following CSF analysis.  
 
CSF inclusion criteria:  
Cases of proven and probable bacterial meningitis were included in the main study analysis. 
Proven case:  
• Presence of a positive Gram’s stain or culture or PCR positivity for any bacteria known to 
cause meningitis in the CSF irrespective of cell count 
Probable case:  
• CSF WCC >50 cells/mm3 (predominantly neutrophils), PCR and culture negative with an 
acute history and biochemical evidence of meningitis (raised CSF lactate, CSF: Blood 
glucose ratio of <0.4, raised CSF protein >0.5g/L). 
• Clumped CSF WCC with >50% neutrophils (if available) with negative PCR/ Culture and 
corresponding biochemical evidence of CSF inflammation (see above) and an acute 
clinical history 
• Positive Gram’s stain or culture/PCR positivity for any bacteria known to cause 
meningitis in the blood with corresponding evidence of inflammation (elevated WCC, 
raised lactate, CSF: Blood glucose ratio of <0.4, raised CSF protein >0.5g/L) in the CSF.  
• CSF WCC >50 cells/mm3 (predominantly lymphocytes only where pre-hospital antibiotic 
use is demonstrated), PCR and culture negative with an acute history and biochemical 
evidence of meningitis (raised lactate, CSF : Blood glucose ratio of <0.4, raised CSF 
protein >0.5). 
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These thresholds were chosen for the following reasons. It is clear that HIV infection in 
adults from sub-Saharan Africa may alter the CSF WCC response in bacterial meningitis 
(Jarvis et al., 2010). A classical cut-off for CSF WCC in ABM is 100 cells/mm3(Brouwer et 
al., 2012), but from anecdotal data from excluded patients collected by the SAM and GLAM 
trials whose CSF WCC cut of was 100 cells/mm3 suggested that many ABM patients with 
HIV infection may have had CSF WCC that were considerably lower than this. For this study 
the WCC cut off was adjusted to 50 cells/mm3. Where clumped cells were reported and no 
formal count was given, it was assumed that the cell count was over the 50 cells/mm3 cut off, 
and these cases were included as probable cases. CSF WCC clumping has been reported 
with diagnostic accuracy of 92-98% sensitivity for diagnosis of bacterial meningitis in children 
compared to other causes of meningeal inflammation (Michelow et al., 2000).  
It is well recognised that ABM in adults causes a very high CSF protein and low CSF 
glucose, data from HIV infected adults with ABM are lacking. The cut off of >0.5g/L for 
protein and CSF:Blood ratio of <0.4 were chosen based on literature from better resourced 
settings (Tamune et al., 2013; van de Beek et al., 2004; White et al., 2012).  
 
In addition to the proven and probable categories, a further category of possible cases of 
bacterial meningitis was created. These included all participants with non-inflammatory CSF 
< 50 WBC/mm3 CSF and culture/gram/PCR negative, in whom the other inclusion criteria 
were fulfilled including: raised lactate (>4mmol/L), CSF: Blood glucose ratio of <0.4, raised 
CSF protein, with an acute history and high clinical suspicion of ABM with no evidence of 
fungal meningitis. In these patients a possibility remained that these patients may have had 
ABM caused by a pathogen not tested for by PCR such as non-typhoidal Salmonellae or E. 
coli. These cases were excluded from the main study analysis due to a probability of acute 
TB meningitis as a causative agent as specific TB culture was not available, but clinical data 
were retained and these cases were subject to a separate mortality analysis as ‘possible 
cases’. 
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Exclusion criteria 
Study patients were excluded at two time points in the study, either at screening or on 
analysis of the CSF after 48 hours. Patients were excluded at screening if they had at least 
one of the following criteria: 
1. Pre-admission diagnosed terminal illness (e.g. metastatic malignancy) 
2. Age < 14 years 
3. Severe head trauma or recent head injury 
4. Other clear source of illness such as intra-abdominal abscess 
 
Study patients were subsequently excluded after review of the CSF results if they met the 
following criteria: 
1. CSF positivity on microscopy, culture or antigen testing for an organism known to cause 
chronic meningitis (fungal/tuberculosis/parasitic meningitis). In cases where CSF 
cryptococcal antigen (CrAg) testing was positive, patients were retained in the study until 
the fungal and bacterial culture results were known. Cases in which the CSF CrAg was 
positive and there was proven evidence of bacterial meningitis in the CSF were included 
in the main study. All other cases where the CSF CrAg was positive were excluded as 
cryptococcal meningitis. 
2. Cases in which the CSF was culture/microscopy/PCR negative, but the CSF WCC was 
greater than 50 cells, with >80% lymphocytes and no pre-admission antibiotics were 
given were excluded.  
3. Subjects with non-inflammatory CSF < 50 WBCs and culture/gram/PCR negative were 
excluded from the main ABM analysis and an alternative diagnosis assigned after clinical 
review. 
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3.3.5 Study site 
This study was conducted in the new Adult Emergency and Trauma Centre (AETC) at 
Queen Elizabeth central hospital (QECH). The AETC was designed to undertake 
assessment of all emergencies in adults, and act as an admission centre for adult medicine 
and surgery to replace the old admission systems for both specialities. Room 6 and ward 4B 
were closed in November 2011 when AETC opened, two months before recruitment started 
to this study. Therefore, the AETC management, clinical and nursing teams were all new to 
the AETC environment and training in procedures such as triage and clinical assessment 
were on-going as study recruitment started.  
The first phase of this study, where only observation of clinical activity was undertaken, was 
necessary to enable a comparison between care provided in the AETC in phase 1 and any 
efficacy of the care bundle in phase 2. Comparison between historical Room 6- 4B data and 
the care bundle would not have been applicable or relevant as the AETC was predicted to 
provide substantially improved care by providing direct access to good quality facilities and 
trained staff and reducing clinical delays compared to the old system. The Ministry of Health 
of Malawi is auditing outcomes under both systems, but no data are publically available. 
 
3.3.6 Study design and sample size 
This study was designed as a before/after study in line with the recommendations by the 
Medical Research Council on trial design for complex interventions on a single site 
(Campbell et al., 2000, Council, 2008). The study was divided into two consecutive phases, 
the ‘before’ group named phase 1 (observational controls) and the ‘after’ group, phase 2 
(implementation of bundle). 
 
3.4.5.1 Admission and recruitment process 
All adults admitted to AETC in both phases with suspected ABM were screened and 
included using identical inclusion criteria to ensure the participants in both phases were 
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matched. To minimise confounding, active recruitment, prospective data collection and 
follow up of all study subjects were identical in both phases.  
 
3.4.5.2 Out of hours recruitment 
One main difference in recruitment between the two phases was present. Funding for an 
additional study nurse became available at the start of Phase 2b, facilitating 24 hour 
recruitment between Sunday 5pm and Saturday 8am. Phase 1 recruitment was between 
Monday to Friday 8am -5pm. Patients admitted out of hours in Phase 1 were recruited from 
the wards following notification from the admitting medical team and the laboratory, acute 
deaths out of hours on the wards and in the AETC in patients meeting the CSF inclusion 
criteria were noted.  
 
3.4.5.3 Recruitment start and end for each phase 
The study timing was planned to ensure data collection was running at peak capacity during 
the cold dry season when it has been noted that more meningitis cases may present to the 
hospital (Gordon et al., 2000). Patient recruitment to phase 2b started at the same time point 
as phase 1, but one year later to minimise the effect of seasonal variation in the presentation 
of ABM. Phase 1 ran between the 2nd of January 2012 and data collection ended on the 31st 
of October 2012. Phase 2a ran between November and December 2012, and Phase 2b ran 
between the 2nd of January 2013 and the 31st of October 2013.  
 
3.4.5.4 Division of phase 2 into pilot and active phases 
Phase 2 was divided into 2a and 2b. 2a was a short pilot phase that involved training the 
study team in the care bundle delivery, where the team were introduced to each bundle 
element sequentially. They underwent bedside assessments of their skill in delivering each 
care bundle element. Phase 2a was followed immediately by phase 2b, the active bundle. 
This element of the study design was chosen due to the complexity of the care bundle to 
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ensure that all study team members were familiar with each target and intervention before 
full active data collection started in Phase 2b.  
 
3.4.5.5 Sample size considerations 
A formal sample size calculation was not performed for this study. No formal studies on care 
bundles for meningitis in adults or children have been done prior to this study from which to 
estimate a potential effect size. Care bundle studies on adults with sepsis in high resource 
settings, which have been used as a model for the design of this study design do not provide 
directly translatable estimates of effect size that could be used for this study. A pragmatic 
plan to recruit equal numbers to each phase with a target of 100 patients per phase was 
therefore made instead. It was decided from the outset that this study would act as a 
feasibility and safety pilot study to assess the care bundle, and it would be under-powered to 
detect any significant difference in mortality between the two phases. 
 
3.4.5.6 Drug prescription and medical care in the AETC 
Medical care in phase 1 was entirely prescribed by the AETC and medical clinical teams, 
and delivered by the BAM study nurses. In Phase 2, the BAM study clinician and nursing 
team instituted the care bundle protocol, and gave any additional treatments prescribed by 
the AETC or admitting medical clinical teams, such as oral fluconazole for suspected 
cryptococcal meningitis. 
 
3.4.5.7 Follow up 
The study team performed daily follow up of all screened patients on the medical wards from 
Monday-Friday until a decision for inclusion or exclusion on CSF grounds was made. Once 
patients were excluded, follow up ceased. Patients and guardians whose CSF results met 
the inclusion criteria were invited to remain in the study, and those who agreed gave written 
informed consent. Included patient follow up on the ward was daily for 10 days or until 
discharge if that was earlier. The patients were then followed weekly by phone call or text 
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message for 6 weeks and invited to a follow up appointment at 6 weeks. If they were unable 
to attend or unreachable by phone, community based follow up was done. This was only 
achieved in the second phase of the study after it became apparent that a significant number 
of patients were lost using telephone based follow up only in phase 1.  
It was made clear to the inpatient team that the study team was not medically responsible for 
the study patient once they were admitted to the ward. At the day 40 outpatient appointment, 
further medical referrals were made by the study team as necessary, such as to antiretroviral 
clinic, if these had not been done at discharge by the medical team.  
 
3.4.5.8 Trial Registration  
This study was registered online with two clinical trials registries. The Pan-African Clinical 
Trials Registry (PACTR) number 201111000338157, and the International Standard 
Randomised Controlled Trials Network (ISRCTN) 96218197. The details of the study were 
published on both registries websites, and kept updated as the study progressed. 
 
3.3.7 Care bundle intervention 
The clinical care bundle intervention tested in this study was designed using two 
concomitant  approaches. Firstly, all published data and guidelines on clinical care bundles 
in the literature for infectious diseases, critical care and emergency medicine, plus general 
emergency resuscitation guidelines for acute medical and surgical emergencies were 
reviewed. The details of these searches can be found in Chapter 2 Section 2.1. The data 
from the analysis of patients with meningitis in Malawi to determine which predictors of poor 
outcome would be amenable to treatment with a care bundle was additionally reviewed 
(Results Chapter 4 Section 4.5.3-4). The data from this analysis was combined with the 
published data and guidelines to create a simple clinical care bundle that would meet the 
resuscitation needs of the screened patients within the resource constraints of the clinical 
environment in Malawi. The care bundle was additionally designed to be a nurse-led 
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intervention that enables a nurse or clinical officer following a detailed protocol to identify 
physiological abnormalities from baseline observations and use the protocol to correct these 
safely over a 6 hour time period. The protocol gives clear clinical targets that should be 
achieved by 6 hours where possible. 
At the end of the 6 hour time period, every effort should have been made to optimise the 
clinical care given with the bundle to normalise physiological abnormalities and stabilise the 
patient prior to ward transfer.  
 
3.3.7.1 Published guidelines on the approach to critically ill medical patients 
The clinical care bundle of early goal directed therapy tested in this study was designed 
primarily based on the ‘ABCD’ approach to resuscitation which has been developed and 
validated by the American and UK resuscitation councils (Council, 2010). These guidelines 
indicate the priority order of emergency life-saving interventions that should be given, 
according to clinical need to patients presenting with acute illness. The most urgent is 
considered the airway “A”, followed by breathing “B” where oxygenation must be optimised, 
and are followed by “C” circulation and “D” disability. The ABCD system however is designed 
primarily for patients in cardiac arrest and not presenting with a severe medical condition 
such as bacterial meningitis. As discussed in chapter 2, the components of the care bundle 
advocated by the Surviving Sepsis campaign were revised, and those which were applicable 
to the needs of the Malawian patient with ABM were determined, based on the clinical 
predictors of poor outcome from the previous analysis. 
 
3.3.7.2 Clinical predictors of poor outcome from bacterial meningitis in Malawi 
The results of the analysis detailed in section 1.5 of this chapter were reviewed. The detailed 
results are presented in Chapter 4 Section 4.5, however coma, altered mental status, 
hypoxia, seizures and anaemia were all independently associated with poor outcome. For 
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each individual predictor of poor outcome, the care bundles from the ABCD and the 
surviving sepsis guidelines were reviewed, along with the literature from appropriate parallel 
specialities such as neurosurgery and adapted for a resource limited environment. The 
literature supporting each care bundle element is discussed in detail in Chapter 2, Section 
2.8. The care bundle tested was designed to optimise clinical care for each predictor with the 
aim to restore normal physiology within a 6 hour observation period. 
 
3.3.7.3 Final care bundle 
The care bundle consisted of eight components, all of which were clinically available in the 
AETC and all of which are recognised existing clinical treatments which have supportive 
evidence of efficacy.  The individual components of the bundle can be seen in Table 3.2 
below, the ABCD order as determined by the Resuscitation Council guidelines.  
A 
Airway support is deemed essential by all guidelines for adults with a GCS of less than 8/15 
at which point airway reflexes are minimal. Altered mental state is associated with raised 
intracranial pressure in meningitis, and the head tilt is designed to reduce ICP while 
optimising oxygenation and minimising aspiration risk, as shown in the neurosurgical 
literature.  
B 
Anaemia and hypoxaemia were identified as predictors of poor outcome; these were 
addressed in the care bundle by the application of oxygen via a concentrator for hypoxic 
patients, and the rapid transfusion of blood where available to those who were determined to 
be profoundly anaemic on a Hemocue test.  
C 
Tachycardia was shown to be independently associated with mortality; very few patients 
were hypotensive in the severity analysis. However hypotension leads to under-perfusion of 
cerebral tissues and therefore fluid resuscitation was given to patients with a clinical 
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definition of shock as determined by the surviving sepsis campaign (Table 3.4) to optimise 
cerebral perfusion.  
 
D 
Seizures at presentation and prior to admission to hospital were associated with poor 
outcome in the severity analysis, and are associated with an altered mental state. Therefore 
acute treatment of seizures and the underlying causes of seizures such as hypoxia and 
hypoglycaemia were addressed in the care bundle using intravenous glucose and facial 
oxygen where indicated. 
 
In addition, early antibiotic therapy is associated with improved outcomes from meningitis 
elsewhere in the world, and in Malawi, trends towards higher mortality from meningitis when 
antibiotic treatment is delayed were observed in a small number of patients in the pilot 
cohort. We attempted to give the first dose of ceftriaxone within one hour of arrival in AETC 
in this care bundle. 
Table 3.2 Clinical components of the care bundle 
Bundle components 
1. Naso-pharyngeal airway if GCS <8 
2. Head up/bed tilt 30° if GCS <11    
3. IV access, 2g ceftriaxone stat 
4. Oxygen via concentrator if SpO2 <93% 
5. IV fluid (Ringer’s Lactate) bolus 20ml/kg  if clinical shock, 125ml/hr if no clinical 
shock (Table 3.4) 
6. Transfusion of packed red cells if haemoglobin <6.0g/dL 
7. Correction of hypoglycaemia with oral dextrose and drinks/food if GCS >11, or 
with iv dextrose 10-50% via a bolus/infusion if GCS <11 
8. Prompt treatment seizures (IV diazepam/lorazepam plus phenobarbitone) 
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This was due to difficulties in assessing staff training when no formalised resuscitation 
training was available that is appropriate to resource limited settings. During phase 2a, 6 
weeks of time were devoted to care bundle training. The senior study nurse led the training 
of the other nurses at the bedside and in a series of practical seminars. Each of 6 weeks 
were devoted to one particular bundle element, and staff debriefed after recruiting a patient 
and following that protocol to discuss how to optimise the delivery of each care bundle 
element. During this time active study patient recruitment continued with a target of one 
patient per day. The study team recruited that patient as a team and delivered the care 
bundle intervention as dictated by the study protocol. The PI was involved in the initial staff 
training and in the daily de-brief meetings where what had been done well and which targets 
had not been met were discussed. The team then decided each day how to take the training 
forward to the next day. By the end of the 6 week period the team were entirely comfortable 
to deliver the care bundle to an individual patient without the support of their peers, but with 
24 access to the PI by telephone. 
 
3.3.7.4 Care bundle delivery and timing 
The intervention care bundle was delivered using defined targets as detailed in Table 3.3 
within the AETC. The duration of the intervention was 6 hours from initial screening, by 
which point all attempts to meet all targets using the protocols had been undertaken. Each 
subject received hourly observations including Glasgow Coma Score (GCS), blood pressure 
and pulse measurements. A lumbar puncture for the diagnosis of ABM was performed at the 
earliest opportunity. After each hourly observation, the study nurse reviewed the care bundle 
progress and added or stopped elements as per protocol. For example if the GCS dropped 
below 11 at hour 4, a head tilt was given.  
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Table 3.3 Targets for EGDT in BAM 
Clinical targets for the care bundle intervention 
Parameter Target Intervention  Test of 
intervention 
Timing of clinical 
assessment 
Medical review <1 
hour of arrival 
Training in recognition of 
the symptoms and signs of 
meningitis and rapid triage 
Timed and 
signed flow 
chart 
Antibiotic therapy 1st dose within 1 
hour of arrival 
Education of importance of 
antibiotics, sepsis flow 
chart 
Timed drug 
chart 
Glucose BM >4 S/L , NG or IV dextrose Repeat BM 
Oxygenation Sp02 >94% Nasal flow 02 from 
concentrator 
Packed red cell Transfusion 
if significant anaemia (Hb 
6.0g/dL)  
Regular Sp02 
monitoring 
Perfusion CRT<2 sec, BP >90 
syst, MAP >70, no 
postural hypotension 
(lying-sitting)/ 
UOP>0.5ml/kg (if 
catheterised 
IV fluid bolus 20ml/kg 
Ringer’s lactate where 
available. 
Repeated fluid 
balance 
assessment at 
1hour then 
repeated 
Seizures  No seizures Acute prompt treatment of 
seizures with IV/PR 
benzodiazepines and IV 
phenytoin if seizures persist 
Seizure chart 
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At the end of the 6 hour study period, the bundle was stopped, and the subject was 
transferred to the medical ward for ongoing routine care as deemed appropriate by the 
admitting clinician. A flowchart of the study process is available in the appendix. Patients 
were discharged to the most appropriate clinical care area in both phases of the study. If 
invasive ventilation or inotropic support was required, they were transferred to intensive 
care. Patients requiring on-going oxygen or control of persistent seizures they were 
transferred to the high dependency unit on the medical ward. All other patients were 
transferred to the main male or female medical wards. 
 
Clinical shock was defined by abnormalities in the following general variables defined in 
Table 3.4. If shock was present then the fluid bolus protocol was instituted as per protocol 
(appendix 1.3).  All protocols are in the appendix .  
Table 3.4 Definitions of shock from the surviving sepsis guidelines 2008 
Organ variables for the definition of clinical shock (Dellinger et al., 2008b) 
General 
variables 
Hemodynamic  Organ dysfunction  Tissue perfusion  
Heart rate >100 
bpm  
Arterial 
hypotension (SBP 
<90 mm Hg 
Acute oliguria* Decreased 
capillary refill (>3 
seconds) 
Tachypnoea 
RR>25 
MAP <70 mm Hg Ileus (absent bowel sounds) Skin mottling 
Altered mental 
status 
SBP decrease >40 
mm Hg 
Blood lactate >4 mmol/L  
*(urine output <0.5 mL/Kg/hr or <45 ml/hr for at least 2 hrs (if catheterised)/ no urine production for 12 hours despite adequate 
fluid resuscitation) 
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3.3.7.5 Staff training 
Staff training formed an important component of bundle delivery during Phase 2a and was 
on-going through Phase 2b, but did not form a specific bundle element. This was due to 
difficulties in assessing and including the effects of staff training in the data analysis. 
 
3.3.8 Laboratory investigations including sample storage 
All patients underwent the following investigations. All research samples were taken from 
surplus blood and CSF at the same draw as for clinical testing, with the exception of day 10 
and day 40 blood taken for microarray studies (Table 3.5).  
Lactate was measured at the bedside in both CSF and blood using a point of care test 
(Lactate Pro, Habdirect). Point of care (POC) lactate tests are comparable to formal 
laboratory measured lactate (Karon et al., 2007).Glucose was measured using a POC 
bedside glucometer (Accu-chek, Aviva, USA). Haemoglobin, Creatinine, Sodium were 
measured in the QECH hospital laboratory. HIV tests were performed either by the hospital 
laboratory or on the hospital wards as part of the Government funded Provider Initiated 
Testing (PITC) and Counselling service for HIV. 
Table 3.5 List of samples taken from BAM patients with informed consent 
Research and diagnostic samples taken 
Tissue type Justification 
Cerebrospinal fluid (CSF)  
Microbiology (microscopy, protein, 
glucose, bacterial/fugal/TB culture) 
Clinical diagnostics (Heyderman, 2005) 
Real-Time PCR Clinical diagnostics and potential marker of poor 
outcome (Carrol et al., 2007a) 
RNA expression storage CSF host RNA expression patterns in ABM 
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Blood  Justification 
Lactate Marker of septicaemia (Jones et al., 2007a) 
Glucose Risk factor for disease severity and seizures (Schut 
et al., 2009b) 
Haemoglobin Marker of severity and to determine transfusion 
requirements  
Sodium (1ml) Risk factor for seizures and disease severity 
(Brouwer et al., 2007)  
Creatinine (1ml) To determine if acute renal failure is present 
(Dellinger et al., 2008b) 
Full Blood Count (2ml) Clinical diagnostics 
HIV antibodies when consent 
given (1ml) 
Clinical diagnostics 
Malaria thick film (1ml) Clinical diagnostics.  
Blood culture (10ml) Clinical diagnostics.  
Real-Time PCR (1ml) Clinical diagnostics and potential marker of poor 
outcome.  
Storage in RNA preservation tubes 
(2-3ml) 
Additional blood samples were requested from 
included participants at day 10 discharge and day 40 
follow up for RNA expression studies of bacterial 
meningitis.  
Nasal swab Culture for S. pneumoniae and genotypic exploration 
of micro-evolution of S. pneumoniae 
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3.3.9 Endpoints and follow up 
The following endpoints were used for this study. 
Primary 
1. Measurement of the proportion of each clinical target achieved by each care bundle 
element at 6 hours 
2. Total proportion of all clinical targets combined together, achieved by the bundle at 6 
hours. 
  
Secondary (measured at day 10 and day 40) 
1. Death 
2. Persistent seizures requiring treatment 
3. Significant neurological disability  
4. Functional ability measured using the modified Rankin Score (mRS) 
5. Efficacy of the care bundle on sepsis outcomes of death at 48 hours, and tissue 
perfusion at 6 hours 
 
Death was measured as a composite secondary endpoint (days to death/last known alive) 
using the following methods: 
Day 10 (acute) survival measured by either a date of discharge (alive) or date of death 
recorded up to 10 days of inpatient antibiotic therapy. 
Day 40 (convalescent) - Final outcome recorded ‘alive or dead’ from follow up or response to 
mobile telephone to 6 weeks. 
 
A history of seizures and functional ability since discharge was taken at day 40, and 
endpoints 2-4 were measured formally using a clinical history, and the mRS. This score is 
well validated and determines outcome based on the following parameters (Table 3.6).  
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Table 3.6 Modified Rankin Scoring system 
mRS (Rankin, 1957; Bonita and Beaglehole, 1988) 
Activity Score 
Normal, able to work all activities of daily living 0 
No significant disability despite symptoms of illness; able to carry out all 
usual duties and activities 
1 
Slight disability; unable to carry out all activities, but able to look after 
own affairs without assistance 
2 
Moderate disability; requiring some help, but able to walk without 
assistance 
3 
Moderately severe disability; unable to walk without assistance or 
unable to attend to own bodily needs without assistance 
4 
Severe disability; bedridden, incontinent and requiring constant nursing 
care and attention 
5 
 
3.3.10 Verbal assent and informed consent 
A two stage, delayed formal informed consent to enable the rapid onset of the bundle 
delivery was used. The consent process was GCP compliant, and consisted of two steps: 
verbal assent by the participant or their guardian on admission and recruitment, and written 
informed consent from the participant or guardian when the subject was stabilised on the 
ward some days later. This was planned for two main reasons. Firstly, the process of verbal 
assent to gain basic agreement for participation was designed to facilitate rapid intervention. 
Verbal assent, followed by formal informed consent for on-going participation at a later date 
is a standardised practice in trials of emergency interventions, is recommended by the FDA 
and has been used in sub-Saharan Africa (Maitland et al., 2011b; consent, 1996). Secondly, 
potential study participants were commonly critically unwell on arrival at the hospital, with 
impaired consciousness, and did not fulfil the requirements for standard GCP informed 
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consent. This has been a problem for all studies that investigate critical illness testing rapid 
delivery of the intervention to a severely unwell participant.  
 
a) Verbal assent 
 When the study participant was identified as a potential study subject at triage in AETC, the 
recruiting study nurse gave verbal details of the study, and requested verbal consent from 
the patient or accompanying guardian for inclusion ‘verbal assent’.  If the answer was 
affirmative, the subject was recruited and monitoring/bundle was started immediately. An 
assent form was signed at this point by the study nurse and the patient or carer.  
b) Deferred verbal assent 
A small number of participants presented who were personally unable to give verbal assent 
to enter the study and did not have an attending guardian who was able to give verbal 
assent. In phase 1, those patients were found on the ward the subsequent day and informed 
consent was taken from the patient or guardian. If those patients had died, minimal mortality 
information was retained from the notes in the CRF to avoid selection bias. In Phase 2, the 
process was changed (with formal permission from COMREC) to ensure high quality clinical 
care was given rapidly to patients presenting without a guardian. Participants were enrolled 
and received the care bundle within the time targets without any assent or consent process. 
Delayed verbal assent was then taken from an attending guardian at the earliest opportunity. 
At any point in both phases if deferred verbal assent or informed consent was denied we 
immediately de-recruited the participants and deleted all study data for that person. 
c) Delayed formal informed consent 
Once the subject was stabilised and able to talk formal written informed consent was 
requested for subjects meeting the CSF inclusion criteria. If a patient took time to become 
stabilised or was unable neurologically to give written consent, this was requested from the 
accompanying guardian. Excluded subjects were formally told they did not have bacterial 
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meningitis and were excluded from the study without going through a consent process. All 
retained samples were discarded for excluded subjects, unless informed consent was 
sought for their use as control samples. If no guardian was present to give informed consent 
when patient was comatose, the subject was included on the basis of best interests, until a 
time when a carer was located to request consent. 
d) Death before informed consent 
Due to the severe and acute nature of bacterial meningitis, a number of participants died 
after giving verbal assent but before informed consent could be obtained. Attempts were 
made to contact the guardians of the dead study participant to request informed consent. 
Where this was not possible, the verbal assent form was deemed adequate consent for data 
retention by COMREC.  
 
e) Informed consent for research samples 
No samples of tissue were analysed, excepting those necessary for acute clinical 
management, until written informed consent was given. If consent was denied, all records of 
that subject were deleted from the main trial database and samples discarded.  
 
3.3.11 Adverse Events 
a) Data monitoring 
A formal data monitoring committee was not considered to be required for this study, as the 
interventions being tested had individually been proven to be effective, and there was no 
blinded/randomised intervention. However, Professor Tim Peto (Professor of Medicine, 
University of Oxford) and Professor Johnstone Kumwenda (Dean of clinical medicine, 
College of Medicine) acted as an independent study monitors to review cumulative monthly 
aggregated reports on all outcomes and SAEs. In addition the study statistician, Dr Brian 
Faragher also reviewed the monthly outcome report and provided comments and feedback. 
132 
 
b) Process of detecting and reporting SAEs 
Any suspected or unexpected serious adverse events (SAE/SUE) were discussed 
immediately with the PI, study nurses and clinical officer and a record form was completed. 
A serious adverse event was classified as an unexpected negative outcome, harm to a trial 
participant, or an occurrence that results in a complaint to the trial team from a participant or 
their carer, or from within the AETC team. The standard definitions of SAE and SUEs can be 
found at 
http://www.mhra.gov.uk/Howweregulate/Medicines/Licensingofmedicines/Clinicaltrials/Safety
reporting-SUSARsandASRs/ 
These standard definitions were adapted for this study, as patients with suspected 
meningitis in Malawi are already critically unwell and at high risk of death or adverse 
outcome. Therefore COMREC deemed it unnecessary to report all adverse neurological 
outcomes formally, but all deaths and potential harms from the study intervention were 
reported.  
An SAE was required in phase 2 the event of any of the following during the care bundle 
delivery: 
• Death 
• Drop in GCS of >2 points 
• New oxygen requirement 
• Presence of pulmonary or suspected cerebral oedema 
• New seizure 
• Respiratory depression 
• Any other concern from a study team member that harm had come to the trial participant 
In the follow up phase all deaths were recorded as SAEs in the acute phase in-hospital. Out 
of hospital deaths were not regularly reported as SAEs.  
All SAEs and SUEs were discussed by the principal investigator with the chief investigators 
and details given to the trial monitor with aggregated mortality data. COMREC were given 
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summary details of mortality at the end of each phase. The study protocol dictated that if the 
CI, IRB COMREC or the study monitor considered it necessary, recruitment would be 
paused, and a meeting of the trial steering committee (TSC) convened to discuss the SAE. 
Several SAEs relating to deaths during the care bundle period in phase 2b were sent to the 
study monitors, but no meeting of the TSC was deemed necessary during the conduct of the 
trial. 
 
3.3.12 Data analysis and statistics 
The study analysis was designed to interrogate the data primarily by intention to treat, and 
then per-protocol.  
 
a) Data management 
Data was collected on a paper case record form (CRF) and transferred by the study team to 
an electronic data capture system ‘REDCap’ (source). In addition PDAs were planned to be 
used for ward based data capture with linkage to the main study computer. 
Originally the study was designed to have pure electronic data capture. However during the 
start of Phase 1, dual paper and electronic data capture to test the system were run. The 
team noticed that data that had been entered from the CFR into the electronic system was 
subsequently missing. The cause of the missing data was extensively investigated, including 
screening for viruses and cross checking the PDAs, no apparent cause was found, but the 
problem continued. Following re-training of the team in the use of RedCap the MLW Data 
manager discovered that the team were not saving entered data in the proper manner as 
originally outlined in the staff training and this was likely the cause of the missing data. The 
decision was taken to continue with dual paper and electronic data capture to ensure a 
robust backup system was in place and to abandon use of the PDAs. The study team for the 
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entire study entered the data onto paper CRFs and then transferred this to the electronic 
system. 
 
The MLW data team regularly cross checked the electronic data against the paper CRF for 
transcription errors and accuracy, after which the data were exported from REDCap to IBM 
SPSS/PASW version 20 and GraphPad5™ software for analysis. The data analysis plan 
was lodged with the COMREC before commencement of the study . 
 
b) Statistical methods 
The following statistical tests were used to compare the intervention (Phase 2) and control 
groups (Phase 1). 
• Composite analysis of each proportion of target achieved 
• Simple mortality proportions 
• Kaplan-Meir survival analyses to establish the pattern of the death rate 
• Chi squared tests and Fisher’s exact test to analyse the significance of differences 
between the two phases fixed endpoints. 
• Logistic regression was used to give an estimate of the size of the change in outcomes 
and to control for confounding. 
• Direct comparison of meningitis severity scores calculated for each phase, developed in 
Chapter 5 to assess the degree of illness severity in each patient on admission in each 
phase. These scores will be compared using parametric tests and logistic regression. 
All statistical tests were two tailed and a significance value of <0.05 determined statistical 
significance. 95% confidence intervals are presented for Odds Ratios. 
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c) Sub-analyses were undertaken of the following groups 
1. Patients presenting where death was predicted by the admitting clinician or occurred 
within the bundle implementation time period (6-8 hrs).  
2. Subjects with normal CSF and an alternative diagnosis such as sepsis by outcome at 48 
hours. 
3. Subjects with abnormal CSF but no formal evidence of proven or probable bacterial 
meningitis on CSF analysis (e.g. ‘possible cases of ABM’, CCM and TBM patients). 
 
Patients who presented with bacterial meningitis in-extremis or with symptoms or signs 
suggesting death within 4-6 hours were included in the intention to treat analysis, but were 
subjected to a separate sub analysis and excluded from the per-protocol analysis. 
All data were analysed using IBM SPSS version 20 (IBM, USA), figures were generated 
using this software with the addition of GraphPad PRISM (GraphPad USA) version 5 and 
version 6 software. 
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4. Bacterial meningitis in Malawi 2000-2012: 
Laboratory surveillance and 
Clinical predictors of mortality in adults and adolescents. 
4.1 Introduction 
This chapter summarises work done in support of the BAM trial, exploring the significant 
data collected in MLW over the last 12 years, both through the microbiological surveillance 
programme and by analysis of data from important clinical studies undertaken during this 
time.  
Section 1 details the changing epidemiology of ABM in both adults and children over twelve 
years through an analysis of data from microbiological surveillance. This is followed by 
Section 2, which is an analysis of the clinical data collected over the same time period, 
testing for possible causes of the very high mortality seen from ABM in Malawian adults and 
adolescents. By putting both the surveillance and clinical data in context, the results 
presented in this chapter provide important background information for the design and 
analysis of the BAM trial, presented in chapter 6. 
 
4.2 Bacterial meningitis surveillance in Malawi 
There are little surveillance data for bacterial meningitis from resource poor regions, 
particularly SAA and estimates of incidence are often based on poor quality data (Peltola, 
2001). MLW was been conducting routine surveillance for invasive bacterial pathogens in 
the blood and CSF of adults and children presenting to QECH for 15 years (Everett et al., 
2011; Gordon et al., 2008; Gordon et al., 2001; French et al., 2010), over which time 
numerous public health interventions have been introduced which may or may not impact on 
bacterial meningitis incidence.  
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These include roll-out of free antiretroviral therapy (ART) and co-trimoxazole prophylaxis, the 
introduction of Hib and PCV vaccination, intense malaria control, prevention of mother to 
child transmission of HIV infection and improvements in childhood nutrition (Roca-Feltrer et 
al., 2012; Chihana et al., 2012; Daza et al., 2006; Floyd et al., 2012; Jahn et al., 2010a).  
Making use of this large surveillance data resource, it was determined if the number of 
meningitis cases and therefore incidence changed during this time period. In addition 
seasonality and patterns in the prevalence of different pathogens causing meningitis were 
examined. 
 
4.2.1 Research questions 
1. Has the number of cases of culture proven bacterial meningitis, and therefor 
incidence changed over 12 years? 
2. Is culture proven bacterial meningitis seasonal? 
Objectives 
1. To examine the laboratory database of CSF culture isolates collected 
between 2000-2012 by pathogen and age group to estimate case burden and 
age-specific incidence. 
2. To examine different pathogens for monthly seasonality against rainfall and 
temperature data. 
 
4.2.2 Specific Methods  
4.2.2.1 Database synthesis  
Laboratory data were collected for each CSF isolate that was culture positive between 2000-
2012, recorded in laboratory books to 2010 and via an electronic reporting system from 2010 
onwards. The paper-based data were then entered into an Excel spreadsheet manually by 
the MLW data team, and collated with the electronic data from 2010. Data available from the 
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paper based system included name, age, sex, ward, date of sample, CSF WCC, gram stain 
and culture result. From 2007, CSF protein and glucose were also reported. From the 
Laboratory Information Management System (LIMS) electronic data these data were also 
available, with the addition of CSF WCC percentages, antibiotic sensitivities and blood film 
results for malaria parasites.  
 
Isolates that appeared as duplicates were removed. A duplicate was defined as the same 
organism originating either on the same day or within 48 hours of the original sample from 
patients matched by name and age or date of birth, or where identical sample numbers had 
been assigned.  
4.2.2.2 Patient groups by age 
Cases were divided into groups based on clinically relevant age groups and bacterial isolate 
from the CSF: neonates (0-3 months of age), expanded programme of immunisation (EPI) 
eligible children (>3 months <5 years), older children (5-14 years), adolescents (15-19 years) 
and adults (>19 years). Over the time period studied, EPI consisted of the following 
vaccinations before the 1st birthday: polio, diphtheria, Hepatitis B, measles and tetanus. Hib 
vaccination was introduced in 2002 and 13 valent pneumococcal conjugate vaccine (PCV-
13) in 2011. 
Neonatal data were excluded from the analysis as this age group are epidemiologically 
distinct to community acquired meningitis (Swann et al., 2014).  
Isolates from patients whose age was not recorded accurately were determined to be adults 
or children by ward of admission. Children whose age was not known were put into a 
separate category of ‘age unknown’ and included in the overall analysis but excluded from 
the age-specific analysis.  
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4.2.2.3 Population and rainfall data. 
Data were obtained from the Ministry of Health of Malawi for population estimates and the 
Malawi meteorological department for two weather stations in Blantyre for temperature and 
rainfall data for the period studied.  
 
4.2.2.4 Meningitis surveillance inclusion and exclusion criteria. 
All CSF isolates that were consistent with bacterial meningitis were included (S. 
pneumoniae, N. meningitidis, H. influenzae, non-typhoidal Salmonellae species, E. coli, S. 
aureus, Group A, B streptococci, Listeria monocytogenes, K. pneumoniae and other gram 
negative pathogens). Isolates that were likely to be due to skin contamination, such as 
Staphylococcus epidermidis, Micrococcus species or Diptheroid Spp. were excluded.  
All fungal isolates were excluded, as were all culture negative samples. 
 
4.2.3 Statistical methods 
4.2.3.1 Surveillance calculations 
The Kruskal-Wallis test was used to detect global significant differences in the distribution of 
non-normal variables among groups of interest. These variables included CSF laboratory 
parameters such as white cell count and glucose by pathogen. If the results of the Kruskal –
Wallis test were significant, pair-wise comparisons were done using Mann-Whitney test. 
Poisson regression was used to derive incident rate ratios, reported with 95% confidence 
intervals. Vaccine efficacy was estimated by comparing the incident rate ratios from data 
prior and post introduction of a vaccine. A p value <0.05 denoted statistical significance. 
Statistical and time series analyses were done using Stata version 11.2 (™Statacorp, 
College Station, Texas). These analyses were done by Dr Mavuto Mukaka  (MLW) and Dr 
Naor Bar-Zeev in consultation with myself and Dr Dean Everett. 
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4.2.3.2 Incidence rates 
Mid-year population estimates were calculated based upon projections from the 1998 (for 
2000-2007) and 2008 Population and Housing Censuses for 2008-12 (Malawi, 1998), using 
a standard estimated resident population (ERP) forecasting algorithm. In Malawi, 
comprehensive annual data on population numbers, birth and mortality rates and net 
migration are lacking. A forecasting algorithm predicts population growth from census data 
each year, modelling on available fertility and death data available for that year. As the 
population of Malawi has expanded significantly over the time period studied, data from two 
successive censuses were used in the population estimates.  Incidence was defined as 
number of cases in a defined period divided by population in each year observed. Changes 
in incidence over time were plotted. 
 
4.2.3.3 Time-Series analysis for seasonality 
Time-series decomposition was used to separate long-term trends from seasonal 
perturbations. This model divides data into separate predicted cyclical patterns (e.g. per-
month seasonality, rainfall) and tests for associations of the cyclical data against a long term 
trend (in this study, meningitis incidence).  To determine whether seasonal perturbation 
differed significantly from baseline, data were trend differenced. The distribution of residual 
fluctuations for each month was compared to baseline with 2-tailed t-tests. To determine the 
impact of rainfall and temperature, an autoregressive integrated moving average model with 
exogenous variables (ARMAX) model was used. This model tests the weighted monthly 
average of the variable tested (meningitis incidence) against changing rainfall and 
temperature over a 12 month cycle for each year. Models using specifications of the 
autoregressive and moving average parameters were compared using the absolute 
percentage error. These analyses were done by Dr Naor Bar-Zeev (MLW). 
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4.3 Results of epidemiology of bacterial meningitis 
4.3.1 Surveillance trends in culture proven bacterial meningitis 
Data on culture positive CSF isolates was available from the laboratory database from 2000 
onwards.  
 
4.3.1.1 All meningitis trends 
Figure 4.1 shows the total numbers of culture positive cases of bacterial meningitis from 
2000-2012 by year. Isolates are sub-divided into adults > 19 years, and children and 
adolescents <19 years compared to all CSF samples received by the laboratory for analysis 
(Figure 4.1, right scale).  
 
There has been a significant decline in the total number of CSF isolates between 2000 and 
2012, 12 year incident rate ratio 0.93 95% CI 0.92-0.94, p<0.001. This decline has been 
entirely in children and adolescents (IRR =0.87, 95% CI 0.85-0.88, p<0.001); the number of 
isolates from adult has remained unchanged (IRR=0.99, 95% CI 0.97-1.0, p=0.135).The 
number of CSF samples received by the laboratory each year remained consistent after 
2002 and hospital admission rates did not change during the study period.  
 
4.3.1.2 Surveillance trends in paediatric bacterial meningitis 
Specific trends in the most commonly isolated pathogens in children and adolescents are 
shown in Figure 4.1. This figure includes all children from birth where the age is known, and a 
small number of children (<5% total) where the age was not recorded but admission under 
paediatrics was noted.  
 
Hib has declined twentyfold from 80 cases/year in 2000 to less than 4 cases in 2012. The 
figure shows that this decline occurred rapidly after Hib vaccination was introduced in Malawi 
in 2002. Figure 4.1 shows the data for Expanded Programme of Immunisation (EPI) eligible 
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children (>3m-<5 years old). Following Hib vaccine introduction in 2002, cases declined 
rapidly in the vaccine eligible age group. The Hib incidence rate ratio (IRR) describes the 
rate of change in incidence over time. The IRR for Hib =0.73, (95% CI (0.69, 0.76) p<0.001). 
This figure is highly significant and gives an estimated vaccine effectiveness of 0.91 (95%CI: 
0.83 to 0.99). Childhood NTS and pneumococcal meningitis cases have also significantly 
declined in children in this age group since 2002; the relevant incident rate rations are: NTS 
IRR=0.85 (95% CI 0.81, 0.89, (p<0.001), S. pneumoniae IRR=0.88 (95% CI 0.85, 0.91 
p<0.001). 
 
On further analysis of the pathogens causing disease in the EPI eligible children age group, 
Hib meningitis has dramatically declined from over 35% of all cases prior to 2002 to 3.5% in 
2005, remaining between 10-15% (Figure 2a). S. pneumoniae accounted for 30-50% of 
cases 2000-2003, the pneumococcus has consistently accounted for >60% of cases since 
2004. Non-typhoidal Salmonellae (NTS) meningitis dropped from 23% of cases pre-2004, to 
less than 10% by 2012. Confirmed meningococcal meningitis has remained consistently at 
<5% (Figure 4.2) 
 
Pathogens listed as ‘other’ have increased in proportion as the other causes have 
decreased. This group includes alpha and beta hemolytic streptococci, groups a and d 
streptococci, Klebsiella pneumoniae, Listeria monocytogenes, Salmonella Enteritidis, 
Staphylococcus aureus and Haemophilus influenzae types a,c and non-typeables. 
143 
 
 
Figure 4.1 Meningitis surveillance data by age group and pathogen 2000-2012 
Figure 4.1a. Total numbers of culture positive cases of bacterial meningitis 2000-2012 by year. 
Isolates are sub-divided into adults > 19 years, and children and adolescents <19 years. All CSF 
samples received by the laboratory measured on the right scale. 
Figure 4.1b. Total numbers of cases of meningitis caused by Hib, Streptococcus pneumoniae and 
non-Typhoidal Salmonellae in all children and adolescents aged <19 years. 
Figure 4.1c. Total numbers of cases of meningitis caused by Hib, Streptococcus pneumoniae 
and non-Typhoidal Salmonellae in EPI eligible children aged >3 months to <5years. 
 
Bacterial meningitis in older children and adolescents is predominately caused by S. 
pneumoniae, causing 65% of infections in the 5-15 year group; Hib caused 8.6%, and NTS 
less than 1% (Figure 4.2). In adolescents the case numbers were few, but S. pneumoniae 
was again the predominant pathogen causing approximately 80% of disease, N. meningitidis 
caused 10% and cases defined as other caused a further 10% of infections (data not 
shown). 
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Figure 4.2 Proportions of CSF culture positive isolates by paediatric age groups per year 
Figure 4.2a: Proportions of culture positive CSF isolates by pathogen per year in EPI eligible children 
aged > 3 months to < 5 years 
Figure 4.2b: Proportions of culture positive CSF isolates by pathogen per year in children aged 5-15 
years. 
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4.2.1.3 Adult bacterial meningitis and cryptococcal meningitis 
Numbers of culture positive CSF isolates in adults over the age of 20 remained unchanged 
over the time period studied. The most common bacterial isolate in adults was 
Streptococcus pneumoniae, cases of Neisseria meningitidis were few (Figure 4.3). Cases 
defined as other are listed in section 4.2.2. 
The most common culture isolate overall was Cryptococcus neoformans, accounting for 70% 
of all culture positive isolates (Figure 4.3). Case numbers of cryptococcal meningitis also did 
not change over the time period studied, despite the rapid roll out of ART. As cryptococcal 
meningitis is very different from bacterial meningitis (see Chapter 1 section 1.1), these cases 
were not included in the overall analysis. 
 
 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
Year Streptococcus pneumoniae Non typhoidal salmonella
Haemophilus influenzae Type B Group B Strep/'Streptococcus agalactiae
Meningitidis other
Cryptococcus neofrormans
        N=129        160       201       262       238       275        251      153       188         162       96 
4.3a 
146 
 
 
Figure 4.3 Proportions of CSF culture positive isolates in adults per year 
Figure 4.3a: Proportions of overall adult meningitis in the 20-49 years age group caused by 
cryptococcal infection compared to bacterial infection (2000-2010). N= number of overall cases that 
year 
Figure 4.3b: Cases of culture positive bacterial meningitis in adults showing the proportion caused by 
different pathogens for each year studied (2000-2012) 
 
4.3.2 Estimates of incidence of bacterial meningitis in Malawi 
Estimates of overall incidence of culture positive bacterial meningitis per 100,000 population 
were derived from the complete culture positive data set for each year studied. Overall 
incidence declined from 49.6 in 2002 to 20 in 2012 (Figure 4.4). 
This decline is driven entirely by the >3 months to <5 years age group (incidence 154.4 in 
2002 to 20 in 2012), and remains unchanged in other age groups (5-15yrs incidence 15.7 in 
2002 to 8 in 2012) (Figure 4.4). The adult incidence of bacterial meningitis remains static 
between 2000-2012 at 12/100000 population despite a peak in 2003-5 (Figure 4.4). 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
Year 
Other Neisseria meningitidis Group B Strep
Hib Non typhoidal salmonella Streptococcus pneumoniae
   N=33     52      73     113     54      81     62      43      77      43      41      54     51 
4.3b 
147 
 
 
 
 
 
Figure 4.4 Estimates of incidence of bacterial meningitis in Malawi by age group 
Figure 4.4a. Estimates of incidence of all bacterial meningitis 
Figure 4.4b. Estimates of incidence of culture positive bacterial meningitis by age group studied.  
 
4.3.3 Seasonality of bacterial meningitis by pathogen  
Seasonality in pneumococcal disease has been described in Blantyre in blood stream 
isolates, seasonality in pneumococcal meningitis has also been observed in previous 
analyses from our centre (Gordon et al., 2000, Everett et al., 2011). It is not clear if other 
pathogens causing meningitis may also be seasonal. We tested for seasonality by 
examining the laboratory admission dates for all CSF culture isolates for different pathogens 
against rain and temperature data for the period studied. Detailed methods are found in 
Chapter 3, section 3.2.2.  
 
4.4a 
4.4b 
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S. pneumoniae meningitis is a seasonal disease occurring in the dry season, with an annual 
trough of cases during the rains (Figure 4.5). The mean numbers of cases of S. pneumoniae 
meningitis occurring each year between December to April were significantly lower than the 
overall mean numbers of cases occurring in the rest of the year (p<0.05). The seasonality 
pattern observed persisted despite the overall decline in disease incidence. Using the 
ARMAX model, rainfall was associated with 28% (95%CI: 13.7% to 41.4%, p<0.001) fewer 
cases of pneumococcal meningitis. Pneumococcal meningitis cases were increased by 
42.8% (95%CI: -1.8% to 87.5%, p=0.06) in hot weather but the confidence interval crosses 
the null point. Numbers of cases of NTS meningitis were above the mean in August to 
December and below the mean in January, but the trend did not reach significance. There 
was no seasonal variation in Hib, N. meningitidis or Group B Streptococci case numbers. 
 
 
Figure 4.5 Seasonality of culture positive pneumococcal meningitis 2000-2010 
 
4.3.4 CSF findings in bacterial meningitis 
CSF biochemical parameters were recorded in the culture data from 2007. CSF white cell 
counts (WCC) with the addition of the CSF protein and glucose were tabulated from 2009 
onwards by pathogen and parameters were compared between adults and children (Table 
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4.1). Data relating CSF parameters to infecting organism in bacterial meningitis from sub-
Saharan Africa, are few (Jarvis et al.,2010). A significantly lower CSF WCC was seen in 
cases of S. pneumoniae meningitis compared to N. meningitidis meningitis in both adults 
and children.  
 
The presence or absence of HIV infection did not affect the CSF WCC count due to in 
pneumococcal meningitis in adults (median CSF WCC in HIV positive 435 cells/mm3 (IQR 
107-1680) (n=297) and 575 cells/mm3 (IQR 196-1740) in HIV negative (n=44), p=0.31).  
Table 4.1 CSF parameters for proven bacterial meningitis in Malawi 
CSF parameters in bacterial meningitis by pathogen and age group 
 
CSF 
parameter 
Spn 
meningitis  
Adults 
(n= 795) 
Spn 
meningitis  
Children 
(n=998 ) 
NTS 
meningitis 
Adults 
(n=28) 
NTS 
meningitis 
Children 
(n=269) 
NM 
meningitis 
Adults 
(n=17) 
NM meningitis 
Children 
(n=22) 
Median 
CSF 
protein 
(g/L)  (IQR) 
2.6  
(0-4.6) 
(n=161) 
2.4  
(0.99-3.59) 
(n=170) 
1.84 
(0.92-3.15) 
(n=3) 
1.84  
(0-5.31) 
(n=26) 
4.53  
(3.23-5.54) 
(n=4) 
1.87  
(1.58-3.20) 
(n=4) 
Median 
CSF 
glucose 
mmol/L 
(IQR) 
0  
(0-0.17) 
(n=161) 
0  
(0-0.33)  
(n=146) 
2.75  
(0-3.08) 
(n=3) 
0.06 
(0-0.44) 
(n=25) 
0.08  
(0-0.98) 
(n=4) 
0.42  
(0.14-0.73) 
(n=4) 
Median 
CSF white 
cell count 
cells/mm3 
(IQR) 
335  
(74-1360) 
407  
(130-1360) 
65  
(5-700) 
560  
(150-2800) 
2320 
(155-5920) 
1970  
(250-6800) 
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Both NTS and cryptococcal meningitis were associated with significantly lower CSF WCC 
than S. pneumoniae and N. meningitidis. CSF protein was significantly higher in bacterial 
meningitis caused by all pathogens (with the exception of NTS) than cryptococcal meningitis 
(Median CSF protein SpN 2.6 g/L (0-4.6) compared to CCM 0.88 (0.51 – 1.62), p<0.001). 
 
Similarly median CSF glucose levels, were significantly lower in S. pneumoniae (0 mmol/L 
(IQR 0-17) compared to cryptococcus (1.99 mmol/L (IQR 0.9 – 3.13) (p<0.001) (adults and 
children). A comparison of CSF biochemistry data by HIV status was not possible. This 
analysis forms part of the BAM CSF data analysis and is presented in Chapter 6 section 
6.3.3. 
 
Data were collected for culture negative CSF specimens from 2007. Of the culture negative 
CSF data, 643 adults had a CSF WCC of >100 cells/mm3 and 796 children had a CSF WCC 
of >20 cells/mm3 suggestive of a bacterial aetiology. These estimates were added to the 
culture positive totals for the time period studied. It was estimated that an additional 29% 
adult and 48% paediatric cases of culture negative bacterial meningitis occurred between 
2007-12. Incidence calculations based on culture positive isolates probably therefore 
represent an under-estimate of the true incidence of bacterial meningitis in adults and 
children in urban Malawi. 
 
4.4  Clinical predictors of poor outcome from bacterial meningitis 
The results from section 4.3 of this chapter, demonstrate that the incidence of bacterial 
meningitis in adults living in Malawi is 100 times higher than in well-resourced countries, and 
several studies have reported a significantly higher associated mortality. Following the 
widespread use of penicillin in the 1940-50s, mortality rates from ABM in resource rich 
settings have improved from 45-50% to 11-25% in the last decade. This improvement is 
associated with early institution of antibiotic therapy and better supportive care (Auburtin et 
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al., 2006; Gjini et al., 2006a). In contrast, adult ABM mortality rates in sub-Saharan Africa 
have been reported to vary between 54-70% without any change over time (Gordon et al., 
2000; Manga et al., 2008; Scarborough et al., 2007) and survivors experience significantly 
higher rates of disabling neurological sequelae compared to European patients (Edmond et 
al., 2010). This section details the results of a study that combined all clinical data that was 
available on adult patients with bacterial meningitis in Malawi to interrogate the data to 
determine clinical predictors of poor outcome. The results of this study were used to inform 
the care bundle intervention tested in a clinical trial that is the main focus of this PhD thesis 
(Chapter 6).  
4.4.1 Research question  
1. What are the clinical predictors on admission to hospital of poor outcome in bacterial 
meningitis in Malawi? 
 
Objectives 
1. To create a database consisting of data from clinical studies of ABM in adults and 
adolescents in Blantyre. 
2. To test the combined data for statistical associations between individual clinical 
parameters and outcome at 40 days of follow up.  
 
4.4.2 Methods details 
4.4.2.1 Inclusion criteria:  
• Age >14 years of age (adult ward admission age), or the age limit defined by the 
contributing study (e.g. age >16 years for the GLAM study). 
• Enrolled in a clinical study of ABM at QECH with either 
o Proven microbiological evidence of ABM (culture or PCR positivity of an 
organism from the list of pathogens used in surveillance in the CSF) 
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o High clinical index of suspicion of ABM plus a CSF white cell count that was 
>50% neutrophils and >100 cells/mm3 in HIV negative or 5 cells/mm3 in HIV 
positive.  
The latter was selected as the CSF inflammatory response in ABM may be 
attenuated in HIV (Jarvis et al., 2010).  
Exclusion criteria: 
• CSF microscopy or culture was positive for either Cryptococcus neoformans or 
Mycobacterium tuberculosis. 
• CSF white cells were > 50% lymphocytes 
• Study specific exclusion criteria: SAM: contraindications to study drug 
(dexamethasone), age < 16years, corticosteroids in the preceding 48 hrs, non-
bacterial meningitis (Scarborough et al., 2007). GLAM: age < 16 years,  type II 
diabetes mellitus, pregnancy, heart failure, CSF WCC <100 cells/mm3 , CSF >50% 
lymphocytes (Ajdukiewicz et al., 2011). 
 
4.4.2.2 Database creation 
Details of the creation of the database are found in Chapter 3, Section 3.2.1.  
 
4.4.2.3 Outcome measures, variable selection & data analysis 
The outcome measure for included trial subjects was mortality, measured at day 40 and at 
day 10. Day 40 was considered the most important measure of outcome, as additional 
mortality from ABM was observed following hospital discharge in both SAM and GLAM, and 
determination of predictive factors for this variable was deemed important. 
Eighteen clinical and demographic parameters were selected on the basis of previous 
published associations and suspected risk factors, and subjected to analysis for associations 
with death (van de Beek et al., 2004; Brouwer et al., 2007; Scarborough et al., 2007; 
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Ajdukiewicz et al., 2011). Age >40 was selected as the current life expectancy in Malawi is 53 
years (Malawi, 1998) . The analysis plan was designed first to test all 18 variables against 
mortality using univariate analysis, followed by multivariate analysis of parameters with a 
significant univariate association. 
 
Due to the heterogeneous nature of the studies included, some significant variables had 
missing data; where >50% of the data were missing, these variables were excluded from the 
multivariate analysis. The multivariate analyses were repeated using multiple imputation 
methods to enable subjects with missing data to be included; this did not alter the results and 
these analyses are not presented. These analyses were done in collaboration with Dr Brian 
Faragher at LSTM. 
 
4.5 Results of clinical predictors of outcome from meningitis 
4.5.1 Included clinical studies 
Five studies were identified. One observational study was excluded as it was conducted 
prior to the introduction of ceftriaxone in 2001 under different admission conditions (Gordon 
et al., 2000). One vaccine trial was excluded as specific clinical data for the patients with 
meningitis were not available (French et al., 2010). The three included studies were two 
clinical trials, testing dexamethasone (Scarborough et al., 2007)  or glycerol adjunct therapy 
(Ajdukiewicz et al., 2011) and an unpublished prospective cohort study investigating risk 
factors for mortality (Table 4.2). All studies recruited patients over the ward admission age 
(14 years, or on study specific age limits) with ABM and used ceftriaxone as the first line 
antibiotic.  
A total of 891 participants were identified. 115 patients were excluded who had either proven 
fungal (n=52) or tuberculous meningitis (TBM) (n=25), or a CSF white cell count of <5 
cells/mm3 (n=38). 
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Table 4.2 Details of studies included in the analysis 
Included studies in the Malawi meningitis database 
Study name  Study 
dates 
Type of study Intervention 
tested 
Number of 
cases 
(number 
included) 
number 
of deaths 
(%) 
Steroids in Adult 
Meningitis study 
(SAM)(Scarborough et 
al., 2007)  
2001-
2004 
Randomised 
Controlled Trial 
Intravenous 
Dexamethasone 
adjunct to 
antibiotics  
465 (433) 233 (54) 
Glycerol in Adult 
Meningitis 
(GLAM)(Ajdukiewicz et 
al., 2011)  
2006-
2008 
Randomised 
Controlled Trial 
Oral glycerol 
adjunct to 
antibiotics 
265 (239) 129 (54) 
Cohort 
observational 
study  
2009 Observational 
cohort 
No intervention 161 (43)  
 
22 (51.1) 
 
A further sixty one patients were excluded because no mortality data were available at day 
10, yielding 715 cases for the analyses (Figure 4.6). 
A relatively high proportion of participants from the cohort study (118/161) were excluded 
compared to 26 from the glycerol trial and 32 from the dexamethasone trial. This was due to 
a high number of patients in this database either not meeting the white cell count inclusion 
criteria for this analysis or having mortality data available.  
Free access to HIV treatment become routinely available during the study period; co-
trimoxazole prophylaxis in 2002 and anti-retroviral therapy (ART) from 2004 (Everett et al., 
2011). 
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Figure 4.6 Selection of cases for the Malawi meningitis database 
 
4.5.2 Patient characteristics and clinical and laboratory findings 
The median age was 31 years (inter-quartile range IQR 25-38) and half were female 
(50.3%). 20 participants (2.8%) were adolescents. 608/695 (87%) of those tested were HIV 
antibody positive, of which 36 (5.9%) were on ART (Table 4.3). CD4 cell counts were not 
routinely measured during the time period studied. 
The overall mortality rate was 45.3% in hospital by day 10, and 54.3% by day 40, with no 
significant difference across the three studies (Table 4.3). Altered mental status and coma 
were common. The median presenting Glasgow Coma Score (GCS) was 12 (IQR 9-14.0) 
and 113 (17.4%) of participants presented with a GCS of 8 or less. 319 (44.6%) participants 
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experienced an acute seizure and 89 participants experienced seizures after discharge. 
Fever >38°C (88.5%), headache or history of headache (99%) and neck stiffness (75%) 
were common, however photophobia was rare (15.5%). Septic shock was uncommon; the 
median pulse rate was 100 beats per minute (IQR 88-116) and the median mean arterial 
pressure (MAP) was 86 mmHg (IQR 79.9-96.7). Neurological disability (with the exception of 
post discharge seizures) and hearing loss were reported differently across the included 
studies and could not be sufficiently standardised for inclusion on the analysis.  
CSF culture was positive in 419 of 712 specimens (59%) (Table 4.3). S. pneumoniae was 
the most common isolate (356/419, 85%) followed by N. meningitidis (17/419, 4%). Other 
isolates included NTS, E. coli, Group A streptococci and H. influenzae. The median CSF 
white cell count was 480 cells/mm3 (IQR 170-1680). CSF opening pressure was not routinely 
recorded. Blood cultures were positive in 185/664 (28%) of individuals; the most commonly 
isolated organisms being (126/185, 68%), enteric gram negative organisms (27/185, 15%) 
and N. meningitidis (8/185, 4%). Of 352 pneumococcal CSF isolates where paired blood 
culture data were available, 139 (40%) were positive.  
 
Comprehensive data on antimicrobial resistance were not available. Pneumococcal serotype 
was determined in 128 of 352 isolates using MLST serotyping; 56 (43.8%) were serotype 1.  
Other serogroups were 6 (4.7%), 7 (3.1%), 9 (4.7%), 12 (3.9%), 14 (4.7%), and 19 (3.1%). 
Mortality was 59% (33/56) for the participants infected with serotype 1 and 50.1% (36/71) for 
the other serogroups. There were too few data to analyse this trend further.  
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Table 4.3 Characteristics of patients included in the Malawi meningitis database  
Baseline characteristics of included study participants 
Characteristic on 
presentation 
 
Number of observations 
available 
Value (% or Inter Quartile Range 
IQR) 
Clinical observations   
Deaths at day 10  715 324 (45.3) 
Deaths at 40 days 668 363 (54.3) 
Female sex  715 364 (50.3) 
HIV positive  694 607 (87) 
Antiretroviral therapy 607 35 (5.7) 
Out of hours admission  655 315 (48) 
Median age  715  31 (25-38) 
History of acute headache  691 683(99) 
Neck stiffness  715 536 (75) 
Photophobia  683 106 (15.5) 
Median Glasgow Coma Score  649 12.0 (9-14) 
GCS >8-<11 (significant 
alteration of mental status)   
649 169(26) 
GCS <8 (coma) 649 113 (17.4) 
Recorded acute seizure 714 319 (44.9) 
Seizure post discharge 416 89 (21) 
Median mean arterial blood 
pressure (mmHg) recorded  
593  86 (79.9-96.7) 
Median pulse (bpm)  596  100 (88-116) 
Mean temperature (°C) 
recorded  
668  38.1 (37.2-39) 
Median recorded oxygen 
saturations  
 
 
207  96% (93-97) 
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Microbiology Number of observations 
available 
Value (% or Inter Quartile Range 
IQR) 
Positive CSF culture  712 419 (58.8) 
S. pneumoniae n= 356 (84.9) 
N. meningitidis n= 17 (4.1) 
H. influenzae n=3 (0.7) 
Other n=43 (10.2) 
Median CSF white cell count 
(cells/mm3)  
707  480 (170-1680) 
Positive blood culture 660 185 (27.8%) 
S. pneumoniae n= 126 (68.4) 
N. meningitidis n= 8 (4.1) 
H. influenzae n=1 (0.4) 
Enteric Gram negative n=27 (14.9) 
Other n=23 (12.4) 
Blood tests  Median (IQR) 
Sodium (mmol/L)  43  135 (130.9-139.1) 
Haemoglobin (g/dL)  643  10.8 (9.0-12.7) 
Glucose (mmol/L)  546  6.7 (6.0-98.7) 
Creatinine (mg/dL) 40 1.1 (0.9-1.2) 
  
 
4.5.3 Results of data analysis 
Eighteen parameters measured on admission were subjected to univariate analysis for 
associations with survival at day 10 (n=715) and day 40 (n=668). There was no statistically 
significant difference in the association with outcome for all tested variables between these 
two time points except pneumococcal culture and therefore the day 40 follow up data are 
presented (Table 4.4).  
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The following clinical parameters were significantly associated with poor outcome on 
univariate analysis: age, clinical presentation with altered mental status, acute and post 
discharge seizures, hypoxaemia, tachycardia, hyponatraemia, anaemia and treatment with 
glycerol. Neither gender, out of hours admission, HIV antibody status, blood glucose, mean 
arterial blood pressure, oligo-anuria, respiratory rate, nor serum creatinine were associated 
with poor outcome (Table 4.4). Of the 339 participants with a pathogen isolated from the 
CSF, 181 (54%) died by day 40 - univariate OR 0.923 (0.68 : 1.25) p= 0.61. As culture of S. 
pneumoniae in the CSF and HIV status have been associated with mortality in other studies 
of bacterial meningitis (Nyasulu et al., 2011; Domingo et al., 2009) these data were added to 
the multivariate model with the other tested variables.  Coma scores were grouped into three 
clinically relevant categories: <8, 8-11 and >11. Oxygen saturations, post discharge 
seizures, respiratory rate, anuria, creatinine and sodium had >50% of data missing and were 
excluded from multivariate analysis. Seizures were divided into acute (pre-hospital and in 
hospital) and seizures during follow up. Haemoglobin and pulse rate were divided into 
clinically significant groups to ease the clinical interpretation of the results. Hb was 
categorized as <5g/dL, 5-8.5g/dL, 8-11.5g/dL, 11-14.5g/dL and >14.5g/dL. Pulse was 
categorised into normal (<100 beats per minute), mild (100-120 bpm) and severe 
tachycardia (>120 bpm). 
 
4.5.4 Results of the multivariate analysis to derive clinical prognostic markers 
of outcome 
Presentation with coma was the strongest independent predictor of outcome after 
multivariate analysis; OR for death with a GCS <8/15 was 5.9 (95% CI 3.31 : 10.86) 
p<0.001, GCS of 8-11 was 1.665 (1.08 :  2.5 ) p=0.007 (Table 4.4). Acute seizures were 
associated with death, OR 1.55 (1.08 : 2.24) p=0.019. The severity of anaemia was 
associated with a corresponding increasing risk of mortality, OR death of haemoglobin (Hb) 
5-8g/dL was 3.41 (1.61 : 7.23) p=0.001; at Hb <5g/dL the OR was 6.34 (1.86 : 21.62) 
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p=0.003. Every 1g/dL increase in haemoglobin was associated with a 12% reduction in 
mortality, OR 0·88 (0.82-0.94). Tachycardia >120 bpm was also associated with death, OR 
1.80 (1.08 : 2.99) p=0.023. Glycerol receipt was independently associated with mortality 1.88 
(1.09 : 3.25) p=0.023. Age >40 years was not significant, OR 1.33 (0.86 : 2.06) 
p=0.20.Neither CSF pneumococcal culture positivity nor HIV status were significantly 
associated with mortality at day 40. The OR of death were 0.70 (0.49 : 1.02) p=0.06 for 
pneumococcal infection, and  1.18 (0.70 : 2.00) p=0.52 for HIV infection. No parameter 
reaching non-significance at the univariate level was shown to have significant association at 
the multivariate level. 
Mortality was not seasonal; 279 (36%) of cases presented in the cold winter season (May-
September), with 145 (52%) deaths and 388 (64%) cases presented during the remaining 
hot months of the year with 217 (56%) deaths p=0.34 (Figure 4.7).  
 
4.5.4.1 Delays to presentation to hospital and clinical care 
Presentation out of routine working hours comprised 318 (44.5%) of admissions. For a 
subset of patients with culture proven ABM ‘the observational cohort’, (n=26) data were 
collected prospectively relating to the patient pathway on a standard form to investigate 
delays in presentation, investigation and initiation of therapy.   Nine of 26 patients (35%) died 
before day 10.  Median self-reported journey time to QECH was 0.8 hours (IQR 0.5-1.6) in 
non-survivors, and 1.5 hours (IQR 0.7-2.0) in survivors. Median time from presentation to 
medical review was 2.8 hours (IQR 0.8-5.8) in non-survivors and 1 hour (IQR 0.6-3.0) in 
survivors. The median time from presentation at the hospital with meningitis to receipt of 
intravenous antibiotics was 5.0 hours (IQR 2.5-8.9) in non-survivors and 2.7 hours (IQR 1.7-
6.0) in survivors. No time difference reached statistical significance.  
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Figure 4.7 Seasonal admission and outcome data for adults with ABM 2000-2009 
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Table 4.4 Predictors of poor outcome from bacterial meningitis 
Table 4: Univariate and multivariate predictors of poor outcome in adults with bacterial meningitis 
Parameter Day 40 Univariate (unadjusted) Multivariate (adjusted)** 
Alive Dead Odds ratio (95% CI) p Odds ratio (95% CI) p 
Sample size  304 363     
Age mean (sd) 31.5 (10.7) 34.2 (11.4) 1.023 (1.009 : 1.038)‡ 0.002   
 ≤ 40 years 256 285 (52.7%) --- --- --- --- 
 > 40 years   48   78 (61.9%) 1.460 (0.981 : 2.171)   0.062 1.327 (0.858 : 2.055)   0.204 
Gender male 149 177 (54.3%) --- --- --- --- 
 female 155 186 (54.5%) 1.010 (0.754 : 1.370)   0.948 0.894 (0.621 : 1.287)   0.548 
HIV status negative   43   37 (46.2%) --- --- --- --- 
 positive 254 316 (55.4%) 1.446 (0.904 : 1.370)   0.124 1.184 (0.700 : 2.001)   0.528 
 not known 7 10     
Out of hours admission no 138 173 (55.6%) --- --- --- --- 
 yes 134 162 (54.7%) 0.964 (0.700 : 1.328)   0.824 0.949 (0.661 : 1.362)   0.777 
 not known 32 28     
GCS mean (sd) 12.2 (2.8) 10.2 (3.6) 0.825 (0.786 : 0.867)‡ <0.001   
 ≥ 11 205 168 (45.0%) --- --- --- --- 
 8 – 11   69   94 (57.7%) 1.662 (1.146 : 2.411)   0.007 1.665 (1.086 :   2.554)   0.007 
 <8   20   84 (80.8%) 5.125 (3.021 : 8.695) <0.001 5.999 (3.314 : 10.861) <0.001 
 not known 10 17     
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Table 4. Univariate and multivariate predictors of poor outcome in adults with bacterial meningitis continued 2 
Parameter Day 40 Univariate (unadjusted) Multivariate (adjusted)** 
Alive Dead Odds ratio (95% CI) p Odds ratio (95% CI) p 
1 or more acute no 216 207 (48.9%) --- --- --- --- 
seizure episodes yes 87 156 (64.2%) 1.871 (1.353 : 2.588) <0.001 1.552 (1.075 : 2.241)   0.019 
 not known      1 0     
Seizure post-discharge no 271   57 (17.4%) --- ---   
 yes 23   64 (73.6%) 13.230 (7.591 : 23.057) <0.001 † † 
 not known 10 242     
SpO2 mean (sd) 95.2 (2.7) 93.5 (5.7) 0.888 (0.806 : 0.978)‡   0.016 † † 
 >95   52   48 (48.0%) --- ---   
 92 – 95   26   32 (55.2%) 1.333 (0.696 : 2.552)   0.385 † † 
 <92   11   29 (72.5%) 2.856 (1.287 : 6.339)   0.010   
 not known 215 254     
Pulse rate mean (sd) 96.9 (18.6) 103.1 (19.0) 1.018 (1.008 : 1.027)‡ <0.001   
 <100 172 162 (48.5%) --- --- --- --- 
 100–120   39   57 (59.4%) 1.552 (0.979 : 2.459)  0.061 1.422 (0.844 : 2.397)  0.186 
 >120   44   76 (63.3%) 1.834 (1.194 : 2.816)  0.006 1.800 (1.084 : 2.987)  0.023 
  
not known 
 
           49 68     
164 
 
 
Table 4. Univariate and multivariate predictors of poor outcome in adults with bacterial meningitis continued 3 
Parameter Day 40 Univariate (unadjusted) Multivariate (adjusted)** 
Alive Dead Odds ratio (95% CI) p Odds ratio (95% CI) p 
MAP (mmHg) mean (sd) 89.7 (13.0) 89.0 (15.5) 0.996 (0.985 : 1.008)‡   0.530   
 <90 152 174 (53.4%) --- --- --- --- 
 90-100   57   66 (53.7%) 1.011 (0.667 : 1.533) 0.957 0.972 (0.622 : 1.520) 0.902 
 >100   44   56 (56.0%) 1.112 (0.708 : 1.745) 0.645 1.107 (0.636 : 1.925) 0.720 
 not known 51 67     
Respiratory rate mean (sd) 23.8 (  9.6) 24.2 (  6.3) 1.007 (0.954 : 1.064)‡   0.790 † † 
 not known 246 299     
Anuria no 208 252 (54.8%) --- --- --- --- 
 not known 96 111     
CSF culture positive for  
   
no 145 180 (55.4%) --- --- --- --- 
yes 158 181 (53.4%) 0.923 (0.680 : 1.253)   0.606 0.704 (0.488 : 1.016)   0.061 
 not known 1 2     
Plasma glucose  mean (sd) 7.3 (  2.7) 7.4 (  3.8) 1.007 (0.957 : 1.059)‡ 0.793   
(mmol/L) ≥9 46 45 (49.5%) --- --- --- --- 
 6-9 90 102 (53.1%) 1.159 (0.703 : 1.909) 0.563 1.292 (0.748 : 2.234) 0.358 
 ≤6 101 123 (54.9%) 1.245 (0.764 : 2.028) 0.379 1.423 (0.763 : 2.653) 0.268 
 not known 67 93     
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Table 4. Univariate and multivariate predictors of poor outcome in adults with bacterial meningitis continued 4 
Parameter Day 40 Univariate (unadjusted) Multivariate (adjusted)** 
Alive Dead Odds ratio (95% CI) p Odds ratio (95% CI) p 
        
Haemoglobin (g/dL) mean (sd) 11.4 (  2.9) 10.5 (  2.9) 0.893 (0.841 : 0.949)‡ <0.001 
 >14 50 32 (39/0%) …. ….   
 8-11 104 134 (56.3%) 2.013 (1.206 :   3.360) 0.007 2.598 (1.422 :   4.747) 0.002 
 5-8   26   45 (63.4%) 2.704 (1.404 :   5.210) 0.003 3.404 (1.603 :   7.229) 0.001 
 <5     4   11 (73.3%) 4.297 (1.259 : 14.662) 0.020 6.343 (1.861 : 21.624) 0.003 
 not known 67 93     
Glycerol treatment no   58   53 (47.7%) --- --- --- --- 
 yes   47   76 (61.8%) 1.770 (1.051 : 2.978) 0.032 1.884 (1.092 : 3.249) 0.023 
 not known 199 93     
Na (mmol/L)* median (range) 137 (125:199) 132 (115:152) 0.928 (0.834 : 1.032)‡ 0.166 † † 
 not known 283 341     
Creatinine (mg/dL)* median (range) 1.05 (0.7:1.5) 1.15 (0.5:10.8) 4.441 (0.682 : 28.925)‡ 0.119 † † 
 not known 286 341     
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4.6  Summary and discussion of results findings from Chapter 4 
In this chapter, a systematic analysis of all cases of bacterial meningitis that had been 
admitted to QECH between 2000-2012 was done. The two approaches covered in this 
chapter (systematic surveillance and analysis of clinical trial data) demonstrate important 
trends in bacterial meningitis, with clear differences between adult and paediatric disease. In 
addition predictors of poor outcome in adults have been identified.  
Marked differences exist between adult and paediatric bacterial meningitis. The incidence of 
paediatric disease is very high, particularly children under the age of 5 years, but has fallen 
dramatically in response to vaccination campaigns, improvements in child health and 
potentially also the reduction of vertical HIV transmission. In contrast ABM in adults has a 
lower incidence, however, incidence has not fallen in response to major public health 
interventions including the roll-out of ART. S. pneumoniae is the primary cause of bacterial 
meningitis in both groups now Hib and GBS incidence have fallen. N. meningitidis remains a 
sporadic disease with low incidence in both groups.  
Adult bacterial meningitis incidence in Malawi is 12/100 000 population in Malawi in this 
study, more than 100 times higher than estimates from the UK and the US of 0.1-1.4/100 
000 (Gjini et al., 2006b; Thigpen et al., 2011; Okike et al., 2014). The incidence data 
presented here are the first formal incidence estimates from SSA based on systematic 
surveillance rather than meta-analysis of clinical study data. The estimate from this study is 
based on culture positive isolates, and therefore this figure may be a substantial under-
estimate compared to the true figure (Wu et al., 2013). Further data presented in this thesis 
from the BAM study on the frequency of culture negative but PCR positive meningitis will 
assist in improving this estimate of the burden of adult disease (Chapter 6). Incidence 
estimates from this region of ABM in adults preceding the HIV epidemic are lacking, but 
many centres have reported increasing case numbers since the start of the HIV epidemic 
(Molyneux et al., 2003; Schutte et al., 2000).  Causes for such a high burden of ABM in this 
region are not fully understood, but high rates of pneumococcal carriage, seasonal disease 
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with 20% of disease caused by S.pneumoniae serotype one, a high burden of HIV infection 
underpinned by poverty with high rates of poor housing and overcrowding may all be 
implicated (Glennie et al., 2011; Everett et al., 2012; Cornick et al., 2011; Roca et al., 2012; 
Huang et al., 2004).   
From the monthly rain and temperature data, pneumococcal meningitis is clearly a seasonal 
disease. Peaks in cases occur in the cool, dry season each year, a pattern that has 
persisted despite the fall in paediatric disease. Adult mortality is static at approximately 50% 
throughout the year. Seasonality of pneumococcal meningitis has been reported from West 
and central Africa ‘the meningitis belt’, coinciding with the better known seasonal epidemics 
of meningococcal disease that occur regularly in that region in the hot dry weather preceding 
the onset of the rains (Molesworth et al., 2003; Gessner et al., 2010). Seasonality in 
meningitis during the rainy season has been reported from Uganda, but no seasonality was 
found in another study in Tanzania, neither centre has a systematic surveillance programme 
in place (Williams et al., 1986; Wiersinga et al., 2004). Very few centres beyond the 
meningitis belt undertake routine meningitis surveillance, so it is not known if seasonality 
occurs in other regions, but it is intriguing that the seasonal pattern of pneumococcal disease 
in Blantyre occurring in the dry season matches that of the West African centres, despite 
Malawi being over 3000km from the meningitis belt region. 
Invasive pneumococcal disease is strongly associated with HIV infection, particularly in 
Africa, and in 87% of cases of probable or proven meningitis were HIV co-infected (French 
et al., 2010). It is surprising that  the roll out of ART and better care for HIV infected adults 
has not resulted in a decline in pneumococcal meningitis when a decline has been seen in 
invasive bloodstream infections (Everett et al., 2011). The immunology group at MLW have 
previously demonstrated high rates of pneumococcal carriage with broad serotype diversity 
in HIV infected adults despite the initiation of ART (Glennie et al., 2013). Further work from 
this group has shown that poor T cell responses to pneumococci are present in HIV co-
infected adults, irrespective of CD4 count (Glennie et al., 2011).  It is therefore a reasonable 
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hypothesis that persistent defects in immune control in the nasopharynx and potentially the 
CSF compartment could account for the continuing high incidence of pneumococcal ABM in 
adults. In the meningitis belt, changes in weather, particularly hot weather and viral co-
infection with respiratory pathogens has been associated with increased invasive 
meningococcal disease from the natural carriage state (Mueller et al., 2008). This has not 
been studied in Malawi, but it is likely that temperature changes and influenza season that 
coincide with the peaks of disease seen in these data influence in the incidence of 
pneumococcal meningitis. 
 ART roll out, which has led to nearly 350 000 adults nationally alive on ART at the end of 
2012 has also failed to impact on the prevalence of cryptococcal meningitis as well as 
pneumococcal meningitis. The reasons for this are unclear, but over the time period studied 
more adults have started ART with a low CD4 count and no clinical evidence of CCM, rather 
than presenting with a first episode of CCM as a presentation of new HIV disease. The static  
rates of CCM in adults are therefore likely to be due to fewer patients presenting with new 
CCM in the absence of ART, and increasing numbers of patients presenting as part of an 
immune reconstitution inflammatory syndrome (IRIS) in the first 12 months of ART (Walker 
et al., 2012; Parkes-Ratanshi et al., 2011).  
Despite the clear association between pneumococcal meningitis and HIV infection, HIV was 
not a predictor of poor outcome in the clinical mortality analysis. 87% of adults in the 
database were HIV infected; the numbers of HIV negative patients were small. Patients with 
HIV-infection have higher rates of pneumococcal disease and altered T-cell immunity to 
pneumococcal infection, so why the presence of HIV-infection did not predict mortality is 
intriguing (Glennie et al., 2013; Glennie et al., 2011).  The results are not stratified by CD4 
count as these data were unavailable for the database, however it is likely that the majority 
of patients were severely immunocompromised as IPD is a WHO stage 3 condition. Multiple 
factors are likely to be implicated in the pathological causes of poor outcome including highly 
virulent bacteria that produce high levels of toxins, consumption of complement within the 
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CSF compartment and  likely overall defects in host responses to pneumococci that occur 
irrespective of HIV infection (Wall et al., 2012; Goonetilleke et al., 2012; Wippel et al., 2013). 
This will be the subject of further work after the completion of this thesis. 
Poor outcome from bacterial meningitis was predicted by altered mental state and coma, 
seizures, anaemia, tachycardia and hypoxaemia. These variables were taken forward into 
the care bundle design to test if supportive clinical measures and early antibiotics may be 
feasible and effective in the AETC environment at QECH (Chapter 3 Section 3.3.5). It is 
clear that patients present very unwell to a hospital which has profound limitations on clinical 
resources available for treatment and supportive care. Optimisation of resuscitation with 
targeted restoration of normal physiological variables and early antibiotic therapy presents 
an opportunity to improve the clinical management of these very sick patients and potentially 
improve outcome. The results of goal directed therapy delivered as a care bundle are 
detailed in Chapter 6. 
The predictor variables identified in this analysis were taken forward to synthesise a clinical 
predictor score for adults with bacterial meningitis, the results of which can be found in the 
following Chapter 5. 
Summary 
S.pneumoniae is the predominant cause of ABM in both adults and children in Blantyre. 
Paediatric ABM cases have significantly declined over the last 12 years, adult disease 
incidence is static. Pneumococcal meningitis is a seasonal disease in Malawi, mortality is not 
seasonal. Mortality is highest in adults presenting with a severe clinical phenotype including 
seizures, altered mental state and anaemia, HIV was not a predictor of mortality. The results 
from this chapter have led to the development of a severity score to predict outcome from 
ABM, and the design of a clinical trial to test if optimized clinical management of the clinical 
features associated with poor outcome is feasible in Malawi. 
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5 Development of a prediction tool for adult bacterial meningitis 
in sub-Saharan Africa: Malawian Adult Meningitis Score 
(MAMS) 
 
5.1  Introduction 
Individual predictors of poor outcome from severe meningitis in adults, as detailed in the 
previous chapter, are of interest to both clinicians and clinical scientists studying disease 
pathogenesis, and for use in developing and assessing clinical interventions. However 
individual predictors are of little practical use to the treating clinician at the patient bedside as 
few directly useful clinical data can be derived from each predictor in a clinical situation.  
 
Severity scores have been developed for many illnesses to attempt to synthesise individual 
predictor variables into reliable bedside tools, the ascertainment of the risk of a poor 
outcome can assist stratifying or escalating clinical care as necessary (Adams and Leveson, 
2012). For adults, a number of severity scores are in existence for infectious diseases in 
well-resourced settings, particularly sepsis (APACHE-II, SOFA) and pneumonia (CURB-65). 
These scores have been well-validated prospectively in multiple studies after publication of 
the original score data and are in regular clinical use (Knaus et al., 1985; Bauer et al., 2006; 
Richards et al., 2011). A well validated score for diagnosis of ABM in children exists, but few 
severity scores have been developed for children specific to meningitis (Nigrovic et al., 
2012). Several scores have been developed to predict outcome from intensive care for 
children with meningococcal septicaemia (Castellanos-Ortega et al., 2002; Castellanos-
Ortega and Delgado-Rodriguez, 2000), these patients are very different to adults with 
bacterial meningitis and no paediatric score has been tested on or validated on adult data.  
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Few severity scoring systems exist for adults with ABM. The first such score was developed 
in the USA (Aronin et al., 1998), using retrospectively collected data with small numbers of 
patient data in both the discovery and validation datasets. A predictive index or formal score 
was not developed by this group; patients were only divided into low/medium/high risk of 
negative outcome according to three predictors of outcome derived from the discovery 
cohort. Despite good concordance (a comparison of observed number of outcomes to the 
predicted number of outcomes) in the small independent validation dataset of 0.81 (95% CI 
0.71 – 0.92) this score has not entered routine clinical use and has not been validated 
prospectively (Aronin et al., 1998).  One severity score for bacterial meningitis has been 
developed prospectively in Europe (Weisfelt et al., 2008). This score was derived from data 
collected in a large study of dexamethasone for bacterial meningitis (de Gans and van de 
Beek, 2002) and validated on data from the European Dexamethasone cohort study 
(Weisfelt et al., 2006a). Patients in these studies were predominately of white European 
ethnicity, were middle aged and many had co-existent medical conditions such as diabetes. 
The study team derived a nomogram from the discovery data and validated it against the 
separate discovery data. The concordance index for the Dutch score was 0.84 (95% CI 0.81 
- 0.86). This score was then validated externally against two datasets from clinical trials of 
dexamethasone for bacterial meningitis, done in Malawi and Vietnam (Schut et al., 2012).  
The score performed poorly when applied to both datasets, but particularly to Malawian data 
from the SAM trial (Scarborough et al., 2007); the concordance index of the Dutch score in 
Malawi was 0.68 (95% CI 0.63 : 0.73) (Schut et al., 2012). From the comparison of the 
clinical parameters of the patients in the two cohorts, the Malawian patients were 
considerably different from the Dutch patients with Malawian patients being significantly 
younger (median age in Europe 55 years compared to 31 years in Malawi p<0.001), having 
high rates of HIV co-infection (<1% in Europe and 90% in Malawi p<0.001) and much lower 
CSF WCC (median 3000 cells/mm3 in Europe and 480 cells/mm3 in Malawi p<0.001). It was 
clear that due to the failure of the European score and the marked differences between the 
two populations, that a score derived from patient data collected in sub-Saharan Africa 
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would be necessary. A locally derived score with good predictive index would have the 
potential to be used in further clinical research projects in the region, as well as be a useful 
clinical tool. In this chapter, similar methodology to the European group was used to derive a 
severity prediction score for adults with bacterial meningitis in Malawi.  
 
5.1.1 Overview of severity score development including validation loop 
processes 
To develop a severity scoring system, it is ideal to have two separate data sets, one to be 
used for discovery of the score, and the other for validation (Cook, 2008, Adams and 
Leveson, 2012). Separate datasets for discovery and validation allow for confidence in the 
power of the score to predict outcome in different circumstances. Validation within the same 
dataset, even if cases are randomly selected, is subject to the homogeneous nature of one 
dataset and the high probability of the randomly selected cases being very similar to those in 
the derivation cohort and hence excellent concordance but low transferability (Adams and 
Leveson, 2012). 
The severity score is derived from the discovery cohort, and tested against the validation 
cohort for predictive performance.  If performance is sub-optimal, the discovery process is 
refined and re-run on the discovery cohort, and then the revised score is tested again 
against the validation cohort. The ‘validation loop’ process must be repeated until optimum 
concordance between predicted and true outcome is reached in the validation data (Figure 
5.1). External validation of the severity score is then undertaken either using independent 
data from an outside source, or subsequently tested in a prospective clinical trial.  
Where one large study cohort dataset exists, data can be divided into separate discovery 
and validation cohorts by random selection (Cook, 2008). If this methodology is used then 
further external validation is required before the score is tested prospectively in a clinical 
setting (Cook, 2008). 
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Figure 5.1 Processes for developing severity scoring systems 
 
Based on the extensive literature for development of severity scoring systems, a ratio of 2:1 
(discovery : validation) is  ideally required for, either if one dataset is split for discovery and 
validation, or if two different datasets are used (Cook, 2008). If one dataset is split, greater 
than 50% of all available cases must be used for discovery to ensure the predictors derived 
from the discovery data are as accurate as possible and all biases and missing data 
minimised. As the discovery process is based on logistic regression modelling, the largest 
possible numbers should be entered into the modelling process to increase the power and 
ensure accuracy in determining the risks of each variable in predicting poor outcome. 
Remaining data are then used for validation (Cook, 2008). A smaller number of cases are 
required for validation as this process checks the accuracy of the original predictive score 
derived from the predictive variables only (Adams and Leveson, 2012).  
Once data are correctly selected, regression modelling is then done on the data to determine 
the predictors of poor outcome. Two different approaches are then available for creation of 
the score; decision tree modelling or development of a nomogram. Decision tree modelling is 
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best used for scores that assist in diagnoses, or discrimination between two conditions, as 
the outcomes from a decision tree are based on binary decisions at all levels (Adams and 
Leveson, 2012). A nomogram is better used for outcome prediction as the nomogram 
creates a severity index that can then be applied to the validation data to determine an 
individual risk of poor outcome on a scale rather than as a binary variable yes/no (Cook, 
2008). The nomogram approach was used in this chapter for development of the meningitis 
severity score.  
 
5.2  Methods 
5.2.1 Objectives and research questions 
Research question 
Can a prognostic risk scoring system be derived from existing meningitis clinical trial data 
that will reliably predict poor outcome? Will this score be useful to compare predicted 
outcome from admission variables in BAM across the two trial phases? 
Objectives for this chapter 
1. To utilise the existing data used to describe individual predictor variables developed 
in Chapter 4, Section 4.5.4 as a discovery cohort to develop a severity prediction 
score. 
2. To validate this score against BAM data collected in the first observation phase to 
assess sensitivity and specificity of the score in predicting mortality at day 40 post 
admission with bacterial meningitis.  
 
Data analysis for this chapter was done in conjunction with Dr Mavuto Mukaka and Dr Brian 
Faragher. Dr Mukaka performed the random selection to divide data from the meningitis 
database into discovery and validation data, created the nomograms performed each 
validation exercise, calculated the concordance index for each nomogram, drew the 
receiver-operated curves and estimated the sensitivity and specificity of the final nomogram. 
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All other analyses were performed by myself. Dr Faragher provided guidance and support to 
both myself and Dr Mukaka and verified the final data. 
 
5.2.2 Inclusion and exclusion criteria for MAMS 
5.2.2.1 Discovery cohort: 
Adults and adolescents with ABM, meeting the criteria for inclusion in the historical database 
for discovery of predictive variables for day 40 mortality were included (Chapter 4 Section 
4.5.4). These patients had been recruited to one of the SAM, GLAM and pilot studies. 
Patients who received glycerol in the GLAM trial were excluded due to the additional 
mortality attributed to glycerol receipt. The inclusion of these cases in the discovery cohort 
would have potentially confounded the derivation of a severity scoring system (Ajdukiewicz 
et al., 2011). The full inclusion and exclusion criteria for this database can be found in 
Chapter 4 Section 4.4.2. 
 
5.2.2.2 Validation cohort:  
Adults over the age of 14 years with proven or probable ABM recruited to BAM phase 1 were 
originally planned to be the primary validation cohort. However due to small numbers of 
patients recruited to BAM phase 1 (n=71), additional cases were randomly selected from the 
Malawi meningitis database and also included to ensure the validation cohort had adequate 
numbers for validation.  
The latter data from the Malawi meningitis database were randomly selected and removed 
from the database prior to the extraction of complete case data for the discovery process. 
The full inclusion and exclusion criteria for the BAM study can be found in Chapter 3 Section 
3.3.4 BAM inclusion criteria varied from the meningitis database inclusion criteria by 
including patients who met the following criteria: aged >14 years with either proven ABM on 
CSF culture or PCR, or probable ABM with a typical presenting phenotype, a CSF WCC >50 
cells/mm3 >50% neutrophils and with the following biochemistry: CSF:Blood glucose ratio of 
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<0.4, protein >0.5g/L and CSF lactate >4mmol/L. The only difference between the inclusion 
criteria for the two datasets were he CSF WCC inclusion criteria in the meningitis database 
had a CSF WCC cut off of >5 cells/mm3 in HIV infected and >100 cells/mm3 in HIV negative 
individuals. No discrimination was made using CSF biochemistry or PCR data in that 
database. 
 
5.2.3 Derivation of the MAMS discovery and validation cohorts 
5.2.3.1 Sample sizes  
From the available data from the Malawi meningitis database and the BAM Phase 1 data, it 
was estimated that a total of 600 cases with complete day 40 mortality data would be 
available for the score discovery and validation. Using the 2:1 ratio (Cook, 2008), 400 cases 
would be used for discovery and 200 for validation. It is estimated that the accuracy of 
validation data is optimal when the number of cases available for validation is >200 (Cook, 
2008). To achieve this, 71 cases were available from BAM for validation and 543 in the 
meningitis database for discovery and validation. The 543 cases from meningitis database 
were randomly split into 80 complete cases for validation and 400 complete cases for 
discovery, using the ‘sample’ command’ in STATA-10 by Dr Mukaka. 
  
Discovery cohort: From the meningitis dataset described in Chapter 4, Section 4.5, 
complete case data were derived for all potential variables to be tested in the severity score. 
The 400 complete cases discovery cohort was saved separately, and univariate analysis 
using logistic regression was done on this dataset to obtain odd’s ratios for day 40 mortality 
with 95% confidence intervals for each variable tested using SPSS version 20. To ensure 
that there was no selection bias, these data were compared against those generated from 
the larger dataset (Chapter 4 Section 4.5.3-4) to ascertain if the sample was truly random 
and matched the larger dataset. If the 95% confidence intervals overlapped for each 
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variable, it was concluded that there was no major bias in the random selection of these 
cases.  
Validation: This dataset comprised of complete case data from BAM Phase 1 merged with 
randomly selected data from the Malawi meningitis database that did not overlap with the 
discovery cohort. BAM Phase 2 data were not appropriate for MAMS development as these 
patients had received the care bundle intervention and therefore were not matched to either 
the BAM Phase 1 or the Malawi meningitis database patients. Relevant variables from BAM 
Phase 1 were recoded and renamed, and merged into the validation database using SPSS 
version 20, so the coding and names of all variables matched the discovery database.  
5.2.3.2 Study endpoints 
Survival or non-survival at day 40 was used as the endpoint for both databases. Only cases 
where these data were available were included in either the discovery or validation cohorts. 
Mortality was chosen as the sole endpoint as limited morbidity data were available for the 
day 10 or day 40 endpoint in the meningitis database. Day 40 was chosen over day 10, as 
additional deaths occurred in the time between day 10 and day 40 in all included studies in 
the meningitis database, and it was important to capture the risks of these additional deaths 
in the severity score.  
 
5.2.3.3 Methods for multivariate analysis  
Using exactly the same statistical methodology for Chapter 4 Section 4.4.2, the discovery 
cohort was subjected to multivariate logistic regression analysis. This was done by including 
all variables that were statistically significant on the univariate analysis at the 5% level, with 
the addition of variables that were determined in the analysis of the Malawi meningitis 
database (Chapter 4 Section 4.5.3-4) to be important confounders, such as age and HIV 
status. Several models were generated using this methodology and then compared. 
a) The first model reported variables as continuous variables (such as GCS and age). 
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b) The second reported the same continuous variables categorised as clinically important 
groups such as coma/altered mental status/normal mental status. These groupings were 
first made on well-established clinical parameters, such as GCS <8 = coma, GCS >8<11 
severe altered mental status, GCS >11<15 mild altered mental status (Teasdale and 
Jennett, 1976).  
c) The third model was generated using groupings that were made by creating clinical cut-
offs in the database, to match those used in the Dutch scoring system, such as CSF 
WCC </>1000cells/mm3 (Weisfelt et al., 2008). 
d) The fourth model was generated by quartile ranges around the median. This was done to 
establish if the clinical cut offs (derived from other, more well-resourced settings) were 
relevant in Malawi, or if new cut-offs needed to be generated that were more appropriate 
for Malawi. 
 
The odds ratios of the different groups and cut off points were compared to the OR 
generated from the continuous variable. Appropriate cut offs for the nomogram were 
selected on the basis of the highest OR for a particular set of groupings or clinical cut offs 
with associated statistical significance. 
 
5.2.4 Synthesis of the MAMS nomogram 
A severity score was derived from this analysis using a nomogram using the approach 
described by Cook et al (Cook, 2008). The nomogram was computed in R statistics package 
http://www.r-project.org/. Points indicating severity were applied on a sliding scale to each 
predictor associated with mortality, with fewer points associated with a better outcome. For 
example, if low GCS was associated with death, then the lower the patient’s GCS the more 
points were be added to the total severity prediction score. The number of points for each 
predictor was calculated in R, based on the original coefficient of the logistic regression 
model that derived the association between the predictor and outcome. The points for each 
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variable were added together, and the final score was read against a predictive percentage. 
The maximum number of points assigned from each nomogram was associated with 95-
100% prediction of negative outcome by six weeks after illness onset, and the lowest 
number of points associated with a less than 10% chance of predicted poor outcome. The 
total numbers of points available differed between nomograms, depending on the variables 
included. 
 
5.2.4.1 Validation of the nomogram 
Using the validation dataset, each patient had a predictive risk of death calculated by the 
nomogram. The predictive risk index was broken down into 10 percentiles, from 0-10 
through to 90-100% risk of negative outcome. A table was synthesised that detailed the 
number of patients with the actual outcome in the validation data for each percentile group, 
compared to the number predicted by the nomogram for each percentile. 
The agreement between the two columns was then calculated using Kappa to assess the 
degree of agreement, comparing concordance for the data between random associations 
and the actual agreement. Statistical significance between the two agreements was set at 
<0.05. 
The sensitivity and specificity of the nomogram as a predictive tool was also assessed using 
Receiver Operated Curve (ROC) curves, an area under the curve (AUC) was determined 
using the same methodology in the attempt to validate the Dutch score against Malawian 
data (Schut et al., 2012). Chi squared testing was used to look for associations between true 
and predictive outcomes. In addition, sensitivity and specificity of the final nomogram were 
calculated, and from this, the positive and negative predictive values of the nomogram were 
estimated.  
The preliminary nomograms and the associated validation data were presented for 
discussion with the MLW scientific community and the nomograms were revised following 
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comments. If the sensitivity and specificity of the nomogram were not adequate, the entire 
derivation process was repeated and the nomogram adjusted. Four validation loops were 
required to optimise the nomogram for acceptable performance (see section 5.5.3 in the 
results). 
The final nomogram was selected on the basis of the performance in the validation exercise 
with the aim for the concordance index to improve or match the data from the Dutch score 
(discovery index 0.84, 95% CI 0.80-0.87, validation index 0.81, 95% CI 0.74-0.87). Multiple 
nomograms produced were compared against each other to produce the final optimised 
nomogram (summarised in Section 5.3.4). This nomogram was then put forward for further 
testing against BAM phase 2 data (Results Chapter 6 section 6.3.6).  
 
5.2.5 Methods for dealing with missing data 
5.2.5.1 Random imputation of all missing data 
To increase the number of cases available in the discovery cohort and to account for missing 
data, five rounds of random imputation, as done on the Dutch meningitis score data (Weisfelt 
et al., 2008) were done by Dr Mukaka on the Malawi meningitis database prior to case 
selection for the discovery and validation cohorts. Identical univariate and multivariate 
regression analysis was performed on both the complete case data and on this larger 
imputed dataset and the results compared. Important differences, which resulted in changing 
of statistical significance of predictors were identified. The results of these comparisons can 
be found in section 5.3.2. When taken forward, these differences subsequently significantly 
changed the nomogram between the imputed dataset and the complete case dataset. 
Following review of these two datasets with Dr Mukaka and Dr Faragher, it was decided that 
the imputed dataset did not accurately represent the original cases as the predictors were 
altered by the imputation exercise, suggesting serious biases in the missing data. The table 
generated from the imputed dataset can be seen in Table 5.3. The complete case dataset 
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was used for the discovery exercise to generate the nomograms tested, and carefully 
selected management for individual missing data was done. 
 
5.2.5.2 Testing for systematic biases 
Following the finding that random imputation to the entire dataset altered the significance of 
several variables in the multivariate analysis, the database was interrogated for systematic 
biases in the missing data. Univariate analyses were done for each positive predictor 
variable using logistic regression against day 40 mortality using SPSS version 20. Data were 
grouped for each variable into quartiles around a median, with an additional option within 
that variable coded for missing data. Odds ratios for missing data and the relevant groupings 
within that variable were calculated and compared. Where the OR for the missing variable 
was significant at the 0.05 level, systematic bias was suspected. If the OR was not 
significant to that level, it was concluded that no systematic biases existed within that data. 
 
5.2.5.3 Completing missing data in the final dataset 
If a systematic bias in the data was found, the missing variable was then coded into the 
group where the nearest significant OR was seen. For example, if the OR for day 40 death 
for variable x to be missing was 2.5 (95% CI 1.3 : 4.6), and a variable grouping y had a 
matched OR within the same 95% CI, the missing data were re-coded as variable group y 
(Cohen, 1985). 
Where significant numbers of missing data were identified within a variable, but no 
systematic bias in the missing data was identified, the missing data for that variable only 
were completed by 5 rounds of random imputation (Cohen, 1985). The random imputation 
was done in STATA by Dr Mukaka.  
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5.3 Results 
5.3.1 Final univariate and multivariate analysis results on the discovery 
dataset 
The results of the univariate and multivariate associations with day 40 mortality are 
presented in Table 5.1. Continuous variables with even distribution were presented as 
means with standard deviation, variables with skewed distribution were presented as 
medians with interquartile range. The following parameters were significantly association 
with mortality : GCS (univariate OR mortality 0.84 (95% CI 0.78 : 0.89), p<0.001), seizure 
episodes (1 seizure OR 1.66 (95% CI 1.01 : 2.72) p=0.043; 2 or more seizures OR 2.12 
(95% CI 1.06 : 4.23) p=0.033), temperature (OR 1.2 (95% CI 1.03 : 1.42) p=0.02), pulse rate 
(OR 1.02 (95% CI 1.01 : 1.03) p<0.001), CSF WCC (OR 1.0 (95% CI 1.0 : 1.0) p<0.001) and 
Haemoglobin (OR 0.89 (95% CI 0.83 : 0.95) p=0.01). Other variables not significantly 
associated with mortality included age, gender, HIV status, out of hours admission, mean 
arterial blood pressure, blood glucose, and respiratory rate (Table 5.1). Oxygen saturations 
on pulse oximetry (SpO2) were associated with mortality (OR 0.80, 95% CI 0.64 : 0.98, 
p=0.038) but the data were available for less than 50% of the total number of cases and  
could not be included in the multivariate model (Table 5.1). 
 
The variables with significant associations with mortality (with the exception of SpO2) were 
taken forward into the multivariate model, only GCS (OR 0.80 (95% CI 0.73 : 0.87) p<0.001), 
pulse (OR 1.01 (95% CI 1.00 : 1.03) p=0.02), CSF WCC (95% CI OR 1.0 (1.0 : 1.0) 
p<0.001), and Hb (OR 0.86 (95% CI 0.79 : 0.95) p=0.002) retained significance for 
association with death (Table 5.1). Interaction terms were run between variables that were 
might have been expected on clinical grounds to have been included in the multivariate 
model, particularly seizures. One interesting interaction found was between seizures and 
GCS. This led to loss of significance for seizures in the multivariate model due to the 
interaction with the more powerful effect of GCS  
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Table 5.1 Predictors of mortality in the MAMS discovery cohort 
Univariate and multivariate predictors of poor outcome in the MAMS discovery cohort. 
Parameter Day 40 Univariate (unadjusted) Multivariate (adjusted)** 
Alive Dead Odds ratio (95% CI) P Odds ratio (95% CI) p 
Sample size  195 205     
Age mean (sd) 31.8 (11.1) 33.9 (11.2) 1.01 (0.99 : 1.03) 0.061 1.00 (0.98 : 1.03) 0.71 
 ≤ 40 years 160 164 --- ---   
 > 40 years 35 41 1.14 (0.69 : 1.88) 0.60 1.01 (0.56 : 1.81) 0.96 
Gender male 100 100 1.1 (0.74 : 1.64) 0.62 * * 
 female 95 105 …    
HIV status negative 25 17 …  * * 
 positive 165 184 1.39 (0.36 : 5.27) 0.62   
 not known 5 4     
Out of hours admission no 87 93 1.07 (0.70 : 1.62) 0.74 * * 
 yes 83 95 0.93 (0.62 : 1.41) 0.74   
 not known 20 22     
GCS mean (sd) 11.9 (2.9)  0.84 (0.78 : 0.89) <0.001 0.80 (0.73 : 0.87) <0.001 
 > 11 130 95 …    
 8 – 11 49 56 1.56 (0.98 : 2.49) 0.06 1.66 (0.97 : 2.82) 0.63 
 <8 16 54 4.61 (2.5 : 8.5) <0.001 5.19 (2.46 : 10.93) <0.001 
1 or more acute  None 146 128 …    
seizure episodes One 
seizure 
35 51 1.66 (1.01 : 2.72) 0.043 1.14 (0.64 : 2.04) 0.65 
 Two 
seizures 
14 26 2.12 (1.06 : 4.23) 0.033 1.0 (0.42 : 2.36) 1.0 
Temperature °Celcius mean (sd) 38.2 (1.2) 38.5 (1.3) 1.2 (1.03 : 1.42) 0.02 1.07 (0.85 : 1.36) 0.56 
SpO2 (%) mean (sd) 95.6 (2.0) 93.9 (3.6) 0.80 (0.64 : 0.98) 0.038   
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† : proportion of missing data >50% excluded from MV analysis ‡ : odds ratio for a unit increase in predictor variable  *: non-significant variable not put forward for multivariate analysis
 >95 23 13 …    
 92 – 95 9 7 2.65 (0.63 : 11.1) 0.60 † † 
 <92 4 6 1.37 (0.41 : 4.56) 0.18 † † 
Pulse rate (beats/min) mean (sd) 97.7 (18.4) 105.4 (19.2) 1.02 (1.01 : 1.03) <0.001 1.01 (1.00 : 1.03) 0.02 
 <100 114 91 …    
 100–120 29 36 1.55 (0.88 : 2.72) 0.123 1.51 (0.81 : 2.80) 0.19 
 >120 32 57 2.23 (1.34 : 3.73) 0.002 1.90 (1.06 : 3.38) 0.029 
MAP (mmHg) mean (sd) 90.6 (13.1) 90.4 (16.4) 0.99 (0.98 : 1.01) 0.92 * * 
 <90 103 101 1.02 (0.53 : 1.98) 0.93   
 90-100 34 39 1.2 (0.56 : 2.55) 0.63   
 >100 36 44 1.28 (0.60 : 2.70) 0.51   
 not known 22 21 …    
Respiratory rate 
(breaths/min) 
mean (sd) 23.0 (3.5) 23.1 (2.7) 1.01 (0.81 : 1.25)‡   0.91 † † 
 not known 180 184     
CSF White cell count 
(cells/mm3) 
Median 
(IQR) 
1122  
(288 : 3160) 
395  
(132 : 1040) 
1.0 (1.0 : 1.0) <0.001 1.0 (1.0 : 1.0) <0.001 
CSF culture positive for  
   S. pneumoniae 
no 90 93 --- --- --- --- 
yes 104 111 1.03 (0.69 : 1.53) 0.87 0.475 (0.26 : 0.87) 0.015 
 not known 0 2     
Plasma glucose  mean (sd) 7.6 (2.8) 7.8 (4.2) 1.01 (0.96 : 1.08) 0.60 * * 
(mmol/L)        
Haemoglobin (g/dL) mean (sd) 11.4 (2.9) 10.4 (3.1) 0.89 (0.83 : 0.95) 0.001 0.86 (0.79 : 0.95) 0.002 
 >14 35 22 ..    
 11-14 69 62 1.43 (0.76 : 2.69) 0.260 1.16 (0.53 : 2.50) 0.71 
 8-11 69 80 1.85 (0.98 : 3.43) 0.054 1.64 (0.77 : 3.84) 0.19 
 5-8 19 33 2.76 (1.27 : 6.00) 0.010 2.35 (0.84 : 5.89) 0.067 
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The multivariate model was run for a second time including all variables tested by  univariate 
analysis l, irrespective of significance levels (Table 5.2). 
The multivariate predictors of mortality in this model were GCS (OR 0.80 (95% CI 0.73 : 
0.88) p<0.001), CSF WCC (OR 1.0 (95% CI 1.00 : 1.00) p<0.001), and Haemoglobin (OR 
0.87 (95% CI 0.79 : 0.97) p=0.008). CSF culture positivity for S. pneumoniae was associated 
with reduced chances of death compared to non-pneumococcal culture (OR 0.475 (95% CI 
0.26 : 0.87) p=0.015), and pulse lost significance in this model (OR 1.01 95% CI (0.99 : 1.03) 
p=0.06). Individual ORs for continuous variables put into clinically relevant categories are 
also shown in Table 5.5. 
  
Variables that were suspected of being important potential confounders, such as age, 
gender, HIV status and out of hours admission were not significantly associated with death 
in this model (Table 5.2), and no evidence of confounding was seen.  
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Table 5.2 Analysis of the discovery cohort, complete results 
Multivariate analysis of the discovery data including all variables in the MV analysis, irrespective of univariate significance 
Parameter Day 40 Univariate (unadjusted) Multivariate (adjusted)** 
Alive Dead Odds ratio (95% CI) p Odds ratio (95% CI) p 
Sample size  195 205     
Age mean (sd) 31.8 (11.1) 33.9 (11.2) 1.01 (0.99 : 1.03) 0.061 1.0 (0.98 : 1.03) 0.87 
 ≤ 40 years 160 164 --- ---   
 > 40 years 35 41 1.14 (0.69 : 1.88) 0.60 0.75 (0.25 : 2.22) 0.60 
Gender male 100 100 1.1 (0.74 : 1.64) 0.62 0.86 (0.50 : 1.48) 0.59 
 female 95 105 …    
HIV status negative 25 17 …    
 positive 165 184 1.39 (0.36 : 5.27) 0.62  6.67 (0.63 : 70.3) 0.11 
 not known 5 4     
Out of hours admission no 87 93 1.07 (0.70 : 1.62) 0.74   
 yes 83 95 0.93 (0.62 : 1.41) 0.74 1.04 (0.61 : 1.77) 0.88 
 not known 20 22     
GCS mean (sd) 11.9 (2.9) 10.0 (3.5) 0.84 (0.78 : 0.89) <0.001 0.80 (0.73 : 0.88) <0.001 
 > 11 130 95 …    
 8 – 11 49 56 1.56 (0.98 : 2.49) 0.06 1.67 (0.93 : 3.05) 0.08 
 <8 16 54 4.61 (2.5 : 8.5) <0.001 4.56 (1.97 : 10.58) <0.001 
 not known 0 0 …    
1 or more acute  None 146 128 …    
seizure episodes One 
seizure 
 
35 51 1.66 (1.01 : 2.72) 0.043 1.15 (0.6 : 2.19) 0.66 
 Two 
seizures 
14 26 2.12 (1.06 : 4.23) 0.033 0.92 (0.35 : 2.50) 0.88 
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Temperature mean (sd) 38.2 (1.2) 38.5 (1.3) 1.2 (1.03 : 1.42) 0.02 1.04 (0.78 : 1.39) 0.75 
SpO2 (%) mean (sd) 95.6 (2.0) 93.9 (3.6) 0.80 (0.64 : 0.98) 0.038 † † 
 >95 23 13 …    
 92 – 95 9 7 2.65 (0.63 : 11.1) 0.60 † † 
 <92 4 6 1.37 (0.41 : 4.56) 0.18 † † 
 not known       
Pulse rate (beats/min) mean (sd) 97.7 (18.4) 105.4 (19.2) 1.02 (1.01 : 1.03) <0.001 1.01 (0.99 : 1.03) 0.06 
 <100 114 91 …    
 100–120 29 36 1.55 (0.88 : 2.72) 0.123 1.43 (0.74 : 2.80)  
 >120 32 57 2.23 (1.34 : 3.73) 0.002 2.43 (1.24 : 4.80) 0.01 
 not known       
MAP (mmHg) mean (sd) 90.6 (13.1) 90.4 (16.4) 0.99 (0.98 : 1.01) 0.92 1.0 (0.98 : 1.02) 0.96 
 <90 103 101 1.02 (0.53 : 1.98) 0.93 0.73 (0.36 : 1.45) 0.26 
 90-100 34 39 1.2 (0.56 : 2.55) 0.63 0.62 (0.28 : 1.41) 0.36 
 >100 36 44 1.28 (0.60 : 2.70) 0.51  … 
 not known 22 21 …    
Respiratory rate 
(breaths/min) 
mean (sd) 23.0 (3.5) 23.1 (2.7) 1.01 (0.81 : 1.25)‡   0.91 † † 
 not known 180 184     
CSF White cell count 
(cells/mm3) 
Median 
(IQR) 
1122  
(288 : 3160) 
395  
(132 : 1040) 
1.0 (1.0 : 1.0) <0.001 1.0 (1.00 : 1.00) <0.001 
CSF culture positive for  
   S.pneumoniae 
no 90 93 --- --- --- --- 
yes 104 111 1.03 (0.69 : 1.53) 0.87 0.475 (0.26 : 0.87) 0.015 
 not known 0 2     
Plasma glucose  mean (sd) 7.6 (2.8) 7.8 (4.2) 1.01 (0.96 : 1.08) 0.60 1.01 (0.93 : 1.10) 0.73 
(mmol/L)        
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Haemoglobin (g/dL) mean (sd) 11.4 (2.9) 10.4 (3.1) 0.89 (0.83 : 0.95) 0.001 0.87 (0.79 : 0.97) 0.008 
 >14 35 22 ..    
 11-14 69 62 1.43 (0.76 : 2.69) 0.260 1.07 0.86 : 2.49) 0.88 
 8-11 69 80 1.85 (0.98 : 3.43) 0.054 1.60 (0.71 : 3.61) 0.26 
 5-8 19 33 2.76 (1.27 : 6.00) 0.010 1.85 (0.68 : 5.04) 0.23 
 <5 3 8 4.2 (1.01 : 17.73) 0.048 5.75 (0.88 : 37.8) 0.07 
 not known 0 0     
† : proportion of missing data >50% so variable excluded from multivariate analysis   ‡ : odds ratio for a unit increase in predictor variable
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5.3.2 Missing data 
The missing data analysis was undertaken only in variables with adequate numbers for 
inclusion in the multivariate analysis and significant association with day 40 mortality. 
Missing outcome data were found in the Malawi meningitis dataset used to derive the 
discovery data (n=598 cases, 543 with day 40 mortality data available), the 55 cases with 
missing outcome data were excluded. From this dataset, 400 complete cases (cc400) had 
been randomly selected for discovery, with remaining 143 cases potentially to be used for 
validation.   
Firstly, 5 rounds of random imputation were done in STATA on the n 543 dataset to 
complete the missing data for the predictive variables. Only variables that were predictive of 
poor outcome on multivariate analysis, and where >50% of data were present were included 
in the imputation exercise. The univariate and multivariate analysis performed on the cc400 
dataset as detailed above was repeated on the n543 imputed dataset. The results are 
presented in Table 5.3 and are highlighted in red font. 
Important discrepancies were identified between the cc400 and the imputed n543 dataset. 
These included increasing significance in the imputed data for Hb between 5-8 g/dL group 
(OR 2.82 (95% CI 1.02 : 7.82) p=0.046 imputed compared to 1.85 (95% CI 0.68 : 5.04) 
p=0.21 in the cc400 data), and an increasing weight for GCS <8/15 in the imputed data (OR 
7.94 (95% CI 4.02 : 15.68) p<0.001 compared to OR 4.56 (95% CI 1.97 : 10.58) p<0.001 in 
the cc400 data). These significant differences suggest that serious systematic biases are 
present in the missing data and imputation of the missing data leads to different results in 
the analysis of the imputed data compared to the complete case data. The imputed dataset 
was discarded and the missing data management strategy was revised. The concern that 
the imputation exercise had failed due to systematic bias in the missing data led to a further 
analysis of the database for systematic biases in the missing data.
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Table 5.3 Analysis of the discovery data after random imputation 
Multivariate analysis of discovery data showing pooled results of 5 rounds of random imputation in the n=543 dataset 
Parameter Day 40 Univariate (unadjusted) Multivariate (adjusted)** 
Alive Dead Odds ratio (95% CI) p Odds ratio (95% CI) p 
Sample size  187 213 …    
Age mean (sd) 30.9 33.7 1.03 (1.01 : 1.04) 0.01 1.02 (0.99 : 1.04) 0.099 
 ≤ 40 years 158 168 … … … … 
 > 40 years 29 45 1.46 (0.87 : 2.44) 0.15 1.50 (0.80 : 2.80) 0.21 
Gender male 87 108 1.18 (0.80 : 1.75) 0.40 * ∆ 
 female 100 105 0.84 (0.57 : 1.25) 0.40   
HIV status negative 23 16 …    
 positive 164 197 1.72 (0.88 : 3.78) 0.11 0.71 (0.32 : 1.57) 0.40 
 not known 0 0 …    
Out of hours admission no 86 98 …    
 yes 84 96 1.00 (0.66 : 1.51) 0.98 1.07 (0.66 : 1.73) 0.78 
 not known 18 18 …    
GCS mean (sd) 11.9 9.8 0.80 (075 : 0.86) <0.001 0.76 (0.69 : 0.83) <0.001 
 > 11 113 67 …    
 8 – 11 49 70 2.40 (1.50 : 3.87) <0.001 3.17 (1.80 : 5.57) <0.001 
 <8 25 76 5.13 (2.98 : 8.83) <0.001 7.94 (4.02 : 15.68) <0.001 
 not known 0 0     
1 or more acute  None 138 132 …    
seizure episodes One seizure 
 
34 45 1.38 (0.84 : 2.29) 0.20 0.94 (0.50 : 1.74) 0.83 
 Two + 
seizures 
15 36 2.5 (1.31 : 4.80) 0.005 1.62 (0.75 : 3.50) 0.22 
191 
 
 
  Alive Dead Odds ratio (95% CI) p Odds ratio (95% CI) p 
SpO2 (%) mean (sd) 95.5 92.3 0.88 (0.76 : 1.03) 0.11 
(0.08 t-
test) 
  
 >95 18 18     
 92 – 95 10 9 0.90 (0.30 : 2.74) 0.85 † † 
 <92 5 9 1.80 (0.50 : 6.43) 0.36 † † 
 not known       
Pulse rate (beats/min) mean (sd) 97.9 106.0 1.03 (1.01 : 1.04) <0.001 1.03 (1.01 : 1.04) 0.001 
 <100 122 99 …    
 100–120 49 69 1.74 (1.10 : 2.73) 0.017 1.71 (0.99 : 2.95) 0.051 
 >120 16 45 3.47 (1.85 : 6.50) <0.001 4.14 (1.85 : 9.28) 0.001 
 not known 0 0 …    
MAP (mmHg) mean (sd) 89.8 (13) 89.3 (16) 0.99 (0.98 : 1.11) 0.71 * * 
 <90 99 111 0.89 (0.53 : 1.52) 0.67   
 90-100 37 37 1.12 (0.65 : 1.93) 0.66 * * 
 >100 31 39 1.16 (0.61 : 2.20) 0.65   
 not known 20 26     
Respiratory rate 
(breaths/min) 
mean (sd) 24.4 (4.4) 26.3 (7.5) 1.05 (0.97 : 1.15) 0.23 † † 
 not known       
CSF culture positive for  
   S.pneumoniae 
no 72 104 …  --- --- 
yes 114 108 0.65 (0.44 : 0.98) 0.04 0.28 (0.16 : 0.48) <0.001 
 not known 0 2     
Plasma glucose  mean (sd) 9.5 (10.8) 10.2 (12.9) 1.00 (0.99 : 1.03) 0.56 * * 
(mmol/L)        
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  Alive Dead Odds ratio (95% CI) p Odds ratio (95% CI) p 
Haemoglobin (g/dL) mean (sd) 11.4 (2.7) 10.6 (2.9) 0.91 (0.85 : 0.98) 0.008 0.88 (0.80 : 0.96) 0.004 
 >14 30 25     
 11-14 71 66 1.12 (0.60 : 2.09) 0.73 1.12 (0.52 (2.34) 0.79 
 8-11 71 88 1.49 (0.80 : 2.75) 0.20 2.13 (1.01 : 4.49) 0.046 
 5-8 11 27 2.95 (1.22 : 7.10) 0.016 2.82 (1.02 : 7.82) 0.046 
 <5 4 7 2.1 (0.55 : 8.0) 0.27 4.10 (0.82 : 20.5) 0.085 
 not known 0 0     
† : proportion of missing data >50% so variable excluded from multivariate analysis   ‡ : odds ratio for a unit increase in predictor variable   
*: non -significant variable not used in the scoring system and excluded from multivariate analysis Red font = data statistically different in these imputed data to those generated by the non-imputed 
data analysis 
193 
 
5.3.2.1 Analysis for systematic biases in the missing data 
The systematic bias analysis as detailed in section 2.7.2 demonstrated very few missing 
data points for GCS, CSF WCC and CSF culture (<1%) and there were no systematic biases 
in the missing data for these variables. Due to the small number of missing data points in 
these variables, random imputation was not done. Missing data for pulse were noted in both 
the discovery data (n=400, missing data n=41) and the Malawi meningitis database (n=543, 
missing data n=58). Missing pulse was equally distributed between survivors and non 
survivors in both datasets, (OR death in the Malawi meningitis database was 1.03, 95% CI 
0.59 : 1.79, p=0.91). Due to the large proportion of missing data and the lack of systematic 
bias present, the pulse variable only was subject to 5 rounds of random imputation to 
complete the missing data to make adequate numbers for both discovery and validation. 
 
Significant missing data were also found for haemoglobin. In the larger Malawi meningitis 
database, a value for Hb was missing in 44 cases. The OR of missing Hb with day 40 
mortality was 2.18 (95% CI 1.07 : 4.41) p=0.03. Table 5.4 shows the OR for death by Hb 
grouped into quartiles around the median. 
 
Table 5.4 Haemoglobin and outcome in bacterial meningitis 
Univariate associations with mortality for different groups of haemoglobin 
(g/dL) in the Malawi meningitis database.  
N598 (543 with d40 available) 
Grouping Alive 
255 
Dead 
288 
OR (95% CI) P value 
Missing 17 27 2.18 
(1.07 : 4.41) 
0.031 
<8.9 53 86 2.22  
(1.53 : 3.66) 
0.002 
8.9-10.6 54 64 1.62  
(0.97 : 2.71) 
0.062 
10.6-12.6 61 60 1.35  
(0.81 : 2.24) 
0.246 
>12.6 70 51 Reference  
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Missing Hb had almost identical OR for mortality as Hb below the 25th centile (OR 2.22, 95% 
CI 1.53 : 3.66) and therefore to take account of this systematic bias in the data, all missing 
Hb were recoded as =<8.9g/dL. Multivariate analysis was undertaken on the new dataset 
with imputed pulse and missing Hb recoded as <8.9, and no further biases were found. As a 
result of this analysis, the complete case data (n400) were derived from this dataset to be 
used for nomogram discovery, and the remaining complete cases were added as outlined to 
BAM Phase 1 patient data for validation. 
 
Table 5.5 gives the comparison of the discovery and validation data used in the generation 
of the final MAMS nomogram. Univariate comparisons were made using a Student’s T-test 
of means for normally distributed continuous variables, a Mann-Whitney U test for non-
normally distributed continuous variables, and a Fisher exact test for categorical variables. 
Fisher exact test was used to optimise precision. Where significant differences were seen on 
univariate analysis between the two cohorts, a multivariate analysis model was undertaken 
using binary logistic regression, backwards LR mode (methods Chapter 3 section 3.2.3). 
Only respiratory rate retained significance after correction for the other significant variables 
in this model. 
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Table 5.5 Analysis of variables between discovery and validation cohorts 
Comparison of tested variables between discovery and validation  
Variable Discovery  
N=400 
Validation 
N=193 
Significance 
Mean Age (std) 32.9 (11.1) 31.8 (10) 0.25  
Female Gender 200 (50%) 108 (52.2) 0.61  
HIV co-infection 349/391 (87%) 157/193 (81%) 0.002 
Out of hours  180/358 (50.3%) 83/190 (43%) 0.17 
Day 10 mortality 164/400 (41%) 103 (49%) 0.04 
Day 40 mortality rate 205/400 (51%) 115/193 (59%) 0.065 
Mean GCS (std) 10.9 (3.3) 10.9 (3.4) 0.86 
Acute 
seizures 
One 86 (21.5%) 29/151 (19.2) 0.54 
Two or more 40 (10%) 15/151 (10%) 0.90 
Mean Temp (°C) (Std) 38.3 (1.2) 38.3 (1.1) 0.91 
Mean SpO2(%) (Std) 94.4 (2.9) 94.6 (5.5) 0.71 
Mean Pulse 
(beats/min) (Std) 
101 (19.2) 102 (20.5) 0.64 
Mean MAP (mmHg) 
(Std) 
90.5 (15.3) 89.7 (17.3) 0.60 
Mean RR (breaths/min) 
(Std) 
23.9 (3.2) 26.6 (8.1) 0.01 
Median CSF WCC 
(cells/mm3) (IQR) 
545  
(170 – 2000) 
452  
(211 – 1545) 
0.42  
CSF culture Negative 153 (38%) 
SpN 215 (53.8%) 
NM 13 (3.3%) 
Hib 3 (0.8%) 
Gram negative 8 
(2%) 
Other 6 (1.5%) 
Negative 70 
(33%) 
SpN 110 
(53.1%) 
NM 4 (1.9%) 
Hib 0 (0%) 
Gram neg 12 
(5.8%) 
Other 11 (5.3%) 
Reference 
0.51 
0.50 
0.99 
0.013 
0.009 
Mean Plasma glucose 
(mmol/L) (Std) 
7.7 (3.6) 7.2 (2.7) 0.12 
Mean Hb (g/dL) (Std) 10.7 (2.7) 10.4 (2.7) 0.22 
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5.3.3 Summary of validation loop processes 
5.3.1.1 Validation of all variables compared with significant variables only 
Two nomograms were synthesised from the original cc400 discovery cohort of non-imputed 
data and tested against the complete case validation database, prior to any imputation or 
missing data analysis. The first (Figure 5.2a) included only variables that were significant on 
the multivariate analysis (including pneumococcal culture that was significant on MV but not 
UV analysis). 
 
Figure 5.2.a 
 
Figure 5.2 Preliminary nomograms from original complete case data 
 
Points 
0 10 20 30 40 50 60 70 80 90 100 
Haemoglobin  
16 15 14 13 12 11 10 9 8 7 6 5 4 3 
GCS  
15 14 13 12 11 10 9 8 7 6 5 4 3 
Pulse   
50 60 70 80 90 100 110 120 130 140 150 160 
Log CSF WCC 
5 3 1 
4 2 0 
Pneumococcal Culture   
Pneumo positive 
Pneumo negative 
Total Points 
0 20 40 60 80 100 120 140 160 180 200 220 240 
Risk score % 
 5    8 12   18 27   38 50  62 73  82 88  92 95  97 98 
 
Points 
0 10 20 30 40 50 60 70 80 90 100 
Age 
10 35 60 
Haemoglobin 
16 15 14 13 12 11 10 9 8 7 6 5 4 3 
GCS 
15 14 13 12 11 10 9 8 7 6 5 4 3 
Number of Seizure 
0 2 
1 
Pulse 
50 60 70 80 90 100 110 120 130 140 150 160 
HIV Status Negative Positive 
Temperature 
41 37 
40 36 
Mean Arterial Blood Pressure 
160 120 90 60 
Log CSF WCC 
5 3 1 
4 2 0 
Pneumococcal culture Pneumo positive 
Pneumo negative 
Gender 
female 
male 
Total Points 
0 20 40 60 80 100 120 140 160 180 200 220 240 260 280 
Risk score % 
 5    8 12   18 27   38 50 62 73   82 88  92 95   97 98 
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Preliminary nomograms synthesised prior to any missing data or random imputation analyses. 
Figure 5.2.a contains only variables with statistically significant association with negative 
outcome at day 40, Figure 5.2.b contains all variables tested. All units are identical to those 
represented in the tables 
 
The second Figure 5.2b included all variables tested in the regression analyses irrespective 
of significance. For both nomograms, only 79 cases in the validation database had complete 
case data to validate all the variables included in the nomogram, with no imputation of 
missing data. Validation data for these nomograms were as follows: ROC Area under the 
curve (AUC) all included variables 0.77 (95%CI 0.66 - 0.88), significant variables only 0.75 
(0.65 - 0.85) (Figure 5.3).  
 
Figure 5.3 Receiver Operator Curve (ROC) comparing predictive power of both original 
nomograms 
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When the two nomograms were evaluated against the true outcome, the significant variables 
nomogram was more accurate, with an agreement of 37.5% (against a random agreement of 
7.81% p<0.001, Kappa 0.32), (Table 5.6) compared to the all variables nomogram with an 
agreement of 12.5% (against a random agreement of 9.38% p=0.37, Kappa 0.034) (Table 
5.7). As the all variables nomogram was clearly inferior, only the significant variables 
nomogram was taken forward to the validation step. 
Table 5.6 MAMS agreement data for initial nomogram containing significant variables 
only 
Summary of agreement data between observed and predicted deaths by MAMS in the 
original variables only with statistical significance with outcome nomogram 
% Risk of 
death  
Total number of 
participants 
Observed Deaths 
(%) 
Deaths predicted by a  
Nomogram 
≤10 0 - - 
11-20 6 0   (0) 1  (17) 
21-30 8 2  (25) 2  (25) 
31-40 0 - - 
41-50 35 12  (34) 14  (40) 
51-60 15 6  (40) 8  (53) 
61-70 14 9  (64) 9  (64) 
71-80 10 6  (60) 7  (70) 
81-90 11 9  (82) 9  (82) 
90-10 5 4  (80) 5  (100) 
Total 104 48  (46) 55  (53) 
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Table 5.7 MAMS agreement data for initial nomogram containing all tested variables 
Summary of agreement data between observed and predicted deaths by MAMS in the 
original all included variables nomogram 
Risk score 
% 
Total number of 
participants 
Observed Deaths 
(%) 
Deaths predicted by a  
Nomogram 
≤10 0 - - 
11-20 6 0   (0)   1  (17%) 
21-30 4 1  (25) 1   (25) 
31-40 - - - 
41-50 22 8   (36) 9   (41) 
51-60 15 6   (40) 8   (53) 
61-70 14 12  (86) 9   (64) 
71-80 7 3   (43) 5   (71) 
81-90 10 8  (80) 9   (90) 
90-10 6 5   (83) 6  (100) 
Total 84 43  (51) 48 (57) 
 
However, as only complete case data without imputation had been used for the validation 
exercise for these nomograms, the validation data were too few to produce accurate 
validation and there were concerns that substantial missing data (>50% (79/193 cases) were 
likely to have a major influence on the power of the nomogram. The missing data analysis 
detailed in Section 5.3.2 was undertaken. 
 
5.3.3.2 Significant variables nomogram after the missing data analysis 
The validation exercise for the significant variables nomogram was repeated after the 
missing data exercise as detailed in section 5.3.2 (Figure 5.4). Using data with missing Hb 
coded as <8.9 g/dL and pulse imputed increased the validation dataset from 79 cases to 193 
cases.  
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Figure 5.4 Nomogram using significant variables, post missing data completion 
 
The significant variables nomogram validated well after completion of the missing data, with 
AUC of 0.74 (95% CI 0.67 : 0.82) (Figure 5.5), and agreement of 62.5% compared to random 
agreement of 14.1 (p<0.001) and Kappa of 0.6 (Table 5.8).  
Sensitivity and specificity of this nomogram were calculated by Dr Mukaka. Sensitivity 
was74% and specificity was 55%.  
 
 
Figure 5.5 ROC for the nomogram in Figure 5.4  
 
Points 
0 10 20 30 40 50 60 70 80 90 100 
Haemoglobin        
16 15 14 13 12 11 10 9 8 7 6 5 4 3 
GCS 
15 14 13 12 11 10 9 8 7 6 5 4 3 
Pulse 
50 60 70 80 90 100 110 120 130 140 150 160 
Log CSF WCC 
100,000 1,000 10 
10,000 100 
Pneumococcal culture  
Pneumo positive 
Pneumo negative 
Total Points 
0 20 40 60 80 100 120 140 160 180 200 220 240 260 280 
Risk score % 
  5    8 12   18 27   38 50   62 73  82 88  92 95 98   3 
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Table 5.8 Summary of MAMS agreement data after missing data analysis 
Summary of agreement data between observed and predicted deaths by MAMS in the 
significant variables only nomogram after completion of the missing data 
Risk score 
% 
Total number of 
participants 
Observed Deaths 
(%) 
Deaths predicted by a  
Nomogram 
≤10 2 0(0) 0(0) 
11-20 4 0(0) 1(25) 
21-30 11 1(9) 3(27) 
31-40 - - - 
41-50 47 20(43) 20(43) 
51-60 19 10(53) 10(53) 
61-70 28 18(64) 18(64) 
71-80 27 20(74) 20(74) 
81-100 54 45(83) 48(89) 
Total 192 114(59.3) 120(62.5) 
 
 
5.3.3.3 Continuous compared to categorical variables 
The first nomograms contained all continuous variables represented as ordinal data. We 
subsequently explored the effect of categorising these variables, first into clinically relevant 
groupings derived from standardised clinical definitions (e.g. GCS <11 = altered mental 
status, GCS <8 = coma, Section 5.2.3), and then into quartiles around the median. The 
multivariate analysis was run on the different groupings and the OR’s of associations with 
mortality compared between the clinically relevant and quartile groupings. These data can 
be found in the following:  Table 5.9, Table 5.10, Table 5.11, Table 5.12. 
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Table 5.9 Analysis of Haemoglobin with outcome by group category 
Comparison of Haemoglobin association with mortality when categorised into clinical or statistical groups 
Variable  Cc400 N 543 with d40 available 
 grouping Alive 
195 
Dead 
205 
OR  
(95% CI) 
P value grouping Alive 
255 
Dead 
288 
OR (95% CI) P value 
Hb 
classical 
Missing 0 0   Missing 17 27 2.56  
(1.17 : 5.59) 
0.018 
 <5 3 8 4.24  
(1.05 : 17.5) 
0.048 <5 4 10 4.03  
(1.14 : 14.2) 
0.030 
 5-8 19 33 2.76  
(1.27 : 6.01) 
0.01 5-8 24 42 2.82  
(1.40 : 5.69) 
0.004 
 8-11 69 80 1.84  
(0.98 : 3.43) 
0.54 8-11 95 108 1.83  
(1.04 : 3.32) 
0.034 
 11-14 69 62 1.43  
(0.75 : 2.69) 
0.27 11-14 73 75 1.66  
(0.92 : 2.98) 
0.090 
 >14 35 22   >14 42 26   
Hb 
quartiles 
Missing 0 0   Missing 17 27 2.18 
(1.07 : 4.41) 
0.031 
25th 
centile 
<8.9 37 68 2.49  
(1.41 : 4.38) 
0.002 <8.9 53 86 2.22  
(1.53 : 3.66) 
0.002 
25-50th 8.9-10.8 49 50 1.38  
(0.79 : 2.42) 
0.255 8.9-10.6 54 64 1.62  
(0.97 : 2.71) 
0.062 
50-75th 10.81-
12.6 
52 45 1.17  
(0.66 : 2.06) 
0.576 10.6-12.6 61 60 1.35  
(0.81 : 2.24) 
0.246 
75th 
centile 
>12.6 57 42   >12.6 70 51   
Hb cut off 
<9.0 
Missing 0 0   Missing 17 27 1.68  
(0.89 : 3.20) 
0.10 
 <9.0 38 69 2.09  
(1.33 : 3.31) 
0.002 <9.0 54 88 1.73 (1.16 : 2.57) 0.007 
 >9.0 157 136   >9.0 184 173   
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Table 5.10 Analysis of GCS and outcome by group category 
Comparison of Glasgow Coma Score and association with mortality when categorised into clinical or statistical groups 
Variable  Cc400  N598 (543) 
 grouping Alive 
195 
Dead 
205 
OR death  
(95% CI) 
p grouping Alive 
255 
Dead 
288 
OR death  
(95% CI) 
P 
Median 
GCS 
(IQR) 
 13  
(10-15) 
10  
(7-13) 
0.83  
(0.78 : 0.89) 
<0.001  13  
(10-15) 
10  
(7-13) 
0.81  
(0.77 : 0.86) 
<0.001 
GCS 
Classical 
Missing 0 0   Missing 4 8 3.12  
(0.91 : 10.63) 
0.069 
 <8 16 54 4.61  
(2.49 : 8.46) 
<0.001 <8 34 97 4.45 
(2.79 : 7.08) 
<0.001 
 8-11 49 56 1.56  
(0.98 : 2.49) 
0.06 8-11 61 83 2.12  
(1.42 : 3.21) 
<0.001 
 >11 130 95   >11 156 100   
GCS 
quartiles 
Missing 0 0   Missing 4 8 3.89  
(1.10 : 13.75) 
0.034 
 <9 47 90 3.76  
(2.13 : 6.65) 
<0.001 <9 55 127 4.50  
(2.73 : 4.71) 
<0.001 
 9-11 31 37 2.34  
(1.22 : 2.51) 
0.011 9-11 40 53 2.58  
(1.47 : 4.53) 
0.001 
 11-14 60 49 1.60  
(0.89 : 2.88) 
0.113 11-14 80 61 1.48  
(0.89 : 2.47) 
0.128 
 >14 57 29   >14 76 38   
GCS cut 
off <9.0 
Missing 0 0   Missing 4 8 2.56  
(0.75 : 8.60) 
0.13 
 <9.0 47 90 2.46  
(1.60 : 3.78) 
<0.001 <9.0 55 127 2.95  
(2.01 : 4.32) 
<0.001 
 >9.0 
 
148 115   >9.0 
 
196 153   
GCS cut 
off <11 
Missing 0 0   Missing 4 8 3.12  
(0.91 : 10.63) 
0.069 
 <11 78 127 2.44  
(1.63 : 3.65) 
<0.001 <11 95 180 2.95  
(2.07 : 4.20) 
 
 >11 117 78   >11 
 
156 100   
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Table 5.11 Analysis of CSF WCC and outcome by group category  
Variable  Cc400  N543 
 Grouping Alive 
195 
Dead 
205 
OR death  
(95% CI) 
P 
value 
Grouping Alive 
255 
Dead 
288 
OR death  
(95% CI) 
P value 
CSF WCC 
prev 
validated 
Missing 1 0 0.00  
(0.0 : 0.0) 
1.0 Missing 1 0 0.00  
(0.0 : 0.0) 
1.0 
 <1000 94 149 2.83  
(1.86 : 4.29) 
<0.001 <1000 130 205 2.35  
(1.63 : 3.35) 
<0.001 
 >1000 100 56   >1000 124 83   
CSF WCC 
median 
(IQR) 
 1122  
(288 - 
3160) 
395 
(132 - 
1040) 
1.00  
(1.00 : 1.00) 
<0.001  960  
(280 – 2915) 
405  
(140-1131) 
1.0 (1.0 : 1.0) 0.094 LR 
<0.001 on 
M-W-U test 
CSF WCC 
quartiles 
Missing 1 0 0.00  
(0.0 : 0.0) 
1.0 Missing 1 0 0.00  
(0.0 : 0.0) 
1.0 
 <170 34 66 4.61  
(2.53 : 8.4) 
<0.001 <155 44 78 3.26  
(1.96 : 5.40) 
<0.001 
 170-545 45 55 2.91 
(1.62 : 5.22) 
<0.001 155-480 58 82 2.60  
(1.60 : 4.21) 
<0.001 
 545-2000 46 55 2.84  
(1.58 : 5.10) 
<0.001 480-1680 60 78 2.39 
(1.47 : 3.87) 
<0.001 
 >2000 
 
69 29   >1680 92 50   
CSF WCC 
Log 10 
Missing 1 0 0.00  
(0.0 : 0.0) 
1.0 Missing   0.00  
(0.0 : 0.0) 
1.0 
 <10 2 9 9.0 
(1.46 : 55.47) 
0.018 <10 5 15 6.85 
(1.78 : 26.3) 
0.005 
 10-100 14 32 4.57 
(1.42 : 14.64) 
0.010 10-100 21 44 4.78 
(1.71 : 13.4) 
0.003 
 1e2-1e3 78 108 2.76 
(0.99 : 7.69) 
0.051 1e2-1e3 104 106 3.20 
(1.27 : 8.0) 
0.013 
 1e3-1e4 88 50 1.13 
(0.40 : 3.21) 
0.81 1e3-1e4 108 76 1.60 
(0.63 : 4.09) 
0.31 
 1e4-1e5 12 6   1e4-1e5 16 7   
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Table 5.12 Analysis of pulse rate with outcome by group category 
 
Comparison of pulse rate (beats per minute) and association with mortality when categorised into clinical or statistical groups 
 Cc400  N598 (543) 
 Grouping Alive 
195 
Dead 
205 
OR death  
(95% CI) 
P 
value 
Grouping Alive 
255 
Dead 
288 
OR death  
(95% CI) 
P value 
Pulse 
previously 
validated 
Missing 20 21 1.12  
(0.58 : 2.15) 
0.72 Missing 28 30 1.03  
(0.59 : 1.79) 
0.91 
 Pulse 
<120 
155 145   Pulse 
<120 
201 208   
 Pulse 
>120 
20 39 2.08  
(1.16 : 3.74) 
0.014 Pulse 
>120 
26 50 1.85  
(1.11 : 3.10) 
0.018 
Pulse 
Median 
 98  
(88-108) 
102  
(90 – 
120) 
1.02  
(1.01 : 1.03) 
0.004  98  
(88-110) 
100  
(90-120) 
1.01  
(1.00 : 1.02) 
<0.0001 
Pulse 
Classical 
Missing 20  
 
21 0.99  
(0.52 : 1.90) 
0.99 Missing 28 30 1.19  
(0.67 : 2.10) 
0.53 
 <100 95 74   <100 145 130   
 100-120 48 53 1.55  
(0.88 : 2.72) 
0.123 100-120 56 78 1.55  
(1.02 : 2.35) 
0.038 
 >120 32 57 2.23  
(1.33 : 3.72) 
0.002 >120 26 50 2.14  
(1.26 : 3.64) 
0.005 
Pulse 
quartiles 
Missing 20 21 1.41  
(0.68 : 2.93) 
0.34 Missing 28 30 1.28  
(0.69 : 2.37) 
0.43 
 <88 58 43   <88 73 61   
 88-100 56 48 1.15  
(0.66 : 2.0) 
0.61 88-100 72 69 1.14  
(0.71 : 1.84) 
0.57 
 100-118 29 36 1.67  
(0.89 : 3.13) 
0.12 100-118 38 55 1.73  
(1.01 : 2.95) 
0.044 
 >118 32 57 2.4  
(1.33 : 4.31) 
0.003 >118 44 73 1.98  
(1.19 : 3.29) 
0.008 
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In summary the OR for the quartile groupings were more powerful than that using the 
clinically relevant groups (Tables 5.9-12), and a nomogram was synthesised that included all 
variables categorised into these groups (Figure 5.6).  
 
Figure 5.6 Nomogram for significant variables, categorised into quartiles 
 
The validation data for this nomogram was as follows: AUC 0.69 (0.62 : 0.78), with poor 
associated agreement (Figure 5.7, Table 5.13).  
 
Figure 5.7 ROC for agreement of the nomogram in Figure 5.6  
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Table 5.13 MAMS agreement data with categorical data 
Summary of agreement data between observed and predicted deaths by MAMS in 
the significant variables only nomogram, using categorical data instead of 
continuous data 
Risk score 
% 
Total number of 
participants 
Observed Deaths 
(%) 
Deaths predicted by 
the Nomogram 
≤10 2 0(0.0) 0 
11-20 1 0(0.0) 0 
21-30 8 1(13) 2(25) 
31-40 40 15(38) 17(43) 
41-50 29 18(62) 16(55) 
51-60 28 17(61) 18(64) 
61-70 32 25(78) 24(75) 
71-80 36 29(81) 31(86) 
81-90 17 10(59) 16(94) 
90-10 - - - 
Total 193 115(60) 124(64) 
 
Kappa from these data was 0.16 (Std 0.1) p=0.056, demonstrating substantially less 
agreement than the continuous variables nomogram. Therefore it was decided the 
nomogram would be more powerful with all variables other than represented on a continuous 
scale. The range for CSF WCC was large, so this was log10 transformed to accommodate 
the range on the scale. 
 
5.3.3.4 Validation of the nomogram with the expansion of pneumococcal variable into 
pathogenic categories 
In an attempt to improve the specificity of the nomogram, an analysis was done to check the 
accuracy of each variable when the final outcome was mis-classified by the nomogram. 
Although the numbers were small, it was noted that the predicted outcome in several cases 
was wrongly predicted by the variable ‘CSF culture’. This variable was binary with either 
positive pneumococcal CSF culture or ‘non-pneumococcal culture including culture 
negative’. This latter category included cases of meningococcal and Hib meningitis with zero 
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mortality, and gram negative (predominately E. coli) meningitis with 85% mortality. To test if 
more detailed categorisation improved predictive performance, this variable was exploded 
into three categories (Hib/meningococcus/other, pneumococcus or culture negative, and 
Gram negatives including E. coli) (Figure 5.8).  
 
Figure 5.8 Nomogram showing continuous variables, with explosion of bacterial culture 
 
Validation of the subsequent nomogram was substantially worse than the preceding 
nomogram with AUC 0.67 (95% CI 0.60 : 0.75) (Figure 5.9); agreement was only 37.5% 
against random agreement of 9.3% (p<0.001) (Table 5.14), the Kappa value was 0.31. 
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Figure 5.9 ROC curve for the nomogram in Figure 5.8 
 
Table 5.14 MAMS agreement data with an expanded bacterial culture category 
Summary of agreement data between observed and predicted deaths by 
MAMS in the significant variables only nomogram, using the variable 
‘pneumo’ exploded into three categories 
Risk score 
% 
Total number of 
participants 
Observed 
deaths 
Predicted 
deaths 
 n n (%) n (%) 
≤10 51 20 (39) 3 (6) 
11-20 47 27 (57) 7 (15) 
21-30 32 18 (56) 8 (25) 
31-40 0 0 (0) 0 (0) 
41-50 34 26 (76) 14 (41) 
51-60 5 4 (80) 3 (60) 
61-70 6 4 (67) 4 (67) 
71-80 4 3 (75) 3 (75) 
81-90 13 12 (92) 12 (92) 
Total 192 114 (59) 54 (28) 
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5.3.4 Final MAMS nomogram and validation data 
As the validation exercise showed that expansion of the variable for CSF culture reduced the 
predictive power of the nomogram, and continuous variables were more powerful than 
categorical variables, the final MAMS nomogram was chosen on the basis of the optimal 
predictive power found during the validation cycles (Figure 5.10). 
 
Figure 5.10 Final nomogram to predict outcome from ABM in Malawian adults 
 
This nomogram has the four variables associated with mortality all represented as 
continuous variables, and CSF culture represented as a binary variable pneumococcal 
culture/non-pneumococcal culture. The nomogram has an AUC of 0.74 (95% CI 0.65 : 0.82), 
shown in the ROC curve in Figure 5.11. This AUC or concordance statistic, is within the 
confidence intervals of the Dutch meningitis score (validation concordance 0.81 (95% 0.74 : 
0.87), and therefore is likely to perform similarly. Table 5.15 summarises the agreement of 
the MAMS prediction with actual outcome for each percentile of predictive risk. 
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Figure 5.11 ROC showing sensitivity and specificity of the final MAMS nomogram 
 
Table 5.15 MAMS validation data for the final nomogram 
Summary of validation agreement of MAMS for different risk groups. N=192 
Risk score % Number of participants Observed Deaths (%) Predicted Deaths (%)   
≤10 2 0(0) 0(0) 
11-20 4 0(0) 1(25) 
21-30 11 1(9) 3(27) 
31-40 - - - 
41-50 47 20(43) 20(43) 
51-60 19 10(53) 10(53) 
61-70 28 18(64) 18(64) 
71-80 27 20(74) 20(74) 
81-100 54 45(83) 48(89) 
Total 192 114(59.3) 120(62.5) 
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The final validation data for the MAMS nomogram show optimal agreement, with a Kappa 
value of 0.6 (Std Err 0.1), and agreement of 62.5% against random agreement of 14.1% 
p<0.00 for all the nomograms tested in the validation exercise.  
Table 5.16 shows a summary of all the nomograms tested with a comparison of the 
validation data by each nomogram. 
Table 5.16 Summarised MAMS validation data for each nomogram 
Summary of validation for each nomogram tested in the MAMS validation loops 
 AUC Observed 
mortality 
Predicted 
mortality 
Actual 
agreement 
p Kappa  
(StdErr) 
Significant 
variables only 
non-imputed 
0.75  
(0.65-0.85) 
46% 53% 37.5% <0.001 0.32 
All variables 
only non-
imputed 
0.77  
(0.66–0.88) 
51% 57% 12.5% 0.37 0.03 
Variables post 
missing data 
completion 
0.74  
(0.67-0.88) 
59.3% 62.5% 62.5% <0.001 0.6 
Variables 
categorised 
into quartiles 
0.69  
(0.62-0.78) 
60% 64% 26% 0.056 0.16 
Variables with 
pnuemo 
exploded 
0.67  
(0.60-0.75) 
59% 28% 37.5% <0.001 0.31 
Final MAMS 
nomogram 
0.74  
(0.6-0.82) 
59.3% 62.5% 62.5% <0.001 0.6 
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5.4 Summary and Discussion 
The final MAMS nomogram compares well with the nomogram presented by the Dutch 
meningitis group (Table 5.17) (Weisfelt et al., 2008). The concordance statistic in MAMS in 
the validation dataset of 0.74 falls within the confidence intervals of the Dutch data,  
concordance of their score in the validation dataset was 0.81 (95% 0.74 - 0.87) (Weisfelt et 
al., 2008).  The Dutch score did not perform well against Malawian data when tested 
(concordance 0.68 95% CI 0.63 - 0.73) (Schut et al., 2012). The AUC of the final nomogram 
for MAMS does not fall within the confidence intervals of the European score applied to 
Malawian data, and therefore it is clear that MAMS performs better using Malawian data 
than the European score when applied to the same data. 
 
Table 5.17 Comparison of MAMS and EMS validation data 
Summary of validation data from European Meningitis Scores and MAMS 
 Concordance  
(95% CI) 
European Meningitis Score (EMS) 0.81 (0.74 - 0.87 
EMS Applied to Vietnam 0.70 (0.65 - 0.75) 
EMS applied to Malawi 0.68 (0.63 - 0.73) 
MAMS 0.74 (0.6 - 0.82) 
 
 
MAMS appears to have optimal predictive power in the mortality percentiles between 40-
80%. Over prediction of poor outcome is seen in both <40% percentile and the >80% 
percentile, by 20% in the former and 5% in the latter. Although the numbers are small, the 
power of the nomogram is clearly less at these more extreme ends of the nomogram. It was 
thought that this was due to misclassification of poor outcome by causative pathogen (Hib/ 
N. meningitidis had 0% mortality in the discovery database and E. coli had 85% mortality), 
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but when the CSF culture variable was expanded to account for this, the power of the 
nomogram was significantly reduced. These unexpected deaths could be due to another 
predictive factor that has not been yet measured due to lacking information, such as 
bacterial serotype (Harboe et al., 2009; Gessner et al., 2010), lactate clearance or 
oxygenation (Arnold et al., 2008), or by late causes of death such as pulmonary embolism or 
nosocomial pneumonia that are hard to diagnose in a resource limited hospital, and data are 
currently lacking. No predictive scoring system can fully take account of unusual events or 
unpredictable deaths.  
 
MAMS was derived using a virtually identical methodology to that used by the Dutch team, 
and the final validation data of MAMS compared well against the validation data of the Dutch 
score. There are substantial differences between the patients from whom the data for that 
score were derived compared to Malawian data, particularly relating to the age, HIV co-
infection and CSF WCC and mortality rates. Patients in Europe were more likely to be older 
(52 v 31 years p<0.001), less likely to have had prior antibiotic treatment (9% v 26% p<0.01), 
and less likely to be HIV co-infected (<1% v 90%, p<0.001) (Schut et al., 2012). CSF WCCs 
in Europe were high compared to Malawi (mean 3000 cells/mm3 compared to 480 cells/mm3 
p<0.001). The cut off used in the Dutch score of CSF WCC <1000 cells/mm3 means that 
most of the Malawian patients would be assigned a high mortality score. As 90% of the 
patients in that study had HIV co-infection, it is possible that a low CSF WCC response to 
bacterial meningitis may be a marker of advanced HIV infection and possibly worse 
prognosis. In addition data on haemoglobin are not given in either paper from the Dutch 
authors, but it is likely that the European patients are less likely to be as profoundly anaemic 
as the Malawian patients (Lewis et al., 2005; Hedstrand and Killander, 1977), and that 
anaemia may also be a surrogate marker for advanced HIV co-infection and meningitis in 
Malawi as seen in cases of tuberculosis and non-typhoidal Salmonella infection (Bedell et 
al., 2012).  
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The failure of the Dutch score to validate against the Malawian data is possibly due to the 
low age of the Malawian patients compared to the Dutch cohort, and the power of anaemia 
and very low CSF WCC to predict outcome in the Malawian patients. However the Dutch 
score also failed in a cohort of Vietnamese patients with bacterial meningitis, where the HIV 
co-infection rate was also low, and the mortality rate was much lower at 11%  than in both 
Malawi (55%) and Europe (21%) (Schut et al., 2012). These patients had also a lower age 
(41 v 56 years p<0.001), but had high CSF WCC (2990 v 3000 cells/mm3 p0.02). 
S.pneumoniae was the causative pathogen only in 12% of Vietnamese patients compared to 
51% of Dutch patients and 55% of Malawian patients (p<0.001), the predominate organism 
in Vietnam was Streptococcus suis (26%) (Schut et al., 2012). Why that score performed 
differently in different populations is unclear, but suggests that ABM may have different 
pathophysiology in different hosts from different geographical regions. 
 
Neither MAMS nor the Dutch meningitis score predicts outcome perfectly, and the absence 
of additional data on other potential risk factors that may be associated with poor outcome is 
likely to weaken both the scores. It is clear that inflammation associated with meningitis 
pathogenesis with the CSF compartment, brain and systemic inflammatory responses 
results in alterations of measurable physiology such as GCS and pulse, but the differences 
particularly in the CSF WCC response between different groups may indicate different host 
responses to the meningitic pathogen. Further discussion of the host responses to infection 
in the CNS is found in Chapter 8 Section 8.3.2. 
 
MAMS underwent multiple changes to the nomogram during the validation loop processes to 
attempt to improve the predictive power. The first of these changes, optimising the missing 
data improved the performance of the score. However subsequent validation loops, including 
different ways of categorising of the variables weakened the predictive power, due to 
categorisation of the data, and variables represented as continuous data are optimal for this 
scoring system. This is likely to the loss of one degree of freedom with a continuous variable, 
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whereas two degrees of freedom are lost when the data are categorised. From this exercise 
it is clear the individual predictors of poor outcome for each patient are heterogeneous, and 
by creating categories for each variable, the number of cases placed in each category had 
significant disparities between them and were not homogeneous. The final nomogram only 
contains one binary variable, CSF culture, as explosion of this variable also lessened the 
predictive power of the score. These variations in the data were only discovered through the 
rigorous validation loop processes that MAMS went through in development, with full 
confidence that the optimal score for these data has been derived. 
 
In the EMS in comparison, most of the variables were binary or categorical with the 
exception of age and GCS. It is not clear from that paper why the authors chose to use 
predominately binary variables compared to continuous variables when in MAMS continuous 
variables were more powerful (Weisfelt et al., 2008). In addition, in derivation of the EMS, 
the authors used 5 rounds of random imputation on all variables in the dataset and do not 
report if any biases were found. The validation for that score was done on European 
Dexamethasone Study, where patients who received Dexamethasone were included despite 
the receipt of dexamethasone being a factor in influencing outcome (Weisfelt et al., 2008). In 
the Malawian data, patients who received a treatment associated with outcome were 
removed, to avoid confounding in the data for the receipt of glycerol (Ajdukiewicz et al., 
2011).  
 
When evaluating a severity score, it is important that not only the discovery cohort and 
validation cohort are as separate as possible, but that they are also matched for 
demographic parameters of the patients on whom the score is tested (Cook, 2008). The 
MAMS discovery and validation datasets are equally matched. Although univariate 
significances were noted between HIV status, day 10 mortality, CSF culture results and 
respiratory rate, only respiratory rate retained significance between the discovery and 
validation datasets when tested in a multivariate model containing all univariate significant 
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variables. Therefore these results give us confidence that the validation data for the score 
are accurate and translatable can be drawn. Other variables not included in the Malawi 
meningitis database were collected in BAM and will be tested as predictors of poor outcome, 
including respiratory rate, hypoxaemia and hyper-lactataemia (Chapter 6 Section 6.3.7). 
 
The original data from which MAMS was derived and validated against contained significant 
missing data. The Dutch score also had missing data in their complete case dataset 
(Weisfelt et al., 2008). In that study, the authors used random imputation to complete the 
data for score derivation, however when this approach was tried with the MAMS discovery 
data, significant differences were seen in the ORs of predictors of poor outcome. Systematic 
biases were found in the Malawian data, particularly due to the collection of Hb data, where 
missing Hb was significantly associated with poor outcome and this altered the results of the 
random imputation exercise. It is possible to speculate that Hb data were more likely to be 
collected on patients that survived to ward admission, either because the sample was taken 
on ward admission, or because the patient survived long enough on the ward for the study or 
clinical team to collect the data from the laboratory. Neither the SAM nor GLAM studies, from 
which the majority of data for this study were derived were funded for routine Hb 
measurements at the bedside and relied on the availability of hospital results (Scarborough 
et al., 2007; Ajdukiewicz et al., 2011).  
Management of the missing data increased the number of cases available for validation and 
therefore the power of the nomogram, but possibly may have introduced separate biases 
through imputation of pulse and the re-coding of the Hb variable. No systematic biases were 
detected in further analysis of the data once imputed, and the possibility of ongoing biases 
influencing the completed missing data is low.  
 
MAMS in comparison with the Dutch severity score shows that patients in Malawi with a 
severe clinical phenotype including severe anaemia and abnormal CSF WCC response are 
likely to have a poor outcome, and predictors of poor outcome are different in different 
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geographical settings. It is unclear at this stage if these differences can explain the failure of 
adjunctive treatments such as dexamethasone in Malawi, or if patients with ABM in Malawi 
have completely different responses to pathogens causing ABM to those in better resourced 
settings.  The presence of important predictors such as low CSF WCC and severe anaemia 
indicate a severely weakened host immune system that may not be able to respond fully to 
invasive pathogens, correlations between these parameters and CD4 count will be explored 
in Chapter 7 Section 7.3.3. HIV co-infected Malawians have higher rates of pneumococcal 
carriage and altered mucosal and serum responses to pneumococcal carriage (Glennie et 
al., 2011), it remains to be determined if HIV is also a determinant of altered immunological 
responses within the CSF compartment.   
Other potential prognostic indicators that have been demonstrated either in European or 
Malawian data include CSF bacterial load, persistence of pneumolysin in the CSF, hyper-
lactataemia, severe immunosuppression and pre-hospital and in-hospital delays to diagnosis 
and treatment (Darton et al., 2009; Wall et al., 2012; Gamper et al., 2001; Wall et al., 2013c). 
Most pathophysiological variables such as bacterial load are not suitable for inclusion in a 
bedside severity scoring system, but the addition of bedside measurements including 
oxygen saturations and blood lactate may increase the power of the MAMS nomogram to 
predict outcome and therefore have optimal clinical and research utility. This will be explored 
in data from BAM (Chapter 6). 
 
MAMS was developed to provide objective data on predicted severity of patients presenting 
to the BAM study to compare the sequential phases in order to minimise confounding biases 
introduced by the before/after study design. Individual MAMS will be used as an adjunct in 
the analysis of BAM, to compare the baseline severity and changing prognosis over 6 hours 
of monitoring for the care bundle intervention between Phases one and two in the following 
chapter. These analyses will assist in determining the relative mortality risk of patients 
entering that study undergoing either routine medical care or receipt of the clinical care 
bundle, compared to the secondary endpoints of actual mortality and morbidity. 
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In conclusion, the MAMS nomogram has potential to be a useful research and clinical tool. 
Further validation of this nomogram, in the context of a clinical trial with the addition of 
prospective data collection for additional variables that may be important predictors is 
required before MAMS can be used by the wider clinical community. In addition external 
validation within sub-Saharan Africa from independent data would provide important data to 
inform the development of the MAMS nomogram. 
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6 Early Goal Directed Therapy for Adult Meningitis in Malawi 
 
6.1 Introduction 
Early Goal Directed Therapy (EGDT) is a term for protocolised medical care delivered in the 
form of a targeted clinical care bundle over six hours (Rivers et al., 2001; Dellinger et al., 
2004). Interestingly, the evidence for EGDT suggests that the overall effect of a clinical care 
bundle is greater than that would be predicted from the evidenced based efficacy of the 
individual components (Barochia et al., 2010; Dellinger et al., 2013; Chamberlain et al., 
2011). All studies to date, with the exception of a limited study in Uganda (Jacob et al., 
2012), have tested the concept of EGDT in resource-rich, or emerging country 
environments.  
No trial has ever tested EGDT for acute bacterial meningitis (ABM) in any setting. However 
guidelines directing urgent care in the emergency department for suspected ABM in adults, 
particularly early antibiotic therapy do exist, based on the existing evidence base 
(Heyderman, 2005; Tunkel et al., 2004; Fitch and van de Beek, 2007; van de Beek et al., 
2002). ABM in Africa is an appropriate illness in which to test EGDT, as shown in Chapter 4, 
Section 2 and Chapter five, the mortality rates are high, patients are critically unwell, and 
urgent care is a major priority to optimise outcome (Wall et al., 2013c).  
The clinical care bundle tested in this study was derived from available literature to optimise 
care based on the clinical parameters associated with poor outcome in the historical ABM 
data (Chapter 4 section 4.4.3-4). Detail as to the choice of study design are given in Chapter 
2 Section 2.6.2) 
Feasibility testing in an observational design study of any complex intervention is 
recommended by the guidelines published by the Medical Research Council (MRC) prior to 
testing in a formal parallel design trial (Campbell et al., 2007; Council, 2008). EGDT requires 
the use of additional resources within the ED for patient care, including nursing and clinical 
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personnel and clinical resources such as intravenous fluids and oxygen (Rivers et al., 2001). 
Feasibility testing is essential in this setting where no previous data exist to either guide 
study design for EGDT in resource limited settings, or to design a care bundle of EGDT for 
ABM.  
This chapter details the results of the pilot study designed to test the feasibility of delivering 
EGDT for acute adult meningitis in QECH in Blantyre, Malawi.  
 
Data in this chapter are also presented exploring the causes of culture negative meningitis in 
Malawian adults for the first time. Culture-negative meningitis is an important phenomenon, 
both in our understanding of the epidemiology of bacterial meningitis, and at the patient 
bedside. Real-time PCR was used in this study to test for the DNA of three common 
pathogens causing ABM in Malawi, to determine the causes of culture negative ABM and to 
explore the underlying causes of why CSF may be culture negative.  
 
6.2  Methods 
Detailed trial methods can be found in Chapter 3, Section 3.4. A detailed examination of the 
literature supporting each individual care bundle element is found in Chapter 2 Section 2.8.  
A summary of the relevant research questions, objectives, and endpoints are given here. 
The inclusion/exclusion criteria, ethical approvals, consent processes for acute care 
interventions, detailed study design, recruitment and follow up procedures and study 
analysis plans are detailed in Chapter 3, Section 3.4. 
6.2.1 Research questions and objectives 
1. Is the delivery of a clinical care bundle of resuscitation over a 6 hour time period for adults 
with suspected bacterial meningitis feasible and safe in a central teaching hospital in 
Malawi?  
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2. Can early goal directed therapy impact on mortality and neurological morbidity from acute 
bacterial meningitis in Malawian adults? 
 
Specific objectives 
1. To assess the feasibility of achieving each clinical target by using the clinical bundle, 
and perform a composite assessment of all targets achieved by the care bundle. 
2. To assess the relative change in mortality due to ABM in adults receiving the bundle 
compared to standard hospital care. 
 
6.2.2 Study endpoints 
Primary 
Total proportion of all clinical targets combined, achieved by the bundle at 6 hours. 
Secondary (measured at day 10 and day 40) 
1. Death 
2. Composite poor outcome (Death or significant disability with mRS ≥2) 
3. Persistent seizures requiring treatment 
4. Significant neurological disability  
5. Functional ability measured using the modified Rankin Score (mRS) 
 
Death was measured as a composite secondary endpoint (days to death/last known alive) 
using the following methods: 
Day 10 (acute) survival measured by either a date of discharge from hospital up to 10 days 
of inpatient antibiotic therapy. 
Day 40 (convalescent) - Final outcome recorded ‘alive or dead’ from follow up or response to 
mobile telephone to 6 weeks. 
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A history of seizures and functional ability since discharge was taken at day 40, and 
endpoints 2-4 were measured formally using the mRS (Chapter 2 Section 3.3.9 Table 3.6). 
Neurological disability was considered as mRS ≥2 points.  
 
6.2.3 Study design 
This study was designed as a before/after clinical trial at single centre, with two sequential 
cohorts of patients receiving either standard clinical care with monitoring from the study team 
in year 1 (Phase 1) or EGDT delivered as a resource-appropriate clinical care bundle in year 
2 (Phase 2).  
The goal directed targets were: 
1. Time of <1 hour to see a doctor/clinical officer and receive parenteral antibiotics  
2. Treat hypoxaemia for patients with SpO2 of <94% on admission to SpO2 of >94% 
3. Treat shock and optimise perfusion with IV fluids and blood for patients with at least 
one or more parameter of clinical shock as defined by the 2008 surviving sepsis 
guidelines (Dellinger et al., 2008b)  
4. Treat severe anaemia with blood 
5. Insert an airway if the patient was in coma (GCS <8) 
6. Raise the head to 30 degrees if the patient had significantly altered mental status 
(GCS <11)  
7. Control seizures by the end of the 6 hour observation period 
8. Correct hypoglycaemia to above 4mmol/L if present.  
 
6.2.3.1 Diagnosis of bacterial meningitis 
All CSF samples were processed by the MLW laboratory. Detailed methods are found in 
Chapter 3 Section 3.1. In addition, a subset of patient samples stored on admission had 
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multiplex real-time PCR performed for S. pneumoniae, N. meningitidis and Hib, and the 
results were used to determine causes of culture negative meningitis. 
 
6.3 Results  
6.3.1 Participant recruitment 
Six hundred and six patients were screened by the study team in the two phases. Eleven 
patients did not meet the screening inclusion criteria, and a further 65 declined verbal assent 
and were not recruited. Five hundred and forty one patients were initially included in the 
study (Figure 6.1). Of these, 135 met the CSF inclusion criteria, and 132 gave informed 
consent for their data to be retained and were followed up.  
Of the 132 participants who met the CSF inclusion criteria, 74 had culture proven ABM, and 
27 participants had a negative CSF culture but subsequently had a proven pathogen on 
PCR. The remaining 31 participants had CSF that was culture and PCR negative (when 
tested) but otherwise met the inclusion criteria, and were included as probable ABM cases.  
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Figure 6.1 BAM trial recruitment summary 
 
6.3.2 Causes of meningitis 
Table 6.1 shows the results of CSF culture for screened patients and trial participants. S. 
pneumoniae was the commonest cause of ABM, representing 46% of culture positive cases. 
N. meningitidis and E. coli were rare, no cases of Hib or non-typhoidal Salmonellae 
meningitis were seen. 
Pathogens listed as ‘other’ included alpha haemolytic streptococci, group A and B 
streptococci, S. aureus and gram negative pathogens including non-typhoidal Salmonellae.  
Multiplex real-time PCR (RT-PCR) was done on 159 whole CSF samples stored at -80°C. Of 
these samples, seven were from excluded patients with normal CSF (acellular, culture 
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negative with normal biochemistry) who acted as control samples, 88 were from proven or 
probable ABM, and 64 were from patients with possible ABM.  
Table 6.1 Results of PCR for BAM 
Bacterial multiplex RT-PCR per BAM inclusion group 
Inclusion 
category 
CSF 
culture 
results 
Pneumococcal 
DNA detected 
Meningococcal 
DNA detected 
Hib DNA 
detected 
PCR 
negative 
No 
result 
Excluded 
not ABM 
n=7 
NG  
n= 7 
 
0 0 0 7 0 
Included 
proven/ 
probable 
ABM  
n=88 
NG  
n=41 
12 5 0 22 2 
SpN  
n= 40 
38 0 0 0 2 
NM  
n= 1 
0 1 0 0 0 
Hib  
n= 0 
0 0 0 0 0 
E. coli 
n= 1 
0 0 0 0 0 
Other 
GNR 
n= 4 
0 0 0 0 0 
Other  
n= 1 
0 0 0 0 0 
Possible 
ABM n=64 
NG  
n= 64 
7 1 0 55 1 
NG = no growth 
Bacterial DNA was not found in any of the excluded samples (Table 6.1), but was found in 
culture negative CSF from both the included proven/probable meningitis group and the 
possible meningitis group. 
CSF culture and PCR results were compared (Table 6.2). All CSF culture positive cases for 
S. pneumoniae and N. meningitidis tested were also PCR positive. DNA was detected in 18 
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CSF culture negative cases and from two where bacterial contamination was reported and 
N. meningitidis DNA detected in six.  
Table 6.2 Comparison of culture and PCR data per pathogen 
Comparison of meningitis data from bacterial culture and PCR from BAM 
Bacterial 
culture 
result 
PCR 
negative 
SpN DNA 
positive 
NM DNA 
positive 
PCR  
Not done 
Total 
No growth 12 18 4 16 50 
SpN 0 36 0 25 61 
NM 0 0 1 3 4 
E. coli 1 0 1 0 2 
Other 2 1 1 3 7 
Contaminant 2 2 0 4 8 
Total 17 57 7 51 132 
 
Of the 82 cases of pneumococcal meningitis, 61 were detected by culture, and an additional 
21 (25%) were detected by PCR. Of the ten cases of meningococcal meningitis, four were 
detected by culture and an additional six were detected by PCR (60%). 
 
H. influenzae DNA was not detected in any samples. S.pneumoniae therefore accounted for 
82/132 (61%) of proven ABM cases, and N. meningitidis accounted for 10/132 (7.5%) of 
cases. 18% of CSF samples were PCR and culture negative. 
None of the patients in the possible group had a positive blood culture. Therefore of the total 
59 cases of pneumococcal meningitis in the sample set tested with PCR, 32% were 
diagnosed by PCR alone. One culture positive case of meningococcal meningitis was 
included in the PCR study, a further 6/7 (85%) cases of ABM caused by N. meningitidis were 
detected by PCR alone. ABM caused by Hib was not detected either by culture or PCR, and 
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ABM with other pathogens on culture including E. coli and other gram negatives did not have 
pneumococcal DNA detected (Table 6.2). 
These results were then tabulated against the receipt of antibiotics within the last 14 days for 
included participants to determine if antibiotic consumption altered the yield of either 
bacterial culture (by killing viable organisms for culture) or PCR (Table 6.3). 
Table 6.3 CSF PCR and culture results with antibiotics 
Comparison of CSF results by culture and PCR with recent receipt of antibiotics. 
 No prior 
antibiotics 
Prior 
antibiotics 
Unknown 
CSF culture positive  
n= 74 
35 (47%) 32 (43%) 7 (9%) 
CSF culture negative 
n=50 
16 (32%) 29 (58%) 5 (10%) 
CSF culture contaminated 
n= 8 
0 8 (100%) 0 
CSF PCR positive 
n= 64 
27 (42%) 30 (47%) 7 (11%) 
CSF PCR negative  
n=17 
3 (17%) 14 (83%) 0 
CSF PCR not done  
n=51 
21 (41%) 25 (49%) 5 (10%) 
 
Fewer patients whose CSF was culture negative had not received prior antibiotics (32% 
compared to 58% with receipt of antibiotics) p=0.02 (Chi squared test, Table 6.3). Small 
numbers of patients had a negative CSF PCR, more patients who had received antibiotics 
had a negative CSF PCR (83% compared to 17% with no antibiotics), however there was no 
significant relationship p=0.11 (Table 6.3). 
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6.3.2.1 Bacterial sub-type analysis 
Serotyping was not done routinely during this study, and these data are not available.  
Historically, serotypes one and five have been the most common causes of IPD and ABM in 
Malawi (Everett et al., 2012).   
All of the 4 cases of culture proven N. meningitidis meningitis were serogroup W135.  
6.3.2.2 Bacterial resistance patterns 
Antibiotic sensitivities are detailed in Table 6.4. Resistance to Co-trimoxazole was 
commonest, 100% of E. coli, 80% of and 75% of N. meningitidis isolates were all resistant to 
co-trimoxazole in vitro. Resistance rates to chloramphenicol and penicillin, the two most 
commonly prescribed parenteral antibiotics for ABM in the region were also high on disc 
testing, formal MIC testing was not done (in isolates:, 11% were resistant to penicillin and 
24.5% resistant to chloramphenicol), but no isolates were resistant to both antibiotics. No in 
vitro resistance to ceftriaxone was noted in this study. All meningococcal isolates were 
resistant to penicillin on disc testing, although the numbers are small. As disc testing, not 
MIC testing was used, from local data these are likely to be intermediate resistance (Cornick 
and Bentley, 2012). 
Pre-hospital antibiotics were widely prescribed (Table 6.5). Co-trimoxazole was the most 
frequently reported antibiotic, 20% of cases were taking this drug. Of the culture positive 
cases, 16 (26%) were taking Cotrimoxazole at the time of admission, and 13 (86%) of those 
16 isolates were co-trimoxazole resistant. It is not clear whether patients had received 
cotrimoxazole for an acute indication or was long term prophylaxis for HIV co-infection, as 
per the Malawian guidelines for the treatment of HIV (Government, 2012). 
Penicillin was the second most commonly prescribed antibiotic, with 15% of patients already 
taking this drug when admitted with ABM. Multiple other antibiotics were also prescribed in 
the community, although the overall numbers are small. 
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Table 6.4 Antibiotic sensitivities in CSF isolates 
Antibiotic sensitivities of CSF isolates to prescribed antibiotics  
Pathogen Number of cases resistant to each antibiotic (%)  
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S.pnemoniae 
N=61 
0 
(0%) 
7 
(11%) 
49 
(80%) 
Not 
tested 
5  
(8%) 
Not 
tested 
15 
(24.5%) 
33 
(54%) 
0 
(0%) 
0 
(0%) 
N. 
meningitidis 
N=4 
1 
(25%) 
4 
(100%) 
3 
(75%) 
0  
(0%) 
Not 
tested 
0 
(0%) 
0  
(0%) 
Not 
tested 
1 
(25%) 
0 
(0%) 
E. coli 
N=2 
1 
(50%) 
NA 2 
(100%) 
1 
(50%) 
1 
(50%) 
1 
(50%) 
1  
(50%) 
Not 
tested 
0 
(0%) 
NA 
Other n=15 0 2 
(13%) 
5 
(33%) 
0 1 
(7.5%) 
0 0 1 
(7.5%) 
0 0 
 
Only two patients were on TB treatment at the time of admission, and no patients were on 
anti-malarial treatment, despite eight patients having malaria co-infection (Table 6.5). Three 
patients had received both parenteral penicillin and chloramphenicol from a health centre 
before transfer. None had received ceftriaxone. 
Time from start of community prescribed antibiotic and admission with ABM was varied. Of 
the sixty seven patients whom were taking antibiotics, 29 (43 %) had been given the 
antibiotic within 24 hours of admission, 10 (15%) within 48 hours, and 8 (12%) within 48-72 
hours. Only twenty (30%) of patients had been taking antibiotics for longer than 72 hours, of 
whom 17 had taken that drug for 7-14 days or longer.  
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Table 6.5 Frequencies of antibiotic consumption 
Pre-hospital antibiotics 
Antibiotic 
n=88 
Frequency (%) 
n=132 
Penicillin/Amoxicillin 20 (15%) 
Co-trimoxazole 26 (20%) 
Ciprofloxacin 5   (3.8%) 
Erythromycin 8   (6.1%) 
Antimalarial including QNN* 0   (0%) 
Tetracycline 0   (0%) 
Ceftriaxone 3   (2.3%) 
Metronidazole 3   (2.3%) 
TB treatment (RHEZ) 2   (1.5%) 
Fluconazole 1   (1%) 
Parenteral penicillin 11 (8.3%) 
Parenteral Chloramphenicol 6   (4.5%) 
Parenteral Gentamicin 3   (2.2%) 
*QNN = Quinine 
 
6.3.3 Clinical presentation with ABM 
71 participants with ABM were recruited in Phase 1, and 61 in Phase 2. Table 6.6, Table 6.7, 
Table 6.8, and Table 6.9 detail the clinical presentation of these patients, comparing clinical, 
microbiological and laboratory parameters in the two phases. The patients were evenly 
matched for age, sex and HIV co-infection (including WHO stage and CD4 count); however 
some important differences were noted. These included more patients having clinically 
defined WHO HIV stage 3 or 4 illness in P1 (56% compared to 39% p=0.05), and longer time 
to presentation in P1 (Table 6.6).  Markers of septic shock (MAP, pulse, lactate, capillary 
refill time) were equally matched between the two phases Table 6.8. The clinical history was 
obtained from the accompanying guardian in 108/132 (81%) of cases, with only 15 (11%) of 
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patients able to give a history to the study team. This did not differ by phase. Fourteen 
patients gave a history of involvement with a traditional healer for the acute illness prior to 
admission (8 in P1 and 7 in P2). 
Petechial rash was observed in eleven patients in Phase 1 and none in Phase 2 (p=0.001) 
Table 6.7, seven with culture positive pneumococcal disease and four with negative CSF 
culture. CSF culture for N.meningitidis was negative in all of these patients, PCR was done 
in the four culture negative patients, all of which were negative for meningococcal DNA. 
Equal numbers of patients in both phases gave a history of otitis media (9 P1 and 8 P2 
p=1.0). Significantly more patients in Phase 2 gave a history of vomiting (3 in P1 and 23 in 
P2 p<0.001). Patients in Phase 1 took longer to present to hospital (p=0.005), were more 
likely to have pre-hospital seizures (28% v 14.5% p=0.04), and had lower oxygen saturations 
(96% v 97% p=0.042) and higher respiratory rates (26 v 21 breaths per minute, p=0.007) at 
presentation (Table 6.7, Table 6.8, Table 6.9).  
A history of a meningitic illness in the past was given by nine patients, 3 had documented 
ABM, one had cryptococcal meningitis (CCM) and 4 the cause was unknown. No patient 
gave a history of TB meningitis. Twenty patients gave a history of previous or chronic otitis 
media. 
At history of at least one WHO HIV stage 3 or 4 defining illnesses was present in 56 (42%), 
equally divided between the two phases (P1 30/71 (42%),  P2 27/61 (44%) p=0.86); the 
most common of which was significant weight loss of >10% of body weight in 26 patients. 
Oral or oesophageal candidiasis had been treated in 29 patients, 20 patients gave a history 
of TB, 13 community acquired pneumonia of which 4 were admitted, persistent fever was 
present in 14 (10%). Few patients had Kaposi Sarcoma (KS) (2), shingles (2) or chronic 
diarrhoea (7). 
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Table 6.6 Demographics of BAM participants 
Baseline characteristics of study participants including demographics and clinical 
history. 
Characteristic on 
presentation 
 
Value or Median value  
(% or Inter Quartile Range IQR) 
Univariate significance 
of differences between 
two phases 
Clinical observations Phase 1 
N=71 
Phase 2 
N=61 
P value 
Female  30 (42%) 21 (34%) 0.37† 
Median age (years) 32 (25 – 42) 34 (27.5 – 43.5) 0.14† 
HIV positive  42/60 (70%) 40/52 (77%) 0.65† 
Clinically defined WHO 
HIV stage 3/4 
40 (56%) 24 (39%) 0.059† 
History of WHO stage 
3 or 4 condition 
30 (42%) 27 (44%) 0.86 
Antiretroviral therapy 20/60 (33%) 14/57 (24.5%) 0.20† 
Out of hours BAM 
team admission  
23 (32%) 1 (1.6%) <0.001† 
Median Pre-hospital 
symptom duration 
(hours) (IQR) 
48 (48 – 72) 48 (24 – 72) 0.005 § 
<24 hrs 13 27 Ref 
24-48 hrs 25 20 0.35 
48-72 hrs 21 12 0.009 
72-96 hrs 5 1 0.041 
>96 hrs 7 0 0.99 
Pre-hospital 
antibiotics 
35/63 (55%) 34/57 (60%) 0.58† 
History of acute 
headache  
68 (96%) 56 (93%) 0.40† 
Pre-hospital seizures 20 (28%) 9 (14.8%) 0.049† 
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Table 6.7 Clinical features of BAM participants 
Characteristic on 
presentation 
 
Value or Median value  
(% or Inter Quartile Range IQR) 
Univariate 
significance of 
differences between 
two phases 
 Phase 1 
N=71 
Phase 2 
N=61 
P value 
Neck stiffness  52 (73%) 42 (68%) 0.35† 
Photophobia  9 (12%) 17 (27%) 0.024† 
Cranial nerve palsy 1 (1%) 3 (4.9%)  
(III = 2 VIII = 1) 
0.27† 
Moribund on 
admission 
11 (15.4%) 4 (6.6%) 0.08† 
Subjective hearing 
loss 
10 (14%) 5 (8.2%) 0.21† 
Clinical evidence of 
pneumonia* 
9 (12.6%) 9 (14.8%) 0.46† 
Clinical evidence of 
anaemia* 
9 (12.6%) 5 (8.2%) 0.29† 
Clinical evidence of 
shock* 
45 41 0.85† 
Focal limb weakness 5 (7%) 2 (3%) 0.29† 
Pre-illness modified 
Rankin Score >2  
2 (3%) 4 (6.5%) 0.53† 
Acute seizures in 
AETC  
7/62 (11%) 7/58 (12%) 0.55† 
*Clinical pneumonia defined as fast breathing with history of cough and audible chest signs consistent with pneumonia. 
*Clinical anaemia defined as objective extreme pallor of the palms and conjunctivae, or bedside hemocue of Hb <6.0g/dL. 
*Clinical shock defined as CRT>2 sec, BP <90 mmHg or MAP <70 mmHg, Pulse >100 bpm, lactate >4mmol/L 
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Table 6.8 Presenting physical parameters of BAM patients 
Characteristic on 
presentation 
 
Value or Median value  
(% or Inter Quartile Range IQR) 
Univariate 
significance of 
differences between 
two phases 
 Phase 1 
N=71 
Phase 2 
N=61 
P value 
Glasgow Coma Score  13 (10 – 14) 13 (11 - 14) 0.80† 
GCS >8-<11  12 (16%) 10 (16.4%) 0.63≠ 
GCS <8  14 (20%) 6 (9.8%) 0.09≠ 
Median mean arterial 
blood pressure 
(mmHg)  
90 (75 – 105) 92 (82 – 104) 0.59 § 
Pulse (bpm)  101 (85 – 116) 99 (86 – 119) 1.0 § 
Capillary refill time 
(seconds) 
1 (1-2) 1 (1-2) 0.66 § 
Temperature (°C) 
recorded  
38.2 (37.1 – 39.1) 38 (36 – 39) 0.01 § 
Oxygen saturations  96 (94 – 98) 97 (94 – 97) 0.042§ 
Respiratory rate 26 (22 - 32) 21 (19 – 26) 0.007 § 
Estimated body mass 
index (BMI) 
22.4 (20.9 – 24.1) 23 (21.1 – 24.3) 0.59 § 
MAMS (IQR) n=39 
 
157 (132 - 182) 149 (110 - 190) 0.61 
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Table 6.9 Laboratory results in BAM patients 
Microbiology Phase 1 
N=71 
Phase 2 
N=61 
P  
CSF culture  No growth                23 (32%) 27 (44%) 0.057 ≠ 
         34 (47%) 27 (44%) 0.11 
N. meningitidis         3 (4.2%) 1 (1.6%) 0.59 
E. coli                       1 (1.4%) 1 (1.6%) 0.27 
Other                       3 (4.2%) 4 (6.6%) 0.08 
Contaminant            7 (10%) 1 (1.6%) Reference 
CSF parameters Phase 1 
N=71 
Phase 2 
N=61 
P  
CSF white cell count 
(cells/mm3)  
68  
(16 – 288) 
241  
(8.5 – 1116) 
0.64† 
CSF protein (g/L) 2.84 (1.8 – 5.4) 2.73 (1.85 – 4.16) 0.61 § 
CSF : Blood glucose 
ratio 
0.34 (0.10 – 0.46) 0.13 (0.01 – 0.16) 0.04 § 
CSF lactate (mmol/L) 9.8 (7.8 – 11.1) 10.0 (9.1 – 11.2) 0.42 § 
Positive blood culture 20 (28%)  
(18/20) 
8 (13%) 
(3/8) 
0.06 ≠ 
Blood parameters    
Haemoglobin (g/dL)  11.9 (10.3 – 13.3) 11.6 (9.9 – 13) 0.85 § 
White cell count 9.6 (6.3 – 14.4) 10.2 (5.8 – 17.5) 0.56 § 
Platelet count 228 (129 – 315) 206 (148 – 299) 0.92 § 
CD4 count 97 (41 – 293) 131 (76 – 249) 0.94 § 
Positive test for P. 
Falciparum Ag 
5/53 (9.4%) 3/61 (4.9%) 0.46 † 
Glucose (mmol/L)  7.1 (5.6 – 8.6) 7.4 (6.0 – 9.2) 0.56 § 
Blood lactate (mmol/L) 2.9 (2.2 – 5.6) 3.4 (1.9 – 5.75) 0.65 § 
Creatinine (mg/dL) 0.99 (0.73 – 1.07) 0.9 (0.72 – 1.30) 0.89 § 
Sodium (mmol/L)  140 (138 – 144) 139 (133 – 149) 0.95 § 
† Fisher exact test ≠ univariate logistic regression § Mann-Whitney U test of medians 
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Of the 34 patients on antiretroviral therapy (ART), 28 were taking stavudine, lamivudine and 
nevirapine (d4T/3TC/NVP) and 3 were taking second line tenofovir, lamivudine and efavirenz 
(TDF/3TC/EFV), the regime was unknown in a further 3 patients (Table 6.10).  
Table 6.10 Antiretroviral treatment in BAM  
Duration of ART in adults presenting with ABM n=34 
Time period on ART All ART d4T/3TC/NVP TDF/3TC/EFV 
<1 month 6 5 1 
1-3 months 7 7 0 
3-6 months 4 4 0 
6-12 months 5 4 1 
>12 months 8 7 1 
 
There were no differences between the numbers of patients on ART in either phase (Table 
6.6). 
6.3.4 Results of the clinical targets achieved. 
6.3.4.1 Patients with bacterial meningitis 
The primary endpoint for this study was the total proportion of all clinical targets combined, 
achieved by the bundle at 6 hours. 
Eight clinical targets were set in Phase 2, and first the proportion of each target achieved by 
the care bundle was assessed, and then the composite target achievement was calculated.  
Table 6.11 shows the proportion of patients in both phases who met the criteria for treatment 
for each target and subsequent proportion of patients who did not meet the target set by the 
end of 6 hours across the phases. This was defined by either no change in the clinical 
parameter treated by the targeted care bundle element, or lack of availability of resources to 
meet that target. For example, the target for hypoxaemia (defined as SpO2 <94%) was to 
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achieve oxygen saturations above that level by the end of the six hour time period. If the 
patient remained hypoxic by the end of 6 hours, that patient did not meet the target set. 
It must be noted that nasopharyngeal airways and head tilts were not routinely available in 
the AETC during phase 1, but all other treatments and equipment were available. The study 
team monitored the care given by the AETC in Phase 1 of the study and delivered the 
protocolised care in Phase 2 in the AETC. 
Time to see a clinician was short in both phases and no differences were observed between 
the two phases. This was not a specific target but identified as necessary for the prescription 
of antibiotics, and therefore delays at this stage could seriously influence time to receipt of 
parenteral antibiotics. However there was no difference observed between the phases in 
time to clinical review. In contrast the time to receive antibiotics, and the proportion achieving 
the 1 hour target was significantly improved by use of the care bundle in Phase 2 (median 
time 1:55 in P1 and 1:13 in P2 p<0.001, 14% met the 1 hour target in P1 and 44% in p2 
p<0.001). Airway protection and head elevation were more likely to occur in Phase 2, with no 
patients receiving either intervention in P1 and 77% and 89% receiving at either in P2 
(p=0.04 and 0.002 respectively).
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Table 6.11 Targets achieved in BAM  
Clinical targets achieved by phase for patients with ABM at the end of 6 hours  
Parameter Target Phase 1 
N=71 
Phase 2 
N=61 
Univariate 
significance 
Timing of clinical 
assessment  
Medical review <1 hour of 
arrival 
Median time hh:mm (IQR) 
0:26 (0:10 – 1:01) 
Median time hh:mm (IQR) 
0:22 (0:15 – 0:45) 
 
0.73 
Proportion that 
met the target 
 Proportion seen in <1 hour 
n=44/62 (70%) 
Proportion seen in <1 hour 
n=48/57 (84%) 
 
0.12 
Antibiotic therapy 
timing 
1st dose within 1 hour of 
arrival 
Median time hh:mm (IQR) 
1:55 (1:10 – 2:52) 
Median time hh:mm (IQR) 
1:13 (0:42 – 1:58) 
 
<0.001 
Proportion met  
antibiotic target 
 Proportion IVABx <1 hour  
n=6/49 (14%) 
Proportion IVABx < 1 hour 
27/61 (44%) 
 
<0.001 
Brain protection Airway if GCS <8 given? 
Head tilt if GCS <11 given? 
n=0/14 (0%) 
n=0/26 (0%) 
n=7/9 (77%) 
n=17/19 (89%) 
0.04 
0.002 
Oxygenation on 
admission  
Give oxygen if Sp02 <94% Proportion SpO2 <94% on 
admission  
= 18/66 (27.2%) 
Proportion SpO2 <94%  on 
admission  
 = 15/61 (24.5%) 
 
 
0.84 
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Oxygenation on 
discharge 
 Proportion SpO2 >94% on 
discharge to ward  
= 30/37 (81%) 
Proportion SpO2 >94% on 
discharge to ward 
= 48/53 (90.5%) 
 
 
0.22 
Perfusion status 
on admission  
CRT<2 sec, BP >90 mmHg 
or  MAP >70 mmHg, Pulse 
<100 bpm, lactate 
>4mmol/L 
Proportion with one or more 
feature of shock on admission  
=45/69 (65%) 
 
Proportion with one or more 
feature of shock on admission  
= 41/61 (67%) 
 
 
 
0.85 
Perfusion status 
on discharge 
 Proportion without shock on 
ward discharge  
=20/37 (54%) 
Proportion without shock on 
ward discharge 
=31/53 (58%) 
 
 
0.82 
Blood transfusion Haemoglobin <6g/dL 
Transfusion in AETC? 
2/39 (5%) 
0 (0%) 
3/45 (6%) 
2/3 (66%) 
1.0 
0.4 
Seizures  Control of AETC seizures 
by ward discharge 
 
7/7 (100%) 
 
6/7 (85%) 
 
1.0 
Hypoglycaemia on 
admission 
Blood glucose >4 
throughout care bundle 
Proportion <4mmol/L  
0/53 (0%) 
Proportion <4mmol/L  
1/61 (1.6%) 
 
0.71 
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The proportion of patients requiring oxygenation was identical on admission for both phases, 
the number who still required oxygen at the end of the 6 hour observation time period 
decreased from 18% in P1 to 9% in P2, but the number of observations was small and this 
difference was not statistically significant. It must be noted that oxygen therapy in P1 was not 
recorded, but all patients with SpO2 of <94% in P2 received oxygenation via a concentrator. 
A substantial number of patients had clinical evidence of shock in both phases (65% in P1 
and 67% in P2 p=0.85) and although this did decrease by the end of the 6 hour observation 
period, there was no difference in the proportion of patients with shock across the phases 
after the shock protocol was given in P2 compared to P1 (46% v 41.5% p=0.82). 
Very few patients either required blood transfusion or treatment of hypoglycaemia in either 
phase; no data were available for the one patient who required a follow up blood glucose 
measurements in P2 who was hypoglycaemic. Two of three patients in P2 who required 
blood acutely in AETC received it, compared to no patients in P1. These differences were 
not statistically significant. Acute seizure activity was well controlled in both phases with only 
one patient discharged to the ward from the entire study who continued to seize. 
 
6.3.4.2 Target achievement for screened and excluded patients 
Data from patients who were subsequently excluded from the study were then examined, as 
these patients had the potential to benefit from the care bundle, particularly those with 
pneumonia and sepsis. The overall achievement of the individual targets was reviewed 
across all screened participants, including those with ABM for a wider feasibility assessment.  
Data were collected for the clinical targets for all screened participants. Table 6.12 details 
the proportion of each clinical target achieved by the different phases in all screened 
participants. 
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Table 6.12 Targets achieved in all screened participants 
Clinical targets achieved by phase for all screened patients at the end of 6 hours  
Parameter Target Phase 1 
N 263 
Phase 2 
N 290 
Univariate 
significance 
Timing of clinical 
assessment  
Medical review <1 hour of 
arrival 
Median time hh:mm (IQR) 
0:40 (0:15 – 1:20) 
Median time hh:mm (IQR) 
0:30 (0:16 – 0:54) 
 
0.01 
Proportion that 
met the target 
 Proportion seen <1 hour  
n= 150/253 (59%) 
Proportion seen < 1 hour  
n= 222/279 (80%) 
<0.001 
Antibiotic therapy 1st dose within 1 hour of 
arrival 
Median time hh:mm (IQR) 
2:30 (1:34 – 3:30) 
Median time hh:mm (IQR) 
1:10 (0:50 – 2:01) 
 
<0.001 
Proportion that 
met the antibiotic 
target 
 IVABx <1 hour  
n= 16/239 (7%) 
IVABx <1 hour  
119/290 (41%) 
<0.001 
Brain protection Airway if GCS <8? 
Head tilt if GCS <11? 
0/26 (0%) 
0/41 (0%) 
14/20 (70%) 
56/52 (107%) 
<0.001 
<0.001 
Oxygenation on 
admission  
SpO2 >94% SpO2 <94%on admission  
= 50/263 (19%) 
SpO2 <94%on admission  
 = 56/290 (19%) 
 
1.0 
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Oxygenation on 
discharge 
 Proportion SpO2 >94%on 
ward discharge  
= 185/207 (89%) 
Proportion SpO2 >94%on 
ward discharge  
= 253/268 (94%) 
0.057 
Perfusion status 
on admission  
 Proportion with one or more 
feature of shock on admission  
= 165/267 (62%) 
Proportion with one or more 
feature of shock on admission  
= 186/290 (64%) 
0.59 
 
Perfusion status 
on discharge 
CRT<2 sec, BP >90 mmHg 
or  MAP >70 mmHg, Pulse 
<100 bpm, lac >4mmol/L 
Proportion with no features of 
shock on ward discharge  
= 131/207 (63%) 
Proportion no features of 
shock on ward discharge 
= 170/269 (63%) 
 
 
1.0 
Blood transfusion Haemoglobin >6g/dL 
 
Transfusion in AETC? 
Proportion <6g/dL 
8/149 (5.4%) 
0/8 (0%) 
Proportion <6g/dL 
21/289 (7.3%) 
8/19 (42%) 
 
0.54 
0.04 
Seizures  Control of AETC seizures 
by ward discharge 
 
29/31 (93.5%) 
 
51/54 (94%) 
 
1.0 
Hypoglycaemia Blood glucose >44mmol/L Proportion <4mmol/L  
11/246 (4.5%) 
Proportion <4mmol/L  
11/289 (4%) 
 
0.82 
Hypoglycaemia on 
discharge 
 RBS >4 mmol by end of 
observation period  
= Not done 
RBS >4 mmol by end of 
observation period  
= 5/11 (40%) 
NA 
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Amongst all screened participants, both times to see a clinician and receive parenteral 
antibiotics were substantially reduced in P2 (Table 6.12) with the proportion of patients 
meeting the 1 hour antibiotic target increased from 7% in P1 to 41% in P2 (p<0.001). The 
application of both airways and head tilt to patients meeting the criteria for those 
interventions were also increased from no patients in P1 to 70% and 107% respectively for 
both targets. Equal proportions of patients met the criteria for oxygen (19%) in P1 and P2, 
the number still requiring oxygen on ward transfer dropped to 11% in P1 and 5.5% in P2, 
p=0.057 suggesting a trend towards optimised oxygenation in P2 but was not significant. 
The number and proportions of patients with shock were the same in both phases for both 
admission to AETC (62% and 64% p=0.59) and with on-going features of shock on ward 
discharge 37% and 36.5% respectively p=1.0). Blood transfusion requirements were low, but 
no patients received blood in AETC in P1 and 42% received blood in P2 p=0.04. Equal 
proportions of patients had their seizures controlled across both phases, and the frequency 
of hypoglycaemia was rare. 40% of patients in P2 had their hypoglycaemia successfully 
treated by AETC discharge. 
 
6.3.4.3 Composite target achievements for BAM included patients with bacterial 
meningitis 
To assess the overall proportions of patients in each phase being set and meeting targeted 
therapy, binomial Poisson regression was used to calculate the Rate Ratio (RR) of the 
means of the number of targets required or met between the two phases (Table 6.13). There 
was no difference in the mean number of targets required by the patients across the two 
phases, (2.59 in P1 and 2.52 in P2) RR 1.02 (95% CI 0.85 : 1.22, p=0.7). However the rate 
of target achievement in Phase 1 was significantly less than in Phase 2, the mean number of 
targets achieved in P1 was 0.55 (SE 0.102), compared to 1.57 (SE 0.128) in P2, Rate Ratio 
0.34 (95% CI 0.23 : 0.51) p<0.001.  
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Table 6.13 Composite target achievement in BAM 
Composite achievement of clinical targets between Phase 1 and 2 
Measure Phase 1 Phase 2 Rate ratio  
(95% confidence 
interval) 
p-value 
Mean Number of clinical 
targets per patient  (s.e.) 
2.59  
(0.148) 
2.52  
(0.177) 
1.027   
(0.859  :  1.226) 
  0.773 
Mean Number of required 
targets met per patient       
(s.e.) 
0.55  
(0.102) 
1.57  
(0.128) 
0.348   
(0.234  :  0.518) 
<0.001 
 
Following the examination of the primary endpoint (composite target achievements), the 
proportions of targets achieved per number of targets set were estimated across the study 
phases. The number of patients who met the criteria for one target alone, or two or more 
targets were calculated, and compared across the two phases (Figure 6.2). All patients met 
the criteria for at least one target (IV antibiotics within 1 hour) irrespective of clinical 
seriousness of their illness. 
As the number of targets increased per patient, fewer targets overall were achieved across 
the phases, but the number of targets achieved overall was greater in P2 than in P1. No 
patients set more than four targets were able to achieve more than four targets in either 
phase. Missing data on target achievement for patients recruited out of hours has reduced 
the data available for the P1 analysis.  
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Figure 6.2 Composite proportions of targets achieved by the care bundle 
 
6.3.4.4 Individual target achievements for BAM 
Following the examination of the composite targets, individual target achievements were 
estimated for patients included in the study (Table 6.14). Routine clinical care was not able 
to meet the majority of clinical targets for these patients. However the neither the care 
bundle nor the routine medical care was able to achieve the targets in patients with a 5 or 
more target requirement. 
In addition there are a small number of patients (2 in P1 and 5 in P2) who achieved more 
targets than they were set (Table 6.14). This was due to a clinical deterioration during the six 
hour observation time after admission to AETC that required the addition of further elements 
of the care bundle. The EGDT protocols stipulated that the patients were monitored hourly, 
and if a clinical deterioration was noted during the observation period that required 
protocolised treatment, then that treatment would be instituted. The overall study analysis 
was a comparison of targets set at the start of the monitoring period and those met by the 
end of the period, and the inclusion of these participant data who deteriorated during the 
care bundle led to the discrepancies seen in the Table 6.14.
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Table 6.14 Cumulative target achievement in BAM 
Individual cumulative target requirements across the study phases 
Number of 
targets set 
Number of patients  
per target set 
Phase 1 n=71 (%) 
Number of patients 
meeting target no. set  
in Phase 1(%) 
Number of patients  
per target set 
Phase 2 n=61 (%) 
Number of patients 
meeting target no. set  
in Phase 2 (%) 
One target  
 
16 (22%) 
 
0 targets 
1 target 
 
No data                   
6 (37%) 
3 (18%) 
 
7 (43%)                        
16 (26%) 
 
0 targets 
1 target   
2 targets 
3 targets                 
2 (12.5%) 
10 (62.5%) 
3 (18%) 
1 (6%) 
Two targets  22 (31%) 0 targets 
1 target  
2 targets     
3 targets   
No data            
2 (9%) 
3 (13%) 
4 (18%) 
2 (9%) 
11 (50%) 
20 (33%) 0 targets 
1 target   
2 targets   
3 targets               
5 (25%) 
5 (25%) 
9 (45%) 
1 (5%) 
Three targets  14 (20%) 0 targets 
1 target  
2 targets    
3 targets     
No data           
4 (28%) 
3 (21%) 
4 (28%) 
2 (14%) 
1 (7%) 
11 (18%) 0 targets 
1 target  
2 targets   
3 targets                
2 (18%) 
1 (9%) 
6 (54%) 
2 (18%) 
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Four targets  13 (18%) 0 targets 
1 target  
2 targets    
3 targets   
4 targets   
no data           
4 (30%) 
3 (23%) 
3 (23%) 
2 (15%) 
0 
1 (7%) 
8 (13%) 0 targets 
1 target  
2 targets    
3 targets    
4 targets            
1 (12.5%) 
2 (25%) 
2 (25%) 
3 (37.5%) 
0 
 
Five targets  6 (8%)  0 targets 
1 target  
2 targets    
3 targets   
4 targets 
5 targets             
3 (50%) 
3 (50%) 
0 
0 
0 
0 
3 (5%) 0 targets 
1 target  
2 targets    
3 targets   
4 targets 
5 targets             
0  
0 
1 (33%) 
2 (66%) 
0 
0 
Six targets  0 0 targets 
1 target  
2 targets    
3 targets   
4 targets 
5 targets 
6 targets            
0 
0 
0 
0 
0 
0 
0 
3 (5%) 0 targets 
1 target  
2 targets    
3 targets   
4 targets 
5 targets 
6 targets             
0 
0 
1 (33%) 
1 (33%) 
1 (33%) 
0 
0 
Seven targets  0 0 0 0 
Eight targets 0 0 0 0 
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6.3.5 Mortality and morbidity comparisons between Phase 1 and Phase 2. 
The BAM study was not powered to detect a difference in mortality between the two phases 
as the primary outcome, as no data were available on which to base an estimate of 
predicted mortality difference in ABM by EGDT. Estimates of mortality and morbidity were 
made as exploratory secondary outcome measures. Mortality was measured at discharge 
from AETC, daily on the ward during follow up, by discharge or day 10 whichever was 
earlier, and by 6 weeks post admission at day 40 (Table 6.15). 
Morbidity was measured by questioning to obtain a score on the modified Rankin score 
(mRS), and by physical examination to determine if deafness or neurological weaknesses 
were present. Composite poor outcome of death or disability was made by combining 
patients who either died or had a mRS of >2 points at that time point. Table 6.15 details the 
comparison between P1 and P2 for each of these endpoints. An overall trend towards worse 
outcomes in P2 was seen in all measured parameters at all time points, although these only 
reached statistical significance at the day 10 composite endpoint of death or disability. 
Mortality alone at day 10 was 27/71 (38%) in P1 and 32/61 (52%) in P2, but this did not 
reach statistical significance (p=0.11). However, when combined with morbidity to a 
composite end point, the rate of poor outcome was 33/71 (46%) in P1 and 44/61 (72%) in P2 
(p=0.004).  
Morbidity alone differed between phases at day 10; (6/71 (8%) patients in P1 had mRS >2 
but 12/61 (20%) in P2 had the same score (p=0.056).  
However no patients had persistent significant disability by the 6 week follow up point. 
Despite substantial loss to follow up in P1 (14 patients lost in P1 compared to 1 in P2), day 
40 endpoints were again worse in P2 than P1 without reaching statistical significance. Six 
additional deaths were noted in P2 post discharge compared to one in P1, leading to a day 
40 poor outcome rate of 29/57 (51%) in P1 and 38/60 (63%) in P2. 
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Table 6.15 Mortality and morbidity outcomes in BAM 
Secondary outcome measures  
Outcome Phase 1 
N=71 
Phase 2 
N=61 
Univariate p 
Dead in AETC 4 (5%) 7 (11%) 0.34 
Death day 2 20 (28%) 22 (36%) 0.33 
Death day 10 27 (38%) 32 (52%) 0.11 
Death + disability day 
10 
33/71 (46%) 44/61 (72%) 0.004 
Poor functional ability 
mRS >2 day 10 
6/71 (8%) 12/61 (20%) 0.056 
Deafness day 10 15/71 (21%) 10 (16%) 1.0 
Persistent seizures  
day 10 
1 (1.4%) 0 (0%) 1.0 
Death day 40 28/57 (49%) 38/60 (63%) 0.13 
Death + disability day 
40 
29/57 (51%) 38/60 (63%) 0.19 
Poor functional ability 
mRS >2 day 40 
1/29 (3%) 0/22 (0%) 0.84 
Deafness day 40  6/29 (20%) 7/22 (31%) 0.57 
Persistent seizures  
day 40 
0 0 NA 
 
The cumulative mortality data are represented in Figure 6.3, Kaplan-Meir plot of survival 
comparing the two phases. The data are censored to account for the missing data. 
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Figure 6.3 Kaplan-Meir curve of outcome from ABM by study Phase 
Cumulative survival curve comparing Phase 1 and Phase 2. The difference at 40 days is not statistically 
significant Log rank test p=0.19  
 
6.3.5.1 Adverse events in BAM 
Details of adverse event monitoring are found in Chapter 3 Section 3.3.11. 
Adverse event monitoring was undertaken throughout the study; however details on adverse 
events that could potentially be related to the care bundle were collected specifically in P2. 
Table 6.16 details the SAEs that occurred throughout the study and then specifically in P2 
during the administration of the care bundle. Univariate significance was calculated using the 
Fisher exact test.  
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Table 6.16 Adverse events in BAM 
Frequency of Adverse events  
Event Phase 1 n 
71 
Phase 2 
n 61 
Univariate 
significance 
Death in AETC 4 7 0.34 
Death overall by day 10 27 32 0.11 
Ward based events    
New or worsening focal neurology 5 1 0.56 
New seizures 6 5 0.44 
New or worsening deafness 3 1 0.64 
Decrease in GCS >2 points from previous 
day 
12 34 0.002 
New or worsening pneumonia 2 2 0.61 
Persistent fever 4 4 0.98 
Oligo-anuria 1 1 1.0 
Persistent hypotension requiring fluids 0 0 NA 
Evidence of fluid overload 0 0 NA 
Other 0 0 NA 
AETC events P1 P2 NA 
Pulmonary oedema No data 1 NA 
Suspected cerebral oedema No data 0 NA 
New oxygen requirement No data 1 NA 
Worsening of coma by >2 points  
(survivors to AETC discharge with data) 
5/37 
(13.5%) 
13/53 
(24.5%) 
0.28 
New seizure  4 4 1.0 
Respiratory depression (RR<12 breaths) 0 0 NA 
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The frequencies of adverse events in the ward during 10 days of follow up were similar, with 
the exception of worsening GCS of > 2 points from the previous day, which was recorded 12 
times (17%) in P1 and 34 times (55%) in P2 (p=0.002). The frequency of recording a drop in 
GCS of >2 points during the AETC 6 hour observation period was also greater in P2 (24% v 
13%) but this did not reach statistical significance (p=0.28) (Table 6.16). 
 
6.3.5.2 Adverse events in excluded participants 
Adverse events in patients who did not meet the inclusion criteria were only collected during 
the AETC 6 hour observation period and up to 48 hours ward follow up. SAEs for these 
patients were uncommon, and were only recorded in P2 due to concern about the harm that 
may be caused by the care bundle. The frequencies are as follows: Death 7 (3%), new 
oxygen requirement 3 (1.4%), GCS drop of =>2 points 2 (1%), and new seizure 1 (0.5%). Of 
the seven deaths none were directly attributable to the care bundle as determined by the PI 
and the study monitors, who reviewed the SAE forms and directed that no further action 
should be taken.  
 
6.3.6 Malawi adult meningitis score (MAMS) in BAM 
MAMS scores were tested prospectively in the analysis of BAM, Scores were calculated for 
each patient in BAM across the phases using the nomogram outlined in Chapter 5 Section 
5.3.4. As the score increases, the corresponding risk of poor outcome also increases. 
Therefore it was expected that where a low mortality rate was observed, the MAMS would 
be correspondingly lower for the patients in that phase. MAMS was validated in Chapter 5 to 
mortality at day 40, so day 40 outcome data were used. Where day 40 data were missing, 
day 10 outcome data were used instead to optimise the numbers of patients in the analysis. 
The score was then converted into a risk of poor outcome using the equation developed in 
Chapter 5, Section 5.2.4:  
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Predicted outcomes estimated using MAMS and true outcomes were then compared across 
the two phases, and the agreement calculated using Kappa (Table 6.17). A Kappa value of 
>0.6 was considered to represent good agreement. From the available complete case data 
(n=39) the calculated median MAMS were not different across the phases; median MAMS in 
P1 was 157 (132-182) compared to median MAMS in P2 of 149 (110 – 197) p=0.61. 
Interestingly, the agreement between predicted outcome and actual outcome was very 
different between the phases. The predicted mortality rate for P1 was 64% and for P2 was 
65%. However, the actual mortality rate was 18% in P1 and 71% in P2 (Table 6.17).  
Table 6.17 Performance of MAMS in BAM 
Comparison of the performance of MAMS across the BAM study 
phases complete case data n=39 
Probability 
of poor 
outcome 
group 
Phase 1 
predicted 
deaths 
Phase 1 
actual 
deaths 
Phase 2 
predicted 
deaths 
Phase 2 
actual 
deaths 
0-0.1 0 0 0 0 
0.1-0.2 0 0 0 0 
0.2-0.3 0 0 1 3 
0.3-0.4 1 0 1 1 
0.4-0.5 3 0 1 1 
0.5-0.6 2 1 2 1 
0.6-0.7 3 0 1 1 
0.7-0.8 2 1 1 1 
0.8-0.9 3 2 4 4 
>0.91 0 0 0 0 
Total 14 4 11 12 
Denominator 22 22 17 17 
Mortality 
rate 
64% 18% 65% 71% 
Kappa 0.11 (p=0.42) 0.61 (p<0.001) 
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Agreement of the score therefore between predicted and actual outcome was poor in Phase 
1 but good in Phase 2. Kappa was 0.11 (Std 0.08) (p=0.42) in Phase 1, and Kappa was 0.69 
(Std 0.18) (p<0.001) in Phase 2 (Table 6.17). 
Although good agreement was seen in P2, there were limited numbers of observations 
available to calculate MAMS in BAM (30%). This was due predominantly to missing data in 
two main variables; Haemoglobin because  laboratory results were not always available 
during the study, or CSF WCC when clumps of cells or a clot had been noted . To ensure 
the data were as complete as possible, a missing data analysis was undertaken as done for 
MAMS in Chapter 5 Section 5.2.5. The odds ratios of missing CSF WCC and missing Hb 
were compared with different categories for each variable (log10 CSF WCC and quartiles 
around the median for both CSF WCC and Hb) using logistic regression. In addition Hb was 
also categorised into clinically relevant groupings and these categories compared with the 
OR for missing values. 
Neither  of the missing data reported as either clumped CSF WCC or missing Hb had a 
statistical association with poor outcome  compared to the other categories of that variable 
(OR 1.13 (0.35 – 3.61).and  4.1 (0.69 – 24.9) respectively. It was therefore concluded that no 
systematic bias of missing data with mortality was present, and random imputation could be 
done to increase the numbers available to test MAMS across the phases, as was done to 
complete missing data for the variable ‘pulse’ in the historical data (Chapter 5 Section 5.2.5). 
Random imputation was done in SPSS version 20 and included the following variables in the 
imputation exercise; GCS, pulse, MAP, CSF WCC, CSF culture, age, gender, HIV status 
and Hb.  
The overall median MAMS scores were recalculated from the mean of the pooled imputed 
data from five rounds of imputation and the performance of MAMS was again compared 
across the phases (Table 6.18).  
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Median MAMS in the imputed data in P1 was 151 (127-178) and in P2 was 136 (112-161) 
p=<0.001. 
Using the imputed dataset actually worsened the relationship between predicted outcome 
using MAMS and actual outcome. The imputed data, although weaker than the complete 
case data, did demonstrate the same trend for MAMS to over predict mortality in P1 and 
have better agreement between predicted and actual outcomes in P2 compared with P2 
agreement in the smaller non-imputed dataset (Table 6.18, Table 6.17).  
Table 6.18 Performance of MAMS in BAM after imputation 
Comparison of the performance of MAMS across the BAM study 
phases, showing pooled data from 5 rounds of random imputation  
Probability 
of poor 
outcome 
group 
Phase 1 
predicted 
deaths  
n=68 
Phase 1 
actual 
deaths  
n=68 
Phase 2 
predicted 
deaths 
n=55 
Phase 2 
actual 
deaths 
n=55 
0-0.1 0 0 0 0 
0.1-0.2 0.48 0.6 0.75 2.2 
0.2-0.3 0.7 1 1.6 2.8 
0.3-0.4 2.9 1.6 3.9 6.4 
0.4-0.5 5.6 2.6 4.3 4.8 
0.5-0.6 6.5 4.4 5.3 5.4 
0.6-0.7 7.5 3.2 3.2 4.2 
0.7-0.8 8.5 8 4.4 4.6 
0.8-1.0 5.71 4.4 3.1 3.6 
Total deaths 38.2 25.8 26.6 34 
Denominator 68 68 55 55 
Case fatality 
rate 
56% 38% 48.5% 61.8% 
Kappa 0.1                  p=0.03 0.1                  p 0.003 
 
The poor performance of the imputed data is likely to be due to subtle ascertainment biases 
in the original data, particularly in P1 where missing data may be associated with ward 
257 
 
recruitment compared to AETC recruitment. The imputed analyses are presented here for 
completeness, but due to the weaknesses in the data, no conclusions can be drawn from 
these analyses. 
 
6.3.7 Subgroup analyses 
The finding that the mortality in Phase 1 was lower than that seen in Phase 2 and lower than 
the baseline from the historical meningitis data presented in Chapter 4 section 4.5.3-4, was 
unexpected. Subgroup analyses were undertaken to explore relationships between baseline 
severity indices, specific interventions and physiology over the 6 hour observations in order 
to explore the mortality differences. 
 
6.3.7.1 Tests for survival biases between the phases 
Recruitment patterns between P1 and P2 were slightly different. In P1 funding was only 
available for nurses to recruit patients Mon-Fri 7am-10pm, in P2 further funding was 
available for an additional nurse and recruitment was 24 hours from Sunday night to 
Saturday morning. To detect patients that were admitted with meningitis out of study hours in 
P1, computerised laboratory records were searched daily.  If patients had died by the point 
at which the results were available and therefore it was not possible for the team to obtain 
informed consent, data were recorded from the patient case notes. This approach to 
recruitment raised the possibility of survival biases in the data, that by missing early deaths, 
data recorded would higher rates of survival in P1 compared to P2.  Outcome data were 
analysed using Chi squared testing and univariate logistic regression. Table 6.19 shows 
deaths and composite outcomes across the phases by admission in or out of hours. 
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Table 6.19 BAM outcomes by admission time 
Study outcomes for included participants by admission in or out of hours 
Outcome measure Alive Dead OR (95% CI) p 
Death & 
disability day 
10 
Phase 1 in 
hours n=48 
24 24 (50%) ….. 
Phase 1 out of 
hours n=23 
14 9 (39%) OR 0.61 (0.23 : 1.7)  
p= 0.39 
Phase 2 in 
hours n=60 
29 31 (51%) ……. 
Phase 2 out of 
hours n=1 
0 1 (100%) OR not calculated 
 
Death & 
disability day 
40 
Phase 1 in 
hours n=37 
16 21 (56%) ……. 
Phase 1 out of 
hours n=20 
12 8 (40%) OR 0.5 (0.16 : 1.5)  
p=0.23 
Phase 2 in 
hours n=60 
22 37 (61%)  
Phase 2 out of 
hours n=1 
0 1 (100%) OR not calculated 
p=1.0 
 
Although there were fewer cases admitted out of hours in P1 with a marginally improved 
composite outcome compared to those admitted in hours, these differences were not 
statistically significant. There was therefore no evidence that the observed reduced case 
fatality rate in P1 compared to P2 could be explained by unrecorded deaths occurring 
because of the different recruitment patterns between the two phases.   
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6.3.7.2 Causes of poor outcome 
To explore the mortality rates seen in both phases, an analysis examining the comparison of 
predictors of poor outcome across the study phases was designed to test if variables 
suspected to be associated with poor outcome differed across the phases. Three variables 
were tested in the first analysis by dividing each continuous variable into quartiles around the 
median, and testing if an association existed between outcome and the upper quartiles of 
each variable, against the lowest quartile (assumed to be associated with the best outcome) 
using logistic regression (Table 6.20). These variables were blood lactate (BL), MAMS and 
time to IV antibiotics from admission. High levels of lactate (>4mmol/L) have been shown to 
be an independent predictor of outcome in sepsis (Rivers et al., 2001; Arnold et al., 2008), 
but little data are available examining the relationship between blood lactate and outcome 
from bacterial meningitis as opposed to sepsis. All guidelines for the treatment of ABM 
suggest that rapid IV antibiotic administration is important, and delay may be harmful (van de 
Beek et al., 2012; Koster-Rasmussen et al., 2008). MAMS is a new tool to assess risk of bad 
outcome developed in Chapter 5, differences in outcome by groups of each variable ranging 
from the >75th centile to the <25th centile were tested.  
Blood lactate (BL) was measured on admission in both study Phases and again after 6 hours 
observation in P2. BL was grouped into quartiles around the median, with the expectation 
that the 75th centile would represent the highest blood lactate value and therefore be 
associated with increased mortality as seen in sepsis (Table 6.20). The median lactate was 
3.6mmol/L (IQR 2.0 – 6.0) in survivors to day 40, and 3.4 mmol/L (IQR 1.9 – 5.6) in non 
survivors to day 40 (p=0.70). Mortality was evenly distributed across all quartiles of BL in 
both phases, the OR death in the >75th centile of BL (>5.6 mmol/L) was 1.0 (0.15 : 1.64) in 
P1 and 2.5 (0.58 : 10.6) in P2 p=0.21. 
Median MAMS scores with the associated quartiles were evenly distributed across the two 
Phases with no clear association between higher scores and outcome in either Phase. OR 
death with different quartiles of MAMS scores in P1 were not calculated due to lack of 
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mortality data in the reference category. OR death in P2 with MAMS >187 = 0.37 (0.02 : 6.3) 
p=0.49.  More deaths occurred in the lower quartiles for time to antibiotics in P2 compared to 
P1 stats but this trend did not reach statistical significance (Table 6.22). There was no 
relationship between antibiotic delay and poor outcome. 
 
MAMS was originally validated in a dataset that consisted of BAM Phase 1 data and 
randomly selected data from the historical database (Chapter 5 Section 5.2.2). The failure of 
MAMS to predict outcome accurately in solely Phase 1 data led to testing if the predictors of 
mortality in the historical database detailed in Chapter 4 Section 4.5.3-4, were the same of 
different in BAM patients between the two Phases. In addition further analysis including 
important potential confounders was done (Table 6.21). 
The individual predictors of poor outcome identified from the historical meningitis cohort data 
(Chapter 4 Section 4.5.3-42) were tested in these patients using logistic regression. Mortality 
at day 10 was again used as the endpoint to minimise biases from missing outcome data at 
day 40 in Phase 1.  
Lower GCS strongly correlated with outcome across both Phases: OR GCS with death 0.84 
(0.72 : 0.97) in P1 and 0.67 (0.50 : 0.91) in P2.  
In P1 a higher acute seizure frequency was associated with mortality (Table 6.21) OR death 
in P1 of one seizure was 5.6 (95% CI 1.7 : 18.5) p=0.004, two or more seizures OR death 
was12.3 (1.2 : 121) p=0.03. This trend was also noted in P2. However as all seven patients 
who had one seizure died in P2, and 50% of those with two or more seizures died the OR for 
one seizure alone could not be calculated, and in the two or more seizure group, there was 
no significant association with mortality. All other parameters measured had no association 
with outcome, including those with promising trends in the historical cohort but inadequate 
data for full examination in that dataset such as lactate, oxygenation and respiratory rate. 
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Table 6.20 Association of BAM outcomes with known predictors of outcome 
 All N=132 Phase 1 N=71 Phase 2 N=61 
 Deaths (%) Deaths (%) OR p Deaths (%) OR p 
MAMS  
<130 
130-151 
151-187 
>187 
n=39 
4 (10%) 
1 (2.5%) 
3 (7.5%) 
5 (13%) 
N=22 
0 (0%) 
0 (0%) 
1 (4.5%) 
2 (9%) 
 
….. 
….. 
UC 
UC 
 
 
1.0 
0.99 
0.99 
N=17 
4 (23.5%) 
1 (6%) 
2 (12%) 
3 (17.6%) 
 
…… 
0.08 (0.004 : 1.94) 
0.5 (0.19 : 12.8) 
0.37 (0.02 : 6.3) 
 
 
0.12 
0.67 
0.49 
Lactate 
<2 
2-3.4 
3.4-5.6 
>5.6 
N=100 
10 (10%) 
15 (15%) 
11(11%) 
13 (13%) 
N=39 
4 (10%) 
5 (12.8%) 
4 (10%) 
4 (10%) 
 
…. 
0.78 (0.13 : 4.3) 
1.25 (0.18 : 8.4) 
1.0 (0.15 : 6.4) 
 
 
0.77 
0.81 
1.0 
N=61 
6 (10%) 
10 (16%) 
7 (12%) 
9 (15%) 
 
…… 
2.7 (0.66 : 11.6) 
1.6 (0.38 : 7.1) 
2.5 (0.58 : 10.6) 
 
 
0.16 
0.49 
0.21 
Time to IV antibiotics 
<0:55 
0:55-1:31 
1:31-2:25 
>2:25 
N=110 
7 (6%) 
18 (16%) 
13 (12%) 
13 (12%) 
N=49 
0 (0%) 
6 (12%) 
7 (14%) 
6 (12%) 
 
……… 
UC 
UC 
UC 
 
 
0.99 
0.99 
0.99 
N=61 
7 (11%) 
12 (19.6) 
6 (10%) 
7 (11%) 
 
……… 
3.1 (0.86 : 11.0) 
1.85 (0.43 : 7.9) 
4.3 (0.84 : 22.0) 
 
 
0.08 
0.40 
0.07 
… = reference variable in logistic regression. UC = unable to calculate OR due to lack of mortality cases in the reference value. 
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Table 6.21 Individual predictors of outcome by study phase 
 Phase one n=71   Phase 2 n=61   
 Alive 
44 
Dead 
27 
OR death 
(univariate) 
p Alive 
29 
Dead 
32 
OR death 
(univariate) 
p 
HIV infected 25 16 4.48 
(0.89 : 22.3) 
0.06 18 21 0.97 (0.25 : 3.72) 0.96 
Mean age (Std) 32.7 
(12.2) 
34.1 
(10.6) 
1.0  
(0.97 : 1.05) 
0.61 35.5 (13.3) 37.6 (16.3) 1.00 (0.97 : 1.04) 0.59 
Male Gender 23 18 1.8  
(0.67 : 4.93) 
0.23 20 20 0.75 (0.25 : 2.17) 0.59 
GCS mean (Std) 12.4 (2.8) 10.4 (4.0) 0.84  
(0.72 : 0.97) 
0.02 13.3 (1.6) 11.7 (2.5) 0.67 (0.50 : 0.91) 0.01 
Mean Pulse (bpm)  
(Std) 
102.1 
(23.5) 
104.9 
(25.3) 
1.00  
(0.98 : 1.02) 
0.63 99 (0.2) 104 (22.2) 1.01 (0.98 : 1.03) 0.34 
Acute 
seizures  
None 
One 
Two or more 
37 
6 
1 
12 
11 
4 
… 
5.6 (1.7 : 18.5) 
12.3 (1.2 : 121) 
 
0.004 
0.03 
25 
0 
4 
21 
7 
4 
…….. 
Unable to compute 
1.1 (0.26 : 5.3) 
.. 
 
0.82 
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  Phase 
one n=71 
   Phase 2 
n=61 
   
  alive dead OR death 
(univariate) 
p alive dead OR death 
(univariate) 
p 
Oxygen saturations (%) 
median (IQR) 
96  
(95 – 98) 
96  
(92 –97) 
0.90 (0.78 : 1.03) 0.15 97 (95-97) 97 (90-98) 0.91 (0.80 : 1.0) 0.15 
O2 saturations <94% 9 9 2.2 (0.70 : 6.6) 0.16 4 11 3.2 (0.90 : 11.8) 0.07 
Respiratory rate 
(breaths/minute) 
Median (IQR) 
24  
(20-28) 
28  
(24 –39) 
1.05 (0.99 : 1.12) 0.058 21 (20-24) 22 (19-28) 1.0 (0.96 : 1.17) 0.18 
Blood lactate (mmol/L)  
Median (IQR) 
2.8  
(2.1–5.3) 
3.4  
(2.0–6.3) 
1.0  
(0.87 : 1.30) 
0.54 3.4  
(1.9 – 5.1) 
3.5 (2.8-
6.2) 
1.06 (0.90 : 1.26) 0.43 
Hb (g/dL)  
mean (Std) 
11.5  
(2.3) 
12.1  
(1.9) 
1.1  
(0.77 : 1.6) 
0.53 11.5 (2.4) 11.0 (2.4) 0.91 (0.74 : 1.13) 0.43 
CSF WCC (cells/mm3) 
Median (IQR) 
109  
(26 – 480) 
37  
(8-183) 
0.99  
(0.99 : 1.001) 
0.25 188  
(0.5–1680) 
241  
(17.5 – 
1116) 
0.99  
(0.99 : 1.001) 
0.49 
CSF culture positive 23 11 0.62 (0.23 : 1.65) 0.34 10 17 2.1 (0.76 : 6.0) 0.14 
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6.3.7.3 Mortality by clinical care bundle element 
Mortality per clinical intervention was compared across the phases (Table 6.22). Patients not 
meeting the one hour antibiotic target across both phases did not have significantly 
increased mortality compared to those meeting the target. As expected, altered mental state 
and coma were associated with poor outcome across both phases, however the proportion 
of patients dying was higher in P2 compared to P1 in both categories (GCS <11 mortality P1 
14/26 51%, P2 13/16 83%), (GCS <8 mortality P1 8/14 57%, P2 5/6 83%). Airways were 
inserted in patients with GCS <8 as part of the care bundle, as was a head tilt given to those 
with GCS <11. Both interventions were associated with poor outcome: OR death airway 
insertion P1 2.7 (0.82 : 9.0) p=0.09, OR P2 5.1 (0.56 : 47.3) p=0.14, OR death of head tilt P1 
3.0 (1.0 : 8.3) p=0.03, in P2 OR 5.9 (1.4 : 23.0) p=0.01. However, when corrected for GCS, 
the insertion of an airway, neither intervention were significantly associated with poor 
outcome (OR death with airway insertion 0.96 (0.11 : 7.8) p=0.97, OR death with head tilt 
0.48 (0.07 : 3.04) p=0.44) (Table 6.22).  
 
Specific prescribed interventions were oxygen therapy, IV fluids and medication including 
antibiotics, diazepam, phenobarbitone, anti-malarials and fluconazole for suspected 
cryptococcal meningitis (Table 6.22). No data are available on the number of patients in P1 
prescribed O2 therapy, however receipt of O2 in P2 was significantly associated with poor 
outcome OR 3.83 (1.23 : 11.9) p=0.02. The volumes of intravenous fluid prescribed in P2 
were substantially greater than those in P1 (median volume P1 0.75L IQR 250-750) 
compared to P2 (1.5L IQR 900-2000) p=<0.001. More patients in P1 were not given any IV 
fluid compared to P2 but these differences were not significant. 
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Table 6.22 Targets in BAM and outcome by study phase at day 10 
Targeted therapy Phase 1 n=71 Phase 2 n=61 
Alive 
44 
Dead 
27 
OR (univariate) p Alive 
29 
Dead 
32 
OR (univariate) P 
ABx <1 hr  
 
Yes 
No 
4 
26 
2 
17 
…… 
1.3 (0.2 : 7.9) 
 
0.77 
15 
14 
12 
20 
….. 
1.76 (0.6 : 4.9) 
 
0.26 
Airway  
(GCS <8) 
Yes 
No 
6 
37 
8 
18 
2.7 (0.82 : 9.0) 
……. 
0.09 1 
28 
5 
27 
5.1 (0.56 : 47.3) 
……. 
0.14 
 
Head tilt 
(GCS <11) 
Yes 
No 
12 
31 
14 
12 
3.0 (1.0 : 8.3) 
……. 
0.03 3 
26 
13 
19 
5.9 (1.4 : 23.0) 0.01 
Oxygen therapy Yes 
No 
UK UK Unable to 
compute OR 
 6 
23 
16 
16 
3.83 (1.23 : 11.9) 
…….. 
0.02 
Volume of IV 
fluid prescribed 
No fluid 
IV fluid 
(median 
IQR) 
9 
750 
(250-
750) 
2 
750 
(250-
750) 
0.55 (0.05 : 5.2) 
1.00 (0.99 : 1.0) 
0.60 
0.18 
1 
1700 
(750-
2075) 
1 
1325  
(912-1975) 
 
0.81  (0.37:1.77)  
 
 
0.60 
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Fluid bolus  Yes 
No 
2 
33 
3 
21 
3.7 (0.33 : 44.2) 
……. 
0.28 19 
3 
19 
8 
….. 
2.61 (0.60 : 11.6) 
 
 
0.19 
Volume of blood 
(units) 
No blood 
No. Units 
1 
0 
1 
0 
Unable to 
compute OR 
1.0 0 
1 
1 
1 
Unable to 
compute OR 
0.5 
Diazepam Yes 
No 
11 
33 
4 
23 
0.52 (0.14 : 1.8) 
…… 
0.31 12 
17 
19 
13 
2.0 (0.74 : 5.75) 
…… 
0.16 
Phenobarbitone Yes 
No 
3 
41 
3 
24 
1.7 (0.3 : 9.1) 
….. 
0.53 2 
27 
0 
32 
Unable to 
compute OR 
0.99 
Other 
medication 
(Malaria) 
Yes 
No 
1 
43 
0 
27 
Unable to 
compute OR 
1.0 0 
29 
0 
32 
Unable to 
compute OR 
Unable to 
compute 
Other 
medication 
(Fluconazole) 
Yes 
No 
2 
42 
0 
27 
Unable to 
compute OR 
0.52 0 
29 
1 
31 
Unable to 
compute OR 
1.0 
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IV fluid volumes were the same in survivors and non-survivors  at day 10 in P1; in P2 
survivors received more IV fluid compared to non-survivors but this did not reach statistical 
significance (median volume survivors 1.7L IQR 0.75-2.075L, non survivors 1.32L IQR 0.9-
1.97) OR 0.81  (0.37:1.77) p=0.60. There was no association in either phase with the 
administration of a fluid bolus and death at day 10. The administration of diazepam or 
phenobarbitone was not associated with death overall (OR 1.38 95% CI 0.67 : 2.85), or in 
either phase at day 10 on univariate analysis. However, more patients received diazepam in 
P2 (31/61 50%) compared to P1 (15/71 21%) p<0.001. Numbers of prescriptions of other 
therapies including phenobarbitone, anti-malarial drugs and fluconazole were too small for 
meaningful analysis. 
 
6.3.8 Physiology of patients with ABM. 
All screened patients admitted to the BAM study in AETC were monitored for 6 hours post 
recruitment. Hourly observations were taken for pulse, respiratory rate, oxygen saturations, 
GCS and blood pressure. Systolic and diastolic blood pressure were converted to mean 
arterial blood pressure (MAP) using the following standard equation 
MAP= ((2*diastolic BP)+systolic BP)/3. 
Complete observations were only available for those patients in Phase 1 who were recruited 
by the study team in AETC, and were missing from those recruited retrospectively on the 
medical wards using CSF results. Further missing results were found in patients who died in 
AETC and did not complete the full 6 hours of observation. For completeness, only patients 
with complete case data to the end of 6 hours observation are presented here. By tracking 
the changing physiology over 6 hours it was hoped that patterns could be determined that 
could add further understanding to prediction and causes of poor outcome . Table 6.23 
shows the mean values for each measured parameter at time zero before any treatment had 
been received, at time 3 hours when antibiotics and other prescribed treatments including 
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fluids should have been initiated , and at the last observation at 6 hours post admission. 
Mean values between outcomes by phase are compared using the students T-test. 
Complete case data were available for P1 non survivors n=13, P1 survivors n=24, P2 non 
survivors n=24, P2 survivors n=28. Complete case data were missing either due to death in 
AETC and the cessation of observations, or ward based recruitment in P1, or where data 
had not been collected for a particular hour due to constraints within the study team. As such 
the data do not fully represent the spectrum of patients recruited by BAM, but do show for 
the first time how physiology may change over time in the acute 6 hour period after 
admission with meningitis. All patients included in these analyses were alive at the end of 
the 6 hour observation period. 
Figures Figure 6.4, Figure 6.5, Figure 6.6, Figure 6.7 and Figure 6.8 shows the trend lines for 
each observation by phase and outcome at day 10. Day 10 was selected in all cases for 
analysis as missing data in P1 to day 40 may potentially bias outcome results. After review 
of the graphs with Dr Faragher, formal statistical comparisons of the gradients of the graphs 
were not done, as no important differences in graph slope by outcome were seen in any of 
the physiological sub-sets sets presented. In the following figures, each physiological 
parameter is shown in patients with complete case data only measured over 6 hours from 
admission (T0) to AETC discharge (T6). The data are summarised in Table 6.23. 
All pulse measurements on admission were very similar (Figure 6.4), however a divergence 
occurred between T2 and T3 in P2, where the pulse rate declined over time, the pulse rate in 
P1 remains static over time with no separation by outcome in either phase. The differences 
in pulse at any of the time points are not statistically significant. 
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Figure 6.4 Pulse rate over time in patients with ABM 
Mean Pulse rate with standard deviation over 6 hours by outcome and phase, Data from non survivors 
are depicted in red, and survivors in green. Points represent means, and bars errors around the mean. 
 
Figure 6.5 Mean MAP over time in patients with ABM 
Mean MAP with standard deviation over 6 hours by outcome and phase, non survivors are depicted in 
red, and survivors in green. Points represent means, and bars errors around the mean. 
Mean arterial blood pressure (MAP) was higher in non-survivors in both phases than 
survivors (Figure 6.5). This difference was more marked in P1 and reached statistical 
270 
 
significance by T3 in P1 (Table 6.23), (86.3 mmHg in survivors v 94.4 mmHg in non 
survivors p=0.05), with increasing disparity at T6, (83.8 mmHg in survivors v 98mm Hg in 
non survivors p=0.004) and borderline statistical significance in P2 at T6 (90.2 mmHg in 
survivors v 96.9 mmHg in non survivors p=0.07) (Table 6.23).  
The divergence of MAP and particularly the trend towards increasing MAP in non-survivors 
over time is a novel finding.  
As expected, there were marked differences in GCS by outcome in both phases (Table 
6.23), although the overall mean GCS at all-time points in P1 non survivors were lower than 
in P2 non survivors (Figure 6.6) 
 
 
Figure 6.6 Mean GCS over time in patients with ABM 
Mean GCS with standard deviation over time by outcome and study phase, non survivors are depicted in 
red, and survivors in green. Points represent means, and bars errors around the mean. 
Mean GCS in survivors did not differ by phase in survivors, non survivors in P1 had lower 
mean GCS than non survivors in P2. There were no novel trends in these data, no 
significant declines over time in GCS were noted in any of the groups (Figure 6.6). 
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Figure 6.7 Mean respiratory rate over time in patients with ABM 
Figure 6.4.4 Mean respiratory rate with standard deviation over 6 hours by outcome and study phase, 
non survivors are depicted in red, and survivors in green. Points represent means, and bars errors 
around the mean. 
Respiratory rates are shown in Figure 6.7. Respiratory rates were overall higher in non 
survivors than survivors, increasing over time in P2 non survivors and static in P1 non 
survivors. RR fell in survivors, leading to a significant difference in RR at T3 (RR 26.5 v 29.5 
p=0.099) and T6 (RR 25.5 v 29.6 p=0.05) in P1, this trend did not reach significance in P2 
(Table 6.23).  
 
In comparison, mean oxygen saturation rates across the phases were also similar; however 
a dip in SpO2 was noted in both phases at T3 in non survivors (Figure 6.8). The differences 
between SpO2 by outcome at this time point were statistically significant (Table 6.23). Mean 
SpO2 in P1 non survivors at T3 was 93.3% compared to 96.7% p=0.03, and in P2 mean 
SpO2 in non survivors at T3 was 95.7% compared to 97.2% in survivors p=0.05. However 
these differences resolved by T6 in both phases and mean oxygenation across all groups 
was above 95% at ward discharge for all patients (Figure 6.8). 
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Figure 6.8 Mean oxygen saturations over time in patients with ABM 
Mean oxygen saturation with standard deviation over time by outcome and study phase, non survivors 
are depicted in red, and survivors in green. Points represent means, and bars errors around the mean. 
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Table 6.23 Physiology of meningitis over time in BAM 
Comparison of physiological parameters over time by phase and outcome 
(complete case data).  
 Phase 1 n=37 Phase 2 n=52 
Mean 
(STD) 
Alive 
24 
Dead 
13 
P Alive 
28 
Dead 
24 
p 
Pulse T0 103.3 (26) 104.4 (22) 0.45 99 (19.8) 103.3 (22.6) 0.23 
Pulse T3 105 (21.5) 101.9 (25) 0.35 92.3 (20) 90.8 (20.1) 0.24 
Pulse T6 99.4 (15) 101.0 (17) 0.39 88.2 (22) 87.4 (21.5) 0.44 
MAP T0 89.6 (20.9) 98.8 (28) 0.06 91.2 (20) 92.2 (12.5) 0.40 
MAP T3 86.3 (12.2) 94.4 (16) 0.05 90.3 (14.1) 94.5 (12.5) 0.13 
MAP T6  83.8 (9.3) 98.8 (22) 0.004 90.2 (14.1) 96.9 (17.9) 0.07 
GCS T0 12.7 (2.9) 10.5 (3.2) 0.01 13.3 (1.6) 12.2 (1.9) 0.02 
GCS T3 12.7 (2.7) 10.2 (3.0) 0.003 12.5 (2.6) 11.8 (2.1) 0.16 
GCS T6 12.9 (2.6) 9.9 (3.1) 0.001 12.7 (2.3) 11.2 (3.0) 0.02 
RR T0 27.2 (9.2) 28.3 (8.6) 0.28 22.2 (3.7) 23.6 (7.1) 0.19 
RR T3 26.5 (5.8) 29.5 (7.2) 0.09 24.0 (4.6) 24.5 (7.2) 0.39 
RR T6 25.5 (5.8) 29.6 (8.7) 0.05 23.8 (5.6) 26.4 (8.6) 0.10 
SpO2 T0 95.4 (2.8) 95.0 (4.1) 0.31 95.7 (2.4) 94.5 (7.0) 0.18 
SpO2 T3 96.7 (1.8) 93.2 (8.4) 0.03 97.2 (2.1) 95.7 (4.2) 0.05 
SpO2 T6 97.9 (1.6) 96.2 (3.9) 0.11 96.2 (4.6) 96.3 (4.2) 0.48 
 
A further analysis of the physiological data was undertaken by examining trends in a sub-set 
of the complete case data that were noted to have clinical shock on admission as defined in 
Table 3.4. The complete case numbers available for these analyses were small, P1 
survivors n=14, P1 non survivors n=8, P2 survivors n=18, P2 non survivors n=15 (Figure 
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6.5.1-5). Due to the small numbers and very similar trends to the complete cases data, no 
formal statistical analyses were done on these data. 
 
Figure 6.9 Mean pulse over time, comparing all ABM to those with clinical shock only 
 
 
Figure 6.10 Mean MAP over time, comparing all ABM with those with clinical shock only 
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Figure 6.11 Mean CGS over time comparing all ABM with those with clinical shock only 
 
Figure 6.12 Respiratory rate over time comparing all ABM with those with clinical shock only 
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Figure 6.13 Oxygen saturations over time comparing all ABM with those with clinical shock 
only 
 
In a comparison of shocked patients to all patients, non survivors with clinical shock appear 
to have a marginally more severe clinical phenotype developing over time, with non-
declining pulse rate (Figure 6.9), higher MAPs at T6 (Figure 6.10) slightly greater declines in 
GCS over time (Figure 6.11), increasing or greater respiratory rates (Figure 6.12) and overall 
lower oxygen saturations (Figure 6.13). The small numbers preclude further analyses of these 
trends; however they provide important data to take forward into larger prospective data 
collection. 
 
6.3.9 Excluded patients 
6.3.9.1 Sepsis 
Detailed analysis of the feasibility of targeted therapy for sepsis is beyond the scope of this 
study for several reasons. Firstly the BAM study was designed primarily to recruit patients 
with ABM and not sepsis, so other patients with sepsis will have been missed and selection 
bias is a major issue. Secondly with limited follow up data on these patients, no 
assessments of the safety of EGDT can fully be made from these data, particularly as no 
SAE data were collected after patients were excluded from the main trial.  
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6.4 Discussion 
This study was designed to test if EGDT for ABM in Malawi was feasible as the primary 
endpoint, and determine if the care bundle impacted on mortality as an exploratory endpoint. 
This section will divide into three parts, the first discussing the results of the meningitis 
diagnostic testing, the second the feasibility assessment of the intervention, and the third 
discussing the outcomes observed. 
 
6.4.1 Causes of culture negative meningitis 
DNA of three common causes of bacterial meningitis were tested in culture negative 
samples in this study, S. pneumoniae, N. meningitidis and H. influenzae type b. Both 
bacterial culture and PCR detected cases of the former two pathogens, no cases of Hib were 
detected. The specificity of PCR appeared to be high, all culture positive cases were also 
PCR positive. In addition, PCR detected more cases of pneumococcal and meningococcal 
meningitis than culture alone (32% more cases of S. pneumoniae detected with PCR and 
85% more cases of N. meningitidis detected).  
 
Hib not detected by culture or PCR in this study. In the historical data in Chapter 4 Section 
4.5.2, only 3/715 (0.4%) cases of ABM were due to Hib, the lack of positive culture in a 
sample size of 132 is not unexpected. It is possible that the lack of Hib meningitis in this 
study may be due to indirect effects of the paediatric vaccination programme, although there 
are no data testing for indirect effects of Hib in adults, and adult Hib meningitis is a rare 
disease (Cohen et al., 2010d). Indirect effects of Hib vaccine have been shown in siblings of 
vaccinated children, determination of indirect effects in adults would be very difficult as it is a 
rare adult disease (Adegbola et al., 2005; Muhlemann et al., 1996). As shown in Chapter 4 
Section 4.3.1, Hib meningitis is declining dramatically in vaccine age-eligible Malawian 
children following the roll-out of vaccination in 2010 (Wall et al., 2014a).  
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In this study, a history of antibiotic prescription within 2 weeks of meningitis onset was 
associated with lower rates of bacterial culture in this study, 58% of culture negative cases 
had received prior antibiotics, compared to 32% who had no antibiotic exposure. This 
association is similar to that reported from a surveillance programme in Brazil, where the 
presence of detectable antibiotic in the CSF substantially increased the odds of the sample 
being culture negative but PCR positive (OR 12.2 (95% CI 5.9 – 25.2) (Sacchi et al., 2011).  
Given the high specificity of PCR, and potential very high sensitivity of PCR (Wu et al., 
2013), molecular diagnostics are potentially better than culture in detecting ABM caused by 
common pathogens, particularly when antibiotics have been administered (Wu et al., 2013; 
Sacchi et al., 2011). PCR in whole blood was better at detecting meningococcal sepsis 
compared to blood culture (Carrol et al., 2000), unfortunately blood PCR was not performed 
in this study, particularly to detect if cases presenting with a petechial rash had 
meningococcaemia.  
However PCR should not replace culture completely, as the range of pathogens detected by 
culture as causative pathogens in BAM was greater than that covered by the PCR tool 
alone, and sole reliance on PCR would mean these cases being missed. In addition PCR 
does not yet give useful information such as antibiotic sensitivity, which is crucial data for the 
clinician selecting the correct treatment, and for surveillance to monitor emerging antibiotic 
resistance. PCR therefore has the most utility in culture negative meningitis, where important 
additional information can be derived.  
 
Despite data in this study showing that PCR apparently exceeded culture in detecting more 
cases of both pneumococcal and meningococcal meningitis, formal estimates of sensitivity 
and specificity of PCR to diagnose bacterial meningitis cannot be made from these data. 
Calculation of these estimates uses the classical 2x2 validation analysis, where the accuracy 
of the new test is tested against the current best standard test, with the assumption that the 
latter test is the best. When the new test has estimated higher sensitivity or specificity the 
calculation fails (Hadgu et al., 2005). Latent class analysis (LCA) has been used to model 
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diagnostic accuracy and estimate sensitivity of PCR over culture, but this method also has 
limitations, particularly the model may assign disease free state to a patient with only PCR 
positive meningitis where other factors support the diagnosis such as CSF WCC and clinical 
history are not included in the LCA model and therefore sensitivity is under-estimated (Wu et 
al., 2013; Hadgu et al., 2005; Sacchi et al., 2011). As more detailed diagnostics evolve that 
are not reliant on bacterial viability, newer statistical tools need to be developed to measure 
sensitivity accurately of tests that are potentially better than the measurement standard. 
Given the high sensitivity of PCR, is it possible to justify including PCR negative cases of 
ABM in this study? All cases included in the study met clinical and CSF inclusion criteria for 
the diagnosis of ABM.  
 
The PCR only measured three pathogens, other causes of PCR negative ABM are likely to 
be S. aureus, E. coli, Group A streptococcus and NTS. In addition of the meningococcal 
culture positive patients in this study, all were sero-group W135. Conventional multiplex PCR 
detects meningococcal sero-groups A, B and C, but not all other sero-groups of N. 
meningitidis which contain the citrA gene, including W135 (Wang et al., 2012).  More specific 
meningococcal PCR assays have been developed for other sero-groups of N. meningitidis, 
and the application of these may yield further cases of currently PCR negative 
meningococcal meningitis (Wang et al., 2012).  No studies have evaluated PCR for the rarer 
causes of bacterial meningitis in adults, and therefore given the limitations of both bacterial 
culture and PCR in this setting, cases of probable ABM that are culture and PCR negative 
should remain included in this study, when the clinical and CSF criteria are met.  
 
It is possible that cases of acute TBM or CCM were erroneously included in the culture and 
PCR negative group. CSF TB culture was not available to this study, PCR using the 
GeneXpert® technology was available in Blantyre, but has little data to support use for TBM 
diagnostics; large volumes of CSF are required and the test has relatively low estimated 
sensitivity of 62% (Patel et al., 2013). CSF bacterial culture, when positive for C. 
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neoformans, led to the exclusion of the patient from the study. CSF culture for this pathogen 
is very sensitive in SSA and it is unlikely that many cases of culture negative CCM cases 
were included in this study (Kabanda et al., 2014). In the latter half of the BAM study, 
Cryptococcal Antigen testing (CrAg) by lateral flow assay was introduced as a screening tool 
to the laboratory to all adult CSF samples, CrAg is at least as sensitive as culture in 
diagnosing CCM, and highly specific (Jarvis et al., 2009). Four patients who were CrAg 
positive and fungal culture negative were included in this study; all had concurrent proven 
bacterial infection in the CSF. 
 
Antibiotic sensitivities in this study were commensurate with those seen in previous data 
from MLW (Everett et al., 2011; Cornick et al., 2011; Cornick et al., 2014). Penicillin resistant 
pneumococci are prevalent in this study and in Malawi, but very few isolates were resistant 
to both penicillin and chloramphenicol (Klugman et al., 2008; Cornick and Bentley, 2012). 
Nearly all cases were treated with ceftriaxone, and no ceftriaxone failures were identified in 
the study. Penicillin resistance is predicted to evolve into ceftriaxone resistance, however 
ceftriaxone resistant pneumococci are yet to be identified in Malawi (Cornick et al., 2011; 
Cornick and Bentley, 2012). 
 
6.4.2 Is Early Goal Directed Therapy feasible for bacterial meningitis in 
settings such as Malawi? 
This study tested if the delivery of eight clinical targets or goals, set on an individual patient 
basis according to clinical need for patients presenting with a clinical suspicion of bacterial 
meningitis was feasible in the AETC of Queen Elizabeth Central Hospital in Malawi. 
Although the care bundle included eight targets, the maximum required by any patient was 
six, the mean target number was 2.59 in P1 and 2.57 in P2. Substantially more targets were 
met by the clinical care bundle of EGDT than ordinary clinical care in the composite analysis 
0.55 in P1 compared to 1.57 in P2 p<0.001.  
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The clinical care bundle was designed to improve oxygenation and tissue perfusion, and the 
targets set to achieve these, fluid resuscitation, nasal oxygen at 24% concentration and 
blood transfusion did not lead to significantly increased improvements in the proportions of 
patients with shock and hypoxia compared to routine care in P1 after 6 hours post 
recruitment to the study. The patients screened and recruited in P1 and P2 were equally 
matched, the failure to improve parameters of shock or hypoxia beyond routine care is 
therefore surprising. Data on the use of oxygen in P1 are lacking, however no patients that 
required a blood transfusion in P1 received one, and all shocked patients received minimal 
IV fluids in P1 compared to P2. This pattern was seen not only in the patients with ABM, but 
in the all screened patient analysis as well. It is possible that a proportion of patients with 
refractory shock or hypoxaemia at the end of the 6 hour observation period required more 
intervention than EGDT alone could provide, such as intensive care support, but it is 
intriguing that despite greater volumes of IV fluid, blood and potentially more use of oxygen, 
the proportion of these patients without resolution of shock or hypoxaemia were the same in 
P1 and P2 at the end of 6 hours observation.  
A study of sepsis bundles from Singapore measuring compliance with a target of 
MAP>70mmHg at the end of six hours only achieved this target with aggressive 
resuscitation in 40% of cases with septic shock enrolled into the study (Kuan et al., 2013). 
Causes of hypotension in meningitis and sepsis are multifactorial, in ABM, the central effects 
of inflammation on blood pressure control to maintain intracranial pressure may lead to hypo 
or hypertension, which is not amenable with intravenous fluids (Tureen, 1995; Park and 
Chang, 2000; Park et al., 2003). In all sepsis bundle studies where the bundle was shown to 
have a good outcome, mortality was reported as the primary outcome. All centres publishing 
these studies had access to intensive care support with inotropes for the patients (Barochia 
et al., 2010), very few actual data on the achievability of the blood pressure targets are 
available (Kuan et al., 2013). It is likely that the resources of crystalloid fluid and low flow 
oxygen were inadequate for the physiological needs of these patients with shock. 
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Times to receipt of parenteral antibiotics were significantly improved by the care bundle, 
however the proportion of patients who met the 1 hour target was below 50% in P2. Given 
the degree of complexity in managing these patients and recruiting them with verbal assent 
to the trial, it is un-surprising that this target was not met in so many patients. The 
improvement from a median 2h 20 mins in P1 to 1hr 10 mins in P2 is a substantial 
achievement in such a resource limited environment such as Malawi.  
 
6.4.2.1 What were the challenges in delivery of the care bundle? 
The study team reported that all the care bundle elements were easy to deliver, but the most 
difficult target to achieve was administration of IV antibiotics within one hour. This was due to 
the time taken particularly when dealing with a combative patient with altered mental status, 
added to the time involved in performing the pre-antibiotic LP and obtaining verbal assent, 
while collecting data for study samples and completing the study case record form (CRF). In 
P2 one patient was reported to experience pulmonary oedema as a SAE, another a new 
oxygen requirement, but beyond these small data, it is difficult to conclude that the other 
targets such as oxygenation or improvement in patients with parameters of shock were no 
different across the phases due to difficulties in administering, or harm from the care bundle. 
Lack of access to quality high dependency facilities for patients with on-going medical needs 
after the 6 hour observation period may be associated with high mortality, however all 
patients in P2 who required ongoing oxygen did receive it, but due to resource constraints, 
patients admitted to the HDU or wards did not receive ongoing monitoring.   
 
Study resources were not available to provide on-going medical and nursing care for these 
patients throughout the inpatient admission period. The literature from sepsis EGDT 
suggests that the six hour acute resuscitation window is the important time point in which to 
attempt to correct physiological abnormalities (Barochia et al., 2010), which was used for 
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BAM, the longest time period of any care bundle intervention is 24 hours (Chamberlain et al., 
2011).  
The addition of a new study nurse in P2 enabled 24 hour recruitment between Sunday-
Friday. The change in shift patterns for the BAM study team to take account of time off after 
long night shifts meant that less communication between the study team was possible 
except at handover, and regular meetings were less frequent. The nurse working at night 
was alone and un-supported by the study team, although she did have access to the PI by 
telephone 24 hours per day. Each CRF was reviewed the following morning, and no 
difficulties in either administering the care bundle, or achieving the targets at night were 
noted, and issues were discussed with the study manager before that nurse went off shift. 
The nurses found working independently at night challenging, particularly as little support 
was available from colleagues in the AETC. 
The team had to work within the AETC, becoming integrated particularly in the triage area. 
Constant surveillance by the team manager was required to ensure that the study team were 
able to perform both AETC and study duties without their study work being compromised.  
In addition to internal challenges of recruitment and care bundle delivery, external 
challenges included intermittent supplies of resources including medication and laboratory 
results. As a result the study team had to purchase an independent supply of antibiotics, 
diazepam and fluids to continue administering the care bundle, as hospital supplies were 
erratic. A political crisis led to currency devaluation, which led to marked inflation in prices, 
particularly in fuel, limiting affordability of public transport to many patients.  
 
6.4.2.2 Were the wrong targets set? 
The clinical targets were not derived from other studies of bacterial meningitis, as this 
approach has not been tested in ABM in any setting world-wide. Instead the targets were 
derived from, and based on assumptions that treatment for sepsis with EGDT improved 
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outcomes, and as a serious bacterial infection, ABM may benefit from the same approach. 
Other targets were derived from data on patients with sub-arachnoid haemorrhage and from 
the critical care literature (Chapter 2 section 2.8). Important differences exist between the 
settings and patients in those studies, particularly in the clinical resources available, and the 
high rates of HIV co-infection in patients in Malawi and throughout the region. Further 
discussion of these differences can be found in Chapter 8 section 8.3. 
Despite the significant achievements of the care bundle to meet more targets than routine 
care alone, the failure of the EGDT to improve markers of shock or hypoxaemia beyond 
routine care, suggests these patients may have different physiological responses to invasive 
infection within the CSF compartment. A sepsis-based approach may not be the optimal way 
to improve clinical care and outcomes from bacterial meningitis. This is discussed further in 
Chapter 8 section 8.5.4. These data may be used to derive new targets for an ABM-specific 
care bundle in the future, focusing on potentially treatable abnormalities found in the ABM 
patients, such as rising blood pressure and seizures. 
 
6.4.3 Does EGDT have an impact on outcome from ABM in Malawi? 
This study was constrained by the before/after design into recruiting equal numbers of 
patients over two set time periods, and as such no formal sample size was set. Sequential 
cohort before/after studies are open to the effects of multiple confounders, the most 
important of which is time, but others include changing hospital and patient circumstances, 
varying availability of medications and resources, and changes in staff and available 
expertise. These confounders limit the interpretation of differences found between the 
sequential phases. 
The numbers of patients recruited were smaller than planned based on eligibility from 
historical data (100 per 10 month period), and comparison of the two patient populations in 
P1 and P2 is therefore confounded by time and limited by these small numbers.  
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Important differences were noted between the patients in the two phases. P1 and P2 
patients were equally matched for age, gender, HIV co-infection status and all other 
demographic parameters measured. Physiological variables, CSF culture results and MAMS 
severity scores were also equally matched on admission. The overall numbers are small, 
however marginally better  composite outcomes were noted in P1 compared to P2, with a 
case fatality rate (CFR) at day 10 of 38% in P1 with a 52% mortality rate in P2 p=0.11, the 
composite death/disability rate was 46%  in P1 compared to a composite day 10 outcome 
rate of 72% p=0.004. This trend continued to day 40, with an increased but non-significant 
CFR observed at day 40 in P2 compared to P1 49% compared to 63% p=0.13. With 14 
missing data points for day 40 outcome in P1 compared to 1 in P2, complete conclusions 
cannot be drawn from the mortality data at day 40.  
 
Why patients in P1 had lower mortality than P2 is intriguing. P1 mortality was lower than 
CFRs in the historical meningitis data (Chapter 4 section 4.5.2, n=715), which were 45% at 
day 10 and 54% at day 40, compared to P2 patients whose CFR was 49% at day 10 and 
63% at day 40. In studies from elsewhere in sub-Saharan Africa, mortality rates from ABM 
range from 50-70% (Gessner et al., 2010; Hakim et al., 2000; Yaro et al., 2006), 
commensurate with both the historical database and the case fatality rate (CFR) observed in 
P2.  In comparison, the CFR in the P1 patients was 38% at day 10 and 49% at day 40.   
The MAMS was designed as a tool to test if predicted mortality differed across the study 
phases. It was hypothesised that patients in P2 would have worse physiological parameters 
and hence worse predicted mortality, compared to P1, explaining the difference in CFR 
between the two phases by P2 patients being substantially sicker. Surprisingly MAMS 
scores were identical across the phases, showing that P1 and P2 patients were equally 
matched for their critical illness severity on admission. The agreement between predicted 
and actual outcome was poor in P1 and good in P2, suggesting MAMS has good utility in 
predicting outcome in P2 but not P1.  
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Why, therefore, P1 patients survived despite having equal predictors of poor outcome and 
less intensive medical care compared to P2 is unclear. The P1 CFR of 38% at day 10 and 
49% at day 40 is unusually low for the region and matches more closely data from European 
and American settings, where CFR from pneumococcal meningitis ranges between 20-35% 
(van de Beek et al., 2004; Thigpen et al., 2011; Durand et al., 1993). The high rate of 
survival in P1 is therefore the unusual aspect of the outcome of this study, and warrants 
further investigation. Patients in P1 received marginally later antibiotics and lumbar puncture, 
less parenteral fluids and less diazepam. It is possible that the clinical care received by 
patients in P1 more closely matched that given in more well-resourced settings, and 
therefore resulted in better outcomes. However the mortality differences are small, and the 
study is observational, the hypothesis of more simplified quality medical care leading to 
better outcomes would need to be tested in a parallel randomised study. 
 
From the MAMS scores and the physiological trends presented, it is clear that the P1 non 
survivors had very poor clinical and physiological parameters on admission compared even 
to P2 non survivors. P2 non survivors were matched physiologically more equally with P1 
and P2 survivors than the P1 non survivors, suggesting that P1 non survivors may have had 
a particularly severe physiological phenotype. It is possible to hypothesise that the care 
bundle may have altered the outcome in P2, so that patients who may have been 
physiologically primed to survive at day 10 if they had received care in P1, did not do so. 
However there is not enough evidence from the current study to support this hypothesis, and 
testing of the care bundle concept, revised on the basis of this pilot study in a randomised 
controlled trial with parallel recruitment is required.  
 
Is it then possible that another factor was implicated in the low mortality rates seen in P1, 
such as the quality of routine medical care delivered in the AETC compared to the older 
system of admission (Chapter 3 Section 3.3.5) This system was chaotic and resulted in 
major delays for several hours before clinical review and antibiotics were administered. Or 
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could the mortality differences represent harm from one or more bundle elements in P2, or 
an outbreak particularly aggressive pneumococcal serotype in P2? Serological data are 
awaited for patients with culture proven pneumococcal meningitis in both Phases, and these 
data will be reported in due course. The only differences seen in clinical care bundle 
administration in P2 compared to routine care in P1 were not statistically harmful; larger 
volumes of IV fluid resuscitation were given, airways inserted and head tilts applied, however 
the numbers for each intervention were small and a larger sample would give definitive 
safety information. All the current data support the safety of the care bundle. 
New data are presented monitoring the physiology of patients in both phases over time, the 
first time data of this type have been reported for ABM. In this chapter it was shown that 
rising MAP and falling GCS over time are associated with a high poor outcome. These 
trends suggest that inflammation within the CSF compartment and the CNS tissue are likely 
to be driving the abnormal physiological phenotype and high mortality rates, and not 
traditional peripheral sepsis responses with depressed myocardial function and poor tissue 
perfusion, as were assumed in the design of the care bundle.  
 
To explain the differences in mortality, using the physiological trends, it is clear that either 
more non survivors in P2 could have survived but didn’t, either due to an as yet 
unascertained harmful element of the clinical care bundle, or patients in P1 received better 
care than historically recruited patients in the AETC but were not given part of the care 
bundle that was harmful. The possibilities for a harmful clinical care bundle element that was 
either not given or given in smaller volumes in P1 compared to P2 are larger volumes of IV 
fluids, airway and head-tilt, or administration of diazepam. However one limitation of 
examination of care bundles is that extracting individual data on harm of one care bundle 
element when given with others is statistically impossible, and data are highly confounded 
(Barochia et al., 2010). For example, the more unwell a patient is, the more targets are likely 
to be set, and the more care bundle elements are likely to be received. From her original 
illness severity she has a higher predicted chance of death, and due to the her illness 
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severity will receive more care bundle elements, confounding the analysis of causes of poor 
outcome.  
 
For a true examination of the benefits and harms of a care bundle, a trial with a parallel 
randomised design is required. The BAM study shows that EGDT for meningitis is feasible, 
and the care bundle needs refinement before further testing in a larger trial. This will be 
discussed further in Chapter 8 Section 8.5.3-4. 
An alternative possibility to explain higher rates of non-survival in P2, is the hypothesis that 
P2 non survivors had an additional factor present that influenced mortality within the CSF 
compartment and this will be the focus of the following Chapter 7. 
 
In conclusion, limited early goal directed therapy for bacterial meningitis in Malawi is 
feasible, but the care bundle requires careful re-design encompassing elements of care 
delivered in routine hospital care before testing in a randomised controlled trial to be more 
specific to ABM. 
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7 The relationship between bacterial load, viral co-infection and 
outcome from bacterial meningitis in Malawian adults 
 
7.1 Introduction 
Bacterial meningitis in Malawian adults has an unacceptably high mortality rate of 54% in 
adults (Wall et al., 2013c). Full estimates of morbidity are lacking, but in the SAM trial, ‘any 
disability’ occurred in 47/202 (23%) of the 46% of participants that survived (Scarborough et 
al., 2007). While mortality is obviously the most serious outcome measure for bacterial 
meningitis, survivors that experience morbidity face extreme challenges in a profoundly 
resource-limited environment such as Malawi. Loss of the ability to work and consequent 
reduced income, without any access to governmental or insurance related support, plus 
degrees of dependence on friends or family for activities of daily living puts a substantial 
financial and emotional burden on the family of the patient (Desmond et al., 2013). Poor 
outcome can therefore be defined as either death or survival with poor function, and 
understanding the causes of poor outcome is the first step towards designing improved 
preventative and treatment strategies to reduce incidence, death and morbidity from 
bacterial meningitis in Africa. 
 
In this study, 59 of 132 (44.6%) adults with proven or probable ABM had died by day ten 
post admission, and a further 18 (14%) were disabled (mRS >2 points). By day 40, 66/117 
(56%) had died, and one person (0.8%) was alive with disability, the other survivors were 
healthy. The burden of poor survival was therefore considerable, in the immediate post 
discharge period, particularly as these patients had predominantly died post discharge by six 
weeks.  
 
Clinical bedside predictors of poor outcome have been explored extensively in the previous 
chapters of this thesis. In this chapter, potential laboratory based biomarkers in the blood 
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and CSF were explored to determine if either bacterial load, viral co-infection (as discussed 
in Chapter 2 Section 2.3-4) or the host inflammatory response were associated with a poor 
outcome from ABM in the BAM cohort.  
 
The host inflammatory response is a key determinate of outcome from sepsis and 
meningitis, discussed in Chapter 2 Section 2.2 (van der Poll and Opal, 2008; Kasten et al., 
2010; Mook-Kanamori et al., 2011). Blood lactate is a well-recognised marker of outcome 
from sepsis (Arnold et al., 2008), but the role of either CSF or blood lactate as a biomarker of 
outcome in ABM is less clear. Both blood and CSF biomarkers of inflammation were 
therefore tested against outcome. 
 
To investigate whether there is a relationship between CSF bacterial or viral load and 
outcome, these microbial parameters were analysed with respect to day ten composite 
outcomes, day 40 outcomes were not analysed separately as missing data limited data 
available. The association between CSF cellular and biochemical findings, and outcome was 
also analysed. 
 
7.2  Methods 
7.2.1 Objectives and research question 
Research questions 
a) Is bacterial load associated with outcome from bacterial meningitis? 
b) What is the relationship between bacterial meningitis and viral co-infection? 
c) What is the influence on outcome of markers of inflammation outcome from bacterial 
meningitis? 
 
 
 
291 
 
Objectives 
i) To use multiplex real-time PCR to determine the causes of culture negative 
meningitis   
ii) To estimate the quantity in bacterial and viral copy number of each pathogen 
identified in the CSF using RT-PCR. 
iii) To determine if any of the biomarkers of inflammation including bacterial load and 
viral co-infection are associated with outcome from ABM 
 
7.2.1 Inclusion and exclusion criteria and outcome measures  
The BAM study cohort has been described in detail in Chapter 6. All patients with ABM 
retained in BAM with available samples for PCR testing were used in this study, including 
those with a strong clinical suspicion of bacterial meningitis with abnormal CSF biochemistry 
not meeting the other CSF inclusion criteria above were included in this study (full inclusion 
criteria Chapter 3 Section 3.3.4). All culture negative but PCR positive patients from the BAM 
study were included in the formal BAM trial analysis.  
 
Outcome measures 
The outcome in this study was a composite outcome of healthy survival compared to death 
or disability at ten days post admission. Data were collected to six weeks (day 40) post 
admission, but due to a substantial proportion of missing data at day 40 in the first phase of 
BAM, analysis was confined to the earlier time-point. Disability was measured by the 
modified Rankin score (mRS), and was defined as a score of ≥ 2 points compared to healthy 
survival (mRS <2 points). 
7.2.2 Laboratory methods DNA extraction and PCR amplification 
Bacterial and viral DNA was extracted from whole CSF using standard manual DNeasy kits 
(Qiagen, Germany), with a pneumococcal cell wall extraction step prior to the extraction. 
Real-Time PCR was performed using primers and probes supplied by Fast Track 
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Diagnostics (FTD Holland). Full methods are supplied in Chapter 3 Section 3.1. Bacterial 
loads were estimated using calculations supplied by FTD based on the Ct values. Viral loads 
were calculated using standard curves generated from samples with known DNA quantity 
per sample supplied by FTD. 
 
7.2.3 Data analysis and statistics 
For all tables, binary variables such as gender, HIV status, the number and the proportions 
(as percentages) of the category of interest were summarized.  Normally distributed 
continuous variables were summarised using means and standard deviations (SDs) while 
continuous variables with skewed distribution were summarised using median and range. 
The appropriate measures for specific variables have been indicated in the table. 
Univariate logistic regression was used to assess which variables were associated with 
either viral co-infection or poor outcome compared to healthy survival. The odds ratios were 
reported together with the 95% confidence intervals. Normally distributed variables were 
compared with parametric tests (Students T-test), variables with a skewed distribution were 
log10 transformed and compared with non-parametric tests (Mann-Whitney test and 
univariate logistic regression). All statistical tests were performed at 5% significance level. 
 
7.3 Results 
7.3.1 Is bacterial load associated with outcome from bacterial meningitis? 
One hundred and sixty five CSF samples were stored from BAM for this study, of which 159 
had adequate CSF available and were tested for SpN/NM/Hib DNA using RT-PCR. The 
bacterial loads were calculated for all samples where DNA was detected (n= 56).   
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Pneumococcal bacterial loads were not different to meningococcal loads  (6.5x106 copies/ml 
pneumococcal DNA (IQR 6.7x105-4.8x107) compared to 6.7x105 copies/ml meningococcal 
DNA (IQR 1.06x105 – 1,4x106) p=0.49. 
 
7.3.1.1 Pneumococcal meningitis 
Pneumococcal loads were not significantly associated with worse outcome,  median 
bacterial load in survivors 2.45x106 (6.7x103-8.4x106) copies/ml compared to 1.5x107 
(1.8x106-6.49x107) in non survivors p=0.33 (Figure 7.1, Table 7.1). Due to significant skewing 
in the data, bacterial loads were then log10 transformed and the differences compared. The 
data were grouped into quartiles around the median and univariate regression analysis was 
done to test if higher quartiles of bacterial load were associated with poor outcome. Table 
7.1 shows log10 transformed pneumococcal loads represented as medians by day 10 
composite outcome group, and categorised into quartiles around the median. The quartile 
analysis was to look for trends at either end of the skewed data to see if an effect of high or 
low quartiles was associated with outcome, when no difference between the overall medians 
were seen. 
  
The median log10 bacterial load in survivors with good outcome was 6.38 copies/ml CSF 
(IQR (3.82 – 6.90), compared to 7.19 copies/ml (IQR 6.27 – 7.81), p=0.06 (Table 7.1). When 
corrected for HIV co-infection, the difference between the log transformed loads was 
borderline significant p=0.056. The quartile analysis demonstrated a slight trend towards 
higher quartiles of bacterial load and poor outcome with marginally significant association 
with poor outcome seen in the 50-75th quartile, (OR of poor outcome with a bacterial load in 
this quartile was 8.4 (95% CI 0.94 : 75.0), p=0.057). These data are shown in Figure 7.2. 
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Table 7.1 Bacterial load and outcome 
Univariate associations between bacterial load and outcome 
 Healthy 
survival n= 30 
Death/poor 
survival n= 51 
Univariate OR  
(95% CI) 
Significance 
p 
Median log10 
SpN bacterial 
load Copies/ml 
(IQR) n=57 
6.38  
(3.82 – 6.90) 
7.19  
(6.27 – 7.81) 
1.35  
(0.98 : 1.84) 
0.06 
 
SpN PCR 
negative 
9 15 ….  
<25th centile 8 6 0.45 (0.17 : 1.72) 0.24 
25-50th centile 8 6 0.45 (0.17 : 1.72) 0.24 
50-75th centile 1 14 8.4 (0.94 : 75.0) 0.057 
>75th centile 4 10 1.5 (0.36 : 6.23) 0.57 
 
 
Figure 7.1 CSF bacterial load by outcome 
Median CSF S. pneumoniae pathogenic load by outcome group at day 10. Error bars represent inter-quartile 
range.  
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Figure 7.2 Bacterial load with outcome by quartile  
7.3.1.2 Meningococcal meningitis 
Despite the small numbers of N. meningitidis meningitis, the median bacterial load in 
survivors with good outcome (n=4) was 5.310 (IQR 3.86 – 5.76) compared to 6.1610 (IQR 
5.88 – 6.16) in those with poor outcome (n=3) p=0.02. The small numbers available 
determined that these data could not be included in any more detailed analysis including by 
quartile. 
 
7.3.2 Is viral co-infection in the CSF of adults with bacterial meningitis 
associated with morbidity? 
EBV was detected in the CSF of 34/81(41%) patients included in BAM who were tested for 
EBV, and in 30/50 (60%) of patients who were included in the PCR study, but subsequently 
excluded from BAM on the basis of CSF and bacterial PCR results. EBV was commonly 
detected in the CSF of patients with pneumococcal meningitis (20/57, 35%), and not 
detected in those with meningococcal meningitis (0/7, 0%).  
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CMV was detected in only three patients, all were EBV infected. One further case of CMV 
was detected, in the excluded patient group (Table 7.2).  
Table 7.2 Viral co-infection in meningitis 
Viral copy number per pathogen detected on PCR 
Bacterial PCR result Median EBV viral load 
(IQR)  
copies/ml CSF 
Median CMV viral 
load (IQR)  
copies/ml CSF 
SpN DNA positive 
N=57  
1268  
(977-5185) 
n=20 
1125  
(No IQR) 
n=1 
NM DNA positive 
N=7  
0 
n=0 
0 
n=0 
Hib DNA positive 
N=0 
NA NA 
PCR negative included in BAM 
N=39 
2422  
(1459-6924) 
n=14 
16909 
(1766-16909) 
n=2 
PCR negative and excluded from 
BAM 
N=50 
2149 
(1125-5670) 
n=30 
5028 
 
n=1 
NA = not applicable 
 
No relationship between EBV and outcome at day 10 was determined on univariate analysis. 
EBV DNA was positive in 22/51 patients with poor outcome at day 10, p=0.48. In addition 
both the median viral load and individual quartiles around the median were also unrelated to 
outcome (Figure 7.3 and Figure 7.4, Table 7.3). No relationship exists between EBV loads and 
composite poor outcome at day 10. When corrected for HIV, higher loads of EBV infection 
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were not associated with outcome at day 10 (OR >75th centile of EBV load and poor 
outcome was 0.59 (95% CI 0.13 : 2.16) p=0.49). EBV co-infection was not associated with 
outcome in pneumococcal meningitis (OR 0.66 (95% CI 0.18 : 2.83 p=0.53). 
 
Table 7.3 Viral load and outcome in meningitis 
Relationship between pathogenic loads and composite outcome at day 10 in adults 
included in BAM n=81 
 Healthy 
survival 
n 30 
Death/poor 
survival  
n 51 
Univariate OR  
(95% CI) 
Significance 
p 
Median EBV viral 
load Copies/ml 
(IQR) 
1944  
(1138-6771) 
1913  
(1068-3824) 
1.0 (1.0 : 1.0) 0.35 
No EBV 18 29 ……. ….. 
<25th centile 2 6 1.8 (0.33 : 10.2) 0.47 
25-50th centile 4 5 0.77 (0.18 : 3.2) 0.73 
50-75th centile 2 7 2.1 (0.40 : 11.6) 0.36 
>75th centile 4 4 0.62 (0.13 : 2.7) 0.53 
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Figure 7.3 Median viral CSF load of EBV by outcome  
Error bars represent inter-quartile range.  
 
 
Figure 7.4 EBV viral load with outcome by quartile group 
 
 
Equal numbers of patients with a poor outcome at day 10 had EBV co-infection compared to 
healthy survivors. 
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The relationship between EBV and quality of survival were then explored in a sub-set of 
patients who survived at day 10 with PCR data available, either healthy survival (mRS <2) 
n=26 or had poor survival (mRS =>2) n=16 (Table 7.4). No relationship between EBV viral 
load and the quality of survival at day 10 was observed.  
Table 7.4 Viral load and quality of survival 
 
 
7.3.3 CSF and blood inflammatory biomarkers of poor outcome from bacterial 
meningitis  
In Chapter 4 Section 4.5, an analysis was presented showing clinical predictors of mortality 
at day 40 post bacterial meningitis from 715 adults enrolled in clinical trials or other studies 
of ABM in Malawi. In this section, CSF and blood biomarkers from patients recruited to BAM 
with ABM were examined for potential associations between these biomarkers and outcome. 
These analyses were repeated with correction for HIV co-infection, to determine if HIV had 
impact on blood and CSF inflammatory parameters. 
 
7.3.3.1 CSF results (Table 7.5) 
Eleven CSF variables were recorded for patients in BAM. Data were lacking in some 
variables such as CSF biochemistry when laboratory results were not available, or in 
bedside data such as CSF lactate when the strips were not available. Therefore some 
EBV viral load and quality of survival 
 Healthy survival  
n = 26 
Poor survival  
n = 16 
Univariate OR 
(95% CI) 
Significance 
P 
Median EBV viral load 
Copies/ml (IQR) n=17 
1316  
(1102-6774) 
4667  
(1586-1.6x105) 
1.0  
(1.0 : 1.0) 
0.81 
No EBV 15 10 ….  
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variables in this group did not have adequate data to take forward to multivariate analysis. 
The following CSF variables had no significant association on univariate analysis: CSF 
protein, CSF lactate, the predominant CSF WCC type, culture results, or pneumococcal 
infection on either culture or PCR. The only variable showing significance at the <0.05 level 
was CSF WCC (OR 0.99 (0.99 : 1.0) p=0.04), but this was not significant when corrected for 
other CSF parameters or when the analysis was repeated to correct for HIV co-infection.  
 
7.3.3.2 Blood results (Table 7.6) 
Five markers of inflammation in the blood were measured in BAM, plus the presence of 
bacteraemia. On univariate analysis blood culture positivity for S.pneumoniae was 
associated with good outcome (OR poor outcome 0.29 (95% CI 0.03 : 1.71) p=0.01, but 
when corrected for other variables on multivariate analysis, significance was not retained. 
CD4 count had too few data available to be included in the multivariate analysis. No 
measured blood variables were independently associated with outcome on multivariate 
analysis. Correction for HIV co-infection did not alter the results and these are not presented.  
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Table 7.5 Associations between CSF parameters and outcome in meningitis 
Parameter Good survival Dead or poor 
survival 
Univariate (unadjusted)  Multivariate (adjusted)**  
 N=55 N=77 Odds ratio (95% CI) p Odds ratio (95% CI) p 
CSF protein (g/dL) Median 
(IQR) 
2.76  
(1.71 – 3.72) 
2.83  
(1.91 – 5.79) 
1.18 (0.93 : 1.49) 0.16 1.41 (0.83 : 2.40) 0.98 
CSF: Blood glucose 
ratio 
 0.35  
(0.15 -0.43) 
0.1  
(0.02-0.18) 
0.004 (0.00 : 1.43) 0.06 *  
CSF lactate (mmol/L) Median 
(IQR) 
10.6  
(7.4-11.2) 
9.6  
(9.0-10.8) 
0.96 (0.80 : 1.15)  1.08 (0.76 : 1.53) 0.64 
CSF White cell count 
(cells/mm3) 
Median 
(IQR) 
169  
(32 – 1760) 
56  
(10-300) 
0.99 (0.99 : 1.0) 0.047 0.99 (0.99 : 1.0) 0.31 
CSF WCC reported as 
clumps 
No 31 43 ….    
Yes 24 34 1.02 (0.50 : 2.0) 0.95 *  
CSF culture results No growth 23 27 1.17 (0.26 : 5.2) 0.83   
 SpN 25 36 1.44 (0.32 : 6.30) 0.62 1.12 (0.08 : 15.5) 0.93 
 Other^ 7 14 0.33 (0.23 : 4.7) 0.41 1.23 (0.01 : 1.07) 0.92 
CSF culture or PCR 
positive for  
   S. pneumoniae 
no 30 41 ….    
yes 25 36 1.05 (0.52 : 2.11) 0.88 1.00 (0.19 : 5.12) 0.99 
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UC= unable to compute with logistic regression * = numbers too small for multivariate analysis ^ other culture includes N. meningitidis, E. coli, S. aureus, Group A streptococu
Table 7.6 Association with haematological parameters and outcome in meningitis 
Parameter Good survival Dead or poor 
survival 
Univariate (unadjusted)  Multivariate (adjusted)** 
N=63 
 
N=55 N=77 Odds ratio (95% CI) P Odds ratio (95% CI) p 
Blood culture 
results 
No growth 31 53 0.85 (0.14 : 4.9) 0.86 ….  
SpN 14 7 0.29 (0.03 : 1.71) 0.01 0.21 (0.03 : 1.30) 0.09 
Other ^  4 9 1.31 (0.37 : 4.6) 0.66 1.43 (0.22 : 9.20) 0.70 
Haemoglobin 
(g/dL) 
Median (IQR) 11.9  
(10.1 – 13.4) 
11.4  
(9.9-13.0) 
0.94 (0.79 : 1.13) 0.55 0.94 (0.76 : 1.18) 0.63 
Peripheral blood 
white cell count 
(cells/mm3) 
Median (IQR) 9.8  
(5.8 – 14.7) 
10.7  
(6.9 – 16.1) 
1.01 (0.96 : 1.07) 0.58 1.03 (0.95 : 1.11) 0.41 
Peripheral platelet 
count (cells/mm3) 
Median (IQR) 211  
(131-285) 
206  
(139-331) 
1.00 (0.99 : 1.005) 0.25 1.0 (0.99 : 1.0) 0.54 
CD4 count 
(cells/mm3) 
Median (IQR) 238  
(41-296) 
97  
(72–186) 
0.99 (0.98 : 1.002) 0.14 *  
Blood lactate 
(mmol/L) 
Median (IQR) 2.9  
(1.9 – 5.5) 
3.4  
(2.1-5.6) 
1.05 (0.91 : 1.20) 0.48 0.97 (0.79 : 1.18) 0.77 
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7.4 Discussion 
In this chapter, CSF bacterial loads, CSF viral co-infection and markers of inflammation in 
the CSF and blood of patients recruited to BAM were explored in relation to a composite 
outcome of death/poor survival compared to good survival at ten days post admission. Data 
has been published from Malawi examining some of these variables with relation to binary 
mortality outcome at day 40 (Wall et al., 2014b; Scarborough et al., 2007; Kelly et al., 2012), 
but not using a day ten composite outcome point. This discussion is divided into three 
sections, each relating to the relevance of the findings of the three analyses done in context 
of the previously published data. 
 
7.4.1 Pneumococcal load in CSF of adults with ABM 
Data from the SAM and GLAM trials showed clearly that pneumococcal loads were not 
associated with outcome at day 40 (Wall et al., 2014b). The bacterial loads measured in this 
study did not exhibit a trend towards higher loads and poor composite outcome at day 10. 
The median pneumococcal loads in this study were higher than previously observed; 
6.5x106 (IQR 6.7x105 – 4.88x107) compared to 6.5ₓ105 copies/ml (IQR 1.08 ₓ105 – 2.96ₓ106) 
in the data from the SAM and GLAM study (Wall et al., 2014b). The numbers of cases of 
meningococcal meningitis were too few to analyse in detail, so the focus was on primarily 
pneumococcal meningitis. In this study the overall pneumococcal loads were skewed, log 
transformation to normalise the data distribution were required, a trend towards higher loads 
and poor outcome was seen in the log transformed data when corrected for HIV co-infection.   
 
Previous studies  of  CSF pneumococcal loads in Malawian children also reported log 
transformed data, and found CSF and blood pneumococcal loads were higher in HIV co-
infected children than non-HIV infected children: higher CSF loads were also associated with 
mortality (Carrol et al., 2007a). That study did not look at trends by quartile bacterial load, 
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only continuous data, and utilised data from 77 children, compared to the 57 in this study. 
The HIV co-infection rate in that study was comparable to this study, 62% of children 
compared to 68% of BAM included participants in this study were HIV co-infected (Carrol et 
al., 2007a).  The methodology used to measure the bacterial load in both previous Malawian 
studies relied on a standard curve of sufficient quality to calculate the results (Wall et al., 
2014b; Carrol et al., 2007a). In this study, bacterial loads were estimated based on a 
calculation provided by the company supplying the multiplex kits, and were not 
independently verified. Therefore the estimated data presented may not represent 
completely accurate data, and comparisons with the data from the previous adult and 
paediatric studies are subject to this limitation.  
 
Although a marginal trend towards poor outcome and higher bacterial loads was seen in this 
study, no differences were seen in the previous adult data, with a larger sample size and 
more robust methodology (Wall et al., 2014b). In that study, significantly longer times to 
hospital from symptom onset were recorded compared to other studies where a clear 
relationship between bacterial load and outcome have been shown (Scarborough et al., 
2007; Ajdukiewicz et al., 2011; Darton et al., 2011; Darton et al., 2009; Hackett et al., 2002; 
Rello et al., 2009; Roine et al., 2009), the paediatric Malawian study reported median 3 days 
symptom onset before hospital admission (Carrol et al., 2007a). It is possible that by the time 
the lumbar puncture was done in the Malawian adults in the SAM and GLAM studies, 
bacterial growth in both outcome groups had reached a static rather than exponential growth 
phase, and as such no differences were seen between the groups. It is also possible that 
with impaired CSF WCC responses in these patients, bacterial growth is relatively 
unhindered by immunological control, and as such is less important in determining outcome 
than host factors (Wall et al., 2014b). In the data presented, the CSF WCC were low, but the 
median time to admission was 48 hours (Chapter 6 Section 6.3.3-4), lower than in the 
previous study. It is therefore possible that these samples were taken at an earlier time point 
during the growth phase and not the static phase. 
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As such, with small numbers and estimated data, further studies to explore the relationship 
between composite outcome and pneumococcal load in adults with bacterial meningitis are 
needed from SSA and other settings.  
 
7.4.2 Viral CSF co-infection of adults with bacterial meningitis 
EBV was frequently identified in the CSF of patients included in the BAM study (33%). 
However CMV was only identified in 2.9%, all of whom were co-infected with EBV, and all 
were dead or disabled by day 10. EBV was also detected in 46% of cases that were 
subsequently excluded from BAM and assigned an alternative diagnosis, a rate similar to 
previous studies (Kelly et al., 2012). There were too few cases of CMV infection to analyse 
in detail; EBV was only detected in pneumococcal or culture negative meningitis, and not 
meningococcal meningitis. However, EBV was not statistically associated with HIV co-
infection in patients with meningitis, equal numbers of patients with and without HIV co-
infection had EBV detected, and the measurements of association with outcome did not 
change when corrected for HIV.  This is in contrast to that observed in a study of viral co-
infection in Malawian adults with meningitis, where HIV co-infection was strongly associated 
with the presence of EBV, and the association with mortality became significant when 
corrected for HIV (section 7.3.2) (Kelly et al., 2012). In that study 53% of adults with bacterial 
meningitis were co-infected with EBV and a strong association with HIV co-infection was 
seen. In another study from Zambia, EBV was found in the CSF of 27.5% of HIV co-infected 
adults presenting with CNS opportunistic infections (Siddiqi et al., 2014), a study from 
Angola found EBV in 40% of children with ABM, but no association with outcome was seen 
(Pelkonen et al., 2013). 
 
EBV has rarely been detected in the CSF of adults with bacterial meningitis outside Africa 
(Brouwer et al., 2013, Kleines et al., 2011)and none of these studies detecting reported 
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associations between with other parameters and EBV infection (Kelly et al., 2012, Kleines et 
al., 2011). Concomitant viral infection was not looked for in European studies of patients with 
HIV co-infection and bacterial meningitis. Given the high prevalence of HIV and EBV in SSA, 
it may be that this association is only found within this region (Schaftenaar et al., 2014). 
Further data are required to explore the relationship between EBV, HIV and meningitis in 
other settings. 
 
In contrast with the Kelly study, EBV was not associated with outcome in BAM, either when 
tested as a continuous variable, when categorised into quartiles around the median, or when 
adjusted for HIV co-infection. EBV was also not associated with the quality of survival. An 
association with EBV viral load mortality was reported in the previous Malawian study 
between the highest quartile of EBV load and mortality, when corrected for HIV co-infection 
p=0.02 (Kelly et al., 2012). The lack of association in this study may have been due to 
smaller numbers (149 patients with a 54% prevalence of EBV in Kelly et al compared to 81 
patients with 41% prevalence in this study), as the only association with outcome in that 
study was in the highest quartile of viral CSF load, so the association was small but 
significant. Viral loads per patient (median in BAM 1913 copies/ml CSF (IQR 1095 – 5852) 
compared to 1012 copies/ml (IQR 365 – 7269) in HIV negative and 6849 copies/ml (IQR 511 
– 223323) in HIV co-infected) did not significantly differ between this study and the previous 
study. The Kelly study did not explore EBV co-infection by ABM causative pathogen. In this 
current study, EBV co-infection was equally distributed between pneumococcal, PCR 
negative meningitis, and excluded cases, with similar viral loads in each group. The role of 
EBV in the CSF of African adults with a meningitic illness is not clear, there are limited data 
to determine if it is an active component of CSF inflammation or a by-stander activated by 
inflammatory white cells in the CSF during ABM. Viraemia from latently infected B cells in 
the blood entering the CSF with blood-brain-barrier breakdown is a possible source of CSF 
EBV, however low level circulating CSF virus released from lymphoid tissue within the 
ependymal cells lining the blood brain barrier is also a possible source of virus (Kleines et 
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al., 2011, Salvetti et al., 2009). In the prior Malawian study, active CNS EBV replication 
rather than the detection of latent infection was hypothesised, triggered by bacterial infection 
in the CSF (Kelly et al., 2012). Studies specifically designed to explore this problem are 
required to determine the source of EBV in the CNS of patients with ABM, and explore the 
role of the virus in pathogenesis. 
 
7.4.3 Laboratory predictors of poor outcome 
This analysis was designed to detect biomarkers in the blood and CSF of adults with 
meningitis that were associated with poor outcome. The most striking finding was the relative 
normality of the measured parameters of inflammation and tissue perfusion in the blood, 
including peripheral white cell counts and blood lactate. The CSF data did represent an 
inflammatory picture with very high protein and lactate levels, although CSF WCC were 
overall markedly lower than in other settings (de Gans and van de Beek, 2002; Durand et al., 
1993; Dzupova et al., 2009). 
 
Only CSF WCC was associated with poor outcome on univariate analysis in this study;  
other predictors demonstrated to be predictive in other studies showed no association 
including platelet count, peripheral white cell count, blood lactate, haemoglobin (van de Beek 
et al., 2004; Weisfelt et al., 2008; Weisfelt et al., 2006e; Wall et al., 2013c).  However, 
analysis was significantly limited by the quantity of data available. Pneumococcal culture and 
anaemia were not significantly associated with poor outcome in BAM, which compared to 
their positive correlation in the historical data is interesting (Wall et al., 2013c). The 
differences in the data may partly be explained by the relatively small case numbers in BAM 
compared to the historical cohort (n=132 compared to n=715), with missing data limiting the 
analysis.  
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HIV co-infection was not associated with poor outcome, as shown previously. However the 
proportion of HIV uninfected adults was low (20% of patients were HIV uninfected, a further 
18% did not have a test done so have unknown status. The relatively small numbers of HIV 
uninfected may mean that any statistical association is minimised, leading to a type two 
statistical error. No data have been published from other settings in adult meningitis with 
sufficient numbers to determine if a true association with HIV infection and outcome exists. 
This is the subject of further discussion in Chapter 8, Section 8.3.4. 
 
Very high CSF protein and low CSF: Blood glucose ratios were shown to be potential 
biomarkers for pathogenic severity, as have been shown in a study in the Czech Republic 
(Dzupova et al., 2009), however the analysis of these variables in this study was limited by 
little data available. High CSF lactates were ubiquitous, but lactate production in the CSF did 
not predict outcome, unlike in older studies of ABM, and in TB and cryptococcal meningitis 
(Lu et al., 1999; Vengerov et al., 2008; Lu et al., 2001a) . 
 
Recruitment to Phase 2 was the strongest predictor of poor outcome in the day 10 analysis 
(Chapter 6 Section 6.3.5, 6.3.7). Due to the weight given to this variable in the multivariate 
modelling, it is possible that biomarker data may have had more weight if no differences had 
been seen in outcome across the study phases. The possible causes for the poor outcome 
seen in Phase 2 have been explored extensively in Chapter 6, and because of the strength 
of the association between P2 admission and outcome, full interpretation of the biomarkers 
analysed in this study is not possible. 
 
A larger sample size in a future study would be necessary to determine if any biomarkers 
tested with univariate associations with outcome are true predictors of poor outcomes. All 
patients had abnormally low CSF WCC, and high CSF protein and lactates indicative of CSF 
inflammation, but in contrast measures of inflammation in the blood were limited. No 
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measures of inflammation in either compartment were significantly associated with outcome 
on multivariate analysis. 
 
7.4.4 Limitations, biases and contrasts 
The analyses presented in this chapter have several limitations. Complete data and sample 
collection for the PCR study altered between P1 and P2 (Chapter 3 Section 3.3.6) effectively 
limiting the numbers of samples collected in P1 compared to P2. This change increased the 
data and numbers of samples available for the study, but meant that data collection for 
physiological detail and the PCR study were predominately from patients in Phase 2 where 
mortality was higher. In all other important characteristics these patients were the same on 
admission as those in Phase 1, and the P2 mortality rates were the same as seen in the 
historical database. The extent to which the outcome data were altered by this mortality 
difference is unclear, but this is likely to be minimal. 
Bacterial loads presented in this study are estimated based on calculations provided by the 
company that supplied the PCR kits. These calculations had been extensively validated by 
the company, but were not cross-checked in Malawi against a standard curve of known copy 
numbers, the conventional way to calculate copy number accurately. Viral copy numbers 
were calculated using a standard curve provided by the manufacturer, and therefore the 
results may be more accurate. Definitive conclusions as the relationships between bacterial 
loads and outcome therefore cannot be definitively made. 
Data were missing from this study to allow full inclusion in the analysis of markers of 
inflammation and poor outcome. These related either to missing laboratory data due to 
reliance on hospital laboratory facilities, or periods where test strips for measuring lactate 
and glucose were not available. At QECH during the time of the study these facilities were 
severely limited, and results for HIV-1 antibodies, FBC, CD4 counts and biochemistry were 
commonly lacking. Many CSF samples processed in the MLW laboratory had very abnormal 
310 
 
results produced that were off the scale measured by the laboratory, and were reported as 
‘#’ rather than as a numerical value and as such were not included in these analyses. In 
addition, the lack of numerical CSF WCC data, when many patient samples were reported 
as ‘clumped’ cells limited the data available to determine full trends with CSF WCC and 
outcome as seen in the historical data.   
The presence of entrance to study Phase 2 as an independent predictor of poor outcome 
suggests that admission to that Phase may have made the interpretation of the analysis 
more complex for the other variables included. The differences in data collection between P1 
and P2 may have led to the discrepancies observed between the variables associated with 
poor outcome at day 10 and day 40. These data are potentially confounded by the study 
design. Further data from a prospective study with parallel, randomised design not subject to 
these confounding would provide data from patients randomised to the intervention, and 
would give more robust data comparing biomarkers and outcome.  
 
In conclusion, pneumococcal loads in patients with bacterial meningitis are high, and are not 
associated significantly with outcome. EBV co-infection in the CSF of patients with ABM is 
common, and does not appear to be linked to either mortality or quality of survival, in 
contrast to a previous study. Predictors of poor outcome from ABM in this study appear to be 
associated with poor immune-responses to invasive pathogens within the CSF. Further, 
prospective data collection in a randomised study is required to test these trends and 
laboratory biomarkers further. 
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8 Main Discussion 
 
8.1 Introduction 
The work in this thesis addresses two important questions about mortality from and the 
optimum treatment of acute bacterial meningitis in African adults: 
1) Why is mortality from ABM so much higher in sub-Saharan Africa (SSA) compared to 
other regions and why did have evidence-based adjunctive interventions from other 
regions failed to improve outcome in SSA? 
2) Can the application of the principles of Early Goal Directed Therapy improve quality of 
acute clinical care for adults with suspected ABM in SSA? 
Three main themes arising from this work will be addressed and discussed using a 
framework of the patient journey from symptom onset to outcome: 
a) The causes of high mortality and the evolving picture of ABM in SSA in the last 12 years.  
b) The feasibility of implementing Early Goal Directed Therapy as a protocolised treatment 
approach for ABM and assessment of the practicality and utility of the care bundle in the 
context of the trial and the setting.  
c) Future directions for the study of ABM in SSA, particularly with a focus on reduction in 
case fatality rates in adults.  
The experience of a patient with ABM from symptom onset to final outcome  is influenced by 
many factors, some of which are dependent on the socioeconomic environment of the 
patient (e.g. travelling costs, societal pressures) and some of which are universal (e.g. 
disease recognition in the community and hospital, access to adequate health resources). 
Many interventions have been tested in the hope of improving survival (for example early 
recognition in the community; early antibiotics; adjunctive therapy, management of 
complications) at different points on this pathway. The possible causes of poor outcomes 
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from ABM, particularly in SSA, are complex and multi-factorial. This discussion section will 
first summarise the stages of the patient journey, then discuss themes from this thesis with 
regards to the potential pathogenic causes of poor outcome and the intervention tested in 
this thesis. Finally, future potential adjunctive interventions for ABM in adults in SSA will be 
discussed. 
 
8.2   The patient journey from symptom onset to hospital outcome: where can 
things go wrong for adult patients with bacterial meningitis in SAA? 
An adult with bacterial meningitis will start to experience symptoms in the community, most 
commonly headache and fever (Scarborough and Njalale, 2004). Symptoms of bacterial 
meningitis may progress rapidly, and need to be recognised as life-threatening. Commonly 
the patient will require assistance of a relative, friend or guardian to seek help at a local  
health-centre, or traditional healer (Desmond et al., 2013).  Substantial social and 
community barriers can lead to delay in accessing care locally  (Desmond et al., 2013), 
including failure of appropriate disease recognition and lack of access to qualified health 
professionals.  Once assessed at a health centre, the patient may be referred to a central 
hospital with inpatient facilities, or the diagnosis may be missed and the patient given 
inappropriate treatment or discharged, leading to  delay in referral and admission or even 
death in the community (Cullinan and Pieterick, 1998; Okubadejo and Danesi, 2004; 
Reyburn et al., 2004). Even in resource-rich settings, a diagnosis of meningitis may be 
missed (Brennan et al., 2003) and clinicians at the primary care level in Malawi are less well 
trained and have a far greater workload. In the primary care centre,  although symptoms 
may be mild initially, the rapid progression and potential severity of the disease needs to be 
recognised, a referral made and access to transport and associated travel costs need to be  
available to ensure adequate treatment (Desmond et al., 2013). Most transport only operates 
in the day-time, fuel shortages common and access to ambulances for transport is severely 
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limited or not available (Cullinan and Pieterick, 1998). A patient referred in the evening may 
have to wait until the morning, often without treatment, before the referral can be completed. 
 
By the time the patient arrives in the central hospital, he or she may have deteriorated 
substantially en-route (Harnden et al., 2006; Gjini et al., 2006a; Scarborough and Thwaites, 
2008). Systems and facilities to prioritise very unwell cases are rare in most hospitals in SSA 
(Scarborough and Njalale, 2004). Triage, or early triage and treatment practices are 
recommended by the WHO for adults, but often not in place due to lack of trained staff 
(Robertson and Molyneux, 2001; WHO, 2004).  Clinical care is dependent on the quality of 
the facilities available, including timely access to qualified medical and nursing staff, and 
treatment including parenteral antibiotics, seizure control medications and intravenous fluids, 
and diagnostic facilities.  
 
Once patients have been admitted, ongoing quality ward based care is important, including 
continuation of antibiotic treatment, airway and fluid management,  HIV antibody counselling 
and testing if appropriate , Discharge follow up arrangements are needed to ensure that 
post-meningitis sequelae can be treated. Many limitations  occur in both the ward based 
care and follow up arrangements: lack of test kits precludes a diagnosis of HIV co-infection, 
lack of drugs on the ward limit the treatment options available, and lack of access to the 
correct follow up clinics commonly limits patients’ access to HIV or on-going medical care.  
These limitations are caused predominately by the profound resource constraints that QECH 
and other hospitals in Malawi operate under, combined with weak procurement systems, low 
staffing levels and poor management and organisational structures. A significant number of 
the patients who survive to hospital discharge die in the community of unknown causes 
before their six week follow up visit.  
 
These stages between symptom onset and eventual outcome are summarised in Figure 8.1. 
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Figure 8.1 Patient journey with ABM in Malawi 
Summary of the medical journey of a patient with bacterial meningitis in Malawi indicating 
opportunities for barriers to care and patient costs. 
 
It is clear that barriers and bottle-necks exist at each stage of the patient journey between 
symptom onset and community recovery (Figure 8.1). Any single intervention is not going to 
be able to solve all the problems with healthcare delivery for these patients in a profoundly 
resource-limited environment such as Malawi. Key points on the patient journey have been 
identified in Figure 8.1 where barriers exist and interventions have either been tested or are 
planned. A joined-up approach to meningitis recognition and treatment at both community 
and hospital level is required to improve the overall care of these patients, as has been 
done, particularly for children in more resource-rich settings (Nadel et al., 1998; Thompson 
et al., 2006; Vaina et al., 2013; Harnden et al., 2006). EGDT for bacterial meningitis in 
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Malawi is part of this approach, with the aim to improve early hospital recognition and 
treatment of ABM. 
 
8.3 Persistently high mortality from ABM in African adults 
Survival rates in adult ABM in clinical trials are commonly measured at 48 hours, ten days or 
discharge from hospital and four-twelve weeks post symptom onset, (Scarborough et al., 
2007; Ajdukiewicz et al., 2011; de Gans and van de Beek, 2002; Nguyen et al., 2007; 
Glimaker et al., 2014; Mourvillier et al., 2013). Mortality in all of these studies shows the 
same trend, with high frequency of initial deaths by 48 hours, with additional deaths in-
hospital and further community deaths post discharge. This same pattern was seen in this 
study, with the most deaths occurring early in the illness, but with significant in-hospital and 
out of hospital mortality.  
 
The case fatality rates (CFR) from ABM at day 10 (45%) and day 40 (57%) in BAM were the 
same as those in the SAM (45% and 56% respectively) and GLAM trials (45% and 61% 
respectively) (Scarborough et al., 2007; Ajdukiewicz et al., 2011), and an observational study 
(60%) (Gordon et al., 2000). These high CFRs are typical for the region (Gessner et al., 
2010; Traore et al., 2009; Trachtenberg et al., 2007), and are substantially higher than those 
recorded in other settings (Mourvillier et al., 2013; de Gans and van de Beek, 2002; Nguyen 
et al., 2007; Glimaker et al., 2014; Durand et al., 1993). The CFR for comparison for 
pneumococcal meningitis in more well-resource settings remains at 20-35%, remaining at 
this level despite the introduction of dexamethasone therapy and high quality intensive care 
support (Almirante et al., 1995; Brouwer et al., 2010a; Lepur and Barsic, 2007).  
 
It is disappointing that shorter times from presentation to ART receipt for HIV co-infected 
individuals, and substantial overall improvements in adult mortality in HIV co-infected 
individuals associated with improvements in health-centre level care in Malawi do not appear 
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to have affected mortality in adults with ABM (Sloan et al., 2013; Floyd et al., 2010). This 
may partly be due to the considerable social barriers that many patients meet before arriving 
at the treating hospital, in addition patients with poor outcome present with a features of 
severe disease that are difficult to manage within the resource limitations of healthcare in 
Malawi (Wall et al., 2013c; Desmond et al., 2013). 
 
8.3.1 Prediction of poor outcome from ABM 
A severity score (MAMS), derived from five predictors of poor mortality from previous studies 
was shown to be a good predictor of outcome in BAM Phase 2 and was superior to a  
previous score developed in Europe when analysing  Malawian data (Weisfelt et al., 2008; 
Schut et al., 2012). This observation suggests that severity scores for meningitis may be 
population specific, leading to the inference that significant differences exist in ABM in 
different regions, due to either differences in invasive disease in the host, pathogens or the 
environment. Detailed comparative studies are required to explore this further. 
 
Altered mental state remained the strongest predictor of poor outcome in BAM and  historical 
studies (Wall et al., 2013c), in BAM it was shown that lower GCS combined with rising mean 
arterial blood pressure (MAP) over six hours was predictive of poor outcome. This pattern is 
consistent with rising intracranial pressure (Koenig et al., 2008; Glimaker et al., 2014). An 
association between altered mental state and poor outcome has been observed in many 
studies of ABM in other settings (Flores-Cordero et al., 2003; Ishihara et al., 2009; Lepur and 
Barsic, 2007; van de Beek et al., 2004); no other study has reported outcome with serial 
GCS and MAP measurements.  The underlying causes of altered mental state due to CNS 
inflammation and raised intracranial pressure in ABM are complex, work from developing 
severity scores in Europe and in Chapter 5 shows that as GCS falls, the risk of poor 
outcome increases proportionally (Weisfelt et al., 2008).  
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The measurement of clinical parameters associated with outcome is useful for the 
development of prediction tools, which in turn may have useful roles in future clinical trials. 
These measurements alone do not increase our understanding of the specific causes of 
poor outcome, but, together with data from meningitis pathophysiology from animal models, 
have led to attempts to ameliorate clinical findings associated with poor outcome, such as 
reducing intracranial pressure (Glimaker et al., 2014; Ajdukiewicz et al., 2011), CNS 
inflammation or brain cooling (Scarborough et al., 2007; de Gans and van de Beek, 2002; 
Mourvillier et al., 2013). However, these treatments to date have been targeted at global 
reductions in brain inflammation and swelling, and have met with limited success. 
 
Human post-mortem studies show  that patients who do not survive ABM have a very severe 
inflammatory findings such as reduced synaptic density and cortical necrosis (Wippel et al., 
2013), but these represent only the terminal disease state and therefore provide at best a 
partial insight into the physiology of the disease. Imaging studies with CT scanning or MRI 
would be a good way to see if macroscopic changes such as space occupying lesions, 
hydrocephalus or cerebrovascular accidents exist within the CNS of adults who survive or do 
not survive. The few data available are exclusively from resource-rich settings. In a study of 
patients with suspected ABM on admission to hospital, CT scans were abnormal in 
approximately 24%, with a wide variety of findings.  Focal lesions were most common, 
particularly stroke, mass lesion and disease of the peri-ventricular white matter; non-focal 
lesions including sub-arachnoid haemorrhage, meningeal enhancement and hydrocephalus 
were also seen (Hasbun et al., 2001). Abnormal CT findings on admission in this cohort 
were associated with poor outcome, increased age (>60 years) and an 
immunocompromised state, but details of specific CT changes in the sub-set of patients with 
proven ABM are not included (Hasbun et al., 2001).  This study shows that macroscopic 
brain changes are present in a subset of adults with meningitis, however to date no study 
has related imaging findings to outcome. 
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Cerebral thrombosis on MRI has been shown to be a rare cause of late mortality and 
morbidity from ABM after initial recovery, with infarctions of the brainstem or thalamus in all 
patients. The risk of post-meningitis stroke may be able to be predicted from raised cerebral 
blood flow velocity during the acute illness; further prospective clinical data are needed 
(Klein et al., 2010; Schut et al., 2009a; Klein et al., 2011). Imaging data from proven ABM in 
children shows that infants with late presentation, abnormal mental status and seizures were 
more likely to have abnormal MRI findings, commonly meningeal enhancement, infarcts and 
subdural empyema (Oliveira et al., 2014). MRI is available in Blantyre but was not financially 
or logistically possible during BAM. Nonetheless, future studies may provide evidence for 
risk stratification, based on the degree of cerebral inflammation or presence of stroke, 
leading to additional treatments such as prolonged antibiotics for patients with imaging 
abnormalities or targeted management of stroke-like phenomena. 
 
8.3.2 Host biomarkers of outcome  
Trends towards an association between lower CSF white cell counts and mortality were 
observed in SAM, GLAM and BAM. Low CSF WCC have been associated with poor 
outcome in other more well-resourced settings, although  the median counts recorded in 
those studies are 10 to 100 fold higher than those observed in Malawi (van de Beek et al., 
2004; Weisfelt et al., 2006d). Malawian patients with ABM appear to have substantially lower 
CSF WCC responses to ABM compared to those in other regions, with a univariate 
association between CSF WCC and poor outcome (Wall et al., 2014b).  CSF white cells in 
ABM are made up of predominately neutrophils, which phagocytose and destroy invasive 
bacteria through autolysis (Mook-Kanamori et al., 2011; Nazifi et al., 1997). It is possible that 
inadequate numbers of CSF white cells lead to inability to phagocytose and autolyse 
sufficient bacteria, even in the presence of adequate bactericidal antibiotics leading to 
delayed sterilisation. However in an animal model of meningitis where infiltration of 
neutrophils into the CSF compartment was blocked using  monoclonal antibodies, lack of 
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CSF WCC enhanced animal survival (Tuomanen et al., 1989). No human data exist. CSF 
WCC differed in both adults and children according to specific meningitis pathogens, with the 
meningococcus having a 10 fold higher median cell count than the pneumococcus or NTS 
(Wall et al., 2014a). HIV status had no effect upon the median cell count in adult meningitis 
(Wall et al., 2014a).  
 
Whether the overall lower CSF WCC observed in SSA is associated with pathogenesis, or is 
a function of ethnic neutropaenia is not clear. People of African origin have been noted to 
have lower peripheral neutrophil counts compared to normal ranges derived from Caucasian 
populations (Wells et al., 2006; Kourtis et al., 2005; Bain et al., 1984); no lack of functionality 
has been attributed to the lower peripheral cell  counts (Haddy et al., 1999). Ethic 
neutropenia may be associated with increased risk of HIV acquisition, possibly due to Duffy-
null associated low neutrophil counts (Ramsuran et al., 2011).  
The wide range of CSF neutrophil counts observed in BAM, compared to less variation in the 
peripheral white cell count suggests that that the issue lies with reactivity of the host system 
rather than ethnic neutropaenia and the association with negative outcome supports this. 
Testing which hypothesis is be correct would be possible but complicated, and require fresh 
CSF and peripheral blood samples from patients with meningitis, and peripheral blood from 
matched control patients. Flow cytometry on fresh CSF samples may be able to determine 
expression of different receptors on CSF neutrophils in patients with different counts, cell 
reactivity to pneumococci in the periphery between controls and patients, and gene 
expression in the peripheral blood neutrophils and CSF neutrophils may also provide useful 
data to explore this area. 
 
Interestingly a similar pattern has not been highlighted in studies of children in SSA. Children 
in this region have an overall high CSF WCC in ABM. In a study from South Africa, children 
with ABM had a median CSF cell count of 848 x 106 cells/mm3 (IQR 13 – 10 027x106 
cells/mm3), n=67, 23% were HIV co-infected, 18 patients had cell counts of <300x106 
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cells/mm3 (Michelow et al., 2000). No association between low cell count and outcome was 
tested in that study. A review of prognostic indicators for paediatric ABM in Malawi did not 
look at CSF WCC or peripheral white cell count (McCormick et al., 2012), neither did a study 
examining the relationship between bacterial load and cytokines in CSF with outcome in 
Malawian children with ABM (Carrol et al., 2007a). Other studies of causative factors for 
poor outcome from SSA also did not examine the relationship between CSF or peripheral 
white cell count and outcome (Akpede et al., 1999; Johnson et al., 2007; Pelkonen et al., 
2009). Although details are not given, it is likely that these laboratory data were not available 
for inclusion from systemic surveillance.  
 
A systematic review of poor prognostic indicators in paediatric bacterial meningitis world-
wide showed that overall, low CSF WCC and low peripheral CSF WCC were associated with 
poor neurological outcomes from ABM including coma and seizures (de Jonge et al., 2010). 
Substantial differences existed in the quality of the included studies, those which looked for 
and found CSF WCC to be associated with poor outcome were mostly retrospective studies 
that have been done in both the pre and post Hib vaccine eras, around the start of the HIV 
epidemic (Koomen et al., 2004; Chao et al., 2008; Lovera and Arbo, 2005; Pagliano et al., 
2007; Kaaresen and Flaegstad, 1995; Herson and Todd, 1977). The ranges of CSF WCC 
reported in these studies varied enormously, the numbers available in most studies were 
small. A meta-analysis only showed an association between poor neurological outcomes 
and low CSF WCC; relationships between CSF WCC and other outcomes were not 
significant (de Jonge et al., 2010). 
 
Peripheral neutrophil counts were commonly not available in the BAM study, however total 
peripheral white cell counts were within the normal ranges (Chapter 6 section Table 6.9, 
Table 7.6), despite the presence of invasive pneumococcal infection where a reactive 
neutrophil pleocytosis might have been expected (Nazifi et al., 1997). Lower peripheral blood 
white cell counts were observed in BAM non-survivors, however the trend did not reach 
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statistical significance and there are no historical data for comparison. Further 
understanding/ insights into this issue will be generated from RNA expression analysis of 
whole blood and CSF peripheral blood mononuclear cells (PBMCs) in these patients, to 
determine if patterns of RNA expression differ in either compartment in relation to outcome. 
 
Other markers of inflammation in blood and CSF were not associated with poor outcome in 
BAM, including blood lactate and haemoglobin. The lack of association between blood 
lactate and outcome was surprising, given the extensive evidence in sepsis and septic shock 
that higher lactates directly correlate with poor outcome, particularly failure to clear or reduce 
blood lactate levels with resuscitation (Arnold et al., 2008; Kortgen et al., 2006; Rivers et al., 
2001; Nguyen et al., 2011). The relatively low blood lactate values seen in BAM suggest that 
few patients had septic shock causing poor tissue perfusion, supporting the hypothesis that 
poor outcome was driven by CNS inflammation, not sepsis and shock. 
 
Few studies are available exploring if CSF lactate is associated with poor outcome in 
meningitis, a relationship has been shown in children with cerebral malaria (White et al., 
1985). A single study from Nigeria in children showed that there was a trend towards higher 
CSF lactates and outcome, although this did not reach statistical significance (Imuekehme et 
al., 1997). An animal study showed that high CSF lactate was associated with development 
of deafness after ABM in an animal model of pneumococcal meningitis (Bhatt et al., 1993). 
CSF lactate has been developed as a test to discriminate between viral/aseptic meningitis 
and ABM, not as a marker of outcome (Berg et al., 1982; Brook et al., 1978; Controni et al., 
1977). CSF lactate is produced by anaerobic respiration in active cells in the CSF including 
pneumococci and neutrophils as they autolyse, and is a marker of intense inflammation 
(Mustafa et al., 1989a; Bhatt et al., 1993; Mustafa et al., 1989b; Ammendolia et al., 2009). All 
BAM patients had high CSF lactates (>8mmol/L), commensurate with the high bacterial 
loads seen. No previous studies have attempted to correlate CSF lactate with bacterial load; 
the BAM data showed no significant correlation. 
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A clear relationship was demonstrated between severe anaemia and poor outcome in the 
historical meningitis data presented in Chapter 4 Section 4.5.4 (Wall et al., 2013c). This 
association was not seen in BAM, overall mean haemoglobin measurements were higher 
than the in the historical dataset with only a very small proportion of severely anaemic 
patients (Hb <8.0g/dL). It is not clear why these patients were less anaemic, but the 
introduction of ART, and generalised improved nutritional status of Malawians over the last 
10 years may be contributory (Chihana et al., 2012; Floyd et al., 2012; Jahn et al., 2010b). 
Anaemia in SSA is commonly a marker of severe chronic disease, and possibly a marker of 
the degree of immunosuppression caused by HIV (Lewis et al., 2005; Phiri et al., 2008). 
Future monitoring of trends in anaemia in patients with ABM from other centres in SSA 
would be helpful to explore this further.  
 
8.3.3 The roles of pathogenic bacteria in determining outcome 
Pneumococcal meningitis, particularly amongst adults in Malawi is predominately caused by 
serotype 1 (Everett et al., 2012), a pneumococcal serotype that is rarely carried but causes 
highly lethal epidemics of meningitis in West and Central Africa (Mueller et al., 2012; Yaro et 
al., 2006; Leimkugel et al., 2005). In contrast, serotype 1 is not commonly associated with 
meningitis in Western countries, and is associated with a relatively lower CFR compared to 
other serotypes; important differences in virulence are likely to exist between serotype 1 in 
different continents (Burgos et al., 2012a). 
High levels of pneumococcal toxins and high bacterial loads have been observed in African 
patients with pneumococcal meningitis, and CNS infection is aggressive and rapidly 
progressive (Wall et al., 2012; Mueller et al., 2012; Roine et al., 2014b; Wall et al., 2014b; 
Carrol et al., 2007a).  The two sole few human studies relating bacterial toxins in the CSF to 
outcome from ABM (Wall et al., 2012; Ovstebo et al., 2004) both show a relationship 
between bacterial product and outcome. In both  human post mortem and animal work, the 
pneumococcal toxin pneumolysin causes severe structural neuronal and synaptic damage 
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which may be irreversible and fatal (Wippel et al., 2013). Tests of the host ability to clear 
toxin from the CSF of the animals were not done in this study. The degree to which outcome 
is determined by the pathogen or the host is yet un-determined. 
 
8.3.4 The role of HIV co-infection in outcome 
HIV co-infection was not associated with outcome in either the historical dataset or in the 
BAM trial (Wall et al., 2013c). This finding was unexpected in the context of the important 
role HIV co-infection plays in the acquisition and increased risk of invasive pneumococcal 
disease world-wide and particularly in sub-Saharan Africa. HIV co-infection is associated 
with increasing pneumococcal carriage frequency, and increased rates of pneumonia, sepsis 
and meningitis, despite increasing access to ART (Anthony et al., 2012; Burgos et al., 
2012b; Domingo et al., 2009; French et al., 2010; Grau et al., 2005; Molyneux et al., 2003; 
Nunes et al., 2011; Glennie et al., 2013; Wolter et al., 2014b). 
 
HIV is clearly a significant risk factor for pneumococcal meningitis (Feikin et al., 2010; 
Bekondi et al., 2006; Burgos et al., 2012b; Domingo et al., 2009; French et al., 2010; Gordon 
et al., 2000; Molyneux et al., 2003; Hakim et al., 2000; Wall et al., 2013c), however the role 
of the HIV virus in pathogenesis of ABM is less clear. 
HIV co-infection has been associated with poor outcome in children with meningitis caused 
by both S. pneumoniae and N. meningitidis in South Africa and S.pneumoniae in Malawi 
(Cohen et al., 2010b; Nyasulu et al., 2011; McCormick et al., 2012). In these vertically 
infected children, failure to thrive and age <1 year were also predictors of poor outcome 
(Nyasulu et al., 2011). No differences were noted in mortality for all IPD in adults between 
HIV co-infected and HIV negative individuals in Spain; meningitis mortality was not 
compared (Burgos et al., 2012b). Also in Spain, an earlier study showed HIV co-infected 
adults with bacterial meningitis had a higher case fatality rate than HIV uninfected, but the 
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numbers were very small (n=34) (Domingo et al., 2009). . No causative data were given in 
these descriptive epidemiological studies, but the authors of all the specific meningitis data 
showing an association with HIV and mortality, associate weaker humoral immunity caused 
by HIV co-infection with the increased CFR observed.  
 
In the study of historical Malawian data, concerns were raised that the lack of association of 
outcome with HIV co-infection was due to the small proportion of HIV negative individuals in 
the data analysed (13% of the total) (Wall et al., 2013c). BAM again did not show an 
association between HIV status and outcome again, with 30% HIV un-infected making an 
association between HIV and outcome across a total of 827 patients with meningitis very 
unlikely. Data are lacking from studies of ABM pathogenesis in HIV co-infected humans, but 
it is known that the presence of rapidly dividing bacteria within the CSF triggers a series of 
innate immunological responses from both within the CNS and the periphery to control the 
infection (Mook-Kanamori et al., 2011; Ernst et al., 1983; Fishman et al., 1975; Grandgirard 
et al., 2007; Mertsola, 1991; Tauber et al., 1992; Tauber and Sande, 1984). It is possible that 
these responses are only minimally affected by HIV and that other determinates of the 
outcome of this intense inflammation are likely to be more important in the final outcome 
than the presence of HIV infection. 
 
It is well established that the CNS is a particular reservoir for HIV, and HIV causes specific 
brain related pathology in a small proportion of HIV co-infected individuals (Geffin and 
McCarthy, 2013; Ances and Ellis, 2007). BBB endothelial cells can be activated to suppress 
HIV replication and possibly entry of HIV into the CNS from the circulation; they may be 
important in regulating the interaction between HIV and the CNS (Li et al., 2013). The impact 
of HIV on innate CNS immunology has not been studied in detail. 
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Although comparisons are limited, studies of cryptococcal meningitis (CCM) suggests 
differences when activities of paired Natural Killer (NK) cells and monocytes between the 
blood and CSF are compared during acute infection (Naranbhai et al., 2014) and that 
chemokine responses in the CNS to CCM are different to the blood (Chang et al., 2013). 
These data support the hypothesis of a specific compartmentalised response arising from 
within the CNS in response to the presence of a pathogen; it is unknown if this is instead of, 
or complementary to the peripheral circulation in response to infection in the meninges.  
However, it is not clear if any of these mechanisms described in CCM are relevant to the 
immune attack within the CNS against pneumococci multiplying in the CSF. It is likely that 
failures of immunological mechanisms recruiting inflammatory cells to the CSF, leads to 
abnormal CSF WCC responses and uncontrolled bacterial growth and inflammation and 
poor outcome. The extent to which that this process is affected by HIV is unknown, but as 
HIV co-infection was not associated with outcome, it is unlikely the effects of HIV on 
pathogenesis were significant. This hypothesis will be explored in further work examining 
RNA expression patterns of PBMCs in the blood and CSF of patients from BAM. 
 
8.3.5 The importance of Herpes viruses co-infection in ABM pathogenesis 
In contrast to HIV co-infection, historically EBV has been shown to be positively associated 
with HIV and poor outcome in patients from the GLAM study (Kelly et al., 2012; Ajdukiewicz 
et al., 2011). This analysis was repeated in BAM, there was no association between EBV 
and a composite poor outcome. In a paediatric study from Angola, EBV was isolated in the 
CSF of 13% of children with ABM, with no association with outcome observed (Pelkonen et 
al., 2013). Possible causes for the discrepancy between the Malawian studies may be due to 
smaller numbers available for the BAM analysis, or the increased frequency of ART receipt 
in BAM compared to the SAM and GLAM trials. EBV infection is ubiquitous in SSA and it is 
unclear whether the presence of EBV in the CSF is important in the pathogenesis of ABM, or 
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if the virus is a bystander, produced by actively replicating B-memory cells. (Schaftenaar et 
al., 2014; Kleines et al., 2011; Petrara et al., 2013). 
The presence of CMV infection in the CSF appeared to be associated only with the presence 
of EBV, and strongly associated with mortality in GLAM study (Kelly et al., 2012); the 
numbers were too few to test in BAM. It is likely that CMV is a marker of profound 
immunosuppression and again, it is unclear  if this virus has an active role in pathogenesis of 
meningitis (Siddiqi et al., 2014) (Griffiths, 2004).  
Other herpes viruses including HSV-1, HSV-2 and VZV are not found in adults in SSA with 
ABM, they are found in the CSF of adults presenting with aseptic meningitis (Kelly et al., 
2012; Benjamin et al., 2013). Children with ABM in SSA appear to have these viruses 
present as co-infection, however again the role in pathogenesis of these viruses is unclear 
(Pelkonen et al., 2013). Enterovirus co-infection was also present in a small number of 
patients with ABM in this paediatric study, conclusions are limited by the small sample size 
available (Pelkonen et al., 2013; Pelkonen et al., 2012). 
 
In summary, the pathogenic causes of poor outcome in Malawian adults with ABM are likely 
to be multifactorial, and do not appear to be influenced by horizontally acquired HIV co-
infection. Both host and pathogenic factors are likely to be important, and investigation of 
this area represents an important future step in the understanding of meningitis 
pathogenesis in SSA, and in the development of future adjunctive treatments. The effects of 
pathological features on poor outcome are likely to be compounded by barriers met by the 
patient and guardians between symptom onset and hospital treatment. 
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8.4  The stages of the patient journey with ABM, opportunities for intervention 
8.4.1 Community onset of symptoms, understanding of disease and urgency of 
seeking medical help 
Bacterial meningitis may have either an abrupt acute clinical onset with fulminant disease 
course, or start with mild, non-specific symptoms which then progress over hours to days to 
more fulminant symptoms (Radetsky, 1992). In countries with a high prevalence of malaria, 
the meningitic symptoms of fever, headache, confusion and convulsions, are commonly mis-
diagnosed as malaria (Molyneux, 1996; Walker et al., 1992; Reyburn et al., 2004; Okubadejo 
and Danesi, 2004). 
Perceptions within the community of the high burden of malaria, may lead to inappropriate 
home based malaria treatment in the early stages of a meningitic illness in SSA, where free 
or heavily subsidised combination anti-malaria treatments are easily available (Desmond et 
al., 2013; Aubouy, 2011). A qualitative study from Malawi examining the treatment seeking 
behaviour of patient carers or guardians of both adults and children with subsequently 
proven meningitis showed socially complex healthcare seeking behaviour (Desmond et al., 
2013). In this study male guardians could make decisions and had access to funds to take a 
patient to the health provider of choice, but female guardians could only do so with social 
validation of their social superiors, from whom they had also to access funds for all costs 
incurred (Desmond et al., 2013). Guardians in this situation were commonly directed towards 
a traditional health care provider and a health-centre, in some cases permission to access to 
health centre or hospital was only granted only after deterioration of symptoms or perceived 
lack of effect of traditional remedies. Community perceptions about the poor quality of health 
care available at the health-centre were also important factors influencing delays to hospital 
care (Desmond et al., 2013). A study from Ghana examining attitudes to meningitis in the 
community revealed lack of knowledge of the risks of meningitis and early symptoms 
amongst healthy adults surveyed, an awareness of the high costs involved with a relative 
sick with meningitis and a lack of understanding of the protective effects of vaccination. 
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These areas were identified by the authors as barriers to accessing healthcare in that region 
(Hayden et al., 2013; Akweongo et al., 2013).  
These factors were not studied directly in the BAM study, but were undoubtedly important in 
influencing delays for patients with ABM recruited in all studies of meningitis in Malawi. 
 
The study by Desmond et al led to a novel initiative in Malawi that was conducted during the 
BAM study, where local language radio programmes dealing with important healthcare 
issues including meningitis were broadcast. The programme involved interviews with 
patients and guardians, and a text message/phone in question and answer service. Full 
reports of the response to the programmes are awaited, but preliminary data shows that they 
substantially increased social awareness of important diseases, and the facilities available 
for treatment, counteracting poor community perceptions which may limit health-seeking 
behaviour (Nyirenda 2013 unpublished data). This type of intervention may be very powerful 
in improving community disease recognition and health-seeking behaviours, with 
subsequent reduction in pre-hospital delays and associated mortality and morbidity (Bamani 
et al., 2013; Ndlovu and Sihlangu, 1992). 
 
8.4.2 Health centre management and community treatment/referrals for ABM 
In cases of suspected meningitis and meningococcal septicaemia, early antibiotics are 
advised (Theilen et al., 2008). In well-resourced settings, pre-hospital intramuscular 
antibiotics have been associated with improvements in outcome from meningitis in 
observational studies (Harnden et al., 2006), and primary healthcare providers are 
commonly equipped with antibiotics for this purpose. It is recommended to give a community 
dose of antibiotic rapidly pre-referral to a hospital (Aronin et al., 1998; Fitch and van de 
Beek, 2007), although no randomised controlled trials have been done (Sudarsanam et al., 
2013). Trials from the meningitis belt region showed that single dose, long acting oily 
chloramphenicol is adequate treatment for sensitive meningococcal meningitis in Africa (Wali 
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et al., 1979). However, single dose long acting penicillin is not associated with bacterial 
sterility in the CSF at 48 hours, and is not recommended as monotherapy for meningococcal 
meningitis, without follow up regular parenteral penicillin (Macfarlane et al., 1979).  Single 
dose ceftriaxone is as effective as chloramphenicol for epidemic meningococcal meningitis 
(Nathan et al., 2005). No data on long acting antibiotic therapies are available for the 
treatment of pneumococcal meningitis. Single dose ceftriaxone would be appropriate pre-
hospital therapy for suspected cases of ABM in Malawi, as no ceftriaxone resistance has 
been identified. 
 
The sensitivity of CSF microbial culture is reduced by pre-hospital antibiotic administration 
(Sacchi et al., 2011), but this risk is outweighed by the potential mortality benefits. In Malawi, 
mis-diagnosis of meningitis and delays at crowded and poorly resourced healthcare centres 
potentially contribute to the severe clinical presentation and associated poor outcome from 
ABM in adults and children (Desmond et al., 2013; Scarborough and Thwaites, 2008; 
Cullinan and Pieterick, 1998). No studies of pre-hospital parenteral antibiotics have been 
done in adults in this setting for suspected meningitis. The SAM trial showed intramuscular 
ceftriaxone to be non-inferior to the intravenous route in obtaining adequate CSF levels to 
obtain the minimum inhibitory concentration (MIC) for S. pneumoniae (Scarborough et al., 
2007).  
A study of a paediatric package of care delivered in rural health centres in  Southern Malawi 
showed that for unwell children presenting to a health centre with a presumptive diagnosis of 
either meningitis or malaria (with no access to diagnostic tests for either), delivery of a 
simple package of care including intramuscular quinine and chloramphenicol substantially 
improved mortality in  patients who remained in the centre for complete care, and may have 
reduced mortality for those referred to a central hospital, follow up data are lacking in the 
study for those patients (Cullinan and Pieterick, 1998). This study was observational and 
subject to several biases, but provides interesting pilot data for studies of pre-hospital 
presumptive treatment.  A qualitative assessment showed that the users rated the package 
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easy to use (Cullinan and Pieterick, 1998). Subsequently,  a much larger study to introduce 
the concept of prioritising clinical care for children on the basis of universal clinical predictors 
of severe illness, the ‘Chipitala Robot’ study (translation: Hospital traffic light study) has been 
funded. No results are yet available from this study, which is currently in progress, however 
the mobile phone based triage-tool appears to be acceptable and facilitate referrals to the 
central hospital (Byrne 2013 unpublished data). 
 
A study of health centre administered pre-hospital antibiotics for adults with suspected ABM 
has not been done, but from the evidence currently available, the strategy may have 
significant benefits in  reducing treatment delays and improving outcome.  
 
8.4.3 Delay/travel to central hospitals for diagnosis and treatment  
The time from symptom onset to triage in-hospital was shorter in BAM than in both the SAM 
and GLAM trials.  Pre-hospital delays in ABM in Blantyre are complex, and only partially 
relate to travelling times and mis-diagnosis in health-centres, other social, financial and 
cultural factors are also important (Desmond et al., 2013; Hayden et al., 2013). Increased 
availability of ART and clinical care for HIV co-infected people in Blantyre (Sloan et al., 
2013), may have facilitated community understanding of meningitis and hospital referrals in 
the BAM study.  
 
However obtaining accurate data for illness duration in Malawi is difficult. Patient guardians, 
who frequently provide the history, may not live with the patient, and may fear anger and 
poor clinical care if they admit to delays. Accurate time keeping in such an environment may 
also be challenging. Although a median time of 48 hours from (IQR 24-72 hours) was 
observed in both BAM phases, times of onset were recorded in  days (24/48/72 hours) by 
the study team as more  accurate were difficult to obtain from patients or guardians.  
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Scarborough and Thwaites have suggested that community delays may be due to 
misdiagnosis of ABM as pneumonia, malaria or other cause of headache (Scarborough and 
Thwaites, 2008). Nothing in BAM suggested that this was a significant cause of pre-hospital 
delay in BAM, although errors in diagnosis in the AETC leading to referrals to psychiatry and 
ophthalmology were observed in a small number of patients in P1. 
 
8.4.4 Role of in-hospital delays and pre-treatment with antibiotics on outcome. 
Patients in BAM experienced much shorter in-hospital delays than those in the historical 
database who were admitted through the old Room 6-Ward 4B system (Wall et al., 2013c). 
We expected to find that shorter times to clinical review and parenteral antibiotics would be 
associated with better outcomes, similarly to the sepsis care bundle studies where shorter 
times to parenteral antibiotics were associated with improved survival (Barochia et al., 2010).  
However this association was not observed in either phase of the study.  
 
Pre-hospital treatment with antibiotics did not improve outcome or cause apparent delays in 
referral, although the numbers of patients who received parenteral antibiotics were small. 
Pre-hospital treatment with parenteral antibiotics in other settings has improved outcome 
from severe meningococcal disease, with the exception of those have  a fulminant disease 
when presenting to  primary care (Harnden et al., 2006; Hahne et al., 2006; Perea-Milla et 
al., 2009). No data are available for pneumococcal meningitis in any setting. Although the 
presence of pre-hospital antibiotics was recorded, it the indication was not always clear in 
the BAM study:  patients who received co-trimoxazole may have received this for 
prophylaxis as part of the national HIV treatment programme and not for their meningitic 
symptoms (van Oosterhout et al., 2005; Government, 2010). A specific study designed to 
examine the utility of pre-hospital treatment of meningitis is urgently required. 
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8.4.5 Comparisons of admission characteristics for adults with bacterial meningitis 
Early recognition and diagnosis of ABM on admission to hospital is essential to initiate 
appropriate care (Brouwer et al., 2012; Attia et al., 1999). Important public health 
interventions with substantial benefits have been introduced into Malawi since the SAM trial 
started recruitment, including free access to ART, intensive malaria control, and Hib and 
pneumococcal vaccination (Chihana et al., 2012; Harries et al., 2009; Sloan et al., 2013; van 
Oosterhout et al., 2005; Roca-Feltrer et al., 2012; Daza et al., 2006; Wall et al., 2014a). 
These interventions have resulted in decreased rates of admission with bacterial meningitis 
for children but not adults (Wall et al., 2014a; Bar-Zeev N, 2014). The BAM data were 
compared against the historical meningitis clinical trial data to see if the clinical 
characteristics of patients presenting to BAM had changed, and whether admissions with 
ABM had declined since 2001. There was little difference in the patient profile between 
patients from the historical database presented in Chapter 4, and in the BAM trial presented 
in Chapter 6; the patients have similar median ages, rates of HIV co-infection, frequency of 
pneumococcal disease and disease severity on admission. However, the rate of severe 
anaemia was higher historically, and substantially more patients who were HIV co-infected in 
BAM were receiving ART (42%) compared to those in SAM (0%) or GLAM (5%) 
(Scarborough et al., 2007; Ajdukiewicz et al., 2011).   
 
The surveillance data presented in Chapter 4 suggested that the incidence of adult culture 
positive meningitis has not changed between 2000-2012 (Wall et al., 2014a). It was 
therefore expected that the planned sample size (>100 patients with ABM per year), based 
on estimates from recruitment data from the SAM and GLAM trials would be met easily. 
Instead, recruitment rates were substantially lower than the previous trials. Why this was 
remains uncertain. The BAM trial ran for 20 months, with a mean recruitment rate of 6.6 
cases/month, half the rate of recruitment to the SAM trial (mean 15.1 cases/month) 
(Scarborough et al., 2007), and lower than that in the GLAM trial (mean 10.6 cases/month) 
(Ajdukiewicz et al., 2011). No new facilities treating adults with ABM opened in Blantyre 
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during the course of any of the studies, and therefore reduced case load due to admission 
elsewhere is unlikely. The median symptom history in BAM was also shorter than in GLAM 
and SAM (48 hours compared to >48-72 hours), arguing against increased early deaths in 
the community causing lower recruitment. 
 
All three studies included culture negative meningitis but it is unlikely that decreasing rates of 
culture negative meningitis would account for the decrease in recruitment rate. Differences in 
inclusion criteria could obviously possibly account for the different recruitment rates, 
however the only difference in the CSF inclusion criteria between the three studies were a 
CSF WCC of >100 cells/mm3 in SAM and GLAM, and >50 cells/mm3 in BAM. By using this 
lower threshold, higher recruitment rates for BAM were expected.  All trials recruited daily, 
including out of hours. It is possible that the reduced number of cases seen in BAM could be 
due to an indirect result of increasing ART roll out, and possibly through herd immunity from 
the introduction of pneumococcal vaccination in Malawian children in 2012.  
 
More patients in BAM were on ART (34%) compared to SAM (0%) and GLAM (5%). ART 
has been postulated to reduce the frequency of invasive pneumococcal disease (IPD) in HIV 
co-infected adults, (Almirante et al., 1998; Burgos et al., 2012b) .  
Further surveillance data reporting meningitis trends in Malawi will be very important. It 
remains unclear why the recruitment rate for BAM was so much lower than SAM and GLAM 
despite static pneumococcal disease incidence rates in 2012, 
 
8.4.6 Meningitis Diagnostics and the role of culture negative meningitis 
In the BAM study, CSF culture detected  a pathogen in 63% of included participants, 
compared to 68-72% of participants in the SAM trial, 77% in the Dutch dexamethasone trial 
and 50% in the Vietnam dexamethasone trial (Scarborough et al., 2007; de Gans and van de 
Beek, 2002; Nguyen et al., 2007). The sensitivity of CSF culture in well-resourced routine 
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laboratories is estimated to be  81%, decreasing to <75% when antibiotic activity was 
detected in the CSF (Wu et al., 2013), higher than that seen in clinical trials. This may be 
due to early antibiotic or delay influencing culture viability in the trials, implying molecular 
identification of the causative organism in culture negative patients may be appropriate for 
surveillance (Michael et al., 2010; Sacchi et al., 2011).  
 
Unsurprisingly the utility of PCR was greatest when prior antibiotics had been administered 
(Sacchi et al., 2011). Prescription of antibiotics in the community was common in BAM. With 
increasing access to treatment in health centres for adults and children, particularly 
enhanced HIV care, the proportion of culture negative cases of ABM may increase, limiting 
surveillance of ABM based on culture positive cases only. Enhanced surveillance using 
PCR, particularly for pneumococcal and meningococcal meningitis would give more accurate 
data, but the substantial cost may be prohibitive in this setting (Sacchi et al., 2011). 
 
8.5 Acute in-hospital treatment: Early Goal Directed Therapy in sub-Saharan 
Africa 
8.5.1 The feasibility of EGDT for ABM in a resource-poor setting 
The BAM study is the first study of goal directed therapy for bacterial meningitis, and the first 
formal study of EGDT in SSA. The study was primarily designed as a pilot study to test the 
feasibility of introducing EGDT in QECH. The data presented in Chapter 6 show that the use 
of EGDT for ABM was feasible; significantly more clinical targets were met using the care 
bundle compared to standard hospital management. Times to medical review and parenteral 
antibiotics were faster, airways were used more frequently, greater volumes of IV fluids and 
more sedative drugs were given to patients receiving the care bundle.  
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Despite the widespread introduction of EGDT for sepsis and other uses in critical care in 
resource-rich countries (Rivers et al., 2001; Dellinger et al., 2004; Dellinger et al., 2013; Levy 
et al., 2012; Robb et al., 2010), primary feasibility assessment data for care bundles are 
rarely published. Very few studies have piloted goal directed interventions and undertaken 
feasibility assessments.  
Feasibility testing is important to ensure that the targets set in the care bundle are 
achievable within the time frame set, and that the intervention is appropriate for the disease 
studied (Campbell et al., 2000; Campbell et al., 2007). Feasibility testing is also 
recommended by the MRC guidelines on testing complex interventions, to ensure that 
problems with the study are resolved before the start of a large and expensive clinical trial 
(Campbell et al., 2007; Council, 2008). 
 
In BAM, delivery of targets that were feasibly achieved were: target times for assessment 
and antibiotics, insertion of airway and head tilt, and increased administration of blood and 
fluid for patients who were anaemic or shocked. In the composite assessment, the mean 
targets achieved by the bundle were greater than those achieved by normal, non-targeted 
care, and greater proportions of targets could be met in sicker patients with the bundle 
compared to routine care (Chapter Six, section 6.3.4). These data are encouraging, 
suggesting that despite resource constraints, targeted care is possible. It must be noted that 
the care bundle was delivered by trained research nurses, not those with a large patient 
work-load. This was so changes in physiology with targeted therapy could be monitored 
closely, to determine efficacy of the care bundle. It does not replicate real-life situations in 
most African hospitals. 
 
The first large trial testing EGDT for sepsis reported the relative proportions of each target 
achieved by six hours across the groups, but the authors did not publish prior feasibility data 
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for their sepsis bundle (Rivers et al., 2001). Subsequently most centres adopted the 
evidence based surviving sepsis guidelines (SSG) published after the Rivers study, drawing 
on data from Rivers et al and other studies (Dellinger et al., 2004; Dellinger et al., 2008b; 
Dellinger et al., 2013) then reported problems with implementing care bundles and 
associated required quality improvement processes (Levy et al., 2004).  
Feasibility testing for care bundle studies is difficult. One large study did test for feasibility of 
achievement of the individual care bundle elements. This observational study in Singapore, 
in before/after design introduced a sepsis bundle to the emergency department (ED) of their 
hospital, and measured bundle compliance against the increasing number of targets set for 
patients with correspondingly greater clinical needs (Kuan et al., 2013). Intensive quality 
improvement (QI) initiatives were put in place to facilitate bundle compliance. This study 
showed that as bundle compliance increased with the QI initiatives, mortality 
correspondingly decreased (Kuan et al., 2013). The easiest care bundle elements to achieve 
in that study were measurement of lactate, fluid bolus administration, early antibiotics and 
blood culture draw before antibiotics (Figure 8.2). Achieving the MAP and CVP targets were 
much more challenging, with only 40% completing bundle compliance by the end of 6 hours 
after the fourth round of QI initiatives (Figure 8.2) (Kuan et al., 2013). 
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Figure 8.2 Published care bundle feasibility 
Compliance with bundle targets during four quality improvement initiatives in a hospital in 
Singapore. Care bundle feasibility data published from (Kuan et al., 2013) 
A small number of other studies have also tested sepsis bundles for feasibility. One study 
tested a sepsis bundle of EGDT for feasibility in the emergency departments of four centres, 
reporting that the goal directed algorithms were acceptable to 97% of physicians (McIntyre et 
al., 2008), objective measurements of feasibility were not reported.  
Another observational before/after study across four emergency departments and intensive 
care units, did examine feasibility of use of their sepsis bundle , reporting that time to 
antibiotics was significantly reduced by the care bundle for adults with suspected septic 
shock (99 minutes v 142 minutes p=0.02), and those patients also received significantly 
greater intravenous fluid volumes (Jones et al., 2007b). Absolute mortality differed by 9%, 
with lowered mortality in the bundle group (Jones et al., 2007b). 
Other studies of care bundles with feasibility as the primary objective have examined post 
cardiac arrest cooling protocols, improvement of ICU sedation protocols and acceptability of 
sepsis protocols (Shehabi et al., 2013; Gaieski et al., 2009; Casserly et al., 2011). However, 
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only one study reported the proportion of targets achieved by the care bundle compared to 
previous care (Gaieski et al., 2009). 
 
Only one of the feasibility studies available give composite proportions of targets achieved 
and overall assessments of care bundle delivery achievability (Kuan et al., 2013). Given the 
paucity of data on care bundles and feasibility, the BAM study shows that targeted care is 
feasible in Malawi, and provides important data to inform other centres in SSA considering 
designing EGDT protocols for use in resource limited settings, and has shown comparable 
compliance data to other more well-resourced settings. 
 
8.5.2 The impact of EGDT on outcome for ABM in Malawi 
The main results of the study were disappointing with higher case fatality rates in the 
patients receiving the care bundle compared to standard care at day 10 (72% compared to 
46%  p=0.04), although this difference was not statistically significant by day 40 (63% 
compared to 51% p=0.19). These results are in contrast to all the studies published on 
EGDT and sepsis, with the exception of the PROCESS trial where outcome was equal 
amongst the three groups (Yealy et al., 2014). However, the estimates of effect from these 
BAM data are not as precise as would be seen in a trial with parallel design and random 
selection, due to the observational nature of the study. The explanation for the apparent lack 
of improvement in outcomes with the bundle is not clear. The possibility that the care bundle 
may have been associated with harm cannot be excluded 
 
Patients in both phases had an equal risk of a poor outcome, the median severity scores 
(MAMS) on admission were equal across the study phases. Post admission care on the 
wards or in the outpatient setting did not differ across the study phases. 
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Patients presenting in phase 1 received a good standard of care according to the resources 
available, in line with guidelines from the UK and Holland (Heyderman, 2005; Fitch and van 
de Beek, 2007). Rapid assessment was carried out including LP, appropriate antibiotics 
were given in an acceptable time period and seizures were controlled. These patients 
received conservative parenteral fluids and oxygen if this was required and available. 
Patients in phase 2 who were given EGDT received the same overall baseline of care; in 
addition these patients received antibiotics more rapidly, greater volumes of parenteral fluid, 
more diazepam and more blood. It is impossible to derive a single harmful element from the 
bundle, it is possible that one or more of these elements led to increased harm from care 
bundle delivery associated with the higher mortality observed. Overtreatment with parenteral 
fluids in ABM could lead to increased intracranial pressure and cerebral oedema (Pfister et 
al., 1990), although clinical data are lacking. Excess sedation for patient management 
beyond seizure control also could have a harmful effect (Ume and Gelb, 1988), although an 
independent relationship between either fluid administration or sedative prescription and 
poor outcome was not seen.  
 
The aggressive resuscitation protocol in BAM was based on the guidelines for treatment of 
severe sepsis (Dellinger et al., 2008b), with the underlying assumption that patients with 
ABM would have either meningitis and sepsis, or similar inflammatory responses to 
meningitis that would respond to the sepsis approach (Heyderman, 2005). One component 
of the definition of shock in the SSG that was used in BAM was a pulse rate >100 
beats/minute (Dellinger et al., 2008b). Patients were therefore defined as shocked if they 
had a tachycardia, even if they did not have hypotension or hyper-lactataemia, and were 
resuscitated with the shock protocol. The physiology documented in the observation period 
suggests very few patients had multiple features of shock (as defined by the SSG) and 
instead showed physiological responses to rising intracranial pressure rather than systemic 
inflammatory responses to sepsis (SIRS). It is possible that fluid resuscitation in adults with a 
centrally mediated tachycardia and no other features of shock was harmful, although the 
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numbers are too few to look for trends. Fluid resuscitation is harmful for children in SSA 
presenting with or without clinical evidence of shock, the causes of this harm have yet to be 
fully established, but may be due to lack of available facilities to manage pulmonary oedema 
appropriately (Maitland et al., 2011a). 
Patients with ABM in Malawi appear to have inflammation predominately confined to the 
CNS compartment, and therefore the assumption that treatment based on systemic sepsis 
outcomes for ABM was not necessarily correct.  
 
The relatively low CFR observed in Phase 1 compared to Phase 2 also raises the question 
did patients with ABM recruited to BAM need the full EGDT protocol tested, or did they just 
need good clinical care with rapid diagnostics and appropriate support? Further studies are 
required to answer this question definitively, but it does appear that good quality rapid 
clinical care is appropriate for adults with suspected ABM. 
Definitive conclusions as to the harm or clinical benefit of elements of the BAM EGDT 
protocol cannot be fully drawn from the data. 
 
8.5.3 What is the right approach for the acute resuscitation of ABM in adults in sub-
Saharan Africa?  
The BAM study does not provide definitive data to support guidance for the clinical care of 
adults with ABM. However, results from the study can be extrapolated to support the 
development of a further strategy for acute management of these patients. 
 
The principle of goal-directed therapy was feasible, but the current bundle, with eight 
individual potential targets is in its current format was too complex for routine use outside of 
a research study. Revising the concept of goal-directed therapy, to the design of a simple 
bundle with a focus on the best possible basic clinical management as observed in P1 is 
likely to be safe, effective and reproducible beyond a research setting.  
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Based on the data from BAM P1, a care bundle that would optimise the resources available 
to give the best clinical management for ABM would consist of rapid recognition of ABM, 
parenteral antibiotics within three hours of admission; and management of seizures, 
oxygenation and anaemia if required using available resources. No conclusions can 
currently be drawn from BAM about the most appropriate fluid strategy for bacterial 
meningitis; a study randomising conservative compared to aggressive resuscitation 
strategies is required. 
Based predominately on these, and other observational studies, the surviving sepsis 
guidelines recommend a six hour period for intensive resuscitation to achieve the clinical 
targets set, which can be in the emergency department or after transfer to the intensive care 
unit (Dellinger et al., 2004; Dellinger et al., 2008b; Dellinger et al., 2013). The randomised 
controlled trials of EGDT for sepsis in well-resourced settings tested the relevant 
resuscitation protocol over a six hour window, compared to high quality standard care over 
the same time period, after which time all patients were transferred to high dependency or 
critical care wards for ongoing management (Rivers et al., 2001; Yealy et al., 2014; 2010). In 
two studies, EGDT was superior to routine care (Rivers et al., 2001; 2010), however the 
PROCESS study showed that EGDT was equivalent to good quality routine in-hospital care 
(Yealy et al., 2014).   
 
The full care bundle in the SSG was not appropriate for adults in a resource-limited setting, 
where many resources required are not available, such as central venous monitoring. In 
addition, the SSG bundle is designed primarily for sepsis, not meningitis. Therefore, the 
BAM targets set were appropriate for meningitis in a resource-limited setting, and were 
substantially simpler than those outlined in the SSG. Resuscitation was given over the same 
six hour observation period as per the SSG, testing if targets set were achieved by the end 
of the time; all observation was done in the AETC. 
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Due to limited facilities available, no patients were transferred to the intensive care facilities 
available, most received basic ward based care, with oxygen if required. Beyond attempts to 
obtain blood transfusion and on-going fluid resuscitation in BAM, the only further intervention 
that patients received during the six hour observation period was on-going seizure 
management in a small number of patients. The presence of persistent seizures was 
associated with poor outcome, monitoring and treatment over time is likely to appropriate for 
this small number of critically unwell patients. However, if the fluid resuscitation protocols 
were removed from the care bundle, very few patients would require further treatment during 
the six hour observation window, with considerable resource savings.  
 
None of the large sepsis bundle trials have tested the most appropriate resuscitation time 
period, six hours appears to have been adopted with little evidence to support this time over 
other time-frames. The BAM study does not provide evidence that a six hour monitoring and 
target-driven resuscitation period is required for all patients with suspected ABM in QECH. 
To conserve resources, particularly nursing time and effort, this may not be a useful part of a 
future care bundle for a resource limited setting.  Important parts of the clinical care bundle 
with the strongest evidence base, such as early recognition and delivery of appropriate 
antibiotics need to be tested, but are likely to continue to be important in the management of 
ABM in this setting. Other elements such as the fluid resuscitation protocol and full six hour 
monitoring period may not be required. Any studies testing appropriate in-hospital treatment 
ideally should be combined with a strategy of addressing quality issues in the hospital 
community relating to disease recognition and management of delay, including the 
importance of prompt recognition and treatment to give the best outcomes. 
 
8.5.4 Future directions for EGDT for ABM in sub-Saharan Africa 
The BAM study was observational in design, with sequential phases for observation and 
intervention. The estimates of effect size are subject to observational biases and 
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confounding by time, and as such, cannot provide a definitive answer about  the efficacy of 
EGDT for ABM in Malawi. A randomised controlled trial, with parallel recruitment would 
produce data that was not subject to the limitations of observational studies which include 
observer and allocation biases, and would provide a more accurate comparison between 
routine hospital care and modified EGDT.  
 
Ideal studies testing EGDT are cluster randomised, with randomisation done by hospital and 
by patient (Campbell et al., 2007). This is for two reasons; firstly to minimise ethical issues in 
delivering both routine hospital care and EGDT within an individual centre, where a study 
team who are aware of the clinical evidence behind the care bundle may feel that delivering 
routine care is un-ethical, and  are therefore at risk of biasing the study by improving routine 
care (Huang et al., 2013). Secondly, this design minimises contamination between study 
teams in a single centre. Blinding in a traditional RCT is impossible in studies of EGDT, and 
therefore if EGDT is being tested in an emergency department, with all the educational 
resources required, ensuring that the team delivering routine care were not exposed to, and 
therefore delivered clinical care biased by the presence of the study is difficult (Council, 
2008; Campbell et al., 2000). Cluster randomised design would provide the most reliable and 
robust results by separating the randomisation from a patient to a hospital level. 
   
It is likely that the clinical care delivered by the AETC team in P1 and by the BAM study 
team in P2 is likely to be substantially better than the quality of clinical care in most central 
and district hospitals in Malawi. Expanding the study of a new meningitis care bundle in a 
cluster randomised design beyond the AETC at QECH to multiple centres would determine 
the baseline medical management and CFR for ABM in other hospitals in the region, and 
give a true result as to efficacy of EGDT for ABM. Based on the data from BAM, the care 
bundle would need to be revised before the design of such a trial. Such a care bundle would 
include rapid recognition of suspected ABM and prompt administration of antibiotics, seizure 
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control, correction of hypoxia and hypoglycaemia, with possible randomisation on an 
individual level to conservative or resuscitation fluid strategies.  
 
8.5.5 Ward based care 
Once a preliminary diagnosis of ABM has been made in hospital, the patient is transferred to 
either the medical ward, or medical intensive care unit/high dependency unit, dependent on 
the on-going clinical requirements of the patient (Heyderman et al., 2003; Fitch and van de 
Beek, 2007; Tunkel et al., 2004). In Malawi, the only options are either general medical ward 
care, or care in the high dependency unit for those with persistent seizures or an on-going 
oxygen requirement. 
Strategies to improve outcome from ABM which have been tested in both adults and children 
in SSA are dexamethasone, glycerol, high dose paracetamol, short course compared to 
traditional long course antibiotics and bolus compared to infusion doses of ceftriaxone 
(Ajdukiewicz et al., 2011; Scarborough et al., 2007; Molyneux et al., 2011; Molyneux et al., 
2014; Molyneux et al., 2002; Pelkonen et al., 2011). None of these interventions resulted in 
improvements in outcome, although short course antibiotics were equivalent to long course 
in children. Interventions tested in either ward or intensive care settings in other populations 
include, management of raised intracranial pressure (ICP), hypothermia, and medical 
adjuncts including dexamethasone and glycerol (Glimaker et al., 2014; Mourvillier et al., 
2013; Kilpi et al., 1995; Peltola et al., 2007; de Gans and van de Beek, 2002; van de Beek et 
al., 2010). These interventions have either met with limited success (dexamethasone, 
glycerol, ICP management) in improving outcome, or substantial harm (hypothermia) 
(Mourvillier et al., 2013).  Full discussion of the evidence behind these interventions can be 
found in Chapter 2, Section 2.8. No ward based treatment for ABM has yet to substantially 
improve outcome in adults with bacterial meningitis to the effect sizes seen in sepsis with 
EGDT in well-resource settings. 
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The Malawi Adult Meningitis Severity score (MAMS) was shown in Chapter 5 to predict risk 
of outcome from ABM with good accuracy. This score requires further, prospective 
validation, but may have several roles in the ward based management of patients with ABM. 
However without further data exploring the underlying causes of high mortality in African 
adults with meningitis to inform future trials of acute or ward based therapeutic treatments, 
these interventions may not be the most appropriate next step for the treatment of ABM in 
SSA.  
 
8.5.6 Post hospital care 
A significant number of deaths (5-10% of the total mortality) occur in patients with ABM post 
discharge from hospital in SSA. In BAM, a significant proportion of patients were discharged 
at day 10 with substantial morbidity, 8% in P1 and 20% in P2, although missing data in P1 
do not give an accurate morbidity data by day 40, in P2 66% of those discharged with 
morbidity had died by this time. Very little data are available from BAM to explore the 
possible causes of this. These patients are poorly studied as community follow up is very 
difficult in an environment where transport is expensive, no formal road map or house 
numbering systems exist and patients may not have access to a reliable telephone number. 
 
Patients that die in the community do so without notification, access to cause of death data 
are difficult, as most deaths are not certified and no autopsies are carried out. In the BAM 
study we were able to obtain data on patient outcomes after taking a map of the physical 
address on discharge, and driving to that address and the surrounding areas asking for 
information, and we were able to establish for most patients for whom we had an address 
the eventual six week outcome. We had no access to any data that would support a cause of 
death, beyond those patients who were readmitted and whose notes we could access. 
Studies into post-discharge mortality are urgently required, but obtaining high quality data is 
likely to be complex. 
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In Europe, cerebral thrombosis has been well described as a late complication after 
pneumococcal meningitis, no studies have examined whether this occurs in SSA (Klein et 
al., 2010; Lucas et al., 2013; Schut et al., 2009a). In the analysis presented in Chapter 4, 
seizures post discharge were strongly correlated with risk of death by six weeks, this may be 
due to persistent structural lesions within the CNS  due to ABM, as seen on an older imaging 
study in the USA, or new-onset stroke. No imaging studies are available to explore this 
hypothesis further (Hasbun et al., 2001; Klein et al., 2011; Schut et al., 2009a). There were 
too few patients in BAM who died post-discharge to be able to analyse associations with risk 
factors for late death, however these patients were more likely to have morbidity (mRS ≥2) 
on discharge to those who had healthy survival at six weeks.  
 
Although an increased risk of death from ABM has been observed in the first year on ART in 
SSA (Walker et al., 2012), the time period between discharge from hospital and the six week 
follow up appointment in all meningitis studies in Malawi is likely to be too short for ART to 
be initiated and an IRIS phenomenon to manifest in death (Chang et al., 2014).  
An interesting observation from all trials of ABM in Malawi, is the relatively low frequency of 
deafness in survivors at six weeks which was  <10% in all of the studies across the studies 
(Scarborough et al., 2007; Ajdukiewicz et al., 2011), although this was higher in BAM, 
approximately 20-25% of survivors reported subjective hearing loss, the numbers were small 
and, audiometry data were not sufficient to analyse for trends. Deafness rates of up to 14-
21% occurred in patients with pneumococcal meningitis in the adult dexamethasone trial (de 
Gans and van de Beek, 2002). These discrepancies could be due to ascertainment biases, 
as formal audiometry was commonly not available historically; audiometry was variably 
available in BAM.  
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Overall the causes of late mortality from ABM in SSA are unclear. Future studies should 
focus more on examining this potentially treatable area, to complement pre-hospital and in-
hospital strategies for improving poor outcome from ABM.  
 
8.6 Future directions for bacterial meningitis studies in sub-Saharan Africa 
beyond EGDT  
8.6.1 Utility of severity scoring systems in resource limited settings for ABM 
The Malawi Adult Meningitis Score (MAMS) was shown to have good power in generating a 
risk score for patients with ABM. This score needs further prospective evaluation in the 
context of a clinical trial, but could be used to help answer the following research questions: 
 
a) What is the optimal length of antibiotic therapy? 
A paediatric study in Malawi determined that 5 days of ceftriaxone was non-inferior to 10 
days for bacterial meningitis, it reduced length of stay and was cost-efficient for the hospital, 
the patient and guardians (Molyneux et al., 2011). Currently the Malawian guidelines for 
adult meningitis advise a ten day course of antibiotics. In adult patients at high risk of in-
hospital mortality and complications, such as observed in BAM, SAM and GLAM, it is 
unlikely 5 day courses would be safe for all patients. However for patients stratified by 
MAMS as low risk, for example those with meningococcal meningitis, shorter course 
antibiotics may be a suitable compared to the 10 day standard (Heckenberg et al., 2008; 
Sudarsanam et al., 2013; Girgis et al., 1988). 
 
b) Are adjunctive treatments effective in different risk groups? 
Dexamethasone had differing effectiveness in the three big  trials done in adults in the 
Netherlands, Vietnam and Malawi, being  predominantly effective in the Netherlands on 
pneumococcal meningitis (de Gans and van de Beek, 2002),effective in Vietnam on 
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meningitis caused by Streptococcus suis (Nguyen et al., 2007) and having no effect in 
Malawi (Scarborough et al., 2007). In a study of TB meningitis in Vietnam, dexamethasone 
was most effective in the groups with the worst predicted outcome (Thwaites et al., 2004). It 
is possible that by using MAMS to stratify risk of outcome from ABM, sub-group analyses of 
patients divided by risk group could test if new adjunctive interventions were effective in 
some, but not all patients, and determine if high or low risk patients would be most likely to 
benefit from the intervention. For example, although dexamethasone was ineffective in 
adults with ABM in Malawi, it may have effects in sub-groups of patients with high or low risk 
of poor outcome, MAMS may be useful in permitting such evaluations. 
 
8.6.2 Prospects for future therapies 
No therapeutic adjuncts beyond dexamethasone and glycerol have been tested in clinical 
trials of ABM in SSA (van de Beek et al., 2012). Other interventions such as brain cooling 
have been shown to be ineffective and are not appropriate for use in SSA (Mourvillier et al., 
2013), as is reduction of intracranial pressure (Glimaker et al., 2014). High dose paracetamol 
is ineffective in reducing mortality in children (Molyneux et al., 2014), and is unlikely to be 
effective in adults. Novel treatments including inhibition of specific cytokines using 
monoclonal antibodies are unlikely to be effective or affordable in Malawi (Park et al., 1999; 
Saez-Llorens et al., 1991). Enhancement of macrophage opsonisation of pneumococci using 
P4 presents a potential novel adjunct, however this compound is not yet in phase one 
clinical trials, and may not penetrate the CSF (Bangert et al., 2012), large clinical trials 
testing this compound in adults are many years away. 
 
For adjuncts to be effective in reducing mortality in SSA, a much greater understanding of 
the differences in pathophysiology between bacterial meningitis in sub-Saharan Africa and 
more well-resourced settings is required. Whole blood, CSF, serum and nasal swabs and 
pneumococcal isolates were collected during the course of the BAM study, and these 
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samples will be used to initially to describe and explore host RNA expression, the 
pneumococcal proteome in the CSF and the common serotypes carried in pneumococcal 
meningitis. In addition, optimal clinical care for patients with ABM in resource limited settings 
must be evaluated formally, either using EGDT or consensus guidelines, as the effects of 
new adjuncts are only likely to be observed when optimal antibiotic timing and cerebral 
perfusion and fluid management strategies have been determined by a trial of modified 
EGDT. Data generated from these studies will identify further areas of study and potentially 
new areas for treatment of bacterial meningitis. 
 
8.6.3 Prevention of ABM 
Data presented in Chapter 4 Section 4.3.1 showed that Hib meningitis has decreased 
dramatically following the introduction of vaccination against this pathogen in 2002 (Wall et 
al., 2014a). Early data suggests that paediatric invasive pneumococcal disease may be 
decreasing following improvements in neonatal and maternal mortality rates, prevention of 
mother to child transmission of HIV, and introduction of PCV-13 to the routine infant 
vaccination schedule in 2011 (Jahn et al., 2010a; Wall et al., 2014a; Bar-Zeev N, 2014). 
Pneumococcal vaccination prevents recurrent IPD in HIV co-infected adults in Malawi 
(French et al., 2010), but vaccination of this group as a meningitis preventative strategy is 
unlikely to be cost-effective or realistic in Malawi, (Egere et al., 2012; Ota et al., 2012; Roca 
et al., 2012; Cohen et al., 2010a; French et al., 2010). Clinical trials in this population are 
required. No trials of primary pneumococcal vaccination with PCV-7 or PCV-13 in HIV co-
infected adults in Africa have been reported (Nunes and Madhi, 2012), the older 23-valent 
vaccine in HIV co-infected adults in Uganda did not prevent primary IPD in this population 
(French et al., 2000; Watera et al., 2004).  
 
Substantial protection through herd immunity from childhood vaccination may well be the 
best preventative strategy in current practice.  Indirect effects of PCV-13 vaccination in 
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children may lead to reduction in the burden of disease in both HIV negative and co-infected 
individuals, as has been seen in other settings; trends towards lower rates of IPD are being 
observed in children in Malawi (Burgos et al., 2012b; Muhammad et al., 2013; Hsu et al., 
2009b; Bar-Zeev N, 2014). However, the degree to which childhood vaccination may reduce 
IPD incidence in adults is not yet known, and may be limited. HIV co-infected adults in Africa 
have high rates of pneumococcal carriage compared to adults in other settings, and 
substantially altered humoral responses to carriage (Glennie et al., 2013; Glennie et al., 
2011; Ferreira et al., 2013; Palmu et al., 2012), antibody responses to both vaccination and 
carriage are limited compared to healthy adults (Nielsen et al., 1998; Nunes and Madhi, 
2012; Opravil et al., 1991; Glennie et al., 2013). The widespread use of PCV-13 may also 
result in serotype-replacement disease as has been seen in other settings after the 
introduction of PCV-7, where the overall incidence of IPD has not decreased in many places, 
despite substantial decreases in vaccine-type disease (Byington et al., 2010; Burgos et al., 
2012a; Elston et al., 2012).  
 
Based on current evidence, the best preventative strategy for pneumococcal meningitis in 
Malawi is to ensure adults and children receive appropriate vaccinations, ART and good HIV 
care. Development of improved vaccines that are immunogenic in HIV co-infected 
individuals and that do not cause serotype replacement disease is an urgent public health 
priority. 
 
8.7 Concluding remarks 
Over the course of the pathway from symptoms to management for patients with ABM in 
SSA, it is clear that there are several places where interventions may improve outcome 
(Figure 8.3). The work presented in this thesis started with the remit to try to understand why 
mortality was so high in patients with ABM in SSA, and to test if using a sepsis-orientated 
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approach to resuscitation, adjusted for meningitis and resource limitation was feasible in this 
setting. 
The thesis has helped to better understand the epidemiology of ABM in adults and children, 
the clinical predictors of poor outcome in adults with actual prediction of outcome using 
MAMS; detailed physiological data has shown that compartmentalised CNS responses are 
the cause of poor outcome and not septic shock. Goal-directed therapy is feasible, but it is 
unclear if the care bundle tested in BAM in its current format is appropriate or not for 
bacterial meningitis.  
Several important points on the patient journey present opportunities for further intervention 
to improve mortality (Figure 8.3), in pre-hospital recognition and early treatment, and in 
optimising in-hospital care and post-hospital outcome. The following research questions 
have arisen from this work, which should be the direction that research into ABM in SSA 
should take. 
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Figure 8.3 Points for intervention on the patient journey with ABM in Malawi 
The patient journey with ABM, with points highlighted for intervention. 1 = community 
awareness campaigns. 2 = randomised controlled trial of early antibiotics at health centre 
level. 3 = formal randomised trial of EGDT  4 = new adjunctive ward based therapies. 5 = 
causes of post discharge mortality, to identify avenues for improvements in outcome 
 
i) What are the relative contributions of host and pathogen to early and late 
mortality from ABM in Malawian adults? 
A greater in-depth understanding of the differences in those patients that die and those that 
survive is required to develop future treatments and strategies that will increase the 
proportion of survivors from ABM. Further understanding of the differences between ABM in 
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different populations is also required, the work on severity scoring systems shows that 
different hosts in different countries have different risk factors for death from meningitis.  
 
Studies of the host need to include: blood and CSF gene expression, deeper exploration of 
the host proteome, CSF neutrophil phenotype and function, CNS imaging studies and 
genetic sequencing data to determine if there is a particular host genotype or phenotype that 
is associated with mortality. Equal attention needs to be given to exploring  the pathogen, 
including the relative contribution of different serotypes to outcome, pneumococcal gene 
sequencing and expression, and the pneumococcal secretome (Tjalsma et al., 2000), 
including the proteome produced in active infection. Some of these studies will be done on 
samples collected during BAM, but future prospective studies designed to examine these 
questions in detail are required. 
 
ii) Would community strategies including public information and pre-hospital 
antibiotics improve outcome from ABM in Malawi in both adults and children? 
Very little data are currently available to inform community-based strategies for early 
recognition and treatment of ABM in SSA. Early parenteral community antibiotics are likely to 
be helpful, and unlikely to be harmful, but are the effects of community based treatments are 
likely to be enhanced if recognition of meningitis and health-seeking behaviours are also 
addressed to reduce time from symptom onset to attendance in a health-centre or hospital. 
A large surveillance study of many health centres in a large town or district would be 
required to test if a public information campaign resulted in more frequent attendance or 
diagnosis and referral of ABM in the community. This would then need to be followed by a 
trial testing pre-referral parenteral antibiotics given to adults with suspected ABM.  
 
iii) What is the optimal resuscitation strategy for adults with ABM in SSA? 
The data presented show that EGDT is feasible in Malawi, with similar care bundle 
compliance to sepsis data from Singapore. However, the differences in mortality across the 
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study phases, although limited in analysis by the observational nature of the data, are 
intriguing and require further understanding before future trials of EGDT can be planned.  
Measurable markers of severity of disease caused by ABM have been described in the data 
presented, and are reproducible across studies. The Malawi Adult Meningitis Score shows 
good predictive power with a promise of future utility in clinical research and possibly as a 
bedside tool. 
 
Early Goal Directed Therapy as a concept is feasible in SSA, a cluster-randomised trial of a 
care bundle, modified from the original BAM bundle (Chapter 8 Section 8.5.3) would give 
definitive information to design optimal clinical care guidelines for the management of ABM 
in SSA, which are urgently required to improve in-hospital care and outcome. 
 
iv) What are the causes of late mortality and morbidity from ABM?  
It is clear that poor outcomes are partly due to late in-hospital mortality and out of hospital 
mortality. A study designed to examine the causes of this late mortality, using imaging 
studies and close community follow-up would help to determine if structural CNS 
abnormalities, such as empyema and stroke, or if other factors such as TB or CCM co-
infection, early initiation of ART, or seizures are associated with late poor outcome. 
 
Substantial advances in the understanding of poor outcome from ABM in adults in SSA have 
been made since Scarborough and colleagues published the dexamethasone trial 
(Scarborough et al., 2007). Key points in our improved understanding include the 
determination of clinical phenotype of patients at high risk of poor outcome, including the role 
of persistence of pneumolysin in the CSF, poor white cell responses in the CSF to very high 
bacterial loads, the role of HIV as a risk factor for acquiring ABM, but not as a causative 
factor in mortality, the causes of culture negative meningitis and the role of PCR, and the 
possible role of pneumococcal serotypes and viral co-infections in poor outcome (Wall et al., 
2013c; Wall et al., 2012; Wall et al., 2014b; Wall et al., 2014a; Kelly et al., 2012; Ajdukiewicz 
355 
 
et al., 2011). The studies presented in this thesis shows that outcome from meningitis can be 
predicted with a simple bedside tool, and the strategy of EGDT is feasible in adult medicine 
in Malawi, and may be effective for reduction in meningitis mortality; a larger trial is required 
to provide definitive data on the acute management of ABM in the region. 
 
The definitive aim of any meningitis study must be towards curative strategies that will lead 
to lower case fatality rates. Appropriate studies that should be done subsequently to BAM 
should test enhanced community awareness information campaigns, early community based 
treatment and optimised in-hospital care. 
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Appendices 
Appendix 1.1 BAM study phase 2 clinical care bundle checklist 
Date………………….. Study number ……………………………………………… 
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Care bundle 
element 
Physiological 
abnormality 
Intervention  Required for this 
patient?  
Y = Yes N = No 
Airway support All participants  
GCS < 8 require NP 
airway 
NP airway inserted  
Head tilt 30 
degrees 
All participants  
GCS < 11 require 
head tilt 
Elevate head of bed or 
tilt trolley to 30 degrees 
 
Oxygenation Sp02 <94% Nasal flow 02 from 
concentrator 
 
Glucose RBS <4 S/L , NG or IV dextrose  
Antibiotic therapy 1st dose within 1 
hour of arrival 
Drug chart timing  
Perfusion :- shock CRT*>3 sec, BP <90 
syst, MAP <70, 
postural 
hypotension 
UOP<0.5ml/kg  
IV fluid bolus 20ml/kg 
Ringer’s lactate. 
Repeated if required. 
Total volume of fluid 
given: 
……………………………………. 
 
Perfusion :–  
no shock 
Normal BP/heart 
rate/CRT 
Maintenance fluids with 
IV RL (see drug chart) 
 
Seizures  1 or more seizure in 
AETC 
Acute prompt treatment 
of seizures with IV/PR 
benzodiazepines and IV 
phenobarbitone if 
seizures persist 
Diazepam Y / N 
Chlorpromazine Y / N 
Phenobarbitone Y / N 
*CRT = Capillary Refill Time 
To all ward clinicians 
Your patient has been enrolled in the BAM study and has received a clinical care bundle of early goal 
directed therapy for suspected adult bacterial meningitis while in the AETC during admission. The 
care bundle was delivered over a 6 hour time period. The elements of the care bundle your patient 
received are documented above. We will follow up the patient daily and monitor their progress. 
Please call the BAM team if you have any questions or concerns about the care your patient 
received. 
 
Appendix 1.2 BAM phase 2: Fluid bolus protocol for shocked participants 
 
Shock = CRT>3 seconds, Systolic BP <90, Mean arterial BP < 70, pulse rate > 100, blood lactate 
>4mmol/L, drop of >40mmHg BP from chronic hypertensive BP. 
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If any one or more features are present then start resuscitation protocol 
1. If not present already site an intravenous cannula 
 
2. Assess if evidence of chronic cardiac, liver or renal disease. Each of these will make bolus 
fluid more hazardous to the participant, and will need an alteration to this protocol to be 
prescribed by a clinician. Inform the PI if pre-existing cardiac disease/ 
 
3. Prescribe and administer a fluid bolus of either Ringer’s Lactate, or Saline 0.9% over 30 
minutes. 
4. Calculate your fluid bolus based on the estimated patient weight of 20ml/kg using the chart 
below. If you are unhappy with your estimated weight calculation use a 1000ml bolus for a 
50-60kg individual. 
40kg 800ml 
50kg 1000ml 
60kg 1200ml 
70kg 1400ml 
80kg 1600ml 
90kg 1800ml 
 
5. Check the observations carefully at the next hourly time period.  
 
6. If the participant remains shocked, administer a second bolus over 60 minutes and follow 
points 2-4. This can be repeated until the participant is no longer shocked. If > 2 boluses are 
given call the PI or the medical registrar for a careful clinical assessment. 
 
7. Document in the participant clinical care bundle sheet in the patient notes how many fluid 
boluses the participant received. 
 
8. Once the clinical observations are normal and the patient is not shocked, administer IV fluid 
in standard 3l/24 hours protocol and prescribe this in the clinical notes and discharge the 
participant to the ward at the end of the 6 hour time period. 
 
9. Recheck and document the blood lactate at the end of the 6 hour care bundle period. 
 
10. If the participant is anaemic Hb < 6g/dL on hemocue, organise a unit transfusion of blood. 
Do not stop fluid resuscitation while waiting for blood. There is no evidence that you will 
make a participant more anaemic by giving fluid while waiting for blood. The aim is to 
increase the tissue perfusion, particularly the brain. Substitute blood for fluid in the protocol 
when blood is available. 1 unit of blood has approximately the same volume in terms of 
resuscitation as a litre of saline. 
 
11. STOP the intravenous fluid protocol if any of the following happen:  
a) Sudden increase in respiratory rate of > 5 breaths/minute 
b) Drop in oxygen saturations of more than 3% (e.g. from 94% to 91%) 
c) New chest crackles 
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d) Acute chest pain 
e) Drop in GCS of more than 2 points 
f) New oxygen requirement 
g) A medical doctor diagnoses pulmonary oedema or cerebral oedema. 
 
12. If any features in (11) occur, you MUST inform the PI and complete a SAE form  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 1.3 BAM phase 2: seizure treatment protocol 
Introduction 
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A seizure is defined as one or more jerking movements of any body part caused by abnormal 
electrical activity in the brain. It can be either associated with a loss of consciousness (generalised 
seizure) or no loss of consciousness (partial seizure where the patient is awake). 
Bacterial meningitis is associated with seizures in severe infection and the presence of seizures is 
associated with a significantly worse outcome. Therefore seizure treatment is an essential part of 
the BAM care bundle. Seizures are commonly associated with hypoglycaemia, hypoxia or hypo-
perfusion of the brain, all of which must be corrected for the seizure to stop. 
Protocol 
If a seizure is observed, check the following: 
1. Airway is open or protected using an NP airway. If suctioning is required move the 
participant to the resuscitation area in AETC. 
2. Oxygen saturations are above 94%. If lower than this or unreadable, give oxygen 
immediately. 
3. Site an IV cannula if one is not present already. Check if the blood pressure has been 
stable and >90mmgHg. If the patient is unstable give IV fluids. 
4. Check the blood sugar. If it is lower than 4mmol/L give a bolus of 50% dextrose IV 
5. If the seizure continues despite the manoeuvres in 1-4, give a bolus of IV diazepam 
or Lorazepam if available. Titrate the dose between 1-10mg. Start with 1mg and 
flush through the line with saline. Gradually increase the dose in 1-2mg increments 
until the seizures stop with the smallest dose you can give. 
6. Monitor for respiratory depression with respiratory rate and Sp02. 
7. Re-assess the participant. If the seizures have stopped, continue to monitor. 
8. If the seizure continues or re-occurs check steps 1-4  again quickly. 
9. Give a further IV bolus of diazepam or lorazepam. Watch for respiratory depression 
(p2) 
10. If the seizures fail to terminate or re-occur load with IV phenytoin 15mg/kg  or 
phenobarbitone 600mg loading dose followed by 90mg IV. 
11. Watch for respiratory depression (p2) 
12. If the seizures do not terminate with this treatment, refer to ICU asap for 
anaesthetic management of the seizure. 
Loading protocol for phenobarbitone 
1. Make up 600mg of phenobarbitone in 10-20 mls of saline 0.9%. 
2. Give as a slow push IV over 15-20 minutes. 
3. Watch BP and puse rate using a cardiac monitor if possible. Caution risk of hypotension or 
arrythmias if given too quickly. 
4. Monitor for respiratory depression with respiratory rate and Sp02. 
Respiratory depression 
This is a drop in the respiratory rate of > 5 breaths/minute from baseline or a drop in the Sp02 of 
more than 3%. This will often be accompanied by a significant drop in the GCS or a prolonged post 
ictal period. If respiratory depression is apparent, stop the bolus infusion immediately and insert an 
NP airway. Refer to ICU for respiratory support until the respiratory rate improves. Use a bag and 
mask if necessary to support ventilation until ICU or anaesthetics are available to assist. 
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Appendix 1.4 BAM protocol for management of agitated patients 
 
Protocol: 
1. Good lighting levels to avoid agitation 
2. Use repeated orientation like time and familiar objects 
3. Repeated reassurance  
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4. Avoidance of physical, emotional, or chemical restraints 
5. Minimal distractions, calm environment 
6. Gentle and handle approach  
7. Check RBS to rule out hypoglycaemia 
 
*Sedation should be avoided if at all possible as it may cause worsening of the condition* 
 
Indications for sedation: 
 
In order to carry out essential investigations i.e., lumbar puncture 
To prevent patient endangering himself or other patients 
To relieve distress in highly agitated 
 
*Restless and irritability* 
Give lorazepam 0.5-1mg po or im 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 1.5 BAM treatment of hypoglycaemia protocol Phase 2 
Introduction 
Hypoglycaemia can be defined as a random blood glucose measurement of less than 4mmol/L. This 
can lower the seizure threshold in the brain and cause serious cognitive difficulties. It is important to 
correct hypoglycaemia as soon as it is detected to optimise brain function and reduce the risk of 
further seizures. 
Protocol 
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1. Take a random blood sugar (RBS) on every study participant 
2. If the RBS is greater than 4mmol/L no action is needed 
3. If it is lower than 4mmol/L and the GCS is over 11/15, correct with oral dextrose and 
food/sweet tea. 
4. If however the GCS is less than 11/15 the glucose must be corrected with intravenous 
dextrose. Use the flowchart below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5. At the end of the 6 hour care bundle if the participant is stable and well there is no need to 
check the blood sugar again. If it is still low ensure a handover is given to the HDU the 
participant is being transferred to, and the medical registrar is aware of the persistent 
hypoglycaemia. 
6. Protocol for making up 10% dextrose. Use a 50 ml syringe if available. Take 10mls of 50% 
dextrose solution into the syringe. Add 40mls of saline or ringer’s lactate and mix. Give the 
entire 50ml as a slow push IV . 
Appendix 1.6 BAM nasopharyngeal airway protocol 
Introduction 
In critical illness, a patient may lose involuntary control over the airway. This most commonly 
happens when the patient becomes comatose (GCS<8). A nasopharyngeal (NP) airway provides 
support to the upper airway to keep oxygen flowing between the nose and the back of the pharynx. 
It is not a replacement for a full endotracheal tube which secures the airway but  it may prevent 
common causes of airway obstruction in coma such as tongue displacement, mucous, food boluses 
and vomitus. The use of NP airways is recommended in patients who are unable to tolerate a guedel 
Glucose <4mmol/L? 
yes No 
No further 
action needed 
GCS 
<11/15? 
GCS 
>11/15? 
Give IV dextrose 10-50% and check 
again in 1 hour 
Give oral dextrose tablets 
or sugary drink 
(e.g.fanta/sweet tea) and 
check again in 1 hour 
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(oropharayngeal) airway but who require airways support, or where a guedel airway is not 
appropriate. It will also induce less gagging than an oro-pharyngeal airway.  
A NP airway insertion is contraindicated in suspected cases of facial trauma or basal skull fracture 
where the airway may pass through the skull. It is also contraindicated if CSF is seen to be draining 
from the nose, eyes, ears or mouth of the patient.  In other situations the NP airway is very safe and 
usually very well tolerated. 
Procedure 
1. Determine the Glasgow coma score of the participant. If it is less than 8/15 then an airway is 
indicated as per the BAM protocol 
2. Using suction if necessary ensure the upper airway through the nose is clear 
3. Insert the airway at 90 degrees to the face and push it directly into the nasopharynx. Do not 
angle the airway up or down, but push it directly backwards into the participant’s nose.  
4. Follow the curve of the airway as you push into the nasopharynx as per the image below. 
 
 
5. Insert the airway until only the flared tip remains outside of the nose. Apply oxygen through 
the airway if indicated. 
6. Side effects from long term use of the airway include the following: 
• Mucosal irritation 
• Sinusitis 
• Retropharyngeal ulcers 
• Temporary vocal cord paralysis 
• Temporary deafness 
7. To remove the airway, simply pull it out of the nose towards you. Discard it immediately and 
warn the participant that they may cough as it is removed.  
8. Ensure that you warn the participant’s guardian that they may suffer side effects, if the 
airway is required for more than 2 days. 
 
